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Abstract: This editorial aims to examine the risk factors associated with type 2 diabetes and to discuss
the evidence relating to dietary strategies for managing people with this condition. It is clear from the
evidence presented that a range of dietary interventions can provide useful approaches for managing
people with type 2 diabetes, including the regulation of blood glucose and lipid parameters, and for
reducing the risks of acute and chronic diabetic complications.
Keywords: type 2 diabetes; dietary intake; glycaemic control; dietary management approaches;
micronutrients; macronutrients; nutrition; chronic conditions; lipid parameters
Diabetes is a metabolic condition that is characterized by chronic hyperglycemia and results from
an interplay of genetic and environmental factors [1–4]. Its prevalence is on the increase in the UK
and worldwide, partly due to changes in lifestyle that predispose individuals to obesity and being
overweight [1,3–6]. It is estimated that about 90% of adults currently diagnosed with diabetes have
type 2 diabetes and, based on a World Health Organisation (WHO) report, about 422 million adults
were living with diabetes in 2014 compared with 108 million in 1980 and this condition caused about
1.5 million deaths in 2012 [7,8]. The United States of America has about 30.3 million adults living
with diabetes, and 1.5 million estimated new diabetes cases are diagnosed every year, representing an
increasing prevalence of this condition [9]. Diabetes presents amajor public health challenge despite the
developments in technology and the pharmaceutical industry [9]. These problems may be in the form
of acute or chronic complications and changes in body composition can be profound. In this regard,
Almusaylim et al. [10] conducted a cross-sectional and longitudinal study to evaluate the associations
between variations in glycaemic status and changes in total body, trunk, appendicular fat mass,
and lean mass in men. The longitudinal analyses demonstrated that changes in total body, fat mass and
lean mass, and appendicular lean mass diﬀered among glycaemic groups [10]. In addition, glucose
dysregulation was found to be related to adverse changes in total body and appendicular lean mass.
Therefore, in order to attenuate the problems of diabetes, management strategies usually include
lifestyle changes such as increased physical activities and dietary interventions. Studies that evaluate
the role of nutrition in the management of type 2 diabetes often involve human and animal models
as these approaches enable us to have a broader and more in-depth understanding of the condition.
Sometimes, diabetes may co-exist with other conditions such as stroke and these may present unique
challenges in relation to nutritional interventions.
The current editorial aims to evaluate the risk factors associated with type 2 diabetes and the role
of diet in the management of people with the condition. It involves evidence drawn from human and
animal studies.
In one of the studies, Muñoz-Garach et al. [11] examined the role of vitamin D status, calcium
intake, and the risk of developing type 2 diabetes. According to the authors, the role of vitamin D in
glucose homeostasis appears to be its association with insulin secretion, insulin resistance, and systemic
inﬂammation and this is one of its important non-skeletal functions [11]. In addition, there seems to be
a link between the consumption of dairy products and a lower risk of type 2 diabetes and this has been
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demonstrated in many observational studies although the mechanism and the role of calcium intake in
the risk of developing this condition have not been well established [11]. Therefore, a randomized
controlled trial on the role of vitamin D and calcium in the development of type 2 diabetes will further
elucidate our understanding of the mechanisms of action of these micronutrients [11]. In a related
study, Contreras-Manzano et al. [12] explored cardiovascular risk factors and their association with
vitamin D deﬁciency based on a nationally representative sample of 3260 young Mexican women.
The authors found that the prevalence of vitamin D deﬁciency among the women aged 20 to 49 years
old was a public health problem and that obesity, type 2 diabetes, and high total cholesterol were found
to be associated with vitamin D deﬁciency.
On the other hand, Fernández-Cao et al. [13] conducted a systematic review and meta-analysis in
order to evaluate the eﬀect of dietary, supplementary, and total zinc intake and status on the risk of
developing type 2 diabetes. This was based on the understanding that zinc may have a protective role
against type 2 diabetes [13]. The results showed that a moderately high dietary zinc intake based on
the ‘Dietary Reference Intake’ may reduce the risk of type 2 diabetes by 13% and up to 41% in rural
settings [13]. In contrast, elevated serum/plasma zinc concentration was found to be associated with an
increased risk of type 2 diabetes in the general population, although no relationship was established
between total or supplementary zinc intake and type 2 diabetes [13]. Brandão-Lima et al. [14] also
explored the relationship between the dietary intake of zinc, potassium, calcium, and magnesium
and glycaemic control in patients with diabetes. The authors used multiple linear regression and
binary logistic regression analysis to evaluate the eﬀects of individual and combination intake of these
micronutrients on glycated hemoglobin (HbA1c) and found a high likelihood of inadequate intake
of the micronutrients. In addition, it was noted that the group with a lower micronutrient intake
demonstrated higher % HbA1c (p = 0.006) and triglyceride (p = 0.010) levels [14].
Apart from evaluating the association between micronutrients and the risk of type 2 diabetes,
the role of macronutrients and other metabolites in the development of this condition have been studied
extensively. Song et al. [15] sought to examine whether dietary patterns that explain the variation of
the triglyceride (TG) to high-density lipoprotein cholesterol (HDL-C) ratio were associated with the
incidence of type 2 diabetes in Korean men and women. The authors found evidence that suggests
that dietary patterns associated with low levels of TG/HDL-C ratio may have the potential to reduce
the risk of type 2 diabetes.
Based on the above, it is essential that dietary management approaches that are tailored to meet
the needs of people with type 2 diabetes reﬂect these elements that are aimed at reducing the risk of
acute and chronic complications. In this regard, Hallberg et al. [9] noted in their narrative review that
there is evidence that suggests the possible reversal of this condition through interventions and these
have been incorporated into guidelines. These approaches may involve the use of bariatric surgery,
low-calorie diets, or carbohydrate restriction [9]. In particular, the American Diabetes Association and
the European Association for the Study of Diabetes have recommended a low carbohydrate diet and
support the use of short-term low-calorie diets for weight loss.
A low carbohydrate diet (LCD), replacing some staple foods with nuts such as tree nuts and
groundnuts, has been shown to reduce weight, improve blood glucose, and regulate blood lipid in
patients with type 2 diabetes [16]. However, the consumption of tree nuts is diﬃcult to promote
in patients with diabetes because they are relatively more expensive compared to groundnuts [16].
It remains unclear whether peanuts and tree nuts, including almonds, in combination with LCD have
similar beneﬁts in patients with type 2 diabetes. Therefore, Hou et al. [16] conducted a randomized
controlled trial to compare the eﬀect of peanuts and almonds on the cardio-metabolic and inﬂammatory
parameters in patients with type 2 diabetes. This was a parallel design involving 32 patients with type
2 diabetes [16]. The patients consumed a LCD with part of the starchy staple food being replaced
with peanuts (peanut group) or almonds (almond group) and involved a follow-up period of three
months [16]. The ﬁndings showed that the fasting blood glucose (FBG) and postprandial 2-h blood
glucose (PPG) decreased in both the peanut and almond groups (p < 0.05) compared with the baseline,
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and, following the intervention, there was no signiﬁcant diﬀerence between the peanut group and
the almond group with respect to the FBG and PPG levels [16]. However, compared to the baseline
value, there was a decrease in the glycated hemoglobin level in the almond group (p < 0.05) and no
signiﬁcant diﬀerence was found between the peanut and almond groups with respect to the HbA1c
level at the third month. The authors concluded that when incorporated into a LCD, almonds and
peanuts have a similar eﬀect on improving fasting and postprandial blood glucose among patients
with type 2 diabetes.
In a separate study, Yamada et al. [17] conducted a systematic review of dietary approaches
for Japanese patients with diabetes. The main focus of the review was to elucidate the eﬀect of
an energy-restricted and carbohydrate-restricted diet on the management of Japanese patients with
diabetes [17]. All the randomized controlled trials included in the review showed better glucose
management with the carbohydrate-restricted diet. It was found that carbohydrate-restricted diet,
not the energy-restricted diet, might have short term beneﬁts for managing Japanese patients with
diabetes although the low number of studies included in the review was a limitation [17].
Burch et al. [18] also developed a protocol for a longitudinal study on evaluating how diet changes
with the diagnosis of diabetes. It has been observed that the quality of diets plays a signiﬁcant
role in assisting people with type 2 diabetes to manage their condition and thus reduce the risk of
developing diabetes-related complications [18,19]. This is because diet quality is the extent to which
food intake complies with national or international dietary guidelines or a priori diet quality score and
it inﬂuences glycaemic control in people with type 2 diabetes and has a signiﬁcant impact on the risk of
complications [18,20]. It often includes the macronutrient components of the diet. Thus, Telle-Hansen
et al. [21] summarized the research evidence on randomized controlled trials of the eﬀect of dietary
polyunsaturated fatty acids (PUFAs) on glycaemic control in people with type 2 diabetes. This study
was based on the fact that replacing saturated fatty acids (SFAs) with PUFAs decreases blood cholesterol
levels and prevents cardiovascular diseases and that fat quality may also aﬀect insulin sensitivity and
increase the risk of type 2 diabetes [21]. Evidence from prospective studies has also shown that a high
intake of SFAs can increase the risk of type 2 diabetes, while a high intake of PUFAs reduces the risk
of the condition [21]. Based on this review, while about half of the studies that examined the eﬀect
of ﬁsh, ﬁsh oils, vegetable oils, or nuts found changes related to glycaemic control in people with
type 2 diabetes, the other half found no eﬀects [21]. In addition, it remains unclear whether PUFAs
from marine or vegetable sources aﬀect glycaemic regulation diﬀerently and this is a potential area for
future research [21].
What is clear, however, is that a low glycaemic index (GI) diet is more eﬀective in controlling
glycated hemoglobin and fasting blood glucose than a high GI diet in patients with type 2 diabetes [22].
In a further systematic review and meta-analysis, Ojo et al. [23] sought to evaluate the eﬀects of a low
GI diet on the cardio-metabolic and inﬂammatory parameters in patients with type 2 diabetes and in
women with gestational diabetes mellitus (GDM) and examine whether the eﬀects are diﬀerent in these
conditions. While 10 randomized controlled studies were included in the systematic review, only 9were
selected for the meta-analysis [23]. The results of the meta-analysis found no signiﬁcant diﬀerences
(p > 0.05) between the low GI and higher GI diets with respect to total cholesterol, high-density
lipoprotein (HDL), and low-density lipoprotein (LDL) cholesterol in patients with type 2 diabetes.
With respect to the triglyceride, it increased by a mean of 0.06 mmol/L (0.01, 0.11) in patients with type
2 diabetes on a high GI diet and the diﬀerence compared with the low GI diet group was signiﬁcant
(p = 0.027) [23]. The results from the systematic review were not consistent in terms of the eﬀect of a
low GI diet on the lipid proﬁle in women with GDM [23]. Furthermore, the low GI diet signiﬁcantly
decreased interleukin–6 (p = 0.001) in patients with type 2 diabetes compared to the high GI diet [23].
Nutritional approaches employed in managing patients with type 2 diabetes may also involve the
use of enteral nutrition, including oral nutritional supplements (ONS) [3]. The eﬀectiveness of these
diabetes-speciﬁc formula (DSF) and standard formulas on glycaemic control and lipid proﬁle in patients
with type 2 diabetes continues to generate interest. Based on this, Ojo et al. [1] used a systematic
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review and meta-analysis of randomized controlled trials to evaluate the eﬀect of diabetes-speciﬁc
enteral nutrition formula on cardiometabolic parameters in patients with type 2 diabetes. On the other
hand, Angarita Dávila et al. [3], conducted a randomized cross-over study to explore the eﬀect of
oral diabetes-speciﬁc nutritional supplements with sucromalt and isomaltulose compared with the
standard formula (SF) on glycaemic index, entero-insular axis peptides, and subjective appetite in
patients with type 2 diabetes.
In the review by Ojo et al. [1], it was found that all the fourteen studies included in the systematic
review showed that DSF was eﬀective in lowering blood glucose parameters in patients with type 2
diabetes compared with SF. The results of the meta-analysis conﬁrmed the ﬁndings of the systematic
review with respect to the fasting blood glucose, which was signiﬁcantly lower (p = 0.01) in the DSF
group compared to SF, and the glycated hemoglobin, which was signiﬁcantly lower (p = 0.005) in the
DSF group compared to the SF group [1]. Based on the systematic review, the outcomes of the studies
selected to evaluate the eﬀect of DSF on lipid proﬁle were variable. The authors concluded that the
results provided evidence to suggest that DSF is eﬀective in controlling fasting blood glucose and
glycated hemoglobin and in increasing HDL cholesterol, but has no signiﬁcant eﬀect on other lipid
parameters. They further noted that the presence of low glycaemic index (GI) carbohydrates, a lower
amount of carbohydrates and a higher amount protein, the presence of mono-unsaturated fatty acids,
and diﬀerent amounts and types of ﬁber in the DSF compared with SF may be responsible for the
observed diﬀerences in cardiometabolic parameters in both groups [1].
Angarita Dávila et al. [3] also compared the postprandial eﬀects of oral diabetes-speciﬁc nutritional
supplements with isomaltulose and sucromalt versus the standard formula (SF) on the glycaemic index
(GI), insulin, glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide 1 (GLP-1),
and subjective appetite in peoplewith type 2 diabetes. The subjects were given a portion of supplements
containing 25 g of carbohydrates or reference food following overnight fasting [3]. The glycaemic index
values were low for oral diabetes-speciﬁc nutritional supplements and intermediate for SF (p < 0.001).
The area under the curve for insulin and GIP were lower (p < 0.02 and p < 0.02 respectively) after
oral diabetes-speciﬁc nutritional supplements and higher (p < 0.05) for GLP-1 when compared with
SF [3]. In addition, the subjective appetite area under the curve was greater (p < 0.05) after SF than oral
diabetes-speciﬁc nutritional supplements [3].
The management of type 2 diabetes may also include the administration of insulin. But questions
remain whether the dose of insulin before a meal should be based on glycemia or meal content [24].
Krzymien et al. [24] reviewed existing guidelines and scientiﬁc evidence on insulin dosage in people
with type 1 and type 2 diabetes and explored the eﬀect of the meal composition such as carbohydrate,
protein and fat on postprandial glucose. The authors found that in most current guidelines aimed at
establishing prandial insulin doses in type 1 diabetes, only carbohydrates are counted, whereas in
type 2 diabetes the meal content is often not taken into consideration. Therefore, it was concluded
that prandial insulin doses in managing people with diabetes should take into account the pre-meal
glycemia, as well as the size and composition of the meals [24].
Apart from human studies, research based on the eﬀects of diﬀerent extracts on animal models
have been conducted in an attempt to further elucidate our understanding of their role in diabetes.
Tse et al. [25] assessed the glycemic lowering eﬀect of an aqueous extract of Hedychium coronarium
leaves in diabetic rodents. The study involved streptozotocin-induced type 2 diabetes Wistar rats
and C57BKSdb/db mice. After treatment with Hedychium coronarium for 28 days, glucose tolerance
improved in both of the diabetic animal models. The Hedychium coronarium also signiﬁcantly improved
the lipid proﬁle in streptozotocin-induced type 2 diabetic rats [25]. On the other hand, Vlavcheski and
Tsiani [26] explored the reduction of free fatty acid-induced muscle insulin resistance by Rosemary
extract. It was found that Rosemary extract has the potential to counteract the palmitate-induced
muscle cell insulin resistance [26].
In another study, Huang et al. [27] examined the eﬀects of Tempeh fermentation with Lactobacillus
plantarum and Rhizopus oligosporus on streptozotocin-induced type 2 diabetes rats. The results
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demonstrated that the modulation of serum glucose and lipid levels by lactic acid bacteria occurs via
alterations in the internal microbiota, leading to the inhibition of cholesterol synthesis and promotion
of lipolysis [27]. Furthermore, it was suggested that Tempeh, might be a beneﬁcial dietary supplement
for individuals with abnormal carbohydrate metabolism [27].
Yang et al. [28] also evaluated the combination of freeze-dried Aronia, red ginseng,
ultraviolet-irradiated shiitake mushroom, and nattokinase in order to examine its eﬀects on insulin
resistance, insulin secretion, and the gut microbiome in a non-obese type 2 diabetic animal model.
It was concluded that the combination of freeze-dried Aronia, red ginseng, ultraviolet-irradiated
shiitake mushroom, and nattokinase improved glucose metabolism by potentiating insulin secretion
and reducing insulin resistance in insulin-deﬁcient type 2 diabetic rats [28]. The improvement of
diabetic status ameliorated body composition changes and prevented changes in gut microbiome
composition [28].
Overall, this editorial has demonstrated that a range of dietary interventions can provide useful
approaches for managing people with type 2 diabetes including regulating blood glucose parameters
and lipid proﬁles and for reducing the risks of acute and chronic diabetic complications.
Funding: This research received no external funding.
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Abstract: Background: The prevalence of diabetes is on the increase in the UK and worldwide,
partly due to unhealthy lifestyles, including poor dietary regimes. Patients with diabetes and other
co-morbidities such as stroke, which may aﬀect swallowing ability and lead to malnutrition, could
beneﬁt from enteral nutrition, including the standard formula (SF) and diabetes-speciﬁc formulas
(DSF). However, enteral nutrition presents its challenges due to its eﬀect on glycaemic control and
lipid proﬁle. Aim: The aim of this review was to evaluate the eﬀectiveness of diabetes-speciﬁc enteral
nutrition formula versus SF in managing cardiometabolic parameters in patients with type 2 diabetes.
Method: This review was conducted in accordance with the preferred reporting items for systematic
reviews and meta-analyses. Three databases (Pubmed, EMBASE, PSYCInfo) and Google scholar were
searched for relevant articles from inception to 2 January 2019 based on Population, Intervention,
Comparator, Outcomes and Study designs (PICOS) framework. Key words, Medical Subject Heading
(MeSH) terms, and Boolean operators (AND/OR) formed part of the search strategy. Articles were
evaluated for quality and risks of bias. Results: Fourteen articles were included in the systematic
review and ﬁve articles were selected for the meta-analysis. Based on the ﬁndings of the review and
meta-analysis, two distinct areas were evident: the eﬀect of DSF on blood glucose parameters and the
eﬀect of DSF on lipid proﬁle. All fourteen studies included in the systematic review showed that
DSF was eﬀective in lowering blood glucose parameters in patients with type 2 diabetes compared
with SF. The results of the meta-analysis conﬁrmed the ﬁndings of the systematic review with respect
to the fasting blood glucose, which was signiﬁcantly lower (p = 0.01) in the DSF group compared
to SF, with a mean diﬀerence of −1.15 (95% CI −2.07, −0.23) and glycated haemoglobin, which was
signiﬁcantly lower (p = 0.005) in the DSF group compared to the SF group following meta-analysis
and sensitivity analysis. However, in relation to the sensitivity analysis for the fasting blood glucose,
diﬀerences were not signiﬁcant between the two groups when some of the studies were removed.
Based on the systematic review, the outcomes of the studies selected to evaluate the eﬀect of DSF
on lipid proﬁle were variable. Following the meta-analysis, no signiﬁcant diﬀerences (p > 0.05)
were found between the DSF and SF groups with respect to total cholesterol, LDL cholesterol and
triglyceride. The level of the HDL cholesterol was signiﬁcantly higher (p = 0.04) in the DSF group
compared to the SF group after the intervention, with a mean diﬀerence of 0.09 (95% CI, 0.00, 0.18),
although this was not consistent based on the sensitivity analysis. The presence of low glycaemic
index (GI) carbohydrate, the lower amount of carbohydrate and the higher protein, the presence of
mono-unsaturated fatty acids and the diﬀerent amounts and types of ﬁbre in the DSF compared with
SF may be responsible for the observed diﬀerences in cardiometabolic parameters in both groups.
Nutrients 2019, 11, 1905; doi:10.3390/nu11081905 www.mdpi.com/journal/nutrients7
Nutrients 2019, 11, 1905
Conclusion: The results provide evidence to suggest that DSF is eﬀective in controlling fasting blood
glucose and glycated haemoglobin and in increasing HDL cholesterol, but has no signiﬁcant eﬀect on
other lipid parameters. However, our conﬁdence in these ﬁndings would be increased by additional
data from further studies.
Keywords: diabetes speciﬁc formula; standard formula; type 2 diabetes; enteral nutrition; enteral
tube feeding; lipids; fasting blood glucose; glycated haemoglobin
1. Introduction
Diabetes is a metabolic condition which is characterised by chronic hyperglycaemia and is caused
by a range of factors including genetic inheritance and environmental inﬂuences [1]. The prevalence of
diabetes is on the increase in the UK and worldwide, partly due to the changes in lifestyle, including
lack of physical activity and unhealthy diets, which lead to overweight and obesity [2–5]. In addition,
improvements in technology and the greater awareness of the condition have meant that diabetes is
now better detected and more people are engaging in screening programmes. About 90% of patients
with diabetes are diagnosed with type 2 diabetes [6–8]. The impact of diabetes on the people living
with the condition can be profound in terms of morbidity and mortality, as well as a cost burden to the
National Health Service (NHS). Individuals with diabetes are more likely to be admitted to hospital
and it can have a signiﬁcant eﬀect on the quality of life of patients [9,10]. Diabetes is a major risk
factor for kidney dysfunction, lower limb amputations, retinopathy, cardiovascular disease and other
co-morbidities such as stroke, which can lead to swallowing problems and malnutrition. Based on these
issues, diabetes continues to be a major public health concern in the UK and globally, and strategies
for managing the condition continue to evolve. Often, management relies on lifestyle modiﬁcations
such as increased physical activity levels and the use of dietary interventions in order to prevent the
onset of type 2 diabetes and ultimately reduce the possibility of diabetic complications [11]. However,
in patients who are sedentary and immobile, the use of physical activity as a strategy for managing the
condition is sometimes impracticable.
Therefore, individualswith diabetes and other conditions, such as stroke, which could affectmobility
and swallowing ability, may benefit from enteral nutrition such as oral nutrition supplements and the
use of a nasogastric feeding tube (for short-term feeding) or a percutaneous endoscopic gastrostomy
tube for long-term intervention to deliver enteral feeds and formulas [12]. Usually, these individuals
have functional guts and the essence is to provide adequate nutrition, hydration and medication to these
patients in order to improve their nutritional status and clinical outcomes, including quality of life.
Why it is important to do this review:
The current review focuses mainly on patients with type 2 diabetes from a range of backgrounds,
including those attending diabetes centre/outpatient diabetic clinics, rehabilitation departments,
ambulatory patients, nursing homes and long-term care facilities, and intensive care units. Patients
with diabetes are at a greater risk of developing stroke, peripheral vascular disease, renal impairment
and dementia compared with those without the condition due to chronic hyperglycaemia [13].
The long-term complications of diabetes, including its co-morbidities, have implications for the length
of hospital stay. Thus, while the average length of hospital stay in patients with diabetes as the primary
diagnosis has been estimated to be 4.3 days, it is 8 days in patients with additional diagnoses and 3.1
days in all hospitalisations [14]. The use of enteral feeding in patients with diabetes can present a
range of challenges in the control of blood glucose levels and other cardiometabolic parameters [15].
These parameters, including lipid proﬁle, such as total cholesterol, high density lipoprotein cholesterol,
low density lipoprotein cholesterol and triglyceride, are important biomarkers in patients with type 2
diabetes as they have implications for insulin resistance and cardiovascular mortality.
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In patients with diabetes who are on enteral nutrition, the enteral feeds provided can be in the
form of either Standard Formulas (SF) or Diabetes Speciﬁc Formulas (DSF). Enteral feeding formulas
have a tendency to promote hyperglycaemia and insulinemic responses in patients with diabetes and
in healthy subjects [16,17]. In addition, the eﬀect of enteral nutrition on blood glucose parameters may
be due to the fact that continuous enteral feeding is a source of continuous supply of glucose, providing
10–20 g of carbohydrates per hour, which is not the same during normal eating [15]. The absence
of the normal postprandial glucose peak in patients with diabetes on enteral nutrition makes the
management of hyperglycaemia diﬃcult [15]. On the other hand, the eﬀect of diﬀerent types and
amounts of ﬁbre and mono-unsaturated fatty acids in various enteral feeds may inﬂuence lipid proﬁle
and other cardiometabolic parameters such as fasting blood glucose and glycated haemoglobin in
patients with type 2 diabetes [18]. The role of the diﬀerent enteral feeding formulas such as SF and
DSF and their impact on cardiometabolic parameters in patients with diabetes continues to generate
interest and controversy, and there appears to be no consensus among researchers on the most eﬀective
management strategy for these patients.
DSFs usually contain carbohydrates with low GI such as fructose and large amounts of
monounsaturated fatty acids in varying amounts, which have eﬀect on glycaemic control [17–20].
On the other hand, SFs are often high in carbohydrate and contain only low to moderate levels of lipids
and do not have dietetic ﬁbre [17].
Previous reviews on the use of enteral nutrition in patients with diabetes [16,17,21–23] either
lacked consensus in the recommendations, were based only on glycaemic control or did not involve
meta-analysis. In addition, concerns remain with the use of DSF in terms of the safety and tolerance of
relatively high levels of fat and fructose with respect to lipid metabolism and lactic acidosis, despite its
advantage in improving blood glucose compared with SFs [16,19]. Therefore, this review provides a
quantitative assessment of the relative eﬀectiveness of DSF compared with SF.
Aim: The aim was to evaluate the eﬀectiveness of diabetes speciﬁc enteral nutrition formula
versus SF in managing cardiometabolic parameters in patients with type 2 diabetes.
2. Methods
This study was conducted in accordance with the preferred reporting items for systematic reviews
and meta-analyses (PRISMA) [24].
2.1. Types of Studies and Participants
Only randomised controlled studies were included in this review and participants were patients
with type 2 diabetes.
Inclusion and Exclusion Criteria.
The criteria for considering studies for the review are outlined in Table 1.
Table 1. Criteria for considering studies for the review based on the Population, Intervention, Comparator,
Outcomes and Study designs (PICOS) Structure.
Inclusion Criteria Exclusion Criteria
Population
Patients with type 2 diabetes and on
enteral nutrition irrespective of type
of feeding tube.
Patients with type 1 diabetes.
Pregnant women with gestational diabetes.
Healthy individuals without diabetes on enteral nutrition.
Patients with diabetes on parenteral nutrition and
parenteral plus enteral nutrition.
Studies involving animals
Intervention
Diabetes speciﬁc formulas
Parenteral nutrition, parenteral plus enteral nutrition.(Oral nutrition supplement or
enteral tube feeding)
Comparator Standard formulas (Oral nutritionsupplement or enteral tube feeding) Parenteral nutrition and parenteral plus enteral nutrition.
Outcomes Cardiometabolic parameters Qualitative outcomes such as patient feelings.
Study Design: Randomised Controlled Trials Letters, comments, reviews, qualitative studies
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2.2. Type of Intervention
The intervention for this review was based on diabetes-speciﬁc enteral formula, irrespective of
the type of feeding tube, mode and rate of delivery of the enteral feed and clinical settings.
2.3. Types of Outcome Measures
The following were the outcome measures of interest;
• Blood glucose parameters—Fasting blood glucose and glycated haemoglobin.
• Lipid proﬁle: Total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein
(HDL) cholesterol and triglycerides.
2.4. Search Strategy
Databases encompassing Pubmed, EMBASE, PSYCInfo and Google scholar were searched for
relevant articles based on the Population (Patients with diabetes), Intervention (Diabetes Speciﬁc
Formula), Comparator (Standard enteral formulas), Outcomes (outcome measures) and Study designs
(Randomised controlled studies)—PICOS framework (Table 2) [25]. The use of key words, truncation
symbols, Medical Subject Heading (MeSH) terms and Boolean operators (AND/OR) formed part of the
search strategy. Searches were conducted from the date of inception of databases until 2 January 2019.
The screening of studies and the evaluation of their eligibility and inclusion were in line with
PRISMA [24] guidelines (Figure 1). These procedures were conducted by ﬁve researchers (OO, SMW,
TT, RC, X-HW) and diﬀerences were resolved through consensus.
Table 2. Search method for identiﬁcation of studies.
Patient/Population Intervention Comparator Study Designs CombiningSearch Terms
Patients with type
2 diabetes
Diabetes speciﬁc
formulas
Standard
formulas
Randomised
Controlled Trial
Type 2 diabetes OR
type 2 diabetes
mellitus OR
Diabetes
complications OR
diabetes mellitus,
type 2
Diabetes speciﬁc
formula OR Diabetes
speciﬁc form* OR
Enteral nutrition OR
Enteral* OR Enteral
feed OR Enteral feed*
OR Enteral form* OR
Diabetes formula OR
tube feeding OR
enteral feeding
Randomised
Controlled Trial OR
Randomized
Controlled Trial OR
Randomized
Controlled study OR
RCT OR Randomized*
OR controlled clinical
trial OR placebo OR
randomly OR trial OR
groups
Column 1 AND
Column 2 AND
Column 3
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Figure 1. PRISMA ﬂow chart on selection and inclusion of studies.
2.5. Data Extraction
All the articles from diﬀerent databases were exported to ENDNote (Analytics, Philadelphia, PA,
USA) for de-duplication. Data extraction was carried out by one researcher (OO) and cross-checked by
the other four researchers (SMW, TT, RC, X-HW).
2.6. Assessment of Risk of Bias and Evaluation of Quality
A critical appraisal skills programme (CASP) tool was used to appraise the quality of the articles [26].
In addition, the researchers carried out an assessment of the risk of bias using the domain-based tool
(random sequence generation, allocation concealment, blinding of participants, personnel and outcome
assessment, reporting bias and selective reporting) to evaluate the studies included [27].
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2.7. Statistical Analysis
Articles that met the inclusion criteria for meta-analysis were exported to RevMan (Review
Manager, 5.3) [28] for data analysis. Therefore, cross-over studies and other studies which presented
with diﬃculty in extracting suitable data were excluded from the meta-analysis. The data analysis
included both meta-analysis and sensitivity analysis, the latter being conducted to test the consistency
of the eﬀect of DSFs on the diﬀerent cardiometabolic paramters. The random eﬀects model was used
for the parameters of interest due to the high level of heterogeneity measured by the statistic I2 with
values ranging from 34% to 100%. A p value of 0.10 was used to determine the statistical signiﬁcance
of heterogeneity.
2.8. Eﬀect Size
A forest plot was used to present the results of the meta-analysis and statistical signiﬁcance for
the overall eﬀect of the intervention was determined by a p value of <0.05.
3. Results
3.1. Data Inclusion Decisions
Fasting blood glucose in the studies includedwasmeasured after overnight fasting, using standard
measuring instruments. This is the standard method of measuring fasting blood glucose: the blood
glucose concentrations were expressed as Means. However, the studies by Pohl et al. [29,30] were
expressed as median and interquartile ranges and these were converted to means and standard
deviations [27]. Fourteen studies were included in the systematic review (Table 3) while only ﬁve
studies [29–33] were selected for the meta-analysis (Table 4).
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3.2. Assessment of Risk of Bias in Included Studies
Figure 2 shows the risk of bias summary of the various studies included in the meta-analysis.
All the studies demonstrated low risk of bias in all the areas, except with respect to incomplete outcome
data (attrition bias) where two studies [29,33] showed high risk of bias.
Low risk of bias; High risk of bias 
Figure 2. Risk of bias summary.
Based on the ﬁndings of the review and the meta-analysis, two distinct areas were evident: the
eﬀect of DSF on blood glucose parameters and the eﬀect of DSF on lipid proﬁle.
The eﬀect DSF on blood glucose parameters:
All the fourteen studies included in the systematic review showed that DSF was eﬀective in
lowering blood glucose parameters in patients with type 2 diabetes compared with SF. In particular,
DSF improved glycaemic control and lowered insulin requirements [18,29,31,35–39]. It provided better
clinical outcomes, including reducing the risk of acquired infections and pressure ulcer, reduced body
weight and was safer compared to SF [29,31,32]. In addition, the use of DSF was shown to be eﬀective
in lowering postprandial blood glucose levels compared to SF [20,32,34,40].
Pohl et al. [30] observed that long-term tube feeding with a DSF signiﬁcantly lowered fasting
blood glucose and improved glycaemic control. Similarly, Vaisman et al. [33] reported that DSF
signiﬁcantly improved longer-term glycaemic control in diabetic patients compared to SF. The results
of the meta-analysis conﬁrmed the ﬁndings of the systematic review. With respect to the fasting blood
glucose, it was signiﬁcantly lower (p = 0.01) in the DSF group compared to SF, with a mean diﬀerence
of −1.15 (95% CI −2.07, −0.23) (Figure 3). However, in relation to the sensitivity analysis, there were no
signiﬁcant diﬀerences (p > 0.05) between the two groups with the removal of Pohl et al. [29,30] studies.
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Figure 3. The eﬀect of DSF on fasting blood glucose (mmol/L).
The glycated haemoglobin was signiﬁcantly lower (p = 0.005) in the DSF group compared to the
SF group following meta-analysis (Figure 4) and sensitivity analysis.
Figure 4. The eﬀect of DSF on Glycated Haemoglobin %.
3.3. The Eﬀect of DSF on Lipid Proﬁle
Based on the systematic review, the outcomes of the studies selected to evaluate the eﬀect of DSF
on lipid proﬁle were variable. Craig et al. [31] did not ﬁnd signiﬁcant diﬀerences with respect to LDL
cholesterol and triglyceride between the DSF and the SF groups, but diﬀerences were signiﬁcantly
higher (p < 0.05) in the DSF group in relation to HDL cholesterol. In two other studies [33,35], the level
of HDL cholesterol was signiﬁcantly higher (p < 0.05) in the DSF group compared with the SF group
after intervention, but diﬀerences were not signiﬁcant (p > 0.05) in relation to triglycerides, total
cholesterol and LDL cholesterols. Diﬀerences between DSF and SF were also not signiﬁcant (p > 0.05) in
terms of triglyceride, total cholesterol, HDL cholesterol and LDL cholesterol in other studies [30,32,38].
In contrast, Pohl et al. [29] reported that there was a signiﬁcant diﬀerence (p < 0.05) between the DSF
group and the SF group with respect to triglycerides, but diﬀerences were not signiﬁcant (p > 0.05) in
relation to total cholesterol, HDL and LDL cholesterol. Other studies [36,40] have also shown that DSF
is eﬀective in controlling plasma triglyceride.
Following meta-analysis, no signiﬁcant diﬀerences (p > 0.05) were found between the DSF and SF
groups with respect to total cholesterol, LDL cholesterol and triglyceride (Figures 5–7). However, the
DSF group had a signiﬁcantly higher level (p = 0.04) of HDL cholesterol compared to the SF group
after the intervention, with a mean diﬀerence of 0.09 (95% CI, 0.00, 0.18) (Figure 8). The results of the
sensitivity test for HDL cholesterol demonstrated no signiﬁcant diﬀerences (p > 0.05) between the
two groups when the Craig et al. [31] and Vaisman et al. [33] studies were removed from the analysis.
In addition, the sensitivity analysis showed no signiﬁcant diﬀerences (p > 0.05) between the two groups
with respect to total cholesterol and triglyceride, while signiﬁcant diﬀerences (<0.05) were observed in
relation to LDL cholesterol when the Craig et al. [31] study was removed.
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Figure 5. The eﬀect of DSF on total cholesterol (mmol/L).
Figure 6. The eﬀect of DSF on LDL cholesterol (mmol/L).
Figure 7. The eﬀect of DSF on Triglycerides (mmol/L).
Figure 8. The eﬀect of DSF on HDL cholesterol (mmol/L).
4. Discussion
The ﬁndings of the systematic review and meta-analysis revealed that DSF was eﬀective in
lowering blood glucose (fasting blood glucose and glycated haemoglobin) compared with SF in
patients with type 2 diabetes. However, the sensitivity analysis for the fasting blood glucose did
not demonstrate a signiﬁcant diﬀerence (p > 0.05) with the removal of the Pohl et al. [29,30] studies.
In addition, there were no signiﬁcant diﬀerences (p > 0.05) between the DSF and SF groups with respect
to total cholesterol, LDL cholesterol and triglyceride (although a few studies reported signiﬁcant
diﬀerences with respect to triglyceride). Diﬀerences in the outcomes of studies in the systematic
review were observed with respect to the eﬀect of DSF on HDL cholesterol and the meta-analysis
also showed signiﬁcantly higher levels for the DSF group compared with the SF group. The high
level of heterogeneity in the studies included in the meta-analyses may explain why the results of the
meta-analysis and the sensitivity analysis were not consistent with respect to HDL cholesterol and
fasting blood glucose.
The presence of low glycaemic index (GI) carbohydrate in the form of isomaltulose, the lower
amount of carbohydrate and the higher protein content in the DSF may have contributed to the
ﬁndings of this review [37]. In addition, the presence of mono-unsaturated fatty acids (MUFA) and the
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diﬀerent amounts and types of ﬁbre in the DSF compared with SF may be responsible for the observed
diﬀerences in the fasting blood glucose, glycated haemoglobin and lipid proﬁles in both groups [18,41].
DSFs are usually higher in fat (40–50% of energy with a signiﬁcant portion of MUFA) and have a lower
carbohydrate level (30–40% of energy) and about 15% of energy is derived from fructose and soluble
ﬁbre [20]. DSFs contain carbohydrates with low GI such as non-hydrolysed starches, disaccharides,
ﬁbre and fructose in varying amounts which are aimed at controlling postprandial glucose [17–20].
In contrast, SFs are high in carbohydrate (about 50%) and have low–moderate levels of lipids (about
30%) and do not contain dietetic ﬁbre [17]. A study by Hofman et al. [42] demonstrated that, in 12
enteral formulas examined, the GI ranged from 12 for DSFs up to 61 for SFs. The GI of food is a measure
of how quickly the food is digested and the glucose reaches the blood stream [22,43]. Foods with high
GI rapidly increase blood glucose and insulin responses after consumption [43,44]. The results from
meta-analysis showed that the intake of a low GI diet was associated with reductions in blood glucose
parameters [35,43]. In addition, high soluble ﬁbre-containing foods can improve glycaemic control
partly due to delayed absorption [36].
Therefore, DSFsmay improveglycaemic control throughdelay ingastric emptying, delayed intestinal
absorption of carbohydrate and lower glycaemic response [20]. In the study by Alish et al. [34], the
blend of DSF was made up of low glycaemic and slowly digestible carbohydrates, resistant maltodextrin,
isomaltulose, sucromalt and prebiotic fibres, including fructo-oligosaccharides. These constituents
collectively produce a slow and consistent release of glucose into the blood stream [34]. Isomaltulose is a
naturally occurring low GI slowly digestible carbohydrate [18]. The slower hydrolysation of isomaltulose
during digestion may be responsible for the slower rise in blood glucose in patients with diabetes on
DSF [18]. In addition, the higher protein content of the DSF may have contributed to the lowering of
blood glucose parameters by delaying gastric emptying [18].
The use of high fat content, including MUFA, in the DSF may slow the transit time in the
gastrointestinal tract andslowtheabsorptionof sugarswhich couldhelp improveglycaemic control [35,41].
Diets that are high in MUFA have been shown to increase HDL cholesterol and reduce other components
of the lipid profiles [35,41]. HDL cholesterol is useful for reducing the risk of cardiovascular disease [35].
The result of the meta-analysis of the current review confirmed the positive role of DSF in increasing
HDL cholesterol. However, the sensitivity tests did not demonstrate consistency in terms of the effect of
DSF on HDL cholesterol, which could explain why researchers may be reluctant to recommend the use
of high fat content in DSF due to the risk of alterations in lipid profiles [41]. This may also be due to the
fact that there have been differences in the outcomes of studies on the effect of DSF on lipid profile [41].
5. Limitation
The limitation of this review was that only ﬁve studies were included in the meta-analysis.
In particular, there were fewer studies included for lipid outcomes (three for several parameters) and
therewas substantial variability in the studies. Therefore, the diﬀerences between themeta-analysis and
the sensitivity analysis in some of the parameters suggest that those results were not quite consistent,
which may be due to the high level of heterogeneity of the studies. Therefore, more studies are needed
to address this problem.
6. Conclusions
The results provide evidence to suggest that DSF is eﬀective in controlling fasting blood glucose
and glycated haemoglobin. In addition, DSF was eﬀective in increasing HDL cholesterol but had
no signiﬁcant eﬀect on other lipid parameters. However, our conﬁdence in these ﬁndings would
be increased by additional data from further studies. Additional research would also provide the
opportunity to reﬁne our understanding of the eﬀect of DSF on cardiometabolic parameters.
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Abstract: Oral diabetes-speciﬁc nutritional supplements (ONS-D) induce favourable postprandial
responses in subjects with type 2 diabetes (DM2), but they have not been correlated yet with incretin
release and subjective appetite (SA). This randomised, double-blind, cross-over study compared
postprandial eﬀects of ONS-D with isomaltulose and sucromalt versus standard formula (ET) on
glycaemic index (GI), insulin, glucose-dependent insulinotropic polypeptide (GIP), glucagon-like
peptide 1 (GLP-1) and SA in 16 individuals with DM2. After overnight fasting, subjects consumed
a portion of supplements containing 25 g of carbohydrates or reference food. Blood samples were
collected at baseline and at 30, 60, 90, 120, 150 and 180 min; and SA sensations were assessed
by a visual analogue scale on separate days. Glycaemic index values were low for ONS-D and
intermediate for ET (p < 0.001). The insulin area under the curve (AUC0–180 min) (p < 0.02) and GIP
AUC (p < 0.02) were lower after ONS-D and higher GLP-1 AUC when compared with ET (p < 0.05).
Subjective appetite AUC was greater after ET than ONS-D (p < 0.05). Interactions between hormones,
hunger, fullness and GI were found, but not within the ratings of SA; isomaltulose and sucromalt
may have inﬂuenced these factors.
Keywords: glycaemic index; incretins; subjective appetite; isomaltulose; sucromalt; nutritional
supplement
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1. Introduction
Diabetes mellitus (DM) is a complex metabolic disorder associated with long-term complications
as a result of the interplay of genetic, epigenetic, environmental and lifestyle factors [1]. Nowadays,
DM is considered a pandemic health problem and one of the top 10 killers, responsible for 1.6 million
deaths in 2016 [2]. According to International Diabetes Federation projections, by 2045, 629 million
people will be aﬄicted by DM, exhibiting the fastest rising prevalence of this phenomenon in the
history of humanity, which the highest prevalence rates in North America and the Caribbean [3].
Thus, the epidemiological impact of this disease is translated into higher public health expenditures
worldwide [4,5].
One of the most important strategies for the prevention and treatment of DM has been
correct management of carbohydrate consumption, having been reviewed in dietary guidelines
and recommendations stated by many scientiﬁc organisations worldwide [6]. The American Diabetes
Association (ADA) has highlighted this need, considering nutritional therapy as the fundamental
basis of glycaemic control in DM patients [7]. Besides that, the European Association for the Study
of Diabetes (EASD) has also focused its recommendations on the amount and type of carbohydrates
consumed [8], generating considerable interest in low glycaemic index (LGI) food prescription for
management of DM2 [9]. Indeed, a recent international expert consensus debated about the clinical
role of GI and glycaemic load (GL) in DM management [10], concluding that low GI and low GL diets
have been associated with a reduction in the glycaemic response variability [11], and better appetite
control [12,13]. This phenomenon leads us to hypothesise that lower insulin responses exhibited by
these supplements could promote satiety and fullness [10,12–14].
Nutritional approaches to type 2 diabetes usually include novel strategies in dietary advice,
especially in oral nutritional supplements (ONS) prescription as part of the management of some DM
comorbidities or as a complement for daily diet [15,16]. Any ONS designed for people with diabetes
(ONS-D) provides better control in postprandial glucose and glycated haemoglobin (HbA1c) when
compared with standard supplements [17], since they are lower in total carbohydrate content (with
a variety of sugar substitutes) and enriched with ﬁbre and monounsaturated fatty acids [16,18,19].
Dietary fat and carbohydrate modiﬁcations modulate postprandial glycaemic responses by a reduction
in glucose absorption rate [20].
The increase in peripheral glucose uptake via entero-insular axis peptides (EIAPs) such as
the glucose-dependent insulinotropic peptide (GIP), glucagon-like peptide 1 (GLP-1), and insulin
are a group of synergistic pathways counteracting undesirable glucose postprandial peaks [21].
Furthermore, a decrease in GIP secretion drives to adipocyte hypertrophy arrest and insulin resistance
amelioration [22]. By contrast, GLP-1 has a direct suppression eﬀect on appetite and protects pancreatic
β-cells from programmed cell death [22,23]. It is well known that beverages have a faster gastric
emptying and intestinal transit speed than solid food, which results in a rapid glycaemic response
and lower perception of satiety [13,23]. For these reasons, the strategies of speciﬁc oral supplements
designed for people with diabetes should include adaptation in the overall nutrients content [18,19].
Therefore, variations in both EIAP action and gastric emptying modulation by diet could play
a fundamental role in short-time appetite regulation and energy intake [24,25].
Use of ONS-Ds in malnourished or sarcopenic diabetic patients enhances energy intake and
overall nutritional status, improving glycaemic control, and thus, cause indirect economic beneﬁts [19].
A meta-analysis by Elia et al. [15] on a total of 23 studies and 784 patients receiving oral supplements or
tube feeding showed that when compared with standard supplements, ONS-D signiﬁcantly reduced
postprandial rise in blood glucose, peak blood glucose concentration and glucose area under the curve
(AUCG) with no signiﬁcant eﬀects on HDL, total cholesterol, or triglyceride levels. Furthermore,
this study reported a reduced insulin requirement (26–71% lower) and fewer complications in patients
with ONS-D therapy when compared with standard nutritional supplements [15]. Therefore, in order
to tighten glycaemic control, starch modiﬁcation and sugar substitution [16,26] has become a primary
strategy in the formulation of these supplements [15,16]. However, there is a compelling need to
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conduct more studies in special situations such as hospitalised patients, older people with DM2 or
end-stage kidney disease and patients with cancer [27,28].
Recent evidence suggests a favourable glycaemic response after nutritional supplement intakewith
sucromalt (a natural analogue of sucrosewith a lower glycaemic response) in diabetic patients [18,29,30].
Isomaltulose, another sucrose replacer, is a disaccharide composed of glucose and fructose linked by
an alpha-1,6-glycosidic bond exhibiting prolonged absorption, LGI (GI = 32), and a 20–25% lower
hydrolyzation rate when compared with sucrose [31]. Interestingly, GIP and GLP-1 secretion are
aﬀected by this disaccharide [32], resulting in a better insulin secretion proﬁle [33] and a possible
reduction in postprandial appetite [34].
Moreover, a study by Pfeiﬀer et al. [32] gave evidence on the relationship between high-glycaemic
index carbohydrates and a faster GIP release pattern in patients with fatty liver disease, subclinical
inﬂammation, DM2 and cardiovascular diseases. On the other hand, LGI carbohydrate consumption
would induce a lower GIP release and a higher release of GLP-1 [32], promoting a better metabolic
markers proﬁle in both healthy and type DM2 individuals [18]. Therefore, these authors propose the
GIP release rate as a determining factor in the “metabolic quality” and in consequence, relevant criteria
for the selection of dietary carbohydrates [32].
Several studies inDM-2 subjects have explored incretin release after consumption of oral nutritional
supplements with sucromalt or isomaltulose [18,35]; however, GI and GL have only been studied in
healthy subjects [35,36] and not in diabetic patients. Likewise, the correlation between the glycaemic
response (GI/GL) and SA as well as EIAP behaviour is not suﬃciently well described to date, especially
during ONS-D intake, digestion and absorption time.
Based on available literature, we hypothesised that an ONS-D that contains slow-digesting
carbohydrates (isomaltulose or sucromalt) resulting in a signiﬁcant release of GLP-1 and lower
secretion of both GIP and insulin. As consequence, a reduction in GI/GL index and subjective
postprandial appetite ratings would be found when compared with standard nutritional supplements.
Thus, the aim of this study was to assess sucromalt/isomaltulose ONS-D eﬀects on the glycaemic
response (GI/GL), EIAP release and postprandial SA in type 2 diabetic individuals.
2. Materials and Methods
2.1. Study Design
2.1.1. Design and Ethics Issues
A randomised, double-blind, cross-over study was conducted according to Good Clinical Practice
Guidelines, applicable Food and Drug privacy regulations and ethical principles based on the World
Medical Association-Helsinki Declaration [37]. This research was approved by the Human Research
Ethics Committee of the Endocrine and Metabolic Diseases Research Centre (EMDRC), “Dr. Félix
Gómez”, School of Medicine at the University of Zulia, Venezuela, and then registered in Clinical
Trials.gov (https://clinicaltrials.gov/ct2/show/NCT03829800).
2.1.2. Inclusion and Exclusion Criteria
This study included both male and female DM2 subjects over 50 years old who attended
the outpatient diabetes medical clinic at EMDRC [37]. The only antidiabetic therapies allowed
were diet/physical activity and/or metformin monotherapy. Body mass index (BMI) between
18.5 kg/m2–35 kg/m2 was the only compelling anthropometricmarker in order to be included in this trial.
Patients with diabetes mellitus type 1 (DM1), diabetic ketoacidosis, hypothyroidism/thyrotoxicosis
congestive heart failure, gastric, kidney or hepatic diseases, myocardial infarction, stroke and subjects
with insulin therapy or sulfonylureas, antibiotic therapy or corticosteroids, end-stage organ failure,
or individuals with organ transplantation, coagulation disorder, bleeding disorders, chronic infectious
disease (such as tuberculosis, hepatitis B or C or HIV) were excluded.
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2.1.3. Population, Sample Size, and Patient’s Selection
Taking into account the criteria mentioned above, the whole EMDRC electronic medical record
database was ﬁltered obtaining a population of 57 eligible patients. Literature regarding GI and GL
suggests 8 to 10 subjects for a proper meal/supplement assessment [10,36,38]. Thus, a random selection
of 23 DM2 patients was made with the purpose of obtaining a sample size with a reasonable accuracy
in determining the ONS-D glycaemic impact, GI and GL [36,38]. Since postprandial glycaemia and
glycaemic index was our primary outcome, this study was powered to detect the diﬀerence among
the AUCGs after consuming three oral nutritional supplements (eﬀect size = 0.79) [20,24,35,36,38].
Based on our calculation, at least 15 participants were needed to detect this eﬀect size at 80% statistical
power using a cross-over study design [24]. Assuming an attrition rate of 30%, 23 participants were
recruited in this study. Eligible subjects were contacted by phone and invited to attend a medical
screening visit in order to: (1) be invited to participate in the study, (2) verify if the participant met the
inclusion criteria and, (3) asked to give their written consent before beginning the study.
2.1.4. Anthropometric Assessment
Anthropometric data were obtained in fasting state, using light clothing and no shoes. For weight
determination and electric bioimpedance study, an UM-018 Digital Scale (Tanita, Tokyo, Japan) was
used. Height was measured using a SECA 216 stadiometer (Hamburg, Germany). Body mass index
was calculated using the equation: BMI (kg/m2) =mass (Kg)/height (m2).
2.2. Study Protocol
2.2.1. Oral Nutritional Supplements Composition
In this study, three oral nutritional supplements were examined: (1) non-diabetes-speciﬁc
standard oral nutritional supplements (ET; Ensure® Abbott Nutrition, Columbus, OH, USA); (2) oral
supplements with a blend of slow-digesting carbohydrates including resistant maltodextrin and
sucromalt (GS; Glucerna SR® Abbott Nutrition, Columbus, OH, USA); and (3) oral supplements
composed of lactose, isomaltulose, and resistant starch (DI; Diasip® Nutricia Advanced, Medical
Nutrition, Dublin, Ireland).
The macronutrient composition of these formulas per 100 mL is shown in Table 1. Considering
that two of the supplements contained a relatively low amount of total carbohydrates, a standardised
portion with 25 g of this nutrient was administered in each patient for all tests. This criterion is
recommended when the carbohydrate load in the food is low, in order not to overestimate portion
size [35,38]. Therefore, all supplements were compared with a glucose load of 25 g (GB), as a reference
food (anhydrous glucose dissolved in 250 mL plain water) (100 Kcal) [35,38]. It is important to mention
that there was no signiﬁcant diﬀerence in the volume of formulations supplied in this study (Table 2).
Table 1. Macronutrient composition of the oral nutritional supplements per 100 mL.
Composition ET DI GS
Calories (kcal) 105 104 93
Protein (g) 3.8 4.9 4.3
Fat (g) 2.5 3.8 3.5
Saturates (g) 0.4 0.5 0.3
Monounsaturates (g) 0.8 2.2 2.1
Polyunsaturates (g) 1.3 1.1 0.9
Total carbohydrate (g) 17.3 11.7 10.9
Sugar (g) 10.0 8.3 1.7
Dietary Fibre (g) 1.0 2.0 1.8
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Table 1. Cont.
Composition ET DI GS
Soluble (g) 0.0 1.6 1.8
Non-soluble (g) 0.0 0.4 0.0
Chromium (μg) 12.7 12.0 5.0
Portion size (mL) 100 100 100
Ensure® (ET): A standard oral nutritional supplement which is non-speciﬁc for diabetic patients. Diasip® (DI):
Isomaltulose and resistant starch oral nutritional supplement. Glucerna® (GS): Resistant maltodextrin and sucromalt
oral nutritional supplement.
Table 2. Nutrient composition of oral nutritional supplements based on 25 g available carbohydrate.
Composition ET DI GS
Calories (kcal) 149 223 214
Protein (g) 5.3 10.5 9.9
Fat (g) 3.5 8.1 8.1
Saturates (g) 0.5 1.0 0.6
Monounsaturated (g) 1.1 4.7 4.9
Polyunsaturated (g) 1.8 2.3 2.0
Total carbohydrate (g) 25.0 25.0 25.0
Sugar (g) 14.1 8.3 0.0
Dietary Fibre (g) 0.9 4.3 4.1
Soluble (g) 0.0 3.4 4.1
Non-soluble (g) 0.0 0.8 0.0
Chromium (μg) 12.4 25.8 11.5
Portion size (mL) 141 214 230
Ensure® (ET): A standard oral nutritional supplement not speciﬁc for diabetic patients. Diasip® (DI): Isomaltulose
and resistant starch oral nutritional supplement. Glucerna® (GS): Resistant maltodextrin and sucromalt oral
nutritional supplement.
The three oral nutritional supplements delivered energy ranging from 149 to 223 kcal (Table 2).
Both DI and GS contained 208 kcal per 200 mL versus 205 Kcal per 220 mL, respectively (recommended
daily serving size). Supplement DI had a lower percentage of carbohydrate (47 energy%) and protein
(19%) but higher percentage of fat (32 energy%, of which 18.5% was monounsaturated fatty acids
(MUFAs). On the other hand, the composition of GS was more comparable with DI; a lower percentage
of carbohydrate 47.7% and protein 18.42%, and higher percentage of fat 33.81% (MUFA: 20.5%),
while the composition of ET had a higher percentage of carbohydrate: 55.68%; lower percentage of fat:
29.45%; and protein: 14.87%; with 250 Kcal per 237 mL. The GI values were calculated according to the
information reported in the nutritional labelling of each supplement.
2.2.2. Experimental Protocol
Background Diet, Physical Activities and Other Measurements
Subjects were informed about diet and physical activity restrictions to be followed before each
session, which included: (1) 10–12 h fasting, (2) abstinence from alcohol, caﬀeine or smoking and not
exercising excessively 24 h before each session; (3) avoiding the metformin morning dose or other
medications allowed on trial days until instructed, and to do so at the health centre. Participants were
evaluated before each treatment by a licenced nutritionist. In this evaluation, patients had to submit
a 3 day food record in order to conﬁrm adherence to the meal plan. The day before the administration
of supplements, the nutritionist recommended a standardised dinner before 21:00 and were asked
not to consume anything before arriving at the laboratory except water, which was allowed until
midnight [14,39]. In order to ensure that participants complied with established protocols, they had to
complete a compliance survey. In case they did not comply with the previous test protocols, the test
sessions were rescheduled.
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During the appetite test sessions, patients engaged in 60 min of sedentary activities (word puzzles,
reading, board games, etc.) [14,39]. The activities were performed in a friendly, non-competitive
manner to avoid emotional excitement or stress. Any food-related topics were avoided for the duration
of the sessions [14]. Research team members evaluated the compliance of the experimental protocol
verifying the correct administration to all patients in each visit. Participants had access to water during
the day of the trial. The leading investigator reviewed these records before performing the food
tolerance test. During each test day subjects were allowed to drink water each hour (maximum 150 mL
each hour) immediately after ﬁlling in the appetite questionnaires. Water consumed during the test
session on the ﬁrst day was recorded and repeated on the other test days [14,39].
Randomisation
All participants were randomly assigned to eight consumption tests: two for the standard
glucose solutions and two for each of the three nutritional supplements. This scheme was carried
out with an interval of 1 week between tests in random sequences. The test supplement selection
was randomised using a computerized randomisation matrix. The order of supplement was further
randomised for each subject. The number of tests in each patient was done according to methodological
considerations for glycaemic index protocols [38]. Appetite was assessed twice for the same subject
before and after supplement intake on two diﬀerent occasions [14,39].
Previous-evening lunch standardisation: the dinner consumed by all participants the night
before each session day consisted of meat with boiled rice and a fruit cake for dessert ∼505 kcal [14].
The energy content of this meal was 35% of the daily estimated energy needs of each participant [40].
The distribution of energy in the evening meal was 50% from carbohydrate, 37% from fat and 13%
from protein [14,39].
2.3. Measurement of EIAP/GI and Subjective Appetite Evaluation
2.3.1. EIAP and Glycaemic Index
Participants attended the EMDRC following 10–12 h fasting at 07:00. Both duplicated blood
capillary samples (0.5 mL) and venous samples were taken in basal state, and then each patient was
randomly assigned to drink one of both the ONS (ET DI or GS) supplement or the reference food
(glucose 25 g in plain water) during a period not exceeding 15 min [35,36,38]. The reference food (GB)
(glucose solution) was used for glucose and insulin AUC determination only. Subsequently, samples
of capillary and venous blood were obtained at 30, 60, 90, 120 and 180 min for serum glucose, insulin,
GIP and GLP-1 measurement. During this phase, subjects were comfortably seated in a room with
a quiet environment [38]. This process was repeated seven more times, on diﬀerent days, with one
week interval until all consumption tests were done [36,38].
2.3.2. Subjective Appetite Assessment
The appetite sensations measured in this study were: hunger, desire to eat, prospective food
consumption and fullness assessed on diﬀerent days from those in which the GI was determined.
The visual analogue scale (VAS) chart was supplied in every session [39] and the subjects were asked
to ﬁll this instrument at baseline (0 min), 30, 60, 90, 120, 150 and 180 min after the ingestion of
each supplement. This instrument contemplates four questions: What is your feeling of fullness?
How hungry are you? How intense is your desire to eat? And how much food do you think you could
eat? [14,39].
The VAS structure consisted of 100 mm lines anchored at each end with opposite statements
with a scale of 0 to 100 mm, in which 0 means absence of perception and 100 maximum perception.
The distance between 0 and the marked point (an “x” placed by the participants on the line to indicate
their assessment at that time) was measured to quantify the perceived sensations. The score was
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calculated by measuring the distance in millimetres from the beginning of the line to the “x” position
(from left to right) [39].
The following equation was used to calculate the ratings of subjective appetite [41]: “Subjective
appetite = (desire to eat + hunger + (100 − fullness) + prospective food consumption)/4”.
2.3.3. Laboratory Determinations
Capillary glycaemia was determined by the glucose oxidase method using a portable glucometer
(Optium Xceed, Abbott Laboratories, Dallas, TX, USA) Both intra-assay and inter-assay coeﬃcients of
variation were 3.2 and 10.8%, respectively. Plasma Insulin (mU/L) was measured by an enzyme-linked
immunosorbent assay (10-1113; Mercodia, Uppsala, Sweden) with a minimum detectable limit of
1.0 mU/L, and an intra- and inter-assay variation coeﬃcients of 3.0% and 8.7%. Glycated haemoglobin
HbA1c was determined using a cationic exchange resin separation method (SIGMA, St. Louis, MO,
USA). Plasma total GIP (pg/mL) and GLP-1 (pmol/L) were measured by radioimmunoassay (RIA)
(SIGMA, St. Louis, MO, USA). The minimum detectable limits were 2 pmol/L and 3 pmol/L with
an intra- and inter-assay coeﬃcient of variation for GIP of 3.9% and 9%, and for GLP-1 6.3% and
10.3%, respectively. Total cholesterol, triacylglycerides, and HDL-C were determined by commercial
enzymatic-colorimetric kits (Human Gesellschaft für Biochemica und Diagnostica MBH, Wiesbaden,
HE, Germany). Serum LDL-C levels were calculated according to Friedewald’s equation.
2.4. Data Processing and Statistical Analyses
Statistical analyses were performed using IBM SPSS Statistics for Windows, version 23.0 (IBM
Corp., 2015, Armonk, NY, USA). Shapiro–Wilk test was used for the normality distribution assessment
of quantitative variables.
Incremental areas under the curves (IAUCs) were determined according to the trapezoidal
method for all variables using NCSS statistical software version 12.0 (NCSS, LLC, 2018, Kaysville, UT,
USA). A 2 h glycaemic response curve was generated for each subject for test foods. Any area below
the baseline fasting value was ignored. The calculated median of AUCG for three test foods from
16 participants was compared with the response to reference food or glucose solution (median of two
measurements), and the GI value of the glucose solution was set as 100.
The GI was calculated using the following equation [36,38]: GI = (AUCG value for the test
food/AUCG value for the reference food) × 100.
Data obtained was classiﬁed in low GI (≤55), intermediate (55–69) and high (≥70) [41]. Glycaemic
load (GL) was represented by a derivative measure of the GI of the nutritional supplement tested and
calculated by the following formula: GL = (GI × grams of carbohydrate per food portion)/100 [36,38].
All quantitative variables were presented as mean ± standard error of the mean (SEM). Plasma
glucose, insulin, GIP, GLP-1, perceptions of hunger, desire to eat, prospective food consumption,
fullness and SA had a normal distribution and its arithmetic means were analysed using ANOVA for
repeated measures with the Tukey’s HSD (honestly signiﬁcant diﬀerence) test. Signiﬁcant statistical
diﬀerences between ONS were evaluated through one-way ANOVA. The bivariate relation between
variables such as the AUC, blood glucose, EIAP and SA was analysed by correlation coeﬃcients for
each oral test. Statistical signiﬁcance was accepted at p < 0.05.
3. Results
At the beginning of the study, the initial sample was 23 individuals (12 women, 11 men), but seven
subjects did not complete the trial for diﬀerent reasons: (1) two subjects needed both corticosteroid
and antibiotic therapy; (2) two subjects initiated a vigorous physical activity program by medical
prescription; and (3) three voluntarilywithdrew from the study. At the end of the study, only 16 subjects
(seven women and nine men) completed all the test protocols. Table 3 shows the general characteristics
of the sample.
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Table 3. General characteristics of the enrolled patients.
Sex
Female Male Total
Mean SEM * Mean SEM Mean SEM
Age (years) 54.75 1. 65 57.83 1.35 56.0 1.11
Weight (cm) 87.75 3.73 90.17 1.22 89.0 1.58
Height (m) 1.68 0.04 1.69 0.01 1.68 0.01
BMC (kg/m2) 30.90 0.44 31.04 0.36 30.8 0.26
Waist circumference (cm) 106.00 1.58 111.00 0.89 106 0.77
Base glycaemia
(mmol/L) 7.51 0.40 6.75 0.30 7.05 0.26
Total cholesterol (mg/dL) 209.60 5.71 213.77 8.84 212.10 5.56
High-density lipoprotein (mg/dL) 44.70 4.63 44.30 2.32 44.46 2.16
Low-density lipoprotein (mg/dL) 130.95 4.37 133.28 1.54 132.35 1.87
Triglycerides (mg/dL) 161.70 2.56 158.06 4.45 159.52 2.80
Glycated haemoglobin HbA1c (%) 6.95 0.30 6.98 0.30 6.97 0.20
* Standard error of the mean. There were no signiﬁcant diﬀerences between sexes.
The protocol was well tolerated by all subjects. No individual reported nausea, dizziness or
vomiting after taking the nutritional supplements or the reference product. Basal concentrations of
serum glucose, insulin, GLP-1 and GIP (Table 4 and Figure 1) did not show signiﬁcant diﬀerences
according to sex or amongweekly visits. Similarly, hunger perception, fullness, desire to eat, prospective
food consumption in fasting state and SA ratings (Table 5 and Figure 2) did not show signiﬁcant
diﬀerences among gender or study session (p > 0.05).
Table 4. Serum glucose concentration and EIAP according to each treatment.
Supplement Time (min) Serum Glucose(mmol/L)
Insulin
(mU/L)
GLP-1
(pmol/L)
GIP
(pg/mL)
0 6.52 ± 0.07 6.44 ± 0.32 6.26 ± 0.28 29.64 ± 0.50
30 10.14 ± 0.07 bc 22.84 ± 1.00 bc 12.93 ± 0.21 bc 55.44 ± 0.58 bc
60 10.80 ± 0.12 bd 33.91 ± 0.97 bc 8.35 ± 0.22 bc 62.27 ± 0.89 bc
ET 90 9.39 ± 0.16 b 36.20 ± 0.64 bc 7.78 ± 0.15 b 74.68 ± 0.72 bc
120 8.76 ± 0.17 b 25.90 ± 0.70 bc 7.16 ± 0.27 b 71.23 ± 0.36 bc
150 8.14 ± 0.21 bc 16.80 ± 0.56 bc 6.55 ± 0.12 b 67.77 ± 0.50 bc
180 7.13 ± 0.21 b 9.91 ± 0.81 5.99 ± 0.21 b 62.86 ± 1.26 bc
0 6.64 ± 0.08 6.49 ± 0.11 6.95 ± 0.36 c 29.97 ± 0.40
30 6.68 ± 0.13 ac 17.24 ± 0.31 a 18.16 ± 0.26 ac 45.57 ± 0.42 a
60 9.10 ± 0.06 ac 18.16 ± 0.24 ac 14.75 ± 0.24 ac 50.85 ± 0.15 ac
GS 90 8.53 ± 0.07 ac 19.09 ± 0.20 a 12.73 ± 0.24 ac 54.23 ± 0.21 ac
120 7.92 ± 0.05 ac 14.38 ± 0.16 ac 11.63 ± 0.14 ac 55.99 ± 1.09 ac
150 6.98 ± 0.12 a 12.93 ± 0.19 a 10.86 ± 0.19 ac 57.87 ± 0.31 a
180 6.16±0.10 a 10.87 ± 0.18 8.91 ± 0.21 ac 52.85 ± 1.69 ac
0 6.66 ± 0.10 6.50 ± 0.40 6.20 ± 0.53 28.70 ± 1.07
30 7.47 ± 0.12 ab 19.04 ± 0.27 a 14.51 ± 0.22 ab 46.00 ± 0.71 a
60 10.17 ± 0.05 ab 24.86 ± 0.35 ab 10.26 ± 0.11 ab 56.51 ± 1.12 ab
DI 90 9.10 ± 0.05 b 21.14 ± 0.36 a 8.09 ± 0.17 b 63.78 ± 0.63 ab
120 8.56 ± 0.07 b 17.98 ± 0.30 ab 7.35 ± 0.14 b 61.10 ± 0.51 ab
150 7.33 ± 0.07 a 13.24 ± 0.25 a 6.95 ± 0.09 b 57.52 ± 0.50 a
180 6.61 ± 0.12 11.13 ± 0.21 6.56 ± 0.20 b 45.19 ± 0.96 ab
Treatment groups were deﬁned as a standard nutritional supplement not speciﬁc for people with diabetes
(ET); resistant maltodextrin and sucromalt supplement (GS); isomaltulose and resistant starch supplement (DI).
GIP: glucose-dependent insulinotropic polypeptide; GLP-1: glucagon-like peptide 1; SEM: standard error of the
mean. a p < 0.05 versus ET. b p < 0.05 versus GS. c p < 0.05 versus DI.
32
Nutrients 2019, 11, 1477
Figure 1. Time course and AUC0–180 min of serum glucose, insulin GIP and GPL-1 concentrations
following ingestions ofGB, ET,GS andDI. (A) Glucose in relationwith time andAUC0–180 min, (B) insulin
in relation with time and AUC0–180 min, (C) GIP in relation with time and AUC0–180 min, and (D) GLP-1
in relation with time and AUC0–180 min for all the diﬀerent types of treatments. Data are expressed as
means ± SEM; n = 16. The same colour scheme was used for all the graphs. All AUC0–180 min means
signiﬁcant diﬀerences (p < 0.02) in each group. Treatment groups: (GB) Glucose solution or reference
product; (ET) standard nutritional supplement not speciﬁc for diabetics; (GS) resistant maltodextrin
and sucromalt supplement; (DI) isomaltulose and resistant starch supplement. GIP: glucose-dependent
insulinotropic polypeptide; GLP-1: glucagon-like peptide 1.
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Figure 2. Time course and formula of postprandial perception of hunger, desire to eat, fullness,
prospective food consumption, subjective appetite and AUC0–180 min values following ingestions of GB,
ET, GS and DI. (A) hunger in relation with time and formula; (B) desire to eat in relation with time and
formula, (C) fullness in relation to time and formula, (D) prospective food consumption in relation with
time and formula and (E) subjective appetite in relation with time and formula. Data are expressed as
means ± SEM, (n = 16). Data comparisons about diﬀerences in subjective measurements of appetite
according to consumption tests are described in Table 5. The same colour scheme was used for all
graphs. All means of AUC0–180 min showed signiﬁcant diﬀerences (p < 0.02) in each group. Treatment
groups: (ET) standard nutritional supplement not speciﬁcally for people with diabetes. (GS) Resistant
maltodextrin and sucromalt supplement. (DI) Isomaltulose and resistant starch supplement.
35
Nutrients 2019, 11, 1477
3.1. Glycaemic Response and EIAP Concentrations
Glycaemic curves, as well as the mean and SEM of the glucose AUC0–180 min after ingestion of
both the reference product (glucose) and the nutritional supplements, are shown in Figure 1. Glucose
maximum peak was observed at 60 min (Table 4) for all products but signiﬁcantly higher for GB
15.03 ± 0.20 when compared with ET 10.80 ± 0.12mmol/L (p < 0.001), DI 10.17 ± 0.05 (p < 0.001) and
GS 9.10 ± 0.06 mmol/L (p < 0.001). Glucose at 180 min was signiﬁcantly higher in comparison with
both, fasting level for GB (p < 0.001) and for ET (p < 0.024). The AUC0–180 min of ET (p < 0.001) was
signiﬁcantly higher than DI (p < 0.001) and GS (p < 0.01) (Figure 1).
3.1.1. Insulin
Plasma insulin concentrations increased after the consumption of all supplements and the reference
product, reaching signiﬁcant diﬀerences at 90 min for GB (serum peak) in comparison to ET (p < 0.05),
GS (p < 0.001) and DI (p < 0.001), respectively (Figure 1). At 150 min, ET presented a higher glucose
concentration than DSF (p < 0.001), but no signiﬁcant diﬀerences were found in insulin concentration
between DI and GS (p = 0.976), see Table 4. The AUC0–180 min in insulin response was signiﬁcantly
lower in GS when compared with the other supplements (p < 0.001) (Figure 1).
3.1.2. GLP-1
Maximum GLP-1 concentration was observed at 30 min after the intake of the three supplements,
signiﬁcantly higher for GS in comparison to ET (p< 0.05) andDI (p< 0.05). At 150min, concentrations of
GLP-1 in ET and DI supplements were similar (p = 0.841), but the value of this incretin was signiﬁcantly
higher for GS when compared with both, ET (p < 0.001) and DI (p < 0.001), (Table 4). The AUC0−180 min
of the GLP-1 response was signiﬁcantly higher in GS in contrast to the ET (p < 0.001) and DI (p < 0.001),
(Figure 1).
3.1.3. GIP
The GIP plasma concentration increased after consumption of all supplements. The maximum
peak of this incretin was observed at 90 min with ET and DI, which was higher when compared
to GS levels (p < 0.05). At 150 min, ET presented higher GIP concentrations when compared to GS
(p < 0.001) and DI (p < 0.001), however, DSF levels did not show signiﬁcant diﬀerences (p = 0.844),
Table 4. The AUC0–180 min of the GIP response for GS was lower when compared to DI (p < 0.001) and
ET (p < 0.001, (Figure 1).
3.2. Subjective Appetite Measurements
Hunger sensation, fullness, desire to eat, prospective food consumption and SA from baseline
to 180 min are shown in Figure 2. Consumption of the diﬀerent treatments promoted an immediate
decrease in hunger and desire to eat accompanied by an increase in the perception of fullness, reversing
these sensations over the curve as time passed.
The arithmetic mean of hunger perception decreased after the consumption of all supplements,
registering the lowest level at 30 min for E, while the minimum value for GS was evidenced at 90 min,
signiﬁcantly lower when compared to ET (p < 0.05) and DI (p < 0.05), (Table 5). The AUC0–180 min of
hunger sensation for GS was signiﬁcantly lower when compared to ET (p < 0.001) and DI (p < 0.001),
(Figure 2).
Regarding fullness sensation, the maximum level was found at 30 min in the three groups, without
signiﬁcant diﬀerences between DI and GS, while the peak of fullness sensation was signiﬁcantly
lower with ET (p < 0.05), (Table 5). The AUC0–180 min of this sensation was signiﬁcantly higher in
GS when compared to DI (p < 0.001) and ET (p < 0.05), (Figure 2). On the other hand, the desire to
eat AUC0–180 min was signiﬁcantly lower for GS when compared to DI (p = 0.035) and ET (p < 0.001),
(Figure 2).
36
Nutrients 2019, 11, 1477
This same pattern was evidenced in the prospective food consumption, in which the AUC0–180 min
was signiﬁcantly lower in GS when compared with ET (p < 0.001) and DI (p < 0.001), (Figure 2).
Subjective appetite SA decreased to a minimum value at 30 min and then increased 60 min after the
three treatments for all subjects; this score was higher with ET when compared to GS (p < 0.01) and DI
(p < 0.01), (Table 5). The AUC0–180 min of SA was signiﬁcantly lower with GS than with DI (p < 0.01)
and ET (p < 0.001), (Figure 2).
3.3. Correlation Analysis Between EIAP, Serum Glucose and Subjective Appetite
After ET intake, insulin concentration AUC0–180 min and subjective sensation of fullness were
directly related (r = 0.713, p = 0.021), while an inverse relationship between fullness perception and
GLP-1 concentration AUC0–180 min (r = −0.756, p = 0.011) and serum glucose (r= − 0.687; p = 0.028) was
observed. The value SA was directly correlated with serum glucose (r = 0.659, p = 0.038), see Table 6.
No statistically signiﬁcant correlations were found for AUC0–180 min concentrations of these peptides
with DI and GS.
Table 6. Coeﬃcient correlations between AUC values of glycaemia, EIAP and subjective measurements
of appetite according to consumption tests.
Hunger Fullness Desire to Eat Prospective FoodConsumption
Subjective
Appetite
ET r p r p r p r p r p
Glycaemia 0.060 0.868 −0.687 0.028 0.217 0.547 −0.025 0.945 0.659 0.038
Insulin −0.215 0.552 0.713 0.021 −0.046 0.900 0.362 0.304 −0.437 0.321
GLP-1 −0.133 0.714 −0.756 0.011 0.392 0.262 −0.543 0.105 0.321 0.540
GIP 0.219 0.544 −0.082 0.821 0.486 0.155 0.399 0.253 0.540 0.107
DI r p r p r p r p r p
Glycaemia 0.004 0.992 −0.226 0.530 −0.069 0.849 0.173 0.633 0.357 0.311
Insulin 0.190 0.599 −0.163 0.652 −0.455 0.187 −0.196 0.587 −0.254 0.479
GLP-1 0.483 0.158 0.140 0.700 0.158 0.662 −0.407 0.243 0.098 0.787
GIP 0.294 0.410 0.099 0.785 −0.615 0.058 0.069 0.850 −0.540 0.107
GS r p r p r p r p r p
Glycaemia −0.192 0.595 0.019 0.958 −0.152 0.674 0.128 0.726 −0.154 0.672
Insulin 0.466 0.175 −0.020 0.957 0.217 0.548 −0.175 0.628 0.344 0.330
GLP-1 0.308 0.386 0.072 0.843 0.436 0.208 −0.421 0.226 0.191 0.596
GIP 0.231 0.521 −0.046 0.900 −0.135 0.710 −0.076 0.834 0.086 0.813
Treatment groups: (ET) standard nutritional supplement not speciﬁcally for diabetes patients; (DI) isomaltulose
and resistant starch supplement; (GS) resistant maltodextrin and sucromalt supplement. GIP: glucose-dependent
insulinotropic polypeptide; GLP-1: glucagon-like peptide 1; SEM: standard error of the mean. The values presented
correspond to r coeﬃcients and p-value for all subject correlations between subjective perceptions of appetite and
concentrations hormones according to the treatment group. p-values were signiﬁcant when p < 0.05.
Correlations between baseline and postprandial concentrations at 30, 90 and 120 min of glucose,
EIAP and SA measures were accomplished in all treatments. Insulin at 30 min for ET was inversely
related to hunger sensation (r = −0.745, p = 0.012) and SA (r = −0.849, p = 0.002) (Supplementary
Materials Table S1). DI intake was correlated with glycaemia and prospective food consumption at
30 min (r = 0.775, p = 0.008) and, GLP-1 with the desire to eat at 120 min (r = 0.667 p = 0.035); whereas,
SA was inversely correlated at 30 min with GIP (r = −0.688, p = 0.028) (Supplementary Materials
Table S2).
GS evidenced a direct relationship between glycaemia at 90 min with sensation of fullness
(r = 0.698, p = 0.025) and levels of GIP with sensation of hunger (r = 0.825, p = 0.003). GLP-1 at 30 min
and prospective food consumption were inversely related (r = −0.722, p = 0.018). SA was directly
correlated with blood glucose levels at 30 min (r = 0.711, p = 0.021) (Supplementary Materials Table S3).
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3.4. Glycaemic Index and Glycaemic Load
ET presented a GI mean higher than that calculated for DI (p < 0.001) and GS (p < 0.001),
respectively. Comparing both speciﬁc supplements for diabetics, the lowest value for this indicator
was evidenced in GS (p < 0.001). Concerning GL, ET showed the highest mean compared to the rest of
treatments (p < 0.001), and the lowest mean value for DI (11.28 ± 0.14, p < 0.001), (Table 7).
Table 7. Glycaemic index and glycaemic load according to consumption tests.
Treatment Groups Mean ± SEM
Glycaemic Index (GI)
ET 56.40 ± 0.43 bc
DI 51.44 ± 0.60 ab
GS 47.59 ± 0.49 ac
Glycaemic Load (GL)
ET 23.69 ± 0.18 bc
DI 12.04 ± 0.14 ac
GS 11.42 ± 0.12 ab
Treatment groups: (ET) standard nutritional supplement not speciﬁcally for people with diabetes; (DI) isomaltulose
and resistant starch supplement; (GS) resistant maltodextrin and sucromalt supplement. SEM: Standard error of
the mean. There were no signiﬁcant diﬀerences between sexes. ANOVA and post-hoc Tukey HSD for intragroup
comparisons; p-value was signiﬁcant when p < 0.05. a p < 0.001 versus ET. b p < 0.001 versus GS. c p < 0.001 versus DI.
3.5. EIAP and SA Relation with GI and GL
In relation to each supplement, it was found that hunger sensation AUC0–180 min was directly
correlated with GI (r = 0.777, p = 0.008) and GL (r = 0.777, p = 0.008) for ET; while DI, both GI and
GL were inversely related to GIP (r = −0.867, p = 0.001). GS, GI and GL were inversely related with
fullness sensation (r = −0.698, p = 0.025). SA ratings did not correlate signiﬁcantly with any of these
indexes (p > 0.05), (Supplementary Materials Table S4).
4. Discussion
This study assessed ONS-D with isomaltulose and sucromalt versus a standard oral supplement
on GI/GL, insulin response, incretin release and SA in DM2 patients. In this regard, the main ﬁnding
of this study conﬁrmed that ONS-D intake in diabetic subjects stimulated GLP-1 release, reducing
GIP levels with a subsequent decrease in insulin secretion. This particular EIAP pattern promotes
a lower IG/CG index when compared with a standard supplement. In spite of the former, there was
a reduction of SA and AUC0–180 min after ONS-D intake; only correlation between hunger perception,
fullness and some metabolic variables were found after GS intake.
These ﬁndings conﬁrm that ONS-D consumption promotes a better metabolic proﬁle in diabetic
subjects than standard supplements, allowing greater control in postprandial appetite. Speciﬁcally,
this investigation demonstrates that plasma glucose levels and glucose AUC0–180 min were signiﬁcantly
lower after the ingestion of ONS-D than ET. Our observations are consistent with previous research
carried out with slow-digesting carbohydrates supplements [18,29,42,43]. In this study, after the
consumption of GS, the mean glycaemic peak was consistent with ADA recommendations for glucose
level < 180 mg/dL (9.99 mmol/L), with elevated HbA1c in DM patients [7] and IDF of 160 mg/dL goal,
both in the postprandial period [6]. Similar to observations by Mottalib et al. [42] this study shows that
serum glucose level after ONS-D ingestion returned to baseline in a shorter period (150 min) when
compared with ET (180 min) [42], see Figure 1 and Table 4 [18,29,42]. These diﬀerences in glycaemic
proﬁle can be attributed, at least in part, to the low GI of ONS-D [18,29,35,42], a point of paramount
importance to avoid cardiovascular complications [44] because of pro-inﬂammatory cytokines and
oxygen free radical overproduction [44,45]. In this trial, the consumption of GS produced lower values
of GI/GL, a lower increment of GIP/insulin and more signiﬁcant release of GLP-1.
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Among the diﬀerent factors that inﬂuence the GI of a food, the source and carbohydrate type are
very relevant aspects. High GI carbohydrates diﬀer from those with LGI, not only in postprandial
glycaemic and insulinemic response but also in GIP release [45–47]. In this regard, Pfeiﬀer et al. [32],
suggest a novel concept that encompasses the intake of LGI CHO with a lower release of GIP and
a greater GLP-1 secretion results in improvements of metabolic markers in healthy [45], type 2 and
insulin-resistant individuals [46].
This concept relates to GI of each food to diﬀerent secretory responses of GIP andGLP -1, which are
released in diﬀerent segments of the small intestine [21,45–47]. These authors propose that both a fast
and pronounced GIP release in the proximal small intestine by high GI carbohydrates programming
the intermediary metabolism towards useful energy storage but adversely promoting fatty liver
disease [46], insulin resistance [48], obesity [49], subclinical inﬂammation and hypertriglyceridemia [46].
This program could represent an evolutionary advantage in times that rapid energy storage was
required [32,46]. Complete understanding of the pathophysiological mechanisms of foods with a high
GI provides a basis for the development of nutritional and therapeutic solutions [10,11,41,46].
Nonetheless, it is essential to diﬀerentiate the digestion (di, oligo and polysaccharides) and
absorption rate (monosaccharide), from the particular metabolism of each monosaccharide. This is
because certain simple sugars, such as fructose, with a relatively low GI (=23) [36], could induce
insulin-independent additional metabolic eﬀects [50] on uric acid levels, blood pressure, liver cell
triacylglycerides content and hepatic insulin sensitivity when consumed in high amounts [51]. On the
other hand, tagatose is a low GI (=3) monosaccharide [36], that promoting a GLP-1 release in a similar
extent to fructose without any signiﬁcant GIP secretion response [52] and exhibiting an interesting
glucose-lowering eﬀect [53]. In this study, we assessed two of the most employed slow-digesting
carbohydrates in ONS-D: isomaltulose and sucromalt.
Beneﬁcial metabolic eﬀects have been reported when low GI disaccharides = 32, such as
isomaltulose [31,36], are added to oral supplements in people with DM2 [29]. This disaccharide
has an α-1,6-glycosidic bond replacing the original sucrose´s 1,2-glycosidic linkage by enzymatic
isomerisation rearrangement obtained from beet sugar [33]. This molecular reorganisation leads to
slower digestion and, in consequence, delayed intestinal uptake of glucose and fructose [33,54]. Unlike
sucrose, isomaltulose administration prevents proximal K cells stimulation, secreting less GIP and
promoting a smaller insulin release [32,33]. For its part, the low glycaemic response to sucromalt
showed a sustained increase in GLP-1 secretion at 4 h post intake, suggesting an almost complete
uptake by the small intestine [30]. Thus, it is important to distinguish the eﬀects in GI from those
caused by changes in gut microbiota that occur when sugar reaches the colon and alter microbiome
composition, aﬀecting long-term carbohydrate metabolism and insulin response [55–57].
In this study, ONS-D insulinemic behaviour interestingly showed a lower AUC0–180 min level in ET,
especially after GS at 90 min, the time when the maximum peak of this hormone occurs. Meanwhile,
the maximum insulin concentration after DI intake occurred at the 60 min (Figure 1). The maximum
increase in GIP levels after GS occurred after the rest of the treatments (150 min), but it was only
statistically diﬀerent from ET (Table 4). Likewise, the AUC0–180 min for GIP was lower for ONS-D
compared with the ET, and lowest for GS versus DI, (Figure 1). This ﬁnding could conﬁrm the
theory mentioned above about the eﬀect of slow digestion carbohydrates on the release of insulin
and GIP, although insulinemic peak after ET also occurred in 90 min, but with a much higher incretin
concentration than that produced by ONS (p < 0.05 for both).
It has been proposed that slow-digestion carbohydrates can reach the more distal segments of
the small intestine before being absorbed, hence, stimulating a late-plasma increase of GLP-1 [30,52].
In this trial, the AUC0–180 min of GLP-1 was higher after ONS-D consumption when compared
to ET, and higher for GS when compared with DI, (Figure 1). Our results were similar to those
reported by Devitt et al. [29] regarding metabolic diﬀerences after speciﬁc supplement ingestion
composed of a variety of carbohydrates like tapioca dextrins, isomaltulose, tapioca starch/fructose and
sucromalt in DM2 patients. In this study, patients showed an increase in AUC0–240 min for GLP-1 after
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sucromalt-based supplement intake, but it was only signiﬁcantly higher after supplements made with
tapioca dextrin in comparison with the standard ET [29].
Some beneﬁts of increased GLP-1 secretion in DM2 patients are an improvement in
insulin–glucagon ratio, suppression of endogenous glucose production and the increase in ﬁrst-pass
splanchnic glucose uptake [47,58]. It is currently unclear whether inhibition of L-cell secretion or GLP-1
enhanced degradation entails to the characteristic blunted-eﬀect of this incretin in DM2. Also, the exact
mechanism of GLP-1 eﬀects on glucose control has not yet been elucidated [18,21]. Although there are
studies about this incretin for isomaltulose and sucromalt in healthy subjects [46], other studies have
reported beneﬁts in individuals with metabolic syndrome, obesity and DM2 after isomaltulose versus
sucrose consumption [31,58–60], but few have compared the eﬀects of cross-consumption of pre-loads
elaborated with these types of carbohydrates in DM2. To date, only one study has determined a higher
release of GLP-1 after the consumption of isomaltulose in individuals with diabetes [58]. Our results
showed an AUC0–180 min of GLP-1 higher after the consumption of GS versus DI, (Figure 1) exhibiting
a synergistic eﬀect of these carbohydrates.
In this sense, it iswell-known thatGLP-1 secretion is directly related tomacronutrients composition,
in particular to both carbohydrates and monounsaturated fatty acids (MUFAs) [61,62] without
any signiﬁcant eﬀect on insulin levels [61,63,64]. This is consistent with our results and with the
Mottalib et al. work regarding GLP-1 secretion and MUFA content in ONS-D when compared to
ET [42]. In a study by Printz [65], adequate glycaemic and insulinemic responses were found after the
intake of three enteral supplements for diabetics in subjects with DM2, but no signiﬁcant diﬀerences
in the release of GIP and GLP-1 were found [65]. In fact, carbohydrates used in Printz’s [65] study,
such as glucose, fructose, lactose and maltose [65], probably resulted in both changes in the ﬁnal place
of the intraluminal digestion and the speed of absorption, which could explain these results, especially
when comparing the forenamed carbohydrates with those administered in our study. Even though DI
also contains disaccharides such as lactose, its metabolic proﬁle could be suﬃcient to produce a more
signiﬁcant GLP-1 release of and less GIP than ET, but not enough to produce a better eﬀect on incretins
and insulin than GS. This observation conﬁrms previous ﬁndings that both the amount and type of
carbohydrates and fats inﬂuence incretin release 18,24,29,45], as well as in the GI and GL.
Our study could be one of the ﬁrst demonstrating ONS-D eﬀects on GI in DM2 subjects. In fact,
when compared with glucose solution, the evaluated supplements turned out to have an intermediate
GI value in people with diabetes for ET = 56. Meanwhile for GS = 47 and DI = 51, the result was a low
GI. Whereas, GL was high for ET = 23 and intermediate for GS = 11 and DI = 12, (Table 7). The mean of
these values is higher than the reported in the international GI and GL tables for healthy subjects [36]:
GI for ET = 48, GS = 23, DI = 12; with an intermediate GL: ET = 16, GS = 6 DI = 3. In a randomised
cross-over study conducted by Hofman et al. [35], in which the GI of 12 supplements was evaluated
in healthy subjects, the mean GI value in the ONS-D was 19.4 ± 1.8, and from 42.1 ± 5.9 in standard
supplements [35].
Signiﬁcant diﬀerences have been reported in the GI value of diﬀerent foods and/or typical foods
between healthy subjects and DM2 [66]. It is well known that the subject’s characteristics does not
have a signiﬁcant eﬀect on mean IG values [38], but the variation of the values can diﬀer in diﬀerent
groups, being higher in people suﬀering from type 1 diabetes (29%) than in healthy subjects (22%)
or in DM2 patients (15%) [38]. Our results are comparable with a previous study in which the GI for
a DM oral speciﬁc supplement was assessed in healthy subjects (IG = 27) and DM2 (IG = 54), ﬁnding
a signiﬁcant diﬀerence between groups [67].
This situation can be explained by a greater relative increase in the glycaemic response after
consumption of the reference food (GB) in people with diabetes compared to healthy subjects [38,68].
One possible explanation in that a defective insulin secretion is unable to counteract greater glycaemic
excursions in DM2 patients. At the same time [68], healthy people preserve their insulin secretory
machinery, preventing a greater glycaemic increase especially for the lowest digestion rates [38,68].
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As mentioned above, we found a higher GI for DI, even though a lower GI value has been
reported in healthy subjects when compared to the rest of the treatments [35,36]. However, in the
study conducted by Hofman et al. [35], both supplements GS and DI contained fructose 1.9 g/100 mL,
and a higher amount of MUFAs, DI = 3.6 g/100 mL versus GS = 3.8 g/100 mL than the supplements
evaluated in this study, therefore, it is not possible to make an exact comparison [35].
The GI value for DI in DM2 patients could be explained in part by the quantitative sugar content
(which has an 8.3 g versus 0.0 g to GS per portion given in this study) (Table 2). The rest of the
components like both the amount and type of ﬁbre can also inﬂuence these results. Moreover, soluble
ﬁbre can decrease the GI by many factors such as postprandial glucose ﬂuctuation cushioning, and,
by its action on intestinal motility, on peptide action and gastrointestinal enzymes [29,69,70].
In this study, total ﬁbre concentration in DI was 2 g/100 mL, whose proportion corresponds to the
80:20 ratio of soluble/insoluble ﬁbre compared to GS, whose total amount corresponds to 1.8 g/100 mL
soluble (Table 1). In this regard, identical ﬁbre concentrations generated diﬀerent GI, such is the case of
supplements with 1.5 g/100 mL of ﬁbre and with GI = 26 and 17, respectively, in healthy subjects [35,36],
constituted by diﬀerent ﬁbre mixtures based on fructooligosaccharides, inulin, oligofructose, Arabic
gum, soybean polysaccharides and cellulose. Furthermore, it has been reported that soluble ﬁbre can
stimulate appetite-regulating peptides such as GLP-1 and pancreatic peptide YY (PYY) in rodents as
well as in human [69–71]. It is important to note that DI has resistant starch, whereas GS contains
a modiﬁed and resistant maltodextrin linked to soluble ﬁbre [69]. In a study in healthy subjects,
an increase in peptide YY concentrations and GLP-1 was observed alongside a corresponding decrease
in the sensation of hunger and an increased satiety perception after the consumption of tea with 10 g of
this component [69].
Few investigations about OSF-D intake have correlated SA with incretin concentrations as it has
been evaluated in this study. This indicator was quantiﬁed through a score that included variables
such as perception of hunger, desire to eat, prospective consumption of food and fullness [14]. It was
observed in this investigation that plasma insulin, GIP and GLP-1 were related to some of these
parameters but observing a lower SA ratings AUC0–180 min in the ET (Supplementary Materials
Table S4). It is known that appetite regulation is a complex process stimulated by several central and
peripheral signals in response to energy and, mainly, to food composition, where emotional, sensory
and environmental factors can inﬂuence the overall response [71,72].
There is a lack of consensus regarding GI/GL usefulness in predicting appetite and food
intake [12,73,74]. Although GI is not synonymous with glycaemic response, the debate is anchored to
the controversy toward the eﬀect of postprandial glycaemic level and its eﬀects on SA reduction [14,75].
Some authors state that the evidence about these aﬃrmations are not conclusive [73,76], postulating
that postprandial glycaemic and appetite are not related and considering that insulin response [74],
but not the glycaemic response is the real mediator of the short-term appetite reduction, as shown by
Flint et al. [14,76]. Speciﬁcally, Flint et al. has reported that the maximum insulinemic peak after meal
ingestion was related to a decrease in hunger sensation and a satiety increase.
Likewise, in our study, precisely at 30 min and not at the maximum peak, insulin values were
inversely related to the sensation of hunger and the overall of SA rating after ET intake, but not the
perception of fullness (Supplementary Materials Table S1). However, the same behaviour for these
variables was not evident after the consumption of ONS-D. Possibly, this was due to the higher and
faster insulin increase produced by ET at this point of the curve, based on the type and amount of
non-extended release carbohydrates of this ONS, and more than half corresponded to free sugars
(14.1 g/per portion given in this study) (Table 2). Despite this premise, a relationship between glycaemia
concentration and prospective food consumption 30 min after DI intake was found, (Supplementary
Materials Table S2) and a direct relationship between glycaemic levels in 90 min with the sensation
of fullness after the consumption of GS (Supplementary Materials Table S3). The observed feeling of
fullness could be related to another mechanism produced via carbohydrate type and ﬁbre content in GS,
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a supplement that besides sucromalt also has amylase-resistant maltodextrin, in which ﬁbre-viscosity
addition could increase the fullness sensation [69].
It is important to note there was an inverse correlation between GLP-1 levels and prospective
consumption of food 30 min after GS ingestion (Supplementary Materials Table S3). In other
studies [24,77], a relationship between GLP-1 and delayed gastric emptying has been evidenced.
This gastrointestinal response would inﬂuence the feeling of fullness after GS intake at this curve
time. Niwano [12] showed that high GI foods consumption are associated with increased hunger and
short-term satiety reduction in humans, but not over the long-term [74].
It is relevant to highlight the inverse correlation between GIP and GI/GL after ONS-D
ingestion (Supplementary Materials Table S4). This ﬁnding could conﬁrm the theory proposed
by Pfeiﬀer et al. [32] regarding the role of this incretin as an indicator of “carbohydrate metabolic
quality” [32]. On the other hand, we conﬁrmed our hypothesis that ONS-D with slow-digesting
carbohydrates strongly stimulatesGLP-1 releasewith a subsequent decrease inGIP and insulin secretion,
promoting a lower IG/CG index inDM2 subjectswhen comparedwith a standard supplement. Although
ONS-D reduced the AUC0–180 min of subjective appetite, only GS exhibited both a hunger sensation
decreasing eﬀect and an increased fullness perception in some points of the postprandial response.
Finally, these results were also consistent with Peters et al. [78], who evaluated the digestibility of three
carbohydrates on appetite and its relation to blood glucose levels and postprandial insulin, reporting
that glycaemic response had minimal eﬀects on appetite when the products only diﬀered in the rate
and extension of carbohydrate digestibility [78].
The limitations of our research comprised the lack of evaluation of some variables such as gastric
emptying. Although the number of subjects who completed this study was suﬃcient to assess GI/GL
accurately, a higher number of patients is recommended for SA evaluation. On the other hand, one of
the strengths of this study is that the results of these indicators, especially GI/GL, could be the ﬁrst
of their kind in the literature done in diabetic individuals from Latin America. It is also one of the
ﬁrst to combine these variables with subjective appetite and incretin levels. It would be a matter of
interest to extend the curve’s time after consumption in order to evaluate the intake suppression force
to the following meal, along with intervention protocols regarding intestinal microbiota in this type
of individual.
5. Conclusions
The results of this study showed lower values in postprandial subjective appetite ratings and
better metabolic proﬁle after ONS-D intake when compared to standard supplements. A more
attenuated glycaemic and insulinemic response along with a lower GIP release and higher levels
of GLP-1 conﬁrmed the synergistic eﬀect of slow-digesting carbohydrates along MUFA addition.
Isomaltulose and sucromalt may have inﬂuenced these factors. In this study, GI/GL in subjects with
DM2 after ONS-D consumption were lower than the reference food (glucose solution) and the standard
supplement, and lower for GS than DI.
Strategies in food technology, such as intestinal amylase-resistant dextrins along with new
functional ﬁbres, need to be considered in low GI product development in order to obtain adequately
managed metabolic responses of fullness perception after ONS-D consumption. Our study qualiﬁes
two of these supplements as optimal for prescription in people with diabetes when compared with
a standard supplement. However, it is necessary to conduct more investigations allowing to correlate
long-term appetite suppression with the EG/CG of these supplements.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/11/7/1477/s1,
Table S1: Correlation coeﬃcients between biochemical variables and subjective measurements of appetite in
0, 30, 90 and 120 min at standard oral nutritional supplements not speciﬁc for diabetic patients (ET). Table S2:
Correlations coeﬃcients between biochemical variables and subjective measurements of appetite in 0, 30, 90
and 120 min at isomaltulose and resistant starch supplement (DI). Table S3: Correlations coeﬃcients between
biochemical variables and subjective measurements of appetite in 0, 30, 90 and 120 min at resistant maltodextrin
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and sucromalt supplement (GS). Table S4: Correlations coeﬃcients between glycaemic index and glycaemia load
with AUC values of hormones and subjective measurements of appetite.
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ADA American Diabetes Association
BMI Body mass index
DI Isomaltulose and resistant starch supplement
DM2 Diabetes mellitus type 2
ET Standard nutritional supplement not speciﬁc for diabetics
GB Glucose solution or reference food
GI Glycaemic index
GIP Glucose-dependent insulinotropic polypeptide
GL Glycaemic load
GLP-1 Glucagon-like peptide 1
GS Resistant maltodextrin and sucromalt supplement
HbA1c Glycated haemoglobin (HbA1c)
IDF International Diabetes Federation
ONS-D Oral nutritional supplements speciﬁc for diabetics
SEM Standard error of the mean
VAS Visual analogue scale
LGL Low glycaemic load
AUCG Area under the curve glucose
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Abstract: Background: Type 2 diabetes (T2D) has long been identiﬁed as an incurable chronic disease
based on traditional means of treatment. Research now exists that suggests reversal is possible
through other means that have only recently been embraced in the guidelines. This narrative review
examines the evidence for T2D reversal using each of the three methods, including advantages and
limitations for each. Methods: A literature search was performed, and a total of 99 original articles
containing information pertaining to diabetes reversal or remission were included. Results: Evidence
exists that T2D reversal is achievable using bariatric surgery, low-calorie diets (LCD), or carbohydrate
restriction (LC). Bariatric surgery has been recommended for the treatment of T2D since 2016 by
an international diabetes consensus group. Both the American Diabetes Association (ADA) and
the European Association for the Study of Diabetes (EASD) now recommend a LC eating pattern
and support the short-term use of LCD for weight loss. However, only T2D treatment, not reversal,
is discussed in their guidelines. Conclusion: Given the state of evidence for T2D reversal, healthcare
providers need to be educated on reversal options so they can actively engage in counseling patients
who may desire this approach to their disease.
Keywords: diabetes; diabetes reversal; bariatric surgery; very-low-calorie; low-carbohydrate
1. Introduction
According to 2017 International Diabetes Federation (IDF) statistics, there are approximately
425 million people with diabetes worldwide [1]. In the United States, there are an estimated 30.3 million
adults living with diabetes, and its prevalence has been rising rapidly, with at least 1.5 million new
diabetes cases diagnosed each year [2]. Diabetes is a major public health epidemic despite recent
advances in both pharmaceutical and technologic treatment options.
Type 2 diabetes (T2D) has long been identiﬁed as an incurable chronic disease. The best outcome
that has been expected is amelioration of diabetes symptoms or slowing its inevitable progression.
Approximately 50% of T2D patients will need insulin therapywithin ten years of diagnosis [3] Although
in the past diabetes has been called chronic and irreversible, the paradigm is changing [4,5].
The recent 2016 World Health Organization (WHO) global report on diabetes added a section
on diabetes reversal and acknowledged that it can be achieved through weight loss and calorie
restriction [4]. “Diabetes reversal” is a term that has found its way into scientiﬁc articles and the lay
press alike; “remission” has also been used. While the exact criteria are still debated, most agree that a
hemoglobin A1c (HbA1c) under the diabetes threshold of 6.5% for an extended period of time without
the use of glycemic control medications would qualify [6]. Excluding metformin from the glycemic
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control medications list, as it has indications beyond diabetes, may also be a consideration [7,8].
Likewise, terms such as “partial” (HbA1c <6.5 without glycemic control medications for 1 year)
or “complete” (HbA1c <5.7 without glycemic control medications for 1 year) remission have been
deﬁned by an expert panel as more evidence accumulates that points to the possibility of avoiding the
presumably progressive nature of T2D [9]. It is important to note that the term “cure” has not been
applied to T2D, as there does exist the potential for re-occurrence, which has been well documented in
the literature.
Despite the growing evidence that reversal is possible, achieving reversal is not commonly
encouraged by our healthcare system. In fact, reversal is not a goal in diabetes guidelines. Speciﬁc
interventions aimed at reversal all have one thing in common: they are not ﬁrst-line standard of care.
This is important, because there is evidence suggesting that standard of care does not lead to diabetes
reversal. This raises the question of whether standard of care is really the best practice. A large study
by Kaiser Permanente found a diabetes remission rate of 0.23% with standard of care [10]. The status
quo approach will not reverse the health crisis of diabetes.
A signiﬁcant number of studies indicate that diabetes reversal is achievable using bariatric
surgery, while other approaches, such as low-calorie diets (LCD) or carbohydrate restriction (LC),
have also shown eﬀectiveness in an increasing number of studies. This review will examine each of
these approaches, identifying their beneﬁcial eﬀects, supporting evidence, drawbacks, and degree
of sustainability.
2. Materials and Methods
A literature search was performed as appropriate for narrative reviews, including electronic
databases of PubMed, EMBASE, and Google Scholar from 1970 through December 2018. We reviewed
English-language original and review articles found under the subject headings diabetes, bariatric
surgery, metabolic surgery, very low-calorie diet, calorie restriction, low carbohydrate diet, ketogenic
diet, diabetes remission, and diabetes reversal. References of the identiﬁed publications were searched
for more research articles to include in this review. Selected studies were reviewed and evaluated for
eligibility for inclusion in this review based on their relevance for diabetes reversal and remission.
Either remission or reversal needed to be discussed in the paper or the results were consistent with these
terms for inclusion. Randomized clinical trials and intervention-based studies were given emphasis
for inclusion.
A total of 99 original articles containing information pertaining to diabetes reversal or remission
were included in this narrative review.
3. Results and Discussion
3.1. Bariatric Surgery
Bariatric surgery has long been recognized as a potential treatment for both morbid obesity and
the metabolic processes that accompany it, speciﬁcally T2D. While the eﬃcacy of T2D reversal depends
on the choice of procedure, there is unilateral improvement in glycemia following operation [11], and
bariatric surgery has been found to be superior to intensive T2D medical management. Accordingly, in
2016, the second Diabetes Surgery Summit (DSS-II) released recommendations, endorsed by 45 medical
and scientiﬁc societies worldwide, to use bariatric surgery as a treatment for T2D (bariatric surgery is
currently approved by the 2016 recommendations for adults with a body mass index (BMI) >40, or
>35 kg/m2 with obesity-related comorbidities) [12]. Of interest is the consistent ﬁnding that glycemic
improvements occur rapidly, often within hours to days, and precede weight loss, which likely
represents the enteroendocrine responses to altered ﬂow of intestinal contents (i.e., bile acid signaling
and changes in microbiota and their metabolome) [13–19].
The most commonly performed bariatric surgeries in the United States include laparoscopic and
robotic Roux-en-Y Gastric Bypass (RYGB) or Sleeve Gastrectomy (SG). While surgical treatment is
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based on the principles of restriction and intestinal malabsorption, evidence suggests that there are
more complex mechanisms at play. Bariatric surgery has consistently been shown to dramatically and
rapidly improve blood glucose [20] while allowing decreased oral hypoglycemic medications and
insulin use, eﬀectively reversing diabetes in up to 80% of patients [21] in the short term. In addition
to early post-operative improvement in blood glucose and insulin sensitivity, bariatric surgery has
also been shown to cause alterations in GI hormone release, including ghrelin, leptin, cholecystokinin
(CCK), peptide-tyrosine-tyrosine (PYY), and glucagon-like peptide 1 (GLP-1), that may impact feeding
behavior via the gut–brain axis in addition to modulating euglycemia [22]. Furthermore, microbial
changes in the human gut have been linked to obesity, and surgical alterations to gastrointestinal
anatomy have been associated with dramatic changes in gut microbiota populations with reversion
from an “obesogenic” to a lean bacterial population [13,14,16,19,23,24].
Long-term outcomes from bariatric surgery depend on multiple factors, including type of
surgery performed, patient comorbidities, patient readiness for lifelong dietary change, and ongoing
surveillance. While bariatric surgery has been demonstrated to be safe and eﬀective overall, it is
important to recognize that it is not without risks. Each patient must weigh the risks and beneﬁts
associated with untreated morbid obesity versus those associated with surgery or eﬀective dietary
management and choose accordingly. Surgery of any type can be associated with complications
leading to morbidity or mortality; the complication rates have been stated to be as high as 13%
and 21% for SG and RYGB, respectively. The postoperative mortality rate is 0.28–0.34% for SG and
0.35–0.79% for RYGB; in comparison, an elective laparoscopic cholecystectomy is associated with
overall complication rates of 9.29% and with a 30-day mortality rate of 0.15–0.6%, depending on
the series [25,26]. Signiﬁcant complications include anastomotic leak or hemorrhage, post-operative
readmission, need for reoperation, post-operative hypoglycemia, dumping syndrome, worsening acid
reﬂux, marginal ulceration, and micronutrient deﬁciencies [25–29].
It is important to consider that while short-duration studies have shown early resolution of
comorbidities following bariatric procedures, when followed for multiple decades, there may be
decreased eﬃcacy of disease resolution and increased incidence of hospital admission long-term.
Long-term reversal of T2D and true glucose homeostasis remain uncertain. Weight loss after surgery is
a signiﬁcant predictor of a return to euglycemia post-operatively. Multiple studies have reported initial
T2D remission rates as high as 80% [30,31], however, long-term remission is less durable. The ﬁve-year
follow-up outcomes of the SLEEVEPASS RCT found complete or partial remission of T2D in 37% of SG
and 45% of RYGB patients, which is similar to other studies showing long-term T2D remission in up to
a third of patients [32]. In the large prospective cohort study Longitudinal Assessment of Bariatric
Surgery 2 (LABS-2), the investigators found that long-term diabetes remission after RYGB was higher
than predicted by weight loss alone, which suggests that the surgery itself impacts metabolic factors
that contribute to disease management [31]. Similarly, the STAMPEDE trial—an RCT that followed 150
patients with T2D who were randomized to intensive medical intervention (IMT) versus IMT plus
RYGB versus IMT plus SG for diabetes resolution (deﬁned as HbA1c <6.0%) and followed for ﬁve
years—revealed increased rates of T2D resolution with RYGB (29%) and SG (23%) compared to IMT
alone (5%) (Figure 1). The surgery cohort also demonstrated greater weight loss and improvements in
triglycerides, HDL, need for insulin, and overall quality of life [33–35].
Despite the likelihood of improved glycemic control, there are signiﬁcant ﬁnancial costs for the
patient, health system, and insurance companies associated with bariatric surgery (U.S. average of
$14,389) [36]. Despite the high initial cost of surgery, Pories and colleagues found that prior to surgery,
patients spend over $10,000 per year on diabetes medications; after RYGB, the annual cost falls to
less than $2000, which represents an $8000 cost savings at the individual level [30]. Furthermore,
economic analyses show that surgery is likely to be cost-eﬀective, especially in patients who are
obese [37,38]. In a clinical eﬀectiveness review of the literature that included 26 trials extracted from
over 5000 references, Picot et al. found that bariatric surgerywas amore eﬀective intervention forweight
loss than non-surgical options; however, there was extreme heterogeneity and questionable long-term
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adherence to the non-surgical interventions [39]. After surgery, metabolic syndrome improved, and
there were higher rates of T2D remission compared to the non-surgical groups [39]. Further, while
there were improvements in comorbidities after surgery independent of bariatric procedure, there
was also an increased likelihood of adverse events. While the overall event rate remained low, major
adverse events included medication intolerance, need for reoperation, infection, anastomotic leakage,
and venous and thromboembolic events [39].
It is imperative to consider that one of the requirements of qualifying for bariatric surgery is
demonstration of at least sixmonths of unsuccessful attempts atweight loss using traditional dietary and
exercise advice according to the 2016 Recommendations [12]. There are, however, no requirements as
to what weight loss strategy is employed, which may represent a time point where dietary intervention,
including low-calorie, ketogenic, or carbohydrate-restricted diets, should be utilized. At least two
recent clinical trials have demonstrated safety and eﬃcacy in pre-operative very low-carbohydrate
ketogenic diets before bariatric surgery for increasing weight loss and decreasing liver volume [40,41].
Furthermore, despite technically adequate surgery, an alarming number of patients may still
experience weight regain and/or recurrence of comorbid obesity-associated conditions. In these
patients, eﬀective strategies for dietary intervention are even more important. Approximately 10–15%
of patients fail to lose adequate weight (failure deﬁned as <50% of excess weight) or demonstrate
signiﬁcant weight regain after bariatric surgerywithout evidence of an anatomic or technical reason [42].
Additionally, in 25–35% of patients who undergo surgery, signiﬁcant weight regain (deﬁned as >15%
of initial weight loss) occurs within two to ﬁve years post-operatively [43]. These patients often
require further medical management with weight loss medications, further dietary and behavioral
intervention, and, for some, reoperation. Reoperation can be for either revision for further weight
loss (narrowing of the gastric sleeve, conversion of VSG to RYGB, and increasing the length of the
roux limb) or reversal of RYGB due to health concerns, most commonly associated with malnutrition.
A small cohort of patients (4%) may experience severe weight loss with signiﬁcant malnutrition leading
to hospitalization in over 50%, mortality rates of 18%, and need for reversal of RYGB anatomy. While
the incidence of RYGB reversal is unknown, based upon a systematic review that included 100 patients
spanning 1985–2015, the rate of reversal parallels the increasing rate of bariatric surgery [44].
In the short term, T2D reversal rates with surgery have been reported to be as high as 80%, with
an additional 15% demonstrating partial improvement in T2D despite still requiring medication [17].
Within one week after RYGB, patients experience improved fasting hepatic insulin clearance, reduced
basal de novo glucose production, and increased hepatic insulin sensitivity; by three months and one
year after surgery, patients have improved beta-cell sensitivity to glucose, increased GLP-1 secretion
from the gut, and improved insulin sensitivity in muscle and fat cells [45]. Over time, T2D remission
rates remain high but do decline; Purnell and colleagues reported three-year remission rates of 68.7%
after RYGB [29]. However, Pories published results from a 14-year prospective study with mean
follow-up of 7.6 years, and found 10-year remission rates remained around 83% [46]. In a 10-year
follow-up study of participants from the Swedish Obese Subjects (SOS) study that prospectively
followed patients who underwent bariatric surgery, the authors reported a 72% (n = 342) and 36%
(n = 118) recovery rate from T2D for RYGB at two years and 10 years, respectively [47].
The long-term metabolic impact and risk reduction from surgery remain high in a substantial
number of patients and this route to reversal clearly has the most robust data to support its use.
As evidenced by the dramatic improvements in metabolic state that precede weight loss, bariatric
surgery is far more than merely a restrictive and/or malabsorptive procedure. Large shifts in bile
acid signaling in the lumen of the small intestine, gut nutrient sensing, and changes in the microbiota
community appear to greatly impact overall host health. Further research is ongoing using both
basic and translational science models to identify the role of these various hormones and metabolites;
perhaps there will be a way to one day harness the beneﬁcial eﬀects of bariatric surgery without the
need for anatomic rearrangement.
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3.2. Low-Calorie Diets (LCD)
As diabetes rates have risen to unprecedented levels [1,2], the number of studies examining
diabetes reversal using non-surgical techniques has increased. A handful of studies have reported
successful weight loss with decreased insulin resistance, plasma glucose, and medication use following
a LCD. As early as 1976, Bistrian et al. [48] reported that a very low-calorie protein-sparing modiﬁed
fast allowed for insulin elimination in all seven obese patients with T2D. The average time to insulin
discontinuation was only 6.5 days, and the longest was 19 days. In a study by Bauman et al.,
a low-calorie diet of 900 kcal, including 115 g of protein, led to signiﬁcant improvement in glycemic
control that was mainly attributed to improvements in insulin sensitivity [49]. Furthermore, a study
conducted in obese T2D patients found that a LCD and gastric bypass surgery were equally eﬀective in
achieving weight loss and improving glucose and HbA1c levels in the short term [50]. Weight loss,
however, persisted in the diet-treated patients only for the ﬁrst three months, indicating diﬃculty with
long-term maintenance [47]. Similarly, other studies also reported similar pattern of early blood glucose
normalization without medication use, but the improvements were not sustained long-term [51–53].
Likewise, the study by Wing et al., even though reported signiﬁcant and greater improvements of
HbA1c at 1 year in the intermittently delivered very low-calorie diet, the HbA1c improvement was
not signiﬁcantly diﬀerent than what was reported in the patients receiving low-calorie diet (LCD)
throughout the one year period [54]. Furthermore, the glycemic improvements observed at 1 year
were not maintained through 2-years, even though the group with intermittent very low-calorie diet
had less medication requirement than the group in the LCD arm at 2 years [54]. Lastly, micronutrient
deﬁciencies with the use of calorie restricted diets has been shown and supplementation andmonitoring
for deﬁciencies is a consideration with their use [55,56].
While these previous studies were not assessing diabetes remission or reversal rate per se, they
demonstrated the eﬀectiveness of calorie restriction in achieving weight loss and improved glycemic
control, which are the core goals of reversal. In 2003, the Look AHEAD trial randomized 5145
overweight or obese patients with T2D to an intervention group that received either an intensive
lifestyle intervention (ILI) including calorie restriction and increased physical activity or to a control
group that included diabetes support and education (DSE) [57]. Post hoc analysis of this study revealed
that at one year, 11.5% of the participants in the ILI group achieved remission (partial or complete);
however, remission rates subsequently decreased over time (9.2% at year two and 7.3% at year four).
Nevertheless, the remission rates achieved through ILI were three to six times higher than those
achieved in the DSE group. Lower baseline HbA1c, greater level of weight loss, shorter duration of T2D
diagnosis, and lack of insulin use at baseline predicted higher remission rate in ILI participants [58].
Following the Look AHEAD study, other studies have evaluated a LCD for diabetes
remission [59–61]. Most of these studies assessed remission over a short period of time in a small
study sample. Bhatt et al. reported that six of the 12 individuals achieved partial remission at the
end of the three-month intervention [61]. Ades et al. studied an intensive lifestyle program including
calorie restriction and exercise, and reported that eight of the 10 individuals with recently diagnosed
T2D achieved partial remission at six months, including one with complete remission [60]. The study
ended at six months, therefore long term sustainability was not assessed. Another study assessing a
one-year diabetes remission retrospectively among those undergoing 12 weeks of the intensive weight
loss program “Why Wait” had a much lower remission rate of 4.5%, with 2.3% of them achieving
partial remission, while another 2.3% had complete remission [59]. This study suggests that long-term
maintenance of remission is a challenge. Moreover, diabetes remission was more likely reported in
those who had a shorter diabetes duration, lower baseline HbA1c, and were taking fewer hypoglycemic
medications [59,61].
An initial 2011 diabetes reversal study by Taylor and colleagues showed that a very low-calorie
diet of 600 Kcal/day not only normalized glucose, HbA1c, and hepatic insulin sensitivity levels within a
week, but also led to decreased hepatic and pancreatic triacylglycerol content and normalization of the
insulin response within eight weeks [62]. At 12 weeks post-intervention, many of the improvements
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were maintained, but over a quarter of the patients had an early recurrence of diabetes. Further,
average weight regain during the 12 weeks post-intervention was 20% [62]. As a follow-up to the 2011
study, the same group performed a larger and longer study with eight weeks of a very low-calorie
meal replacement (624–700 kcal/day) followed by two weeks of solid food replacement and a weight
maintenance program of up to six months [63]. In this study, those who achieved a fasting blood
glucose of <7 mmol/L (<126 mg/dL) were categorized as responders, while others were categorized
as non-responders. At six months, 40% of participants who initially responded to the intervention
were still in T2D remission which was deﬁned by achieving a fasting plasma glucose of <7mmol/L; the
majority of those who remitted (60%) had a shorter diabetes duration (<4 years) [63].
These short-term studies were the foundation for a community-based cluster-randomized clinical
trial called DiRECT (Diabetes Remission Clinical Trial). DiRECT enrolled a sample of 306 relatively
healthy participants with T2D (people on insulin or with a diabetes duration longer than six years
were excluded) [64] (Figure 1). They were cluster randomized to either standard diabetes care or
an intervention using low-calorie meal replacement diet (825–853 kcal/day) for three to ﬁve months,
followed by stepwise food re-introduction and a long-term weight maintenance program. At one-year
follow-up, 46% of patients met the study criteria of diabetes remission (HbA1c <6.5% without
antiglycemic medications) [64] and at two years the remission rate was 36% [65]. The DiRECT study
has extended their follow-up an additional three years to assess the long-term impact on remission.
Taken together, evidence suggests that a LCD is eﬀective in reversing diabetes in the short term
up to two years, and its eﬀectiveness was predominantly demonstrated in those with shorter duration
since diabetes diagnosis. It is important to note that a substantial level of calorie restriction is needed to
generate a suﬃcient level of weight loss for reversing diabetes. Short-term intervention with moderate
energy restriction and metformin for modest weight loss was not as eﬀective in reversing diabetes as
compared to standard diabetes care [66]. Lifestyle intervention with severe energy restriction may
have some deleterious eﬀect on the body composition and physiology, which poses a concern for
long-term health [67]. Furthermore, long-term achievement of diabetes remission, adherence to the
diet, and weight loss maintenance after the diet remain a challenge. Studies have also suggested
that physiological and metabolic adaptation of the body in response to caloric restriction may shift
energy balance and hormonal regulation of weight toward weight regain after weight loss [67,68].
Thus, it is crucial that future studies are directed towards assessing the long-term sustainability of
diabetes remission led by LCD and feasibility of this diet on the physiological adaptation and body
composition changes.
3.3. Carbohydrate-Restricted Diets (LC)
Before the discovery of insulin in 1921, low carbohydrate (LC) diets were the most frequently
prescribed treatment for diabetes [69,70]. The paradigm shifted both with the development of
exogenous insulin and later with the emergence of the low-fat diet paradigm. A diet low in fat, which
by default is high in carbohydrate, became the standard recommendation in guidelines around the
globe [71]. Rather than preventing elevations in glucose, the goal became maintenance of blood sugar
control via the increased use of glycemic control medications, including insulin [72]. Over the last
decade, clinical studies have begun to resurrect the pre-insulin LC dietary approach. In response
to the new evidence on the eﬃcacy of carbohydrate restriction, low-carbohydrate has recently been
endorsed as an eating pattern by the ADA and the European Association for the Study of Diabetes
(EASD) [5,73]. In addition, the Veterans Aﬀairs/Department of Defense (VA/DOD) guidelines now
recommend carbohydrate restriction as low as 14% of energy intake in its most recent guidelines for
treatment of diabetes (VA) [74].
LC diets are based on macronutrient changes rather than a focus on calorie restriction [75].
Although the exact deﬁnition varies, a low-carbohydrate diet usually restricts total carbohydrates to
less than 130 grams per day, while a very low-carbohydrate or ketogenic diet usually restricts total
carbohydrates to as low as 20–30 grams per day. Protein consumption is generally unchanged from a
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standard ADA diet (around 20% of intake), with the remaining energy needs met by fat from either the
diet or mobilized body fat stores. Carbohydrate sources are primarily non-starchy vegetables with
some nuts, dairy, and limited fruit [75].
A total of 32 separate trials examining carbohydrate restriction as a treatment for T2D were
found when our search was performed [76–108]. However, for reasons that may include varied
levels of carbohydrate restriction and diﬀering levels of support given, not all studies had results
that would be consistent with diabetes reversal. A number of shorter-term trials have found a
signiﬁcant between-group advantage of a low-carbohydrate intervention for T2D [80,84,92,97]. Data
from longer-term trials are limited, and in some follow-up studies, the between-group advantage
seen initially was lost or reduced, although it often remains signiﬁcantly improved from baseline.
This raises the question of long-term sustainability using this approach. Due to heterogeneity in
methodology and deﬁnition of carbohydrate restriction, the ability to fully examine T2D reversal based
on the existing studies is limited. Based upon a recent systematic review of LC, it appears that the
greatest improvements in glycemic control and greatest medication reductions have been associated
with the lowest carbohydrate intake [109]. In consideration of these limitations, it appears important to
assess the level of carbohydrate restriction, support or other methods given to encourage sustainability,
and length of follow-up.
A study comparing an ad libitum very low-carbohydrate (<20 g total) diet to an energy-restricted
low-glycemic diet in T2D found greater reduction in HbA1c, weight, and insulin levels in the
low-carbohydrate arm [89]. Additionally, 95% of participants in the low-carbohydrate arm reduced or
eliminated glycemic control medications, compared to 62% in the low glycemic index arm at 24 weeks.
Instruction was given in a one-time session with a dietician and included take-home materials for
reference. A slightly longer study (34 weeks) trial [85] found that a very low-carbohydrate ketogenic
diet intervention (20–50 g net carbs per day) resulted in HbA1c below the threshold for diabetes in 55%
of the patients, compared to 0% of patients in the low-fat arm. The education sessions were all online
and included behavior modiﬁcation strategies and mindful eating which was aimed to address binge
eating. New lessons were emailed to the patients weekly for the ﬁrst 16 weeks and then every two
weeks for the remainder of the study.
A small (34 participants) one-year study of an ad libitum, very low-carbohydrate diet compared
to a calorie-restricted moderate carbohydrate diet found a signiﬁcant reduction in HbA1c between
groups favoring the low-carbohydrate arm [86]. At one year, 78% of participants who began the trial
with a HbA1c above 6.5% no longer met the cutoﬀ for the diagnosis of diabetes, no longer required any
non-metformin medication, and signiﬁcantly reduced or eliminated metformin. Total kilocalorie intake
was not signiﬁcantly diﬀerent between the two groups, even with moderate carbohydrate restriction.
Despite equal energy intake, the low carbohydrate group lost signiﬁcantly more weight and had
improved glycemic control, which indicates a potential mechanistic role for carbohydrate restriction
itself. The support given was 19 classes over the 12-month period, tapering in frequency over time.
Another one-year trial [76] found signiﬁcant HbA1c reduction in the subset of patients with
diabetes (n = 54) assigned to an ad libitum low-carbohydrate diet (<30 total grams per day), compared
to an energy-restricted low-fat diet. These results remained signiﬁcant after adjusting the model for
weight loss, indicating an eﬀect of the carbohydrate reduction itself. The support given was four
weekly sessions during the ﬁrst month, followed by monthly sessions for the remaining 11 months.
A metabolic ward study on 10 patients with T2D [96] found that 24-h glucose curves normalized
within two weeks on a very low-carbohydrate diet (<21 g total per day). This was in addition to
medication reduction and elimination including insulin and sulfonylureas After accounting for body
water changes, the average weight loss during the two-week period was 1.65 kg (average of <2% total
body weight which is similar to the results of bariatric surgery, where normoglycemia is seen prior to
signiﬁcant weight loss. Interestingly, despite the diet being ad libitum other than the carbohydrate
limit, the average energy intake decreased by 1000 kcal per day. Assuming no further change in
glycemic control, HbA1c would be 5.6% after eight weeks, which would represent a reduction of 23%
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from baseline. The fact that HbA1c reductions were greater than in other, longer-term outpatient
studies may indicate that support of dietary changes is the key to longer-term success.
In our published trial providing signiﬁcant support through the use of a continuous care
intervention (CCI), we examined using a low-carbohydrate diet aimed at inducing nutritional ketosis
in patients with T2D (n = 262), compared with usual care T2D patients (n = 87) [98] (Figure 1). At one
year, the HbA1c decreased by 1.3% in the CCI, with 60% of completers achieving a HbA1c below 6.5%
without hypoglycemic medication (not including metformin). Overall, medications were signiﬁcantly
reduced, including complete elimination of sulfonylureas and reduction or elimination of insulin
therapy in 94% of users. Most cardiovascular risk factors showed signiﬁcant improvement [110].
The one-year retention rate was 83%, which indicates that a non-calorie-restricted, low-carbohydrate
intervention can be sustained. Improvements were not observed in the usual care patients. The newly
released two-year results of this trial [106] show sustained improvements in normoglycemia, with 54%
of completers maintaining HbA1c below 6.5% without medication or only on metformin. The retention
rate at two years was 74%, further supporting the sustainability of this dietary intervention for diabetes
reversal. Weight loss of 10% was seen at 2-years despite no intentional caloric restriction instruction.
Additionally, this trial involved participants with a much longer duration of diabetes (8.4 years
on average) than other nutrition trial interventions [58,64,65] and did not exclude anyone taking
exogenous insulin. As duration of T2D and insulin use have both been identiﬁed to be negative factors
in predicting remission after bariatric surgery [111,112], the 2-year results of this trial may be even
more signiﬁcant.
It is interesting to note that most studies utilize ad libitum intake in the carbohydrate-restricted
arm. Despite this, in studies that have tracked energy intake, spontaneous calorie restriction has
occurred [113,114]. Inmany trialswhere energy intake has beenprescribed orweight loss has been equal,
an advantage has been seen in glycemic control, weight, or both in the low-carbohydrate arm [86,91,107].
A better understanding of the role that caloric intake, whether prescribed or spontaneous, plays in the
overall success is important. In cases of spontaneous energy intake reduction, elucidating the speciﬁc
mechanism behind this reduction would help in the overall personalization of this approach.
Multiple studies have evaluated side eﬀects or potential complications of carbohydrate restriction.
The diet has been found to be safe and well tolerated although long term hard outcome data is lacking
and should be a focus of future research. A transient rise in uric acid early in very low-carbohydrate
restriction without an associated increase in gout or kidney stones has been documented [84,98,100].
Blood urea nitrogen (BUN) has been found to increase and decrease in diﬀerent studies without an
associated change in kidney function [87,98,100,115,116]. Recently, bone mineral density has been
found to be unchanged despite signiﬁcant weight loss after two years of a ketogenic diet intervention
in patients with T2D [108]. While most studies show an improvement or no change in LDL-C levels
in patients with T2D on a low-carbohydrate diet, there have been two studies that have found an
increase in LDL-C in participants with T2D [99,111]. In one of the studies that found an increase
in calculated LDL-C, a non-signiﬁcant reduction in measured ApoB lipoproteins and unchanged
non-HDL cholesterol were seen. Monitoring LDL-C or a measured value of potentially atherogenic
lipoproteins such as ApoB should be considered. Lastly, micronutrient deﬁciency has been seen with a
carbohydrate restricted diet, supplementation and monitoring should be given consideration with this
intervention [56].
Although the use of very low-carbohydrate diets for diabetes reversal shows promising results,
the lack of longer-term follow-up studies remains a limitation. Follow up is limited to two years, and
therefore longer-term studies are needed to determine the sustainability of the metabolic improvements.
Determining the appropriatemethod of supportmay be a key to the overall successwith disease reversal.
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Figure 1. (A) Mean changes of hemoglobin A1c (HbA1c) from baseline to last published date for each
study retrieved to represent the three methods of reversal; (B) mean changes of weight from baseline to
last published date for each studies retrieved to represent the three methods of reversal. Note: We
chose these three studies to represent the three methods of reversal based on publication date and
relevance to diabetes reversal. Note that baseline characteristics diﬀer. Surgery trial examined by
sleeve gastrectomy and Roux-en-Y gastric bypass separately and were represented as sleeve and bypass
in the graph. Surgery: STAMPEDE [34,35]. Low-calorie diets (LCD): DIRECT [65,66]; carbohydrate
restriction (LC): IUH [99,107].
4. Summary
Additional evidence has become available in recent years suggesting that diabetes reversal is a
possible alternative to consider in place of traditional diabetes treatment and management. In this
paper, we provide a review of three methods that have been shown to successfully reverse type 2
diabetes. The current body of evidence suggests that bariatric surgery is the most eﬀective method for
overall eﬃcacy and prolonged remission, even though concerns associated with surgical complications,
treatment cost and complete lifestyle modiﬁcation after surgery remain challenges for wide adoption
of this approach. While both the LCD and LC dietary approaches are convincing for reversing diabetes
in the short term (up to two years), long term maintenance of diabetes remission is still unproven.
There are limited available data supporting long term maintenance of weight loss and its associated
glycemic improvements in response to LCD; similarly, long-term adherence to a low carbohydrate
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diet will likely remain an obstacle without the development of proper patient education and optimal
support for long-term behavioral change. Moreover, research in understanding the mechanism of
diabetes reversibility in all three approaches and its overlapping mechanistic pathways are lacking;
this is an area for future research emphasis.
There are similar identiﬁed negative predictors of remission for all three approaches. These factors
include longer diabetes duration and increased severity, lower BMI, advanced age, poor glycemic
control, and low C-peptide levels (indicating decreased endogenous insulin production) [117]. Further
exploration into the heterogeneity of these factors will help personalize the approach, determine
realistic goals for each patient, and should be considered during treatment discussions. Ongoing
research into algorithm development will be helpful in this regard.
5. Conclusions
Overall, as a society we can no longer aﬀord or tolerate the continued rising rates of diabetes.
Despite many barriers within the healthcare system as a whole, providers are responsible on a daily
basis for the lives of patients caught up in this unprecedented epidemic. The current standard of care
may be suitable for some, but others would surely choose reversal if they understood there was a
choice. The choice can only be oﬀered if providers are not only aware that reversal is possible but have
the education needed to review these options in a patient-centric discussion.
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Abstract: This study sought to evaluate the associations between changes in glycemic status
and changes in total body (TB), trunk, and appendicular fat (FM) and lean mass (LM) in men.
A population-based study of men aged 20–66 years at baseline were included in cross-sectional
(n = 430) and three-year longitudinal (n = 411) analyses. Prediabetes was deﬁned as fasting
glucose 100–125 mg/dL. Type 2 diabetes (T2D) was determined by: self-reported diabetes,
current anti-diabetic drug use (insulin/oral hypoglycemic agents), fasting glucose (≥126 mg/dL),
or non-fasting glucose (≥200 mg/dL). Body composition was evaluated by dual-energy X-ray
absorptiometry. Longitudinal analyses showed that changes in TB FM and LM, and appendicular
LM differed among glycemic groups. Normoglycemic men who converted to prediabetes lost more
TB and appendicular LM than men who remained normoglycemic (all, p < 0.05). Normoglycemic or
prediabetic men who developed T2D had a greater loss of TB and appendicular LM than men who
remained normoglycemic (both, p < 0.05). T2D men had greater gains in TB FM and greater losses
in TB and appendicular LM than men who remained normoglycemic (all, p < 0.05). Dysglycemia is
associated with adverse changes in TB and appendicular LM.
Keywords: prediabetes; type 2 diabetes; total body fat; total body lean; appendicular fat; appendicular
lean; body composition; cohort study
1. Introduction
Prediabetes and type 2 diabetes (T2D) are major public health issues in the United States.
The national prevalence of prediabetes and T2D among adults aged ≥20 years has increased over time,
with the prevalence of prediabetes rising from 26% in 1988–1994 [1] to 37% in 2009–2012 [2]. Recent
estimates from the Centers for Disease Control and Prevention indicate that 15–30% of prediabetic
cases progress from impaired fasting glucose or impaired glucose tolerance to T2D within ﬁve years.
There are currently 25.8 million adults in the United States with prediabetes that will develop T2D by
2020, which will double the number of individuals affected by T2D [3]. The prevalence of T2D rose
from 7% in 2005 to 12% in 2011 [4], and is projected to increase 165% by 2050 [5].
Case-control and cross-sectional studies have reported inconsistent associations of total body
(TB), trunk, and appendicular fat mass (FM) and lean mass (LM) with prediabetes and T2D diabetes in
middle-aged and older adults, including a positive association [6], an inverse association [7–10], and
no association [6,8,9]. Prospective studies aimed at investigating the relationship between baseline
glycemic status and subsequent changes in TB and regional distribution of FM and LM are sparse and
inconclusive. Some studies reported differences in body composition measurements among glycemic
groups [11–14], but others did not ﬁnd differences [15,16]. The possible explanation for inconsistent
Nutrients 2018, 10, 1878; doi:10.3390/nu10121878 www.mdpi.com/journal/nutrients65
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ﬁndings includes different durations of follow-up period, sample size, and other covariates that were
not adjusted for when investigating the association between various measures of body composition
and glycemic status. We found no epidemiological studies that investigated the association between
glycemic status (men with prediabetes who revert to normoglycemia, or men who are normoglycemic
or prediabetic at baseline and convert to T2D) and changes in the TB and regional distribution of FM
and LM.
The objective of the present analysis was to examine the associations between baseline and
changes in glycemic status with baseline and changes over three years in TB, trunk, and appendicular
FM and LM. The following a priori hypotheses were tested: (1) men with prediabetes or T2D at baseline
would have higher TB and trunk fat measurements but lower appendicular fat than normoglycemic
men; (2) men who were normoglycemic at baseline and developed either prediabetes or T2D would
have increases in TB and trunk FM, and decreases in TB and appendicular LM over the three-year
study compared with men who remained normoglycemic; (3) among men with prediabetes at baseline,
the changes in TB and trunk FM and LM would differ over the three-year study depending on whether
they remained prediabetic or developed T2D versus reverting to a normoglycemic state. Those who
develop T2D would gain TB FM and lose LM, while those reverting to normoglycemia would lose FM
and maintain or gain LM; and (4) men with T2D at baseline would have decreases in TB and trunk LM
over the three-year study compared to normoglycemic men.
2. Materials and Methods
2.1. Study Population
The South Dakota Rural Bone Health Study is a population-based longitudinal study designed to
investigate the impact of lifestyle factors on bone and body composition. The design and rationale of
the study have been described elsewhere [17]. Brieﬂy, adults aged 20 to 66 years, from eight counties
in eastern South Dakota, were eligible for enrollment. A total of 1271 participants were recruited
between 2001–2004 (baseline), and followed for an average of 3.0 years (range of 2.8 to 3.8 years),
and the current analysis was limited to men (n = 544). Among those participants, 410 men farmed
at least 75% of their lives (rural) and 134 men never lived on an active farm (non-rural). The rural
population was divided into Hutterites and non-Hutterites. A Hutterite was deﬁned as a participant of
Hutterite descent who resided on a Hutterite colony. Hutterites are an Anabaptist religious group who
believe in isolated communal living and self-sufﬁciency through an agriculturally advanced lifestyle.
Non-Hutterites were randomly selected from the eight-county region as described elsewhere [17].
Men with chronic use (> six months) of immunosuppressants, anticonvulsants, or steroids or a
diagnosis of type 1 diabetes mellitus at baseline were not eligible for inclusion in the original cohort.
For baseline analyses, we excluded men with missing glucose measures at either baseline (n = 12) or
follow-up (n = 34), baseline body composition measurements (n = 23), or men who withdrew from the
study (n = 45) (Figure 1). For follow-up analyses, we further excluded men who did not have body
composition measurements at follow-up (n = 19). These exclusions led to 430 men in the baseline
analyses and 411 in the follow-up analyses. The study was approved by the South Dakota State
University Institutional Review Board (IRB#1406004), and informed consent was obtained from all of
the participants.
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Figure 1. Flowchart of participants. Abbreviations: DXA, dual-energy X-ray absorptiometry; T2D, type
2 diabetic. Individuals who were unable to be categorized into glycemic groups were excluded.
2.2. Assessment of Covariates
Questionnaires were administered at study enrollment and at three years to obtain information
on demographic and lifestyle characteristics as well as quarterly physical activity and dietary intake
recalls. Information on smoking status and speciﬁc details regarding the use of prescription drugs
was not collected at baseline; however, an 18-month survey was used to obtain this information.
Participants were asked to provide information on types of smoking, such as cigarettes, cigars, and
pipes, and were classiﬁed as smokers or non-smokers. The presence or absence of hypertension at 18
months was based on self-reported information on the use of antihypertensive medication.
2.2.1. Anthropometric Measures
Body height and weight were measured in lightweight clothes without shoes using a calibrated
stadiometer and scale. Standing height was measured to the nearest 0.5 cm in duplicate with a
stadiometer (Seca, Chino, CA, USA). A third measurement was taken if the discrepancy between the
duplicate height measurements was more than 0.5 cm. Weight was measured to the nearest 0.1 kg with
a digital scale (Seca Model 770, Chino, CA, USA).
2.2.2. Physical Activity Assessment
The Paffenbarger Physical Activity Questionnaire (PPAQ) was used to measure the average
amount of time spent in sedentary behaviors and different intensity levels of physical activity during
the past week [18]. Participants were asked to recall how many hours on their usual weekday and
weekend day they spent sleeping, sitting, and engaging inmoderate or vigorous intensity activity. Since
the time spent in sleeping, sitting, and participating in moderate plus vigorous activity was measured,
the remaining time was considered light activity. The PPAQ was administered quarterly over the
ﬁrst three years of the study. To properly report participants’ physical activity, trained personnel
administered the PPAQ by interview. The average time spent in sitting and moderate-plus-vigorous
activity, as well as the average sleeping time, was calculated. The validity and reliability of the PPAQ
have been established to measure physical activity intensities in men [19] and rural populations [20].
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2.2.3. Dietary Assessment
Dietary intake was assessed using 24-h dietary recalls that were conducted at similar times as the
activity recall. Trained interviewers administered 24-h dietary recalls, and dietary recall data were
analyzed using Nutritionist Pro software (version 2.3.1, 2004, First DataBank, Inc., San Bruno, CA,
USA) to estimate macronutrient and micronutrient intakes. For foods not available in the Nutritionist
Pro software, the nutrient composition of the foods was obtained from recipes and entered into the diet
analysis software. Activity levels and nutrient intakes at baseline were the averages of the baseline,
three-month and six-month recalls, and measures at the 36-month visit were the averages of the
30-month, 33-month, and 36-month recalls.
2.3. Ascertainment of Glycemic Status
According to American Diabetes Association classiﬁcations, individuals with a fasting blood
glucose of 100 mg/dL to 125 mg/dL were classiﬁed as having prediabetes [21]. T2D was determined
by one of the following criteria: self-reported T2D, current use of an anti-diabetic drug (insulin or oral
hypoglycemic agents), or a fasting blood glucose concentration ≥126 mg/dL or a non-fasting blood
glucose concentration ≥200 mg/dL [21]. The same criteria for the diagnosis of prediabetes and T2D
were applied at both the baseline and three-year visits. Attempts were made to obtain fasting blood
samples at each visit, and measurements were made in the ﬁeld from a sample of venous whole blood
(with added ethylenediaminetetraacetic acid) using an Accu-Check Advantage glucometer (Roche
Diagnostics, Indianapolis, IN, USA).
2.4. Body Composition Measurements
Body composition was assessed using dual-energy x-ray absorptiometry (DXA) (Discovery,
Software Version 12.01, Hologic, Waltham, MA, USA). A TB scan was completed with boundaries
for the various anatomical regions set according to manufacturer’s speciﬁcations. The step phantom
scan for body composition calibration was completed weekly as suggested by the manufacturer.
Prior to DXA measurements, the Hologic spine phantom was scanned for quality control. All of the
scans were analyzed by the same technician who was certiﬁed by the International Society of Clinical
Densitometry. Scan results were deleted for obese participants with an equivalent epoxy thickness
greater than 12 inches, as determined by the Hologic software, per manufacturer recommendations
(n = 16 men: n = seven Hutterite, n = four rural, n = ﬁve non-rural). DXA-derived measurements of
TB, trunk and appendicular FM and LM were expressed in kilograms. Our coefﬁcients of variation for
TB FM and LM assessed in 15 adults (one male) using triplicate scans with repositioning between each
scan are <1.5%.
2.5. Statistical Analysis
All of the continuous variables were tested for normality before performing the analyses. Analysis
of variance adjusting for multiple comparisons for continuous variables and a Fisher’s exact test for
categorical variables were used to determine statistical signiﬁcance in baseline characteristics among
the glycemic categories. The annual absolute change in each body composition measure was calculated
as the follow-up value minus baseline value divided by length of follow-up in years.
Multiple regression models were used to estimate marginal means ± standard error of the mean
(sem) for baseline body composition parameters and changes in outcome measures by different
categories of glycemic status. Differences in marginal means among glycemic groups were evaluated
using post hoc contrast tests based on the hypotheses. A priori determined covariates (age at baseline,
height, population group, percent time in moderate-plus-vigorous activity, and total daily caloric
intake) were included in all of the models, since they were found to be associated with at least one
body composition measure. The multiple regression models that were used for baseline analyses
included these covariates, and the FM model included the LM of the same compartment (TB, trunk,
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or appendicular), and the LM model included covariates plus the FM of the same compartment.
Multiple regression models for the longitudinal analyses were adjusted for the same covariates, as
well as changes in percent time in moderate-plus-vigorous activity and total daily caloric intake
between baseline and three-year follow-up, baseline measure of the speciﬁc body compartment (TB,
trunk, or appendicular), and baseline and annual changes in the FM or LM of same compartment.
Due to issues with multicollinearity and the problem of body composition measures being components
of both body mass index (BMI) and weight, neither BMI nor weight was included as covariates.
The assumptions of linearity, normality, and homoscedasticity were evaluated visually to ensure no
violation of assumptions. All of the analyses were performed using JMP software (version 13, SAS
Institute, Cary, NC, USA), and the statistical signiﬁcance level was set at p < 0.05 (two-tailed).
3. Results
3.1. Subject Characteristics
At the baseline visit, 358 (83.2%) of the men were normoglycemic, 51 (11.9%) were prediabetic
based on fasting glucose concentrations, and 21 (4.9%) had T2D (14 self-reported a medical diagnosis,
six based on fasting glucose, and one based on non-fasting glucose). Of the 345 men who were
normoglycemic at baseline and for whom glucose and body composition measurements were available
at three years, 272 (78.9%) remained normoglycemic, 65 (18.8%) progressed to prediabetes, and
eight (2.3%) progressed to T2D (ﬁve based on fasting glucose, one based on non-fasting glucose,
one self-reported a medical diagnosis, and one taking anti-diabetic medication). Among the 48
prediabetic men, 19 (39.6%) remained prediabetic, 25 (52.1%) reverted to normoglycemic, and four
(8.3%) progressed to T2D based on fasting glucose concentrations. Of the 18 T2D men who were
diabetic throughout the study, four (22.2%) self-reported a medical diagnosis, 11 (61.1%) were taking
anti-diabetic medication, and three (16.7%) had T2D based on fasting glucose concentrations.
Participant characteristics by glycemic categories at baseline and follow-up are summarized
in Tables 1 and 2. The mean age (+ sem) was 42.7 ± 0.6 years (range: 20 to 66 years), and men
with T2D at baseline were older than those who were normoglycemic. The study population was
37.4% Hutterite, 37.2% rural non-Hutterite, and 25.4% non-rural. Hutterites and married men had a
higher prevalence of prediabetes and T2D than non-Hutterites and single men. Men with prediabetes
weighed more than normoglycemic men. A higher percentage of prediabetic and T2D men were
taking antihypertensive medication than normoglycemic men, and carbohydrate intake was greater in
normoglycemic men than in prediabetic and T2D men. At follow-up, men with T2D had lower caloric
and carbohydrate intake than men who remained normoglycemic throughout the study or men who
were normoglycemic and developed prediabetes (Table 2). Prediabetic men who remained prediabetic
at three years increased their carbohydrate intake, and men who remained normoglycemic throughout
the study increased their weight, time spent in moderate-plus-vigorous activity, and average daily fat
intake. The overall mean changes over the three-year study in percent time in moderate-plus-vigorous
activity and average dietary intake of calories, carbohydrates, fat, and protein were not signiﬁcant
(mean changes were 0.6 ± 0.4%, 10 ± 28 kcal, 1.0 ± 3.8 g, 3.0 ± 1.6 g, and 0.0 ± 1.5 g, respectively), and
changes in caloric and macronutrient intakes did not differ by glycemic categories (data not shown).
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3.2. Cross-Sectional Assessment of Baseline Body Composition in Men with Prediabetes or Type 2 Diabetes
There were no differences in TB, trunk, or appendicular FM or LM among the three glycemic
groups at baseline when covariates were included in the analyses (Table 3). Prediabetic men weighed
more than normoglycemic men.
Table 3. Total body and regional body composition in the 430 men from the South Dakota Rural Bone
Health Study cohort, according to glycemic status at baseline.
Normoglycemic Prediabetic T2D p-Value 1
Participants (n) 358 51 21
Body Weight (kg)
Unadjusted Model 91.1 ± 0.8 a 98.5 ± 2.1 a 95.9 ± 3.3 0.003
Basic Model 2 91.0 ± 0.8 a 97.0 ± 3.2 a 95.9 ± 3.2 0.01
Fat Mass (kg)
Total Body
Unadjusted Model 22.1 ± 0.5 ab 26.4 ± 1.2 b 26.7 ± 1.9 a 0.001
Full Model 3 22.6 ± 0.3 24.0 ± 0.9 23.3 ± 1.5 0.38
Trunk
Unadjusted Model 11.4 ± 0.3 ab 14.2 ± 0.8 b 15.1 ± 1.2 a <0.001
Full Model 3 11.8 ± 0.2 12.6 ± 0.5 11.8 ± 0.9 0.38
Appendicular
Unadjusted Model 9.6 ± 0.2 a 11.1 ± 0.5 a 10.4 ± 0.8 0.01
Full Model 3 9.7 ± 0.2 10.3 ± 0.4 10.1 ± 0.7 0.66
Lean Mass (kg)
Total Body
Unadjusted Model 67.0 ± 0.4 69.9 ± 1.2 66.8 ± 1.8 0.07
Full Model 4 67.1 ± 0.3 67.9 ± 0.8 67.9 ± 1.2 0.56
Trunk
Unadjusted Model 32.7 ± 0.2 a 34.5 ± 0.6 a 34.1 ± 0.9 0.01
Full Model 4 32.7 ± 0.1 33.1 ± 0.4 33.8 ± 0.6 0.24
Appendicular
Unadjusted Model 30.5 ± 0.2 31.6 ± 0.6 a 28.9 ± 0.9 a 0.04
Full Model 4 30.5 ± 0.2 31.0 ± 0.4 30.3 ± 0.7 0.44
Data are means and marginal means ± sem. 1 p-values are from multiple regression models. Means with similar
superscripts are different using a post hoc contrast test. 2 Basic model adjusted for age, height, population group,
percent time in moderate-plus-vigorous activity, and average daily calories. 3 Fat mass models included covariates
in basic model plus lean mass of same compartment (total body, trunk, or appendicular). 4 Lean mass models
included covariates in basic model plus fat mass of same compartment. Abbreviations: T2D, type 2 diabetic.
3.3. Association between Development of Prediabetes and Type 2 Diabetes and Changes in Body Composition
Changes in body composition for the six glycemic groups are shown in Figures 2 and 3. There were
differences among men who developed prediabetes or T2D and men who remained normoglycemic
regarding the annual change in TB and appendicular LM. Among men who were normoglycemic at
baseline, those who progressed to prediabetic lost more TB and appendicular LM than those who
remained normoglycemic (Figure 3). Normoglycemic or prediabetic men who developed T2D also
had greater losses in TB and appendicular LM than men who remained normoglycemic (Figure 3).
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Figure 2. Adjusted marginal means of annual change from baseline in total body (p = 0.02), trunk
(p = 0.06), and appendicular (p = 0.06) fat mass according to categories of glycemic status during
the three-year follow-up. Model included baseline age, height, population group, percent time
in moderate-plus-vigorous activity, average caloric intake, baseline measures of fat and lean mass
in the speciﬁc body compartment (total body, trunk, or appendicular), changes in percent time in
moderate-plus-vigorous activity and average caloric intake, and annual change in lean mass of the
same compartment. Means with similar superscripts are different using post hoc contrast tests based
on hypotheses.
Figure 3. Adjusted marginal means of annual change from baseline in total body (p = 0.004), trunk
(p = 0.24), and appendicular (p < 0.001) lean mass according to categories of glycemic status during
the three-year follow-up. Model included baseline age, height, population group, percent time in
moderate-plus-vigorous activity, average caloric intake, baseline measures of fat and lean mass in
the speciﬁc body compartment (total body, trunk, or appendicular), changes in percent time in
moderate-plus-vigorous activity and average caloric intake, and annual change in the fat mass of
the same compartment. Means with similar superscripts are different using post hoc contrast tests
based on hypotheses.
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3.4. Changes in Body Composition among Prediabetic Men Depending on Reversion to Normoglycemia
There were no differences in the FM or LM between prediabetic men who remained prediabetic
and those that reverted to normoglycemia (Figures 2 and 3). In general, prediabetic men who
reverted to normoglycemia had negative changes in FM, whereas men who remained prediabetic had
positive changes.
3.5. Changes in Body Composition among Type 2 Diabetic Men
Men who were T2D at baseline had greater gains in TB FM (Figure 2) and greater losses in TB and
appendicular LM (Figure 3) than men who remained normoglycemic over the three-year follow-up.
4. Discussion
This is the ﬁrst prospective population-based cohort study investigating the association of
baseline glycemic status and changes in glycemic status over time with changes in TB, trunk, and
appendicular FM and LM. Consequently, the ﬁndings of prior observational longitudinal studies
cannot be compared to our ﬁndings. The ﬁndings of the current study indicate that there were no
baseline differences among glycemic groups in TB, trunk, or appendicular FM and LM. Normoglycemic
men who developed prediabetes or T2D had greater losses in TB and appendicular LM than men who
remained normoglycemic. Men who had T2D throughout the study period had greater gains in TB
FM, and greater losses in TB and appendicular LM, than men who were normoglycemic throughout
the study. No differences were observed in changes in weight or body composition measures among
prediabetic men who reverted to normoglycemia compared to those who remained prediabetic.
Contrary to our ﬁrst hypothesis, we did not ﬁnd differences in TB and regional FM and LM at
baseline among the glycemic groups. The present study differs from other studies [6–8,10,22,23] due
to the adjustment for covariates and inclusion of other body composition compartments (e.g., when
determining whether TB FM was associated with glycemic status, TB LM was included in the statistical
model). The inclusion of these covariates resulted in the relationships becoming non-signiﬁcant.
Consistent with our hypothesis, normoglycemic men who developed prediabetes or T2D had
greater losses in TB and appendicular LM than men who remained normoglycemic, but we found
no association with changes in FM. A positive association between glucose concentrations and
intermuscular adipose tissue has been reported [24], and it has been suggested that hyperglycemia
stimulates the differentiation of mesenchymal stem cells derived from adipose and muscle tissues into
adipocytes by activating the protein kinase C β pathway [25]. Other studies also have reported an
association between hyperglycemia and reduced TB and appendicular LM in men [10]. The underlying
mechanisms of the decline in LM may include elevated circulating concentrations of inﬂammatory
markers and oxidative stress. Biomarkers of inﬂammation, tumor necrosis factor alpha, and C-reactive
protein stimulate the loss of skeletal muscle through the activation of nuclear factor kappa B [26]
and the inhibition of protein synthesis [27]. Oxidative stress contributes to a catabolic and anabolic
imbalance in skeletal muscle, mitochondrial damage, and muscle atrophy and apoptosis [28]. These
ﬁndings indicate that elevated inﬂammation markers in the presence of oxidative stress in prediabetic
and T2D men can induce the loss of TB and appendicular LM. The present ﬁndings from the study
support these reports.
The association of changes in prediabetes status over time with changes in body composition
by compartments have not been previously investigated. A few prospective studies have examined
changes in TB and appendicular FM and LM in prediabetic individuals compared to normoglycemic
controls. Our ﬁndings are similar to other studies reporting no difference in longitudinal changes
in TB and lower extremity LM between individuals with and without prediabetes [14,16,29]. On the
contrary, others have reported a loss in TB FM and appendicular LM that was greater in prediabetics
compared to their normoglycemic counterparts [14,29].
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In addition to greater gains in TB FM among men with T2D than among normoglycemic men,
we found a signiﬁcant loss in TB and appendicular LM among men who either had T2D at baseline
or developed T2D during the study compared to men who remained normoglycemic. By contrast,
Park et al. [15] reported no differences in longitudinal changes in TB and appendicular FM and LM
between older adults with normoglycemia and those diagnosed T2D. Our ﬁndings are consistent with
longitudinal studies that have found T2D men gained TB FM and lost TB and appendicular LM [12–14].
The mechanism for fat gain and muscle loss may stem from insulin resistance in T2D. An excessive
inﬂux of free fatty acids into the systemic circulation resulting from the adipose tissue contributes to
insulin resistance by increasing fat accumulation in the liver leading to decreased insulin clearance,
and increasing fat accumulation in skeletal muscle by impairing glucose transport, decreasing muscle
protein synthesis, and inducing muscle protein breakdown, leading to a reduced muscle surface area
and insulin signaling [30,31].
The strengths of our study include the ﬁrst prospective population-based study of the association
between changes in glycemic status and changes in TB and regional body composition measured
by DXA, our low dropout rate, and our statistical adjustment for the same body composition
compartments. Our study has several limitations. The present study included predominantly white
men, and our ﬁndings may not be generalizable to women or other races. The majority of the men were
farmers who may have different activity patterns and dietary intake than non-farmers, which may
inﬂuence the relationship between dysglycemia and body composition. However, a study conducted
on a representative sample of the United States (U.S.) population reported a similar association between
dysglycemia and reduced lean mass [10]. Another limitation is the sample size of some of the glycemic
categories. We did not observe differences between those men who were prediabetic at baseline and
remained prediabetic, or reverted to normoglycemia as we hypothesized. It is likely that our sample
size (n = 19 and 25, respectively) was too small. Based on the observed means and standard deviations
in changes in TB FM, we estimate that 72 men per group would be needed (α = 0.05, β = 0.20). Despite
the small sample size in some categories, we did observe other differences that we hypothesized,
including differences in changes in TB and appendicular LM between normoglycemic men who
developed prediabetes or T2D and those who remained normoglycemic throughout the study. We
relied on participants’ recall of diagnosis of T2D, antidiabetic medication usage, dietary intake, and
physical activity. A self-reported diagnosis of T2D or the use of antidiabetic medication can lead to
misclassiﬁcation due to recall or reporting errors. Dietary and physical activity recalls may result in
overestimation or underestimation. However, dietary intake and physical activity assessments were
performed quarterly to consider seasonality. The 24-h diet recall [32] and PPAQ [19] are valid measures
of dietary intake and physical activity in adults. Although this was a longitudinal study, given the
period of time between measurements (three years), it is not possible to determine whether changes
in glycemic status preceded changes in body composition or vice versa. Future studies should be
over longer periods of time with more frequent measures of glycemic status and body composition
in order to determine which factor comes ﬁrst: dysglycemia or body composition changes. Only one
fasting or non-fasting blood glucose measurement per visit was obtained for deﬁning prediabetes
and T2D. Although the American Diabetes Association recommends different criteria for screening
for prediabetes and T2D using glycated hemoglobin, fasting blood glucose, and two-hour plasma
glucose after an oral glucose tolerance test [21], numerous studies have reported that using two-hour
plasma glucose test detects more cases of prediabetes and diabetes than using glycated hemoglobin or
a fasting blood glucose test [33–38]; thus, we might have missed men with prediabetes and T2D using
only one fasting blood glucose measurement, which would have made it more difﬁcult to identify
group differences in changes in body composition.
5. Conclusions
In conclusion, (1) there were no differences among glycemic groups in baseline TB and regional
distribution of FM and LM; (2) men who were normoglycemic at baseline and developed prediabetes or
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T2D had greater losses in TB and appendicular LM than men who remained normoglycemic; (3) there
were no differences in changes in body weight or composition among men who were prediabetic at
baseline and remained prediabetic compared to those who reverted back to normoglycemia; and (4)
men who had T2D at baseline had greater gains in TB FM and greater losses in TB and appendicular
LM than normoglycemic men. These ﬁndings add to a growing body of literature on the associations
between changes in glycemic status and body composition.
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Abstract: The relationship between vitamin D status, calcium intake and the risk of developing
type 2 diabetes (T2D) is a topic of growing interest. One of the most interesting non-skeletal
functions of vitamin D is its potential role in glucose homeostasis. This possible association is
related to the secretion of insulin by pancreatic beta cells, insulin resistance in different tissues and its
inﬂuence on systemic inﬂammation. However, despite multiple observational studies and several
meta-analyses that have shown a positive association between circulating 25-hydroxyvitamin D
concentrations and the risk of T2D, no randomized clinical trials supplementing with different doses
of vitamin D have conﬁrmed this hypothesis deﬁnitively. An important question is the identiﬁcation
of what 25-hydroxyvitamin D levels are necessary to inﬂuence glycemic homeostasis and the risk of
developing T2D. These values of vitamin D can be signiﬁcantly higher than vitamin D levels required
for bone health, but the currently available data do not allow us to answer this question adequately.
Furthermore, a large number of observational studies show that dairy consumption is linked to
a lower risk of T2D, but the components responsible for this relationship are not well established.
Therefore, the importance of calcium intake in the risk of developing T2D has not yet been established.
Although there is a biological plausibility linking the status of vitamin D and calcium intake with the
risk of T2D, well-designed randomized clinical trials are necessary to answer this important question.
Keywords: calcium intake; dairy products; vitamin D; type 2 diabetes
1. Introduction
The incidence of type 2 diabetes (T2D) has increased substantially in recent years related, in part,
to higher obesity rates. If current trends continue, more than 642 million people will have diabetes by
2040 [1]. The management and early treatment of T2D are essential to prevent further complications
involving loss of quality of life and premature death. It is unclear whether vitamin D deﬁciency might
be contributing to an increased T2D risk [2].
A vast body of evidence associates vitamin D deﬁciency and T2D [3]. This relationship could
be mediated by the direct and indirect effects of vitamin D on glucose homeostasis such as insulin
secretion, insulin sensitivity, and systemic inﬂammation. However, the extent of this relationship and
its clinical relevance are not well established.
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There is no doubt that vitamin D homeostasis is of vital importance for skeletal health, being
especially important for bone mineralization. Moreover, recent studies have demonstrated that low
vitamin D concentrations are related to other pathologic conditions that were not previously considered,
such as insulin resistance, T2D, metabolic syndrome and cardiovascular diseases. All these diseases
could potentially be developed as a result of vitamin D deﬁciency [4–6].
Moreover, the evidence linking milk and, in particular, calcium intake, insulin secretion and
sensitivity has been related to glucose homeostasis in both prediabetes and T2D [7–9]. However, the
main clinical studies conducted to conﬁrm this hypothesis have yielded inconsistent results.
The aim of the present review is to summarize the recent evidence linking vitamin D and calcium
intake with the development of T2D. We also analyzed different intervention studies with vitamin D
supplements to determine their inﬂuence on glucose metabolism.
2. Methods
We performed a comprehensive literature search on PubMed to identify peer-reviewed articles
on vitamin D levels, vitamin D supplementation and T2D prevention published until December 2018.
Search strategies included the following search terms: vitamin D intake, vitamin D supplementation,
25-hydroxyvitamin D, calcium intake, dairy products, type 2 diabetes, impaired glucose tolerance,
insulin resistance, insulin sensitivity, β-cell function and obesity.
We included a selection of papers that showed original research articles in humans mainly
published in English language; and also in vitro studies, observational studies (prospective and
retrospective) and randomized controlled trials. Finally, we reviewed meta-analyses published
compiling all studies information. Priority was given to larger studies (according to number of
patients included) and the most recent and strongest available evidence.
3. Vitamin D and Type 2 Diabetes (T2D)
3.1. Vitamin D Physiology and Glucose Homeostasis
The term vitamin D includes vitamin D2 or ergocalciferol and vitamin D3 or cholecalciferol. The
main metabolites of vitamin D, which differ in their hydroxylation patterns, are 25-hydroxyvitamin
D or calcidiol (25(OH)D) and 1,25-dihydroxyvitamin D3 or calcitriol (1,25-(OH)2D3). In humans, the
main sources of vitamin D come from the skin through the cutaneous synthesis of vitamin D3 and,
to a lesser extent, from the intake of foods rich in vitamins D2 and D3 or supplements. Circulating
vitamin D is bound to vitamin D binding protein (DBP), which transports it to the liver, there vitamin
D25-hydroxylase converts it to 25(OH)D. This form of vitamin D is primarily converted to the most
biologically active form, 1,25-(OH)2D in the kidneys. This transformation is done by the enzyme
25-hydroxyvitamin D-1alpha-hydroxylase (CYP27B1). The presence of CYP27B1 in multiple tissues,
which also express the vitamin D receptor, suggests that vitamin D could play an important function
beyond bone metabolism.
Both in vitro and in vivo studies have reported that vitamin D may play an important role in
the maintenance of pancreatic beta cell function [10]. This effect could have different explanations.
It could be induced by the activation of the vitamin D receptor (VDR) located in pancreatic beta cells.
It was suggested by the study results that showed how mice without VDR have impaired insulin
secretion [11] and the addition of calcitriol to the culture medium stimulated pancreatic islets and
resulted in an increased insulin secretion [12].
Moreover, vitamin D could also inﬂuence insulin secretion by regulating calcium channel opening
and closure. Calcitriol participates as a chemical messenger interacting with different receptors
regulating calcium ﬂux in beta cells. They are located on the phospholipid layers of plasma membranes.
For this reason, calcium is essential for appropriate insulin secretion by pancreatic beta cells; and,
therefore, insufﬁcient vitamin D may alter normal insulin secretion through alterations in calcium
ﬂux in beta cells [13,14]. In relation to this, the regulation of the protein calbindin, a calcium-binding
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protein, by vitamin D may be another mechanism inﬂuencing insulin secretion. In addition, preclinical
studies show that vitamin D can reduce the hyperactivity of the renin angiotensin system and, thus,
improve the functioning of beta cells (Leung PS. Nutrients 2016 [15]).
An adequate vitamin D level can also improve insulin resistance pathways associated with
diabetes. It is caused mainly by alterations in calcium ﬂux and concentration through the cell
membranes of insulin-responsive tissues [16]. The regulation of extracellular and intracellular calcium
concentrations may promote dephosphorylation of glucose transporter-4 (GLUT-4) driving a reduced
insulin-stimulated glucose transport [14,17]. The 1,25-(OH)2D stimulates the expression of insulin
receptors and, therefore, stimulates insulin sensitivity. In addition, calcitriol could also improve insulin
sensitivity activating the peroxisome proliferator-activated delta receptor (PPAR-d), a transcription
factor that regulates fatty acids metabolism in adipose tissue and the skeletal muscle. Another
interesting study indicates that insulin resistance may also be reduced by the speciﬁc effects of calcitriol
on hepatic lipid synthesis and glucose output, and on skeletal muscle (Leung PS. Nutrients 2016 [15]).
Calcitriol has a central role in a wide variety of metabolic pathways by binding to the VDR, and
the measurement of its substrate 25(OH)D is an important marker for health risks. This receptor is
expressed in an assortment of cells, such as in the pancreatic beta cells of Langerhans, but also in liver,
adipose tissue, and muscle cells [18,19]. The VDR and the 1α-hydroxylase, the enzyme catalyzing
calcidiol to calcitriol conversion, are expressed in primary preadipocytes and recently differentiated
adipocytes [18]. Therefore, in vitro studies suggest that calcitriol regulates the growth of human
adipose tissue and its remodeling. Moreover, fat tissue is a storage site for vitamin D [19]. In contrast, a
higher body mass index (BMI) is associated to lower vitamin D concentrations. Vitamin D, a fat-soluble
hormone, is sequestered in the adipose tissue and, consequently, only small quantities are available
for circulation [20]. On the other hand, since the concentrations of 25(OH)D in serum and adipose
tissue are closely related, obesity can reduce serum 25(OH)D through volumetric dilution and the
distribution of 25(OH)D in larger fat volumes [21].
Vitamin D could also shorten the effects of chronic inﬂammation, and it is well established
that it plays a key role in the pathogenesis of T2D. Therefore, 1,25(OH)2D can protect against
cytokine-induced apoptosis of beta cells directly regulating the activity and expression of cytokines,
with an improvement in insulin sensitivity [22]. Moreover, vitamin D demonstrated the possibility of
deactivating inﬂammatory cytokines associated with insulin resistance and promoting calbindin
expression which involves protection from apoptosis [23]. Finally, vitamin D also reduces the
accumulation of advanced glycation products in experimental studies [24]. These products are related
with the development of T2D complications and have been involved with insulin resistance. Vitamin
D functions related with glucose homeostasis are summarized in Figure 1.
3.2. Vitamin D Status and Its Relationship with T2D in Cross-Sectional and Longitudinal Studies
Serum 25(OH)D concentrations have been noticed to be inversely associated with glucose
homeostasis, insulin resistance, and beta cell function, and forecast lower risks of both metabolic
syndrome and T2D [25–27]. Numerous clinical studies have associated vitamin D inadequacy with
the development of insulin resistance in different populations, not only in adults [5,28,29] but also in
children [30,31].
Consistently, higher baseline 25(OH)D levels have been found to predict better beta cell function
and lower glucose levels in subjects at risk for T2D in longitudinal studies [32]. Overall, data from
observational studies strongly support an association between low vitamin D status and incidence of
T2D [33–35].
We discuss in this review the largest prospective articles and some meta-analyses. In 2013, Afzal
et al. published the results of a prospective cohort study that included 9841 participants who were
followed-up for 29 years. They found an odds ratio for the development of T2D of 1.5 (95% CI
1.33–1.70) between the lowest and the highest quartile of 25(OH)D [34]. More recently, Park et al.
measured 25(OH)D levels in a cohort of 903 adults without diabetes or prediabetes, these authors
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found an inverse dose-response association between 25(OH)D concentration and risk of diabetes. They
proposed a target 25(OH)D of 50 ng/mL; higher than the levels previously suggested in other studies,
in the attempt to inﬂuence and reduce the incidence rate of diabetes [36]. These data are consistent
with the levels published recently by Avila-Rubio et al. in postmenopausal women, the authors link
values of 25(OH)D > 45 ng/dL in these women with better glycemic indexes measured by homeostasis
model assessment (HOMA) [37].
 
Figure 1. Vitamin D functions related with glucose homeostasis.
The multicenter EPIC-InterAct study measured plasma 25(OH)D metabolites: non-epimeric
25(OH)D3, 3-epi-25(OH)D3 and 25(OH)D2. They identiﬁed that plasma non-epimeric 25(OH)D3 (the
major component of total 25(OH)D) was inversely associated with T2D, whereas 3-epi-25(OH)D3 was
positively associated with the incidence of T2D, and 25(OH)D2 was not associated with T2D [38].
Another large cohort was The Melbourne cohort, which included a sample of middle-aged
Australians, the authors showed how vitamin D status was inversely associated with the risk of T2D
and, apparently, this association cannot be explained by reverse causality [39]. If the association was
due to reverse causality, then a much stronger association would be expected to be observed in the
ﬁrst few years of follow-up.
The meta-analysis conducted by Song et al. included 21 observational studies with 76,220 subjects
in total; the authors found a 38% lesser risk of developing T2D in the highest baseline reference
category of 25(OH)D compared to the lowest one (95% CI 0.54–0.70) [35].
Despite the consistency of these results, all these were observational studies and estimation of
causality cannot be completely excluded because of residual confounding agents.
3.3. Vitamin D Supplementation and Risk of T2D: Randomized Trials and Meta-Analysis
In the last decade, more than ten well-designed, randomized trials evaluated the effect of vitamin
D3 supplementation on glucose homeostasis in subjects at risk for T2D and showed inconsistent results.
We have selected a set of studies that analyzed outcomes related to the objectives of this review. Table 1
summarizes the main results of these studies.
In Table 1 we describe the main ﬁndings of the largest trials. Sollid et al. [40] conducted a
randomized clinical trial with approximately 500 prediabetes subjects comparing vitamin D versus
placebo for the prevention of T2D. They supplemented with 20,000 IU cholecalciferol weekly and after
one year, no signiﬁcant differences were reported between those receiving vitamin D and those taking
placebo in any of the glycemic or inﬂammatory markers and blood pressure, regardless of baseline
serum 25(OH)D concentrations.
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Two years later, Forouhi et al. [41] compared, in another large randomized trial including 340
prediabetes or at risk of developing T2D subjects, the effect of supplementation with cholecalciferol or
ergocalciferol (both 100,000 IU/month) versus placebo, for four months. Prediabetes was estimated
by the Cambridge Risk Score [42]. Despite vitamin D supplementation, neither ergocalciferol or
cholecalciferol, resulted in increased 25(OH)D2 and 25(OH)D3 concentrations. No differences in
HbA1c concentration were found between groups. It is important to point out that only half of the
subjects had concentrations of 25(OH)D < 50 nmol/L. This data could inﬂuence the results.
Their results are in accordance with previous ﬁndings by Davidson et al. [43]. They supplemented
a cohort of Latino and African Americans subjects with prediabetes and hypovitaminosis D at baseline
for one year. They used a cholecalciferol dose sufﬁcient to raise serum 25(OH)D levels into the
upper-normal range versus placebo. They did not ﬁnd any effect on insulin secretion or sensitivity, nor
the proportion of subjects who developed T2D or whose oral glucose tolerance test became normal [43].
However, it is possible to ﬁnd some positive effect on glycemic markers in some studies. In this
line, Gagnon et al. [44] reported when they performed a post hoc analysis only including subjects
with prediabetes, an improvement in insulin sensitivity indices was observed. Previously, they gave
a supplement of calcium carbonate 1200 mg and cholecalciferol 2000–6000 UI daily to subjects with
glucose intolerance or recently diagnosed diabetes, but they found no effect on insulin sensitivity or
secretion, and beta cell function. So, despite most clinical randomized trials failing to show a favorable
effect of vitamin D supplementation on glycemic control, insulin sensitivity indices, and incident
T2D [40,41,43–49] in subjects at risk for diabetes, there is some interesting evidence supporting a
beneﬁcial effect of vitamin D on beta cell function. In fact, Mitri et al. [50] reported in 2011 a signiﬁcant
improvement in insulin secretion in 92 prediabetic subjects who were overweight or obese and at risk
for T2D. They were supplemented with cholecalciferol 2000 IU daily and calcium carbonate versus
placebo for four months. An important restriction of the above described studies is that they were
not designed speciﬁcally to assess glycemic homeostasis and the results found correspond to post
hoc analyses.
Although not being designed for this purpose, we would like to point out the results of the Vitamin
D and Omega-3 Trial (VITAL), a large-scale trial that evaluated high-dose vitamin D supplementation.
This study was designed to evaluate the effect of supplementation with vitamin D on incidence of
invasive cancer or cardiovascular events versus placebo. Overall, no differences were found between
groups. However, in Black Americans a potential beneﬁcial effect was found in cancer mortality [51].
A recent meta-analysis conducted by Raﬁq et al. showed an inverse relationship; higher vitamin
D concentrations were associated with lower BMI in T2D patients and non-diabetic subjects at risk
for T2D. But this association was more pronounced in T2D patients. Moreover, the correlation was
directly associated to the BMI quartiles, so the highest BMI quartile had the greatest correlations in
both populations, both T2D and non-diabetic [52].
Tang et al. [53] published a meta-analysis and did not ﬁnd an effect of vitamin D supplementation
on the incidence of T2D. However, the authors suggested a possible dose-response effect of vitamin
D supplementation to improve glucose and insulin metabolism among non-diabetic adults. They
postulated a possible beneﬁt of taking vitamin D supplements in higher doses for the primary
prevention of T2D.
In summary, studies were very heterogeneous in terms of design, duration, and type of
supplement administered and participants characteristics. It is noteworthy that adherence to the
treatment would have played a major role in arguing these results.
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Recently, the design of a new randomized clinical trial has been published and its results can be a
determinant in clarifying many of the uncertainties that exist today. The D2d is a large randomized
clinical trial (including participants from 22 sites across the U.S.) hypothesizing that supplementation
with vitamin D3 daily lowers risk of diabetes in adults with prediabetes [54]. This trial meets people
with a large spectrum of diabetes risk, more convenient for testing the underlying hypothesis. D2d
trial results are expected to answer two important questions: whether vitamin D supplementation is
useful to prevent T2D and how the 2010 expanded American Diabetes Association (ADA) criteria for
prediabetes would impact the natural history of this state previous to diabetes.
3.4. New Thresholds for the Relationship between Vitamin D and T2D
An important question that has arisen is what 25(OH)D levels are necessary to inﬂuence glycemic
homeostasis and the risk of developing T2D. Three recent studies have addressed this issue. Von
Horst et al. found that optimal 25OHD concentrations for reducing IR were around 50 ng/dL in a
randomized controlled study with 81 Asian women [49]. Avila Rubio et al. [37], in a study conducted
in women with postmenopausal osteoporosis, suggested that the established goal of reaching a level
of 25(OH)D > 30 ng/mL was insufﬁcient to improve glucose metabolism in these population. The data
from this study indicates that 25(OH)D > 45 ng/mL are necessary to achieve this goal. These data are
consistent with a cohort study of 903 adults of 12 years of duration in non-diabetic population where
reaching values of 25(OH)D > 50 ng/mL contributed to reach the maximum beneﬁts to reduce the risk
of incident diabetes [36]. Therefore, it is important to establish what 25(OH)D values are necessary to
achieve and, even more importantly, maintain all the potential beneﬁts of vitamin D. The currently
available studies do not allow us to answer this question with certainty.
4. Calcium Intake and T2D
4.1. Mechanistic Studies
To introduce and understand the underlying mechanisms that associates dairy products, and
speciﬁcally dairy components to T2D prevention, mechanistic studies are essential. Further to the
structural role it plays in the skeleton, calcium is an essential electrolyte necessary for many critical
biological functions. Calcium may play a key role in a wide range of functions related to glucose
homeostasis. Calcium regulates insulin-mediated intracellular processes in speciﬁc tissues that respond
to insulin, participates in the secretory function of pancreatic beta cells and the phosphorylation of
insulin receptors. Calcium also down-regulates speciﬁc regulatory genes encoding pro-inﬂammatory
cytokines involved in insulin resistance [16,57,58].
Insulin secretion is a calcium-dependent process [59]. Calcium is vital for insulin-mediated
intracellular processes in those tissues responding to insulin, such as muscle and fat [16,58]. There is a
narrow range of intracellular calcium concentration needed for optimal insulin-mediated functions.
When there are changes in intracellular calcium concentrations in insulin-responsive tissues there is a
contribution to peripheral insulin resistance [17,60] through a dysregulated insulin signal transduction
cascade that leads to a lower glucose transporter activity.
An appropriate range of intracellular calcium concentration is also required for some
insulin-mediated activities in tissues such as liver, adipose and skeletal muscle [57]. It is important to
maintain relatively low intracellular calcium concentrations in these target tissues to have a beneﬁcial
effect on the insulin signal transduction cascade [60] and peripheral insulin sensitivity. In addition,
low intracellular calcium attenuates cytokine-induced inﬂammation, augments vascular relaxation
and inhibits platelet aggregation. It is important to keep in mind that calcium intake should be
considered in the context of dairy intake and dairy products, which provide other important nutrients
besides calcium.
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4.2. Dairy Intake and T2D Risk
Increased dairy consumption is linked to a lower risk of T2D, but the components responsible for
this relation are not well established. The participation of speciﬁc dairy products needs to be further
studied. Calcium, vitamin D, dairy fat, partially hydrogenated oils and speciﬁcally trans-palmitoleic
acid (a natural trans fatty acid found in dairy) are key dairy components. They have been proposed to
inﬂuence some metabolic pathways implicated in T2D prevention.
We have previously reported how vitamin D has a direct effect on insulin secretion by binding to
VDR in pancreatic beta cells and an indirect effect via the regulation of extracellular calcium [13,57,61].
Moreover, vitamin D effects include suppression of inappropriately prolonged inﬂammation by
modulating secretion of proinﬂammatory cytokines.
The role of dietary intake of trans-palmitoleic acid has been related to an improvement in metabolic
regulation, hepatic and peripheral insulin resistance, and suppression of hepatic de novo lipogenesis
and lower levels of fasting insulin, C-reactive protein, triglycerides and blood pressure [62,63].
In the Cardiovascular Health Study (CHS), a prospective cohort analysis about dietary intake of
trans-palmitoleic acid, a signiﬁcantly and considerably 62% risk reduction of incident T2D has been
shown [62]. Moreover, the Multi-Ethnic Study of Atherosclerosis (MESA), a prospective cohort study,
showed that dietary intake of trans-palmitoleic acid was associated with a 48% lower risk of incident
T2D [63].
When we analyzed the fat content of dairy, the evidence ﬁnds relatively consistent results
regarding a beneﬁcial role of fatty dairy products in T2D prevention. But, to date, the differences
between low, regular or high fat dairy are less known. Kratz et al. described in a systematic review
including observational studies [64], that the majority of studies analyzed inversely associated high-fat
dairy products with obesity, T2D and cardiometabolic disease, either signiﬁcantly or insigniﬁcantly.
However, the meta-analysis of cohort studies conducted by Alhazmi et al. showed that saturated fat
ingestion was not associated with a risk of T2D [65].
Furthermore, the evidence regarding the role of speciﬁc types of dairy products (milk, yogurt,
and cheese) is even more limited. Milk has generally been posted as part of total dairy consumption,
and scarce evidence exists on milk particularly. It seems that milk consumption may be associated
with a T2D risk reduction, with not well-established differences between regular-fat or whole fat milk
and T2D [66–68]. The association between cheese consumption and a reduced risk of T2D still needs
to be strongly supported because some ﬁndings are not statistically signiﬁcant [68–71]. Finally, limited
evidence suggested a protective role of fermented dairy products in general (including yogurt, cheese,
buttermilk, and fermented milk), against T2D [69,71].
4.3. Observational Studies
More than twenty observational studies regarding calcium intake and T2D prevention were found.
Different populations have investigated the association between calcium intake and T2D. The largest
are four cohort studies. They were done in the United States (n = 83,779 [72], (n = 41,186) [73]), and the
other two in Asian populations: China (n = 64,191) [74], and Japan (n = 59,796) [75]. They demonstrated
an inverse association between dietary or total calcium intake and T2D risk among women but not in
men, in the United States and in China. In the Japanese study, they found an inverse association in
subjects with higher vitamin D intake.
In Korea, a smaller cohort study conducted in rural areas (n = 8313) also showed an inverse
association between total and vegetable calcium intake and T2D risk among women, as previously
reported [76]. Conversely, a relatively short study (n = 5200) in Australia did not ﬁnd an association
between dietary calcium and T2D [77]. Additionally, other studies provided mixed results when
investigating the association between dairy products and the potential risk of T2D.
More recently, the Korean Genome study, a prospective cohort community-based trial followed
for 10 years, explained the longitudinal associations between dietary calcium intake and the incidence
of T2D [9]. The authors also associated dietary calcium intake and serum calcium levels at the
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baseline survey. They found that higher dietary calcium intake was associated with a lower risk of
developing T2D. These results are important for public health and have implications for predicting
and preventing T2D development. These ﬁndings can provide guidelines for calcium dietary and
calcium supplementation.
At the same time, a Spanish study including more than 500 postmenopausal women without
diabetes showed a decrease in fasting plasma glucose and glycated hemoglobin after the intervention.
This supplementation consisted of a higher dose of vitamin D3 as part of an enriched milk, providing
a daily intake of 600 IU of vitamin D3 and 900 mg of calcium [78].
Another population-based study using a prospective survey of 5582 adults, the Australian
Diabetes Obesity and Lifestyle Study (AusDiab), showed a signiﬁcant inverse association between
the highest tertial of dairy intake and risk of diabetes in men after a following-up period of ﬁve years.
They obtained these results after adjustment for confounding variables such as age, sex, energy intake,
and other potential confounders (adjusted OR 0.53, 95% CI 0.29–0.96 [79]. This inverse association
was non-signiﬁcant in women (adjusted OR 0.71, 95% CI 0.48–1.05). When the authors analyzed
different dairy products (low-fat milk, full-fat milk, yogurt, cheese), they only found signiﬁcant inverse
association with diabetes for low-fat milk (adjusted OR 0.65, 95% CI 0.44–0.94).
The Danish population-based lifestyle intervention study done by Struijk et al. called the Inter 99
Study, explained the association between speciﬁc types of dairy products and T2D incidence. They
did not ﬁnd a signiﬁcant association between total dairy intake and T2D incidence (OR 0.95, 95%
CI 0.86–1.06) and when they analyzed speciﬁc dairy products and T2D no association was reported.
Particularly, cheese and other fermented dairy (including yogurt, and buttermilk) appeared to have a
beneﬁcial effect on glucose regulation markers, with an inverse association with fasting plasma glucose
and glycated hemoglobin [69].
At the same time, the results of the Whitehall II prospective cohort study of working staff of
Civil Service departments, were reported. They followed 4186 subjects for ten year and found that
total dairy consumption was not signiﬁcantly associated with T2D (hazard ratio (HR) 1.30, 95% CI
0.95–1.77). They analyzed all possible dairy (high-fat and low-fat dairy, total milk, yogurt, cheese
and fermented products) and were not associated with T2D risk. But, nevertheless, fermented dairy
products were signiﬁcantly associated with an inverse risk of overall mortality [68].
In the French population, the Data from the Epidemiological Study on Insulin Resistance
Syndrome (DESIR) study analyzed 3435 participants prospectively for nine years. This cohort study
showed that global consumption of dairy products, but not cheese, was inversely associated with new
impaired fasting glycemia diagnosis and T2D (adjusted OR 0.85, 95% CI 0.76–0.94). When analyzing
cheese consumption, they did not ﬁnd an association with T2D (adjusted OR 0.93, 95% CI 0.82–1.06).
Curiously, they reported an inverse relationship between cheese and incident metabolic syndrome
(adjusted OR 0.82, 95% CI 0.71–0.95) [70].
Moreover, data from the Nurses’ Health Study II, including 37,038 women followed-up for seven
years, evaluated the possible inﬂuence of dairy consumption during adolescence with the development
of T2D later in adulthood. They adjusted for risk factors present in adolescence. Those women with the
highest quintile intake of dairy during adolescence (two servings per day) had a 38% lower risk of T2D.
They also adjusted for risk factors appearing in adulthood and still demonstrated a signiﬁcant inverse
association between adolescent dairy intake and T2D (RR 0.73, 95% CI 0.54–0.97). There was a 43%
T2D risk reduction in women with high-dairy intakes for a long time (from adolescence to adulthood),
highlighting the importance of persistence in dairy consumption. They also found a 25% risk reduction
for the highest current dairy consumption (two servings per 1000 kcal), and a 26% and 28% risk
reduction with low- and high-fat dairy consumption, respectively [80]. In contrast, the EPIC Study,
including 16,835 participants in a nested case-cohort analysis including eight European countries,
found no association between total dairy consumption and T2D (HR 1.01, 95% CI 0.83–1.34) [71]. There
were an inverse association between the consumption of cheese and fermented dairy products (cheese,
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yogurt, and thick fermented milk) with T2D (HR 0.88, 95% CI 0.76–1.02 and HR 0.88, 95% CI 0.78–0.99,
respectively).
Recently the PURE study was published [81]. It analyzes the association of dairy intake with
cardiovascular disease and mortality in 21 countries from ﬁve continents. In this study, the dietary
intake of dairy products of 136,384 individuals were recorded using country-speciﬁc validated food
frequency questionnaires. During a follow-up period of 9.1 years, the incidence of cardiovascular
events and mortality was evaluated. The authors concluded that higher consumption of dairy products
is associated with lower risks of mortality and cardiovascular disease.
To date, there are no well-designed randomized controlled trials (RCTs) that have speciﬁcally
studied the relationship between dairy products and the risk of incident T2D. However, there is a
randomized crossover trial with 12 months follow up that need to be considered. It evaluated the
consumption of low-fat dairy (four servings per day) and was associated with better insulin resistance,
without negative effects on body weight and lipid proﬁle [82].
4.4. Systematic Reviews and Meta-Analyses
Three meta-analyses of prospective cohort studies on dairy products and T2D are worth noting.
In a meta-analysis conducted by Tong et al. the highest dairy consumption, compared to the lowest
category, signiﬁcantly reduced the risk of T2D by 14% [67]. They found a signiﬁcant inverse association
for low-fat dairy and yogurt with T2D. This association was not found for high-fat dairy and whole
(regular-fat) milk. They described, in a dose-response analysis, how each additional daily serving of
total dairy showed a decrease of 6% in T2D risk. Especially per each additional serving of low-fat dairy
intake there was a 10% T2D risk reduction.
Elwood et al. have previously demonstrated in their meta-analysis including four prospective
cohort studies on diabetes, that milk or dairy consumption played a protective role against T2D. Per
each additional daily serving there was a 4%–9% risk reduction in diabetes incidence [66]. Pittas et al.
found in their meta-analysis including mostly similar cohort studies that the highest versus lowest
dairy intake (3–5 vs. 1.5 servings per day) was associated with a lower risk of incident T2D [57].
So, we can consider that, to date, there is some strong, consistent, and accumulating evidence
about the inﬂuence of dairy intake on a reduced the risk of T2D [7].
However, it is important to notice possible confounding factors such as fat content in some dairy
products, which can inﬂuence the protective effects of calcium [74,83]. Moreover, calcium intake may
also depend on other products non-dairy foods (for example tofu, ﬁsh, rice, vegetables, and pulses).
It is evident that the main source of dietary calcium differs between populations and different cultures.
5. Nutritional Recommendations for T2D Prevention
An important body of evidence has shown that dairy products can reduce the risk of T2D
signiﬁcantly and probably in a dose-response way.
The value of having an adequate intake of dairy products should be reinforced especially among
those with prediabetes, obesity and metabolic syndrome.
In addition, cultural differences, nutritional habits, economic status and gender are related to the
consumption of milk and dairy products. Unfortunately, a large percentage of the adult population,
particularly older adults, do not to meet the international recommendations for optimal calcium intake
and need to be encouraged to increase daily calcium intake.
Dairy products are largely under-consumed by all age groups and across populations. More than
80% Americans do not meet the minimum dairy requirements of the Dietary Guidelines for Americans
(DGA) [84]. The same problems have been identiﬁed in other cultures, such as the Chinese population.
Their milk intake is still quite low [85].
The amount of calcium needed daily varies by age. The recommendations given by the National
Institutes of Health (NIH) proposed a daily intake of 1000 mg for men between 25 and 65 years [86].
This is the same recommendation for women between 25 and 50 years, with an exception for pregnant
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or lactating women or postmenopausal women not receiving estrogen replacement therapy. They
should take 1500 mg/day [86]. For all subjects, men and women over 65 years, the NIH proposes a
daily calcium intake of 1500 mg [86]. On the other hand, recently updated the US Institute of Medicine
(IOM) recommendation of 1000 mg/day of calcium intake for all adults aged 19–50 years and for men
until age 70 years. They recommend 1200 mg/day for women 51 years or older and both men and
women aged >70 years [87]. They proposed in their guidelines that calcium-rich foods, especially milk
and other dairy products, are the best source of calcium intake because they have showed a higher
absorption efﬁciency. Alternatively, calcium supplementation may help reaching optimal intake for
those subjects who cannot take adequate calcium through diet alone.
Although 25(OH)D blood concentration is the most commonly used biomarker to determine
vitamin D status, there is no global consensus on what the 25(OH)D thresholds are for vitamin D
deﬁciency or insufﬁciency. The main guidelines issued by the IOM and the Endocrine Society differ
on their classiﬁcation of vitamin D status. The differences can be explained because of the various
populations recognized by the guidelines and the way evidence was described. The IOM guidelines
focus on the general healthy population and emphasize on interventional studies. The IOM did not
ﬁnd appropriate evidence linking vitamin D and beneﬁcial effects for non-skeletal outcomes, such as
diabetes. Therefore, the IOM argued that a level of 25(OH)D >20 ng/mL is adequate and enough for
skeletal outcomes, whereas only low evidence data ratify a higher level. Moreover, the IOM proposed
that a level >50 ng/mL should be followed to avoid potential adverse events. In contrast, the Endocrine
Society clinical practice guidelines focus on people at high risk for vitamin D deﬁciency and emphasize
more on observational (epidemiological) studies. The latter guidelines determined that 25(OH)D
concentrations >30 ng/mL are desirable for optimal skeletal outcomes without suggesting any upper
limit to be concern for safety. However, the Endocrine Society guidelines have been criticized for the
way they characterized several subgroups as a high-risk population and their wide recommendations
for screening for vitamin D deﬁciency [88]. There is agreement between both guidelines about the
requirement to reconsider current recommendations in the future when ongoing randomized trials
become available. Thus, two important questions are raised. First, the existence of different thresholds
for different beneﬁcial effects. Second, the harmonization of techniques to determine circulating
25(OH)D concentrations to achieve comparable results [89].
6. Unsolved Questions
In this review, a large body of evidence has been discussed about the intake of calcium and vitamin
D and its association with the incidence of T2D, although the results are inconsistent. To date, several
observational studies and randomized trials have been performed including very heterogeneous
subject populations. They differ in design and duration, and in which range of vitamin D types
and calcium products and various dosing regimens used. Therefore, it seems necessary to clarify
what vitamin D levels are needed to obtain a real beneﬁt, if any, on glycemic status, and this
concentration is probably higher than recommendations currently focused on obtaining a beneﬁt
on bone metabolism. Supplementation with vitamin D at doses around 4000 IU/day may be an option
to increase 25(OH)D levels close to 50 ng/mL and improve homeostasis rates of glucose and insulin
among non-diabetic subjects. Therefore, no consensus regarding whether the general population needs
further supplementation of vitamin D to improve health outcomes has been found.
Furthermore, more research is needed to better understand the role of calcium intake from milk
and speciﬁc types of dairy products (regular fat, skimmed, fermented, non-fermented) on the incidence
of T2D and indices of glucose metabolism.
Establishing if speciﬁc populations such as those with prediabetes, the overweight or obese, could
obtain signiﬁcant beneﬁts with nutritional recommendations regarding the intake of calcium and
vitamin D has become a matter of special interest.
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7. Conclusions and Perspectives
We conclude that the current literature is inadequate for drawing ﬁrm conclusions about the
association between calcium intake and incident T2D, although it appears that a higher consumption
of dairy products may be beneﬁcial for glucose metabolism. Moreover, an adequate level of vitamin D
may also have a helpful effect on T2D prevention, and a potential dose-response effect is suggested.
Nevertheless, speciﬁc studies with a close control of calcium intakes and higher vitamin D
supplementation are needed to better understand their effects on glucose and insulin homeostasis.
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Abstract: Based on a nationally representative sample of young Mexican women aged 20 to 49 years
(n = 3260), we sought to explore whether cardiovascular risk factors and acute myocardial infarction
(AMI) were associated with vitamin D deﬁciency (VDD, deﬁned as 25-OH-D <50 nmol/L). To this end,
we obtained sociodemographic, serum and anthropometric data from the 2012 National Health and
Nutrition Survey (ENSANUT 2012). Analyses were developed through logistic regression models
adjusted for potential confounders. The prevalence of VDD was signiﬁcantly higher in obese women
(42.5%, 95% CI; 37.3–47.9) compared to women with a normal body mass index (29.9%, 95% CI;
23.5–37.1, p = 0.05), in those with high total cholesterol (TC) (45.6% 95% CI; 39.4–51.9) compared to
those with normal TC levels (33.9%, 95% CI 30–38.1, p = 0.03), and in those with insulin resistance (IR)
(44%, 95% CI; 36.9–51.7) or type 2 diabetes mellitus (T2DM) (58.6%, 95% CI 46.9–69.4) compared to
those with normal glycemia (no insulin resistance: 34.7%, 95% CI; 30.9–38.8, p = 0.04 and no T2DM:
34.9%, 95% CI 31.4–38.6, p < 0.001). Utilizing individual models to estimate cardiovascular risk
according to VDD, we found that the odds of being obese (odds ratio, OR: 1.53, 95% CI 1.02–2.32,
p = 0.05), or having high TC levels (OR: 1.43, 95% CI; 1.05–2.01, p = 0.03), T2DM (OR: 2.64, 95% CI;
1.65–4.03, p < 0.001), or IR (OR: 1.48, 95% CI 1.04–2.10, p = 0.026) were signiﬁcantly higher in women
with VDD (p < 0.05). Odds were not statistically signiﬁcant for overweight, high blood pressure,
sedentarism, AMI, high serum concentration of triglycerides, homocysteine, or C-reactive protein
models. In conclusion, our results indicate that young Mexican women with VDD show a higher
prevalence of cardiovascular risk factors.
Keywords: vitamin D deﬁciency; 25-OH-D; women; cardiovascular risk factors; T2DM; obesity
1. Introduction
Receptors for vitamin D (VD) and VD activity have been found in many body tissues, suggesting
non-calcemic eﬀects of VD related to the regulation of cell proliferation and diﬀerentiation, immune
response, insulin production, and insulin sensitivity [1–3]. These recognized actions of VD suggest that
VD plays a role in the prevention of many chronic diseases such as cancer and cardiovascular disease
(CVD) [4], but observational studies have not consistently found any association between VD deﬁciency
(VDD) and chronic conditions such as type 2 diabetes mellitus (T2DM), metabolic syndrome, high
blood pressure (HBP), and other cardiovascular risk factors [5–9]. Moreover, several supplementation
experiments aimed at preventing pathologies associated with VDD have been carried out, but they
have yielded contradictory results as regards to the association of VDD with obesity, insulin sensitivity,
and insulin secretion, casting doubt on the association of these conditions with VDD [10–12].
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In 2013, the three leading causes of disability-adjusted life years (DALYs) in Mexico were diabetes,
ischemic heart disease, and chronic kidney disease, with fasting plasma glucose, high body-mass
index (BMI), and HBP being the main risk factors [13]. It is crucial to understand the role of VDD in
the occurrence of cardiovascular disease, particularly among young women, in order to help prevent
negative health consequences not only for these women in the form of osteoporosis, preeclampsia, or
chronic diseases [14,15], but also for their infants, whose bone health and neurological development
are inﬂuenced by the VD status of their mothers [16,17].
Although little research has been performed concerning VDD inwomen of reproductive age [18], it
is well known that long lactation periods and the use of sunscreen constitute risk factors formiddle-aged
and elderly women [19,20]. Studies in Mexico have revealed high rates of VDD among children and
women of reproductive age (≈36%), with an even higher prevalence observed in the presence of obesity,
in urban areas and in subjects with low dietary intake of VD [21,22].
A recent cohort study in Mexico documented an inverse association between VD intake and
cardiovascular risk factors among adults; however, the sample was not nationally representative and
25-OH-D levels were not measured [23]. In addition, most international reports on the relationship
between VDD and cardiovascular risks have not addressed several cardiovascular risks together,
and few research eﬀorts have focusedonyoung and/or non-pregnantwomen [6]. Therefore, the objective
of this study, conducted among a probabilistic national sample of Mexican women of reproductive
age (20 to 49 years old), was to explore whether VDD was associated with sedentarism, overweight,
obesity, T2DM, insulin resistance (IR), HBP, high total cholesterol (TC), low high-density lipoprotein
cholesterol (HDL-C), high triglycerides (TGs), high homocysteine (Hcy) or C-reactive protein (CRP),
and acute myocardial infarction (AMI).
2. Materials and Methods
Study population: This analysis was performed among a sample of 3260 women participating
in the 2012 National Health and Nutrition Survey (ENSANUT 2012). The ENSANUT 2012 was a
probabilistic population-based survey stratiﬁed by cluster and representative at the national, regional
and urban/rural levels [24]. A detailed description of its sampling method has been published
previously [25]. We analyzed the VD data of 3260 women aged 20–49 years with complete information
on T2DM, serum concentrations of TC, HDL-C, TG, CRP, IR, and high levels of Hcy.
2.1. Sociodemographic Information
Sociodemographic information was collected using validated questionnaires. A Well-Being Index
(WBI) was constructed according to the characteristics of and the property owned by households in
a principal component analysis. The ﬁrst component, representing 40% of total variability with a
lambda of 3.4, was divided into tertiles in order to classify the WBI as low, medium, and high [26].
Localities with fewer than 2500 inhabitants were deﬁned as rural and otherwise as urban. As in
previous ENSANUTs, the country was divided into three regions: north, center (including Mexico City),
and south. An individual was deﬁned as indigenous where one of the members of the household
spoke an indigenous language as his/her mother tongue.
2.2. Anthropometry
Body weight was measured using an electronic scale with a precision of 100 g, (Tanita Co., Tokyo,
Japan), and height using a stadiometer with a precision of 1 mm (Dynatop, Mexico City). These
measurements were performed by specialized personnel utilizing the Lohman method [27], and were
standardized according to the Habitch method [28].
2.3. Blood Samples
Eight-hour-fasting blood samples were drawn from the winter of 2011 to the spring of 2012,
between the latitudes of 14◦ 54’ and 32◦ 31’ N. Blood samples were drawn from an antecubital vein and
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collected in evacuated tubes. Serum was separated by in situ spinning-down at 3000 g. Serum samples
were immediately stored in codiﬁed cryovials and preserved in liquid nitrogen until delivery to the
Central Nutrition Laboratory at the National Institute of Public Health (INSP), in Cuernavaca, Morelos,
Mexico. Thereafter, the samples were preserved at −70◦C in a deep freezer until chemical analysis.
A chemiluminescence microparticle immunoassay was used to measure serum 25-OH-D, with
intra- and inter-assay coeﬃcient-of-variation (CV) results of 1.34 and 3.69%, respectively. This method
has proved acceptable compared to LC/MS/MS (r = 0.73) [29]. Quality control was performed according
to the reference standard serum NIST 968E of the National Institute of Standards & Technology.
The serum concentrations of TC were measured using an enzymatic and oxidation method, glucose by
the glucose oxidase technique, HDL-C by direct enzymatic assay after eliminating chylomicrons from
the sample, TG by lipase hydrolysis, and Hcy and CRP using ultrasensitive monoclonal antibodies in
an Architect CI8200 automatic analyzer (Abbott Lab, Michigan, MI, USA). The intra- and inter-assay
CV results were 1.05 and 1.97% for glucose, 2.2% and 5.7% for TC, 3.5% and 5.02% for TG, 5.3 and 7.4%
for HDL-C, 3.7% and 4.6% for Hcy, and 0% and 1.2% for CRP, respectively. For insulin, the intra-assay
CV was 1.28 uU/mL.
2.4. Vitamin D Deﬁciency
VDD was deﬁned as a serum level of 25-OH-D <50 nmol/L (<20 ng/mL), as in most studies in
Latin America [3,30].
2.5. Deﬁnitions of Outcome Variables
T2DM was deﬁned as diabetes previously diagnosed by a physician or a fasting blood glucose
level of ≥126 mg/dL [31].
Serum biomarkers. The following were considered abnormal serum concentrations: TC >200 mg/dL,
TG >150 mg/dL, and HDL-C ≤50 mg/dL [32]. Hcy >10.4 nmol/L was considered abnormal [33].
Inﬂammation was determined where CRP was >5 mg/dL [34], and IR was deﬁned when homeostatic
model assessment of IR (HOMA-IR) was ≥3.8 [35].
Overweight and obesity were based on the body mass index (BMI) as classiﬁed by the WHO
guidelines (normal BMI ≤24.9 kg/m2; overweight 25–29.9 kg/m2, and obesity >30 kg/m2) [36].
HBP was deﬁned as a previous diagnosis by a physician of hypertension or a systolic blood
pressure >140 mmHg and/or a diastolic blood pressure >90 mmHg [37].
AMI was deﬁned when acute myocardial infarction was self-reported by the subject.
Sedentarism. A lifestyle was deﬁned as sedentary where a woman was classiﬁed as having low
physical activity according to a validated International Physical Activity Questionnaires (IPAQ) [38].
2.6. Statistical Analysis
VDD prevalence rates were reported as proportions with a conﬁdence interval (CI) of 95%; risks
were expressed as odds ratios (ORs) with a CI of 95%. The signiﬁcance level was established at an
alpha <0.05, and regression models were adjusted by age, BMI, dwelling (urban/rural), geographical
region, ethnicity, WBI, and sedentarism, as well as by the survey design, using the module SVY of
STATA SE v14 (College Station, TX, USA, 2013).
Ethical aspects. The ENSANUT 2012 protocol was reviewed and approved by the Research, Ethics
and Biosecurity Committees of the National Institute of Public Health in Mexico. Prior informed
consent letters were signed by all participants.
3. Results
3.1. Characteristics of the Sample
Serum 25-OH-D levels were estimated for 3260 women representing 19 million Mexican women,
aged 20–49 years. In this subsample, 33.4% suﬀered from overweight, 36.4% from obesity and 25% were
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sedentary. The prevalence rates for T2DM and HPB were 7.6% and 19.5%, respectively. The overall
prevalence of cardiovascular risk factors was 48.3%, and within this group, 80.9% had a low HDL-C,
37.1% high TC, 37.1% high TG, 11.8% high Hcy, and 21.6% high CRP (Table 1).
Table 1. Characteristics and distribution of the sample.
Variable Subgroup % (95% CI) *
Age (years)
20–29 36.2 (33, 39.6)
30–39 37.1 (33.8, 40.5)
40–49 26.8 (24.2, 29.6)
Dwelling Rural 21.5 (19.7, 23.4)
Urban 78.6 (76.7, 80.4)
Region of the country
North 22.4 (20.7, 24.2)
Center 47.7 (45.2, 50.2)
South 30.1 (27.9, 32.3)
Well-Being Index
Tertile 1 (lower) 25.5 (23.2, 27.9)
Tertile 2 31.6 (28.8, 34.6)
Tertile 3 (higher) 43.1 (39.7, 46.6)
Ethnicity No 94.7 (93.4, 95.7)
Yes 5.3 (4.3, 6.6)
BMI category
Normal 30.3 (27.2, 33.5)
Overweight 33.4 (30.4, 36.6)
Obesity 36.4 (33.4, 39.6)
Sedentarism
No 70.4 (67.2, 73.3)
Yes 29.6 (26.7, 32.8)
T2DM
No 92.4 (90.4, 94.0)
Yes 7.6 (6.0, 9.7)
HBP
No 87.9 (85.3, 90.0)
Yes 19.5 (17.0, 22.3)
TC
<200 mg/dL 75.8 (72.8, 78.6)
≥200 mg/dL 24.2 (21.5, 27.2)
HDL-C
≥50 mg/dL 19.1 (16.3, 22.2)
<50 mg/dL 80.9 (77.7, 83.7)
TG
<150 mg/dL 62.9 (59.8, 66.0)
≥150 mg/dL 37.1 (34.0, 40.3)
AMI
No 98.7 (98.2, 99.1)
Yes 1.20 (0.81, 1.76)
Hcy <10.4 nmol/L 87.9 (85.3, 90.0)≥10.4 nmol/L 12.1 (9.9, 14.6)
IR
<3.8 HOMA-IR 79.4 (76.2, 82.3)
≥3.8 HOMA-IR 20.6 (17.7, 23.8)
CRP
<5 g/L 78.4 (75.8, 80.9)
≥ 5 g/L 21.6 (19.1, 24.2)
N sample = 3260, n expanded = 19,336,909. CI: Conﬁdence Interval; BMI: body mass index; T2DM: type 2 diabetes
mellitus; HBP: high blood pressure; TC: total cholesterol; HDL-C: high-density lipoprotein; TG: triglycerides; AMI:
acute myocardial infarction; Hcy: homocysteine; IR: insulin resistance; CRP: C-reactive protein * Expanded %
and 95% CI.
3.2. Prevalence of VDD
The overall prevalence of VDD was 37.2%, signiﬁcantly higher among women with T2DM
compared to women without it (58.6% vs. 34.5%, p < 0.05). VDD was also higher among women with
obesity (42.5%) vs. normal BMI (29.9%, p < 0.05), and with high TC (45.6 vs. 33.9%, p < 0.05) and
high TG (41.7 vs. 33.8%, p < 0.09). No diﬀerences emerged regarding the relationships between VDD
prevalence and the other cardiovascular risk factors evaluated independently (Figure 1).
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3.3. Cardiovascular Risk Factors and VDD
We analyzed adjusted logistic models introducing each chronic non-communicable disease and
cardiovascular risk factor as dependent variables together with VDD as the independent variable
(Figure 2 and Table S1). We found that the risk of obesity was signiﬁcantly higher in women with VDD
(OR: 1.53, p < 0.05) than in women without. The risk was also higher when IR (OR: 1.48, p < 0.05),
T2DM (OR: 2.58, p < 0.05) or high TC (OR: 1.45, p < 0.05) was present. These models were adjusted by
other cardiovascular risk factors as confounding variables. No association was signiﬁcant between
VDD and the rest of the cardiovascular risk factors.
In estimating the prevalence of severe VDD (<20 nmol/L), we found that it was notably low (2.3%,
95% CI 1.3–3.9) and had no signiﬁcant relationship with cardiovascular outcomes (data not shown).
We also tested interactions between VDD and age, BMI and sedentarism, and stratiﬁed analysis by oral
use of hypoglycemic (n = 154), antihypertensive (n = 129), and hypolipemic drugs (n = 210), as well as
by menstrual cycle status, and no impact was observed; therefore, the results were not presented.
4. Discussion
Our study found that VDD was associated with a higher risk for T2DM, obesity, and high TC
concentrations in young Mexican women. The major ﬁnding of our analysis was the strong association
between VDD and a greater risk of T2DM, a result also yielded by other cross-sectional studies [39–42].
On the other hand, some published clinical trials have reported an association between VDD and
increased insulin resistance, metabolic syndrome hyperglycemia [43–45], while others have not [12,46].
Several researchers have foundan association between intake ofVDand calciumand theprevention
of T2DM [11]. Other researchers have administered cholecalciferol weekly for six months and found no
diﬀerence in insulin response or insulin sensitivity in adults at risk of diabetes mellitus [12]. However,
for those with prediabetes, VD supplementation has been shown to improve insulin sensitivity [12,47].
Such an eﬀect could be the result of the interaction of calcium ﬂuxes with the VD receptors in the β-cells,
needed for the optimal secretion of insulin [48,49]. 25-OH-D induces synchronous Ca2+ oscillations
with a pattern of pulsatile insulin secretion from the β-cells [50,51]. This may explain the lower level of
insulin sensitivity and secretion, as well as all levels of glucose intolerance. Our study showed that IR
was signiﬁcantly associated with VDD and T2DM.
An association between VDD and increased adiposity among Mexican women has previously
been demonstrated [22]. Our analysis revealed that VDD was 12.6 percentage points higher in obese
women than in those with a normal BMI. We hypothesized that such an association could increase
the risk for high rates of TSDM, metabolic syndrome, hypertension, and dyslipidemias found in the
Mexican population [52,53]. However, it is not yet known if VDD is a cause or a consequence of obesity
in humans, and an ample review of the literature provides evidence for both arguments [54].
Although subjectswith a higher BMI had greater skin exposure for VD conversion, an experimental
exposure to UV rays produced half the amount of serum VD in women with a high as opposed to a
normal BMI [55]. Thus, it is possible that the amount of VD previously contained in the body fat of
obese women was large enough to interfere with the conversion or incorporation of 25-OH-D into
the serum pool. In a clinical trial involving calcium and VD supplements among overweight and
obese individuals, was observed a signiﬁcant reduction of visceral fat [56]. Obese subjects have greater
adipose stores of VD. This enlarged adipose mass in obese individuals serves as a VD reservoir, and the
increased amount of VD required to saturate this depot may predispose obese individuals to have an
inadequate level of 25-OH-D [57].
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Our study found that women with VDD had a 1.43 times greater risk (95% CI 1.03–1.99) for high
levels of TC compared to women with suﬃcient VD concentrations (p = 0.04). This may be a result of
the suppressive eﬀect of VD on the parathyroid hormone (PTH), which reduces lipolysis. Similarly, it
has been suggested that VD increases calcium concentrations, reducing the synthesis de novo and
releasing hepatic TG [58]. Observational studies have reported that women with VDD have a higher
risk of lipid concentration as compared to women with adequate VD status [59–61]. However, in a
meta-analysis involving 12 clinical trials with 1346 subjects, VD supplementation was associated with
improved LDL-C concentrations, but not with improved TG, HDL-C or TC levels [62]. Meanwhile,
a recent randomized controlled trial in postmenopausal women showed positive eﬀects in VD status,
bone mineral density, glucose, TC, LDL-C, and apolipoprotein B100 after 24 months of intake of vitamin
D-enriched milk [63].
Our study found no association between HBP and VDD, reﬂecting the ﬁndings of other
studies [64,65]. However, some observational and randomized clinical trials have found a negative
correlation between the two variables [66,67].
The cross-sectional nature of the 2012 ENSANUT makes it diﬃcult to establish causality. However,
our results are representative for the entire population of Mexican women aged 20–49 years and
for countries with similar socioeconomic characteristics. Another limitation was that data for some
variables were collected by means of self-reporting, potentially introducing a degree of measurement
bias. Nonetheless, data for all variables were collected in a similar manner; thus, the bias will not aﬀect
results for the target population, and the results might even underestimate a potential association.
In our analyses, we adjusted results by menstrual cycle status with no signiﬁcant alteration in the
associations, but we were unable to adjust by the current use of estrogen-containing contraception that
has been associated with increases in 25-OH-D levels in other populations [19,68]. Nevertheless, in our
sample 88% of women had been pregnant and 28% had been sterilized after childbirth. According to
the National Survey Report, in 2012 the rate of use of hormonal contraceptives among Mexican women
was 12.5% for those aged 20–29 years old, 7.3% among 30–39 year-olds, and 4.6 among 35–49 year-olds,
while 42% to 53% reported not using any contraceptive method [69]. Among the strengths of this study
is its population-based sample, that allows for representativeness for Mexican women 20–49 years,
and the fact that the study includes information on VD serum levels and CVD risk factors.
5. Conclusions
The prevalence of VDD among women 20 to 49 years old is a public health problem in Mexico.
Obesity, T2DM, IR, and high TC were found to be associated with VDD. Further research is necessary
to assess the biological mechanisms underlying all of these factors and their association with VDD.
Also, this study provides scientiﬁc evidence supporting the need for public health and nutrition
interventions aimed at improving the vitamin D status of Mexican women.
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Abstract: Zinc could have a protective role against type 2 diabetes mellitus (T2DM). This systematic
review and meta-analysis aimed to evaluate the association between dietary, supplementary, and
total zinc intake, as well as serum/plasma and whole blood zinc concentration, and risk of T2DM.
Observational studies, conducted on cases of incident diabetes or T2DM patients and healthy
subjects that reported a measure of association between zinc exposure and T2DM, were selected.
Random eﬀects meta-analyses were applied to obtain combined results. Stratiﬁed meta-analyses and
meta-regressions were executed to assess sources of heterogeneity, as well as the impact of covariates
on the ﬁndings. From 12,136 publications, 16 studies were selected. The odds ratio (OR) for T2DM
comparing the highest versus lowest zinc intake from diet was 0.87 (95% CI: 0.78–0.98). Nevertheless,
no association between supplementary or total zinc intake from both diet and supplementation, and
T2DM was observed. A direct relationship was found between serum/plasma zinc levels and T2DM
(OR = 1.64, 95% CI: 1.25–2.14). A moderately high dietary zinc intake, in relation to the Dietary
Reference Intake, could reduce by 13% the risk of T2DM, and up to 41% in rural areas. Conversely,
elevated serum/plasma zinc concentration was associated with an increased risk of T2DM by 64%,
suggesting disturbances in zinc homeostasis.
Keywords: zinc intake; zinc status; trace elements; type 2 diabetes mellitus; systematic review;
meta-analysis; epidemiology
1. Introduction
Diabetes mellitus is a major public health challenge worldwide, and is a key contributor to
morbidity and mortality. In 2016, diabetes mellitus was listed as the seventh leading cause of death
globally [1]. According to the International Diabetes Federation (IDF) Diabetes ATLAS, the global
prevalence of diabetes among individuals aged 20–79 years in 2017 was 8.8% (95% conﬁdence interval
Nutrients 2019, 11, 1027; doi:10.3390/nu11051027 www.mdpi.com/journal/nutrients108
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(CI): 7.2–11.3), i.e., 424.9 million people, with a total healthcare expenditure estimated at just under USD
727 billion [2]. The number of people suﬀering from diabetes is expected to increase to 628.6 million in
2045, a prevalence of over 9.9% (95% CI: 7.5–12.7). Around 90% of cases of diabetes are type 2 diabetes
(T2DM) [2]. This disease results from the body’s ineﬀective use of insulin [1], and is the result of the
interaction of multiple genetic and environmental factors [3].
The role of zinc in the etiology of T2DM has been widely reported in recent decades. Longitudinal
large prospective cohort studies, such as the Nurses’ Health Study (NHS) cohort [4] in the USA; the
Australian Longitudinal Study on Women’s Health cohort study [5]; the Malmö Diet and Cancer Study
cohort [6] in Sweden; and the Japan Collaborative Cohort study [7], among others, have investigated
the eﬀect of dietary, supplementary, and/or total zinc intake on the risk of developing T2DM. The
NHS cohort was the ﬁrst to prospectively analyze these relationships, and it reported that the higher
the total and/or dietary zinc intake, the lower the risk of T2DM over subsequent years [4]. Although
a non-signiﬁcant association was observed between supplementary zinc intake and risk of T2DM
in the overall sample, an inverse relationship was seen in those participants with low dietary zinc
intake [4]. There is currently no evidence that supports the use of zinc supplements in the prevention
of T2DM [8]. Nevertheless, a recent clinical trial based on zinc supplementation has found a reduction
in the progression to diabetes in prediabetic subjects [9]. Some subsequent prospective cohort studies,
however, have failed to conﬁrm some of the results reported in the NHS cohort [6,10–12]. A systematic
review of prospective studies that aimed to examine the role of zinc intake and status on the risk of
T2DM revealed inconsistencies between studies, and suggested the possible inﬂuence of confounding
factors on these relationships [13].
Similarly, ﬁndings on the relationship between serum/plasma zinc concentration and T2DM
are contradictory [14–16]. The prospective Kuopio Ischaemic Heart Disease Risk Factor (KIHD)
cohort study of 2220 Finnish men followed over twenty years showed that higher serum zinc
levels were associated with an increased risk of T2DM [14]. Conversely, a cross-sectional study of
128 Russian postmenopausal women found an inverse relationship between serum zinc and T2DM [17].
The relationship between whole blood zinc concentration and T2DM has been investigated by two
studies carried out within the same population-based Nord-Trøndelag Health Study (HUNT3), but
their results were inconclusive [18,19]. The study conducted on newly diagnosed T2DM patients
found a positive association between whole blood zinc concentration and T2DM [18], while the study
performed in previously diagnosed T2DM patients showed no association [19]. In our previous
systematic review and meta-analysis, which aimed to compare whole blood zinc concentration between
T2DM patients and non-diabetic subjects, we observed a lower whole blood zinc concentration in
T2DM patients [20]. It should be noted that diabetic subjects had, at least, 10.2 ± 8.6 years of duration
of diabetes. Therefore, the duration of diabetes may have an impact on this association, and it is
important to clarify this relationship.
The mechanism whereby zinc could have an impact on the risk of T2DM has not been completely
elucidated, however zinc is an essential trace element that is involved in the physiology of carbohydrate
metabolism in many ways. Zinc participates in the adequate insulin synthesis, storage, crystallization,
and secretion in the pancreatic β-cell, as well as action and translocation of insulin into the
cells [21–24]. In addition, zinc seems to play a role in insulin sensitivity through the activation
of the phosphoinositol-3-kinase/protein kinase B cascade [25]. Due to its insulin–mimetic action, zinc
also stimulates glucose uptake in insulin-dependent tissues [26]. Moreover, zinc is implicated in the
suppression of proinﬂammatory cytokines, such as interleukin-1β [27] and nuclear factor kβ [28],
avoiding β-cells’ death and protecting insulin. All of these functions of zinc could support its potential
protective role against diabetes mellitus.
Much remains uncertain concerning the eﬀect of zinc on the risk of developing T2DM. Therefore,
the purpose of this comprehensive systematic review and meta-analysis of observational studies was to
evaluate the association between dietary, supplementary, and total zinc intake, as well as serum/plasma
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zinc and whole blood concentration and risk of T2DM in the adult population. A secondary objective
was to examine potential confounding factors that may impact on these relationships.
2. Materials and Methods
The protocol for this systematic review and meta-analysis of observational studies was registered
in PROSPERO (2015: CRD42015020178) and can be accessed here: (http://www.crd.york.ac.uk/
PROSPERO/display_record.php?ID=CRD42015020178). The study was conducted in accordance
with the Meta-Analyses of Observational Studies in Epidemiology (MOOSE) criteria statement [29].
The MOOSE checklist is shown in Supplementary Materials Table S1.
2.1. Search Strategy
This systematic review and meta-analysis were carried out by six investigators within the
framework of the EURopean micronutrient RECommendations Aligned (EURRECA) Network of
Excellence, one aim of which was to undertake a series of systematic search for studies assessing the
eﬀect of zinc on diﬀerent health outcomes. A comprehensive search was developed in MEDLINE
(Ovid), Embase (Ovid), and The Cochrane Library (CENTRAL) up to January 2019, using search
terms for (“study designs in humans”) AND (Zinc) AND (intake OR status). Additional articles were
identiﬁed through manual searching and citation tracking (Figure 1).
12.135 Records identified through 
MEDLINE (Ovid), Embase (Ovid) 
and The Cochrane Library 
(CENTRAL) 
 
93 Full-text manuscripts excluded: 
15 Without zinc exposure 
3 Without T2DM 
3 Diabetes other than T2DM 
11 Non-observational design 
61 Without measure of association 
 
105 Potentially relevant manuscripts 
identified for further full-text review 
 
12.030 Records excluded based on titles and 
abstracts: 
1648 Children 
440 Without zinc exposure 
5747 Without T2DM 
52 Diabetes other than T2DM 
797 Non-observational design 
676 Without measure of association 
2670 Duplicates 
 
16 Manuscripts included in the 
meta-analyses 
4 Manuscripts retrieved from manual searching 
Figure 1. Flowchart of the selection process.
2.2. Study Eligibility Criteria
Studies were selected according to the following inclusion criteria: (1) studies of observational
design, including prospective cohort, case-control, and cross-sectional; (2) studies conducted on
human adults, with type 2 diabetes mellitus (T2DM) or cases of incident diabetes and healthy control
individuals or controls of non-incident diabetes; (3) publications reported in English, Spanish or other
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European languages; (4) studies that reported a measure of association, such as relative risk (RR),
odds ratio (OD) or hazard ratio (HR), between dietary, supplementary, and/or total zinc intake and/or
serum/plasma and/or whole blood zinc concentration and T2DM, through a multivariable adjusted
analysis that compared the highest quantile of zinc exposure versus the lowest. Studies that compared
user versus non-user of zinc supplements in relation to T2DM were also selected. Other kinds of
observational study designs, such as case reports, case series or ecological studies; reviews; and
experimental or quasi-experimental studies, as well as those with participants diagnosed with diabetes
mellitus other than T2DM, were excluded.
2.3. Study Selection
Titles and abstracts of studies identiﬁed through the literature search were independently screened
for eligibility. Subsequently, the full text of relevant studies was retrieved and examined further against
the inclusion and exclusion criteria. Reasons for excluding studies were recorded. The selection
process was independently completed by members of the research team (JCFC, MWM, VHM, CD,
and NL). A 10% sample was cross-checked by another investigator (MWM) to ensure consistency
between reviewers, and any discrepancy or disagreement was resolved by discussion until consensus
was reached among the reviewers.
2.4. Data Extraction and Study Quality Assessment
One reviewer (JCFC) carried out the data extraction process using a data-extraction spreadsheet.
Two other reviewers (VHM and NL) independently screened the accuracy of the extracted data.
In order to avoid the inclusion of duplicate data in the meta-analyses, some strategies were applied:
ﬁrst, the name of the project was recorded for all studies that met the inclusion criteria, as well as the
geographic location where the studies had been conducted; second, the lists of authors were compared
among them. Complementary data from the same project was included for a qualitative summary.
From each manuscript selected for inclusion, the following data were extracted into an excel
spreadsheet: study identiﬁcation (ﬁrst author’s name, year of publication, and name of the project),
study characteristics (study design, period of follow-up, measure of association, adjustment variables,
quality score, country, geographic regions, geographic area, sample base, matched design, sample size
for each group and total, zinc assessment method, zinc quantiles adjusted for energy, ascertainment of
T2DM, percentage of T2DM subjects, eﬀect size, and 95% conﬁdence interval (CI) for the most adjusted
model), and study population (age, gender, ethnicity, area of residence—dietary, supplementary and
total zinc intake, as well as serum, plasma, and whole blood zinc concentration—BMI, fasting glucose
levels, stage of diabetes). To incorporate relevant data in forms other than the mean and standard
deviation, such as median and the interquartile range, estimation methods proposed by Wan et al., [24]
were applied, which are valid for both normal and skewed data. When covariates of interest were
expressed as a range, the midpoint of the range was assumed. If any of the data were missing, the
authors were contacted for additional data.
The quality of studies selected was evaluated by one research investigator (JCFC) using the
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement [25].
The STROBE checklist is shown in Supplementary Materials Table S2. The quality score was used to
assess its possible inﬂuence on results.
2.5. Statistical Analysis
Meta-analyses comparing the highest versus the lowest quantile of exposure to zinc intake and/or
status were performed when at least two studies with a common exposure in relation to T2DM were
available. For all meta-analyses, eﬀect size and 95% CIs were log-transformed. Estimated standard
errors were calculated from log 95% CIs by subtracting the lower bound of the CI from the upper
bound and subsequently dividing by two times 1.96. The method of a random-eﬀects model and
the generic inverse variance method were used to calculate the pooled eﬀect sizes, reported as OR
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and 95% CI. Relative risks and hazard ratios were deemed equivalent to ORs [30]. The most adjusted
model of the multivariable analysis in the selected studies was used to estimate the eﬀect size in all
meta-analyses. Forest plots were created to visualize individual and global estimates. As the studies
included in the meta-analysis on supplementary zinc intake and T2DM reported exposure either in
quantiles or as dichotomous variable (user versus no user), a stratiﬁed meta-analysis was performed
based on these criteria.
Univariate and multivariate meta-regressions with Knapp–Hartung modiﬁcation [31] were
conducted to examine the potential impact of certain covariates on eﬀect size. To display relevant
results of a single continuous covariate in univariate meta-regressions, bubble plots were created.
This graph represents the ﬁtted regression line together with circles representing the estimates from
each study, sized according to the precision of each estimate (the inverse of its within-study variance).
Multivariatemeta-regressionsmodelswere executed adding the covariatewith the strongest association
in univariate analysis ﬁrst and then adding the next one in turn. Covariates showing collinearity were
removed from the ﬁnal multivariate model. Finally, a meta-regression equation was generated using
the intercept (a), as well as the regression coeﬃcient (b) of a speciﬁc covariate, to know how the eﬀect
size (OR for T2DM) changes with a unit increase in the exploratory covariate (Ln (ORT2DM) = (a) + b ×
(covariate)).
Heterogeneity was assessed by the Cochran Q-statistic and the I2 statistic to quantify the
percentage of variation attributable to between-study heterogeneity [32]. I2 values of 25%, 50%, and
75% were considered as low, medium, and high heterogeneity, respectively [33,34]. Potential sources
of heterogeneity were explored through stratiﬁed analyses and univariate meta-regressions, even if an
initial heterogeneity was non-signiﬁcant [35], using diﬀerent variables. Thus, categorical variables were:
study design, study design and area of residence, measures of association, quality score, geographic
regions, location, sample base, matched design, sample size, zinc intake assessment method, zinc
serum/plasma assessment method, ascertainment of T2DM, diagnostic pattern, percentage of T2DM,
gender, ethnicity, area of residence, group with higher serum/plasma zinc levels, zinc quantiles adjusted
for energy. In addition, continuous variables were also used, such as sample size for each group and
total, period of follow-up (years), quality score (%), percentage of T2DM subjects (%), age in cases
and controls (years), age diﬀerence and ratio between cases and controls (years), serum/plasma zinc
levels in cases and controls (μg/dL), serum/plasma zinc diﬀerence and ratio between cases and controls
(μg/dL), BMI in cases and controls (kg/m2), BMI diﬀerence and ratio between cases and controls (kg/m2),
fasting glucose levels in cases and controls (mmol/L), and fasting glucose diﬀerence and ratio between
cases and controls (mmol/L). Multivariate meta-regressions were also utilized to examine further the
covariates that had a signiﬁcant inﬂuence on heterogeneity in univariate analysis. In addition, the
proportion of between-study variance explained by one or more covariates was estimated through the
adjusted R2 (RA2). Likewise, the percentage of residual variation due to heterogeneity which remains
unexplained by one or more covariates (Ir2) was obtained.
To assess the power of each study on the overall pooled estimates, sensitivity analysis was
performed using the leave-one-out method [36], where one study was excluded at a time, evaluating
the impact of removing each of the studies on the summary results and the between-study heterogeneity.
Furthermore, publication bias was investigated by visual inspection of funnel plots and quantitatively
assessed using Egger’s [37] and Begg’s [38] tests. All analyses were performed with STATA statistical
software, version 15.0. (STATA Corp., College Station, Texas, USA).
3. Results
The literature search strategy generated 12,136 publications, and 16 studies were ﬁnally selected
for this systematic review and meta-analysis of observational studies [4–7,10–12,14–19,39–41]. There
were no studies that were excluded for reasons of language. The details of the selection process and
the reasons for exclusion are shown in the ﬂowchart (Figure 1). The quality of selected publications,
according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
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Statement [42], was high. The compliance percentages of the STROBE items were between 69 and 100%,
14 of the 16 selected studies above 80% [4–7,10–12,14–19,39,41]. The characteristics of the included
studies for meta-analyses are summarized in Tables 1–3.
3.1. Dietary Zinc Intake and T2DM
Seven prospective cohort studies [4–7,10,11] and one cross-sectional study [39] were included in
the meta-analysis of the association between dietary zinc intake and T2DM (Table 1). Five studies
were carried out in the western countries (USA, the Nurses’ Health Study (NHS) cohort [4], the
Multi-Ethnic Study of Atherosclerosis (MESA) cohort [10], and the Coronary Artery Risk Development
in Young Adults (CARDIA) cohort [11]; Australia, the Australian Longitudinal Study on Women’s
Health (ALSWH) cohort [5]; and Sweden, the Malmö Diet and Cancer Study (MDCS) cohort [6]),
and two in the eastern countries (India [39], and Japan, the Japan Collaborative Cohort (JACC) [7]).
This meta-analysis comprised 146,027 participants aged between 18 and 84 years, and of both genders,
belonging to diﬀerent ethnic groups (Hispanic, Caucasian, African American, Chinese or South Asian,
among others), and areas of residence (rural or urban). During the follow-up of participants, between
4.8 years on average in the MESA cohort [10] and 24 years in the NHS cohort [4], 11,511 cases of T2DM
were detected (7.8%). The percentage of T2DM cases was highly variable between the studies, from
2.5% in the JACC study [7] to 14.1% in the Swedish MDCS cohort [6].
Dietary zinc intake was collected using validated food frequency questionnaires (VFFQs) [4,5,7,10],
validated diet history questionnaires (VDHQ) [6,11], or a 7-day dietary record [39]. The mean of dietary
zinc intake ranged from 5.6 ± 1.6 mg/day in urban women from India [39] to 16.7 mg/day in urban
subjects from the USA [11]. Ascertainment of T2DM was carried out through diﬀerent criteria (fasting
plasma glucose (FPG) and/or oral glucose tolerance test (OGTT), and/or self-reported, and/or using
registries from diﬀerent institutions, and/or use of antidiabetic drugs).
To evaluate the association between the dietary zinc intake and the T2DM, a meta-analysis was
conducted (Figure 2). The pooled eﬀect size for T2DM comparing the highest versus lowest dietary
zinc intakes was 0.87 (95% CI: 0.78–0.98), with moderate to high heterogeneity (I2 = 64.5%, p = 0.003).
NOTE: Weights are from random effects analysis
Overall  (I-squared = 64.5%, p = 0.003)
ID
Singh, 1998 (Rural men)
Sun, 2009 (Urban women)
Drake, 2017 (Urban men/women)
Vashum, 2013 (Rural women)
Singh, 1998 (Urban women)
Park, 2016 (Urban men/women)
de Oliveira Otto, 2012 (Urban men/women)
Singh, 1998 (Rural women)
Study
Eshak, 2017 (Rural men/women)
Singh, 1998 (Urban men)
0.87 (0.78, 0.98)
OR (95% CI)
0.61 (0.28, 1.33)
0.92 (0.84, 1.00)
1.07 (0.88, 1.30)
0.50 (0.32, 0.78)
0.85 (0.74, 0.97)
1.27 (0.81, 2.00)
1.41 (0.88, 2.26)
0.58 (0.36, 0.94)
0.64 (0.47, 0.87)
0.90 (0.82, 0.98)
100.00
Weight
2.01
19.64
13.58
5.29
17.00
5.02
4.70
4.60
%
8.62
19.54
  1.25 2.3
Figure 2. Forest plot of pooled eﬀect size of the highest versus lowest dietary zinc intake for T2DM.
Squares represent odds ratios (OR) for each study, and the size of the square is the study-speciﬁc
statistical weight. Horizontal lines indicate the 95% CI of each study. Diamond represents the combined
OR estimate with corresponding 95% CI.
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Through a stratiﬁed analysis based on the area of residence of participants, rural versus urban,
(Figure 3) we observed a higher and signiﬁcant eﬀect size in rural areas (OR = 0.59, 95% CI: 0.48–0.73),
and undetectable heterogeneity (I2 = 0.0%, p = 0.843), meanwhile in urban areas the eﬀect became
non-signiﬁcant (OR = 0.94, 95% CI: 0.86–1.02; I2 = 43.9%, p = 0.113). Subsequently, we used the
adjusted R2 to examine how much of the heterogeneity was accounted for by the area of residence
(Table 4), and we found that the heterogeneity was explained to a great extent (RA2 = 100.0%;
Ir2 = 17.8%). Interestingly, through a stratiﬁed analysis by the covariate “study design and area of
residence”, we observed that this protective eﬀect of dietary zinc intake in rural areas was found in both
cross-sectional and prospective studies (Figure 4). In this analysis, results were statistically signiﬁcant,
and heterogeneity was reduced (I2 = 0.0%, p > 0.050) for all subgroups, except for prospective studies
conducted in urban areas (OR = 1.04, 95% CI: 0.88–1.24; I2 = 50.7%, p = 0.107).
NOTE: Weights are from random effects analysis
.
.
Overall  (I-squared = 64.5%, p = 0.003)
Singh, 1998 (Rural men)
de Oliveira Otto, 2012 (Urban men/women)
Sun, 2009 (Urban women)
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Drake, 2017 (Urban men/women)
Vashum, 2013 (Rural women)
Singh, 1998 (Urban women)
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Singh, 1998 (Urban men)
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Park, 2016 (Urban men/women)
Subtotal  (I-squared = 0.0%, p = 0.843)
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Figure 3. Forest plot of pooled eﬀect size of the highest vs. lowest dietary zinc intake for T2DM
according to area of residence (rural vs. urban). Squares represent ORs for each study, and the size of
the square is the study-speciﬁc statistical weight. Horizontal lines indicate the 95% CI of each study.
Diamond represents the combined OR estimate with corresponding 95% CI.
The corresponding adjusted R2 for this covariate was 90.47%. However, the covariate that showed
the greatest impact on the relationship studied was the percentage of T2DM, both as continuous and
categorized variable. Thus, the stratiﬁed analysis (Figure 5) by this covariate categorized (<5/5–9.9/≥10)
revealed a signiﬁcant protective eﬀect of dietary zinc intake in those studies with <5% of T2DM
(OR = 0.59, 95% CI: 0.48–0.73; I2 = 0.0%, p = 0.843), and those between 5–9.9% (OR = 0.90, 95% CI:
0.85–0.95; I2 = 0.0%, p = 0.627), but not when it was higher than 10% (OR = 1.13, 95% CI: 0.96–1.34;
I2 = 0.0%, p = 0.499). It should be noted that the level of heterogeneity was reduced to 0.0% in all these
subgroups. The importance of this covariate in the assessed relationship was supported by the large
proportion of the between-study variance was explained (RA2 = 100.0%), as well as the undetectable
percentage of the residual variation that was attributable to the between-study heterogeneity, after
entering this covariate into a univariate meta-regression model (Ir2 = 0.0%).
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Subtotal  (I-squared = 0.0%, p = 0.914)
Singh, 1998 (Urban men)
Subtotal  (I-squared = 0.0%, p = 0.367)
Vashum, 2013 (Rural women)
Subtotal  (I-squared = 50.7%, p = 0.107)
0.87 (0.78, 0.98)
1.27 (0.81, 2.00)
0.85 (0.74, 0.97)
0.64 (0.47, 0.87)
0.92 (0.84, 1.00)
OR (95% CI)
1.41 (0.88, 2.26)
0.88 (0.82, 0.95)
0.61 (0.28, 1.33)
1.07 (0.88, 1.30)
0.58 (0.36, 0.94)
0.59 (0.39, 0.89)
0.90 (0.82, 0.98)
0.59 (0.46, 0.76)
0.50 (0.32, 0.78)
1.04 (0.88, 1.24)
100.00
5.02
17.00
8.62
19.64
Weight
4.70
36.53
%
2.01
13.58
4.60
6.62
19.54
13.91
5.29
42.94
  
1.25 2.3
Figure 4. Forest plot of pooled eﬀect size of the highest vs. lowest dietary zinc intake for T2DM
according to study design and area of residence (prospective cohort studies in rural areas, cross-sectional
studies in rural areas, cross-sectional studies in urban areas, and prospective cohort studies in urban
areas). Squares represent ORs for each study, and the size of the square is the study-speciﬁc statistical
weight. Horizontal lines indicate the 95% CI of each study. Diamond represents the combined OR
estimate with corresponding 95% CI.
A multivariate meta-regression model adding the three covariates with a signiﬁcantly higher
impact on the association, showed that only a “percentage of T2DM” continued being signiﬁcant (0.23,
95% CI: 0.02, 0.45, p = 0.037). Once the fourth covariate was introduced, none remained signiﬁcant.
When we analyzed the percentage of T2DM as a continuous variable, similar results were observed
(RA2 = 100.0%, Ir2 = 23.6%). A bubble plot was used to represent this covariate (Figure 6), and it
was found that, as the percentage of T2DM increased, the protective eﬀect of a moderately high
dietary zinc intake was reduced in a relationship deﬁned by the equation of the regression line:
(Ln(ORT2DM) = (−0.4217314) + 0.0437897 × (percentage of T2DM)).
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NOTE: Weights are from random effects analysis
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0.61 (0.28, 1.33)
0.90 (0.85, 0.95)
0.92 (0.84, 1.00)
1.41 (0.88, 2.26)
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Figure 5. Forest plot of pooled eﬀect size of the highest vs. lowest dietary zinc intake for T2DM
according to the percentage of T2DM (<5%/5–9.9%/≥10%). Squares represent ORs for each study, and
the size of the square is the study-speciﬁc statistical weight. Horizontal lines indicate the 95% CI of
each study. Diamond represents the combined OR estimate with corresponding 95% CI.
The eﬀect size ranged between (OR = 0.84, 95% CI: 0.75–0.96) after excluding the study carried
out by Drake et al. [6], and (OR = 0.90, 95% CI: 0.81–0.99), after excluding the study conducted by
Vashum et al. [5]. However, the combined overall eﬀect size remained on the verge of statistical
signiﬁcance after removing the data obtained by Singh et al. [39] in urban Indian women (OR = 0.87,
95% CI: 0.76–1.00), or that of Eshak et al. [7] in Japanese subjects (OR = 0.90, 95% CI: 0.80–1.01). Finally,
for this meta-analysis, an overall symmetry of the funnel plots was observed by visual inspection
(Supplementary Materials Figure S1). This was conﬁrmed by the Egger’s (p = 0.429) and Begg’s
(p = 0.721) tests, indicating the absence of publication bias.
3.2. Supplementary Zinc Intake and T2DM
Three studies of 313,003 individuals assessed the association between supplementary zinc intake
and T2DM (NHS cohort [4], National Institutes of Health-American Association of Retired Persons
(NIH-AARP) Diet and Health Study [12], MDCS cohort [6]) (Table 2). The follow-up period of these
prospective cohort studies ranged between 10 [12] to 24 years [4]. Participants were white (mostly)
women [4] or subjects of both genders [6,12], aged between 33 and 71 years, and from urban areas.
In total, 17,806 patients with incident diabetes (between 6.1 and 14.1%) were identiﬁed according to
diﬀerent diagnostic criteria (self-reported [4,12], or through an FPG ≥ 7.0 mmol/L measured twice, and
institutional registries [6]).
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[Ln(ORT2DM) = (- 0.4217314) + 0.0437897 • (percentage of T2DM)]
Figure 6. Bubble plot with a ﬁtted meta-regression line of the relationship between the Ln(OR) and the
percentage of T2DM. Circles are sized according to the precision of each estimate (the inverse of its
within-study variance).
Supplementary zinc intake was determined using diﬀerent food intake instruments, such as
VFFQ [4], VDHQ [6], or dietary survey, including an FFQ and a short survey [12]. The percentage
of patients with incident diabetes supplemented with zinc was around 12.5% [6,12], meanwhile in
controls of non-incident diabetes, zinc supplementation ranged between 5.7% in the NIH-AARP Diet
and Health Study [12], to 17.7%, in the MDCS cohort [6]. The NHS cohort reported a large increase
in the proportion of women who were supplemented with zinc in 2004 (48.6%) compared with 1980
(6.3%) [4].
The association between supplementary zinc intake and the risk of T2DM was evaluated through
a meta-analysis stratiﬁed by whether the analysis had been done comparing zinc supplement users
versus non-users or comparing the highest versus lowest quantile of supplementary zinc intake, in
order not to introduce bias in the analysis (Figure 7). Results revealed a non-signiﬁcant association
between zinc supplement users versus non-users and T2DM (OR = 0.94, 95% CI: 0.75–1.19; I2 = 85.4%,
p = 0.009), and between higher supplementary zinc intake versus lower and T2DM (OR = 0.95, 95% CI:
0.78–1.16; I2 = 75.3%, p = 0.044), and an elevated heterogeneity in both cases.
Publication bias was unlikely in this meta-analysis, according to Egger’s (p = 0.186), and Begg’s
(p = 0.089) tests (Figure S2).
3.3. Total Zinc Intake and T2DM
The ﬁnal data set for the meta-analysis of total zinc intake and risk of T2DM included only
two large prospective cohort studies [4,6] (Table 2). Nevertheless, both studies comprised 108,429
individuals, 9706 patients with incident diabetes and 98,723 controls of non-incident diabetes. Incidence
of T2DM was 14.1% in the middle-aged Swedish cohort of urban men and women (MDCS) [6], and
7.3% in the American cohort of urban women (NHS) [4]. A VFFQ [4] and a VDHQ [6] were used to
determine the total zinc intake, that ranged from 4.9 to 18.0 mg/day in the NHS cohort [4], and around
12.9 ± 5.4 mg/day in controls of non-incident diabetes and 13.0 ± 6.2 mg/day in patients with incident
diabetes from the MDCS cohort [6].
122
Nutrients 2019, 11, 1027
NOTE: Weights are from random effects analysis
.
.
Overall  (I-squared = 74.1%, p = 0.009)
Drake, 2017 (Urban men/women)
Sun, 2009 (Urban women with high dietary zinc intake)
ID
Song, 2011 (Urban men/women)
Subtotal  (I-squared = 85.4%, p = 0.009)
Sun, 2009 (Urban women with low dietary zinc intake)
Subtotal  (I-squared = 75.3%, p = 0.044)
Zinc supplement users vs non-users
Quantiles of supplementary zinc intake
Study
0.95 (0.85, 1.08)
0.83 (0.71, 0.98)
1.05 (0.92, 1.19)
OR (95% CI)
1.05 (0.98, 1.13)
0.94 (0.75, 1.19)
0.86 (0.74, 0.99)
0.95 (0.78, 1.16)
100.00
21.31
24.79
Weight
30.95
52.26
22.95
47.74
%
  1.7 1.2
Figure 7. Forest plot of the pooled eﬀect size of the highest versus lowest supplementary zinc intake for
T2DM according to the analysis (zinc supplement users/non-users versus quantiles of supplementary
zinc intake). Squares represent ORs for each study, and the size of the square is the study-speciﬁc
statistical weight. Horizontal lines indicate the 95% CI of each study. Diamond represents the combined
OR estimate with corresponding 95% CI.
After pooling data from both studies (Figure 8), we found that total zinc intakewas not signiﬁcantly
associatedwith the incidence of T2DM(OR= 0.95, 95%CI: 0.82–1.11). Therewasmoderate heterogeneity
between the studies (I2 = 56.5%, p = 0.129). Moreover, no evidence of publication bias was found
(p = 1.000) (Supplementary Materials Figure S3).
NOTE: Weights are from random effects analysis
Overall  (I-squared = 56.5%, p = 0.129)
Study
ID
Drake, 2017 (Urban men/women)
Sun, 2009 (Urban women)
0.95 (0.82, 1.11)
OR (95% CI)
1.05 (0.88, 1.25)
0.90 (0.82, 0.99)
100.00
%
Weight
37.99
62.01
  1.7 1.2
Figure 8. Forest plot of pooled eﬀect size of the highest vs. lowest total zinc intake for T2DM.
Squares represent ORs for each study, and the size of the square is the study-speciﬁc statistical weight.
Horizontal lines indicate the 95% CI of each study. Diamond represents the combined OR estimate
with corresponding 95% CI.
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3.4. Whole Blood Zinc Concentration and T2DM
Only two cross-sectional studies carried out within the third survey of the population-based
Nord-Trøndelag Health Study (HUNT3 Survey) were identiﬁed to assess the relationship between
concentration of zinc in whole blood and T2DM [18,19]. The fact that both studies shared part of the
same study sample prevented the execution of a meta-analysis to obtain a pooled result. Nevertheless, a
qualitative summary was conducted to present the ﬁndings of these two studies (Table 3). Participants
in both studies were men and women, mainly Caucasian, and aged around 61.5 ± 8.7 years old,
who lived mainly in rural areas from Norway. The main diﬀerence between these two studies was
the sampling strategy. Hansen et al. [18] selected 876 subjects at high risk for T2DM, but without
previously known diabetes. In this study, 128 previously undiagnosed cases of T2DM, were detected
by screening [18]. In contrast, Simic et al. [19] included 883 subjects, of which 267 had self-reported
T2DM, i.e., they were patients in a more advanced stage of the disease. Curiously, while Hansen et
al. [18] found a signiﬁcant and positive association between a higher whole blood zinc concentration
and the onset of T2DM (OR = 2.19, 95% CI: 1.05–4.59), Simic et al. [19] did not observe any signiﬁcant
relationship (OR = 1.08, 95% CI: 0.59–1.97). Diﬀerences in concentrations of zinc in whole blood
between cases and controls, measured in both studies through inductively coupled plasma mass
spectrometry (ICP-MS), were more evident in the study conducted by Hansen et al. [18] (median in
cases: 799.0 μg/dL; median in controls: 754.0 μg/dL) compared to the one carried out by Simic et al. [19]
(median in cases: 764.3 μg/dL; median in controls: 751.2 μg/dL). It is worth noting that the median
whole blood zinc concentration in the control subjects in both studies was very similar, but not in those
of the diabetic subjects.
3.5. Serum/Plasma Zinc Concentration and T2DM
Six observational studies (one prospective cohort study [14], one nested case-control study [15],
and four cross-sectional studies [16,17,40,41]) were included in the meta-analysis of serum/plasma
zinc concentration and T2DM (Table 3). Four studies were carried out on Chinese urban men and
women between the ages of 40 and 90 years [15,16,40,41], one in Russian women with an average age
of 56.3 ± 5.7 years [17], and one in Finnish men aged between 42 and 60 years [14]. The total number of
cases of T2DMwas 2936, among 8392 participants. The period of follow-upwas between 4.6 years in the
nested case control within the Dongfeng–Tongji (DFTJ) cohort [15], and 20 years in the KIHD study [14].
Serum/plasma zinc concentration was determined mainly by ICP-MS [15–17,40,41], meanwhile the
KIHD used atomic absorption spectrophotometry (AAS) [14]. The levels of serum/plasma zinc in
controls ranged from a median of 57.5 μg/dL to a mean of 172.5 ± 73.0 μg/dL; and in cases from a
median of 63.4 μg/dL to a mean of 169.6 ± 142.4 μg/dL.
The combined eﬀect size of T2DM for the highest versus lowest quantile of serum/plasma zinc
concentrationwas 0.76 (95%CI: 0.29–2.01). However, a high level of heterogeneitywas found (I2 = 97.1%,
p < 0.001). Sensitivity analysis omitting one study at a time and calculating the heterogeneity for the
remainder of the studies showed that the study conducted by Shan et al. [16] substantially inﬂuenced
the overall heterogeneity, resulting in a reduction around 31% of this when it was excluded. In addition,
the elimination of this study and the one carried out by Skalnaya et al. [17], decreased the level of
heterogeneity by 44.5%, showing their impact on results (OR = 1.47, 95% CI: 1.11–1.95; I2 = 53.9%,
p= 0.090). Nevertheless, the exclusion of any other study had a negligible eﬀect on heterogeneity. When
performing stratiﬁed analysis for “sample base” (Figure 9), a signiﬁcant and positive association was
found in the subgroup of “population or community-based studies” (OR = 1.64, 95% CI: 1.25–2.14), and
a low heterogeneity (I2 > 22.5%, p = 0.275). On the other hand, “non-population or community-based
studies” showed a very high level of heterogeneity (I2 > 98.0%, p < 0.001). Likewise, when it was
stratiﬁed by the covariate “group with higher zinc levels”, a relationship between serum/plasma zinc
levels and T2DM (OR = 1.47, 95% CI: 1.11–1.95; I2 = 53.9%, p = 0.090) was observed in the subgroup
of studies with higher zinc levels in the case group compared to controls (Table S3). Meanwhile, a
signiﬁcant negative relationship was found in the subgroup in which controls had higher serum/plasma
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concentration (OR = 0.16, 95% CI: 0.05–0.54), but with a high heterogeneity (I2 = 86.4%, p = 0.007).
Finally, the diﬀerence in mean serum/plasma zinc concentration between cases and controls, as well its
ratio, also explained, to a large extent, the heterogeneity observed (RA2 = 85.2%, for mean diﬀerence;
and RA2 = 92.6%, for mean ratio), as expected.
Although the funnel plot showed some degree of asymmetry (Figure S3), we did not detect any
risk of publication bias according to the Egger’s (p = 0.815) or Begg’s tests (p = 0.707).
NOTE: Weights are from random effects analysis
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Figure 9. Forest plot of pooled eﬀect size of the highest vs. lowest serum/plasma zinc
concentration for T2DM according to the sample base (population/community-based studies vs.
non-population/community-based studies). Squares represent ORs for each study, and the size of
the square is the study-speciﬁc statistical weight. Horizontal lines indicate the 95% CI of each study.
Diamond represents the combined OR estimate with corresponding 95% CI.
4. Discussion
This systematic review and meta-analysis of observational studies found an inverse association
between dietary zinc intake and T2DM. This could suggest a potential beneﬁcial role of zinc from diet
to prevent the risk of this disease. In addition, the relationship seemed to be more evident in rural
areas, and when the proportion of T2DM cases in the population was low or moderate. Conversely,
a non-signiﬁcant association between total or supplementary zinc intake and T2DM was observed,
although data are limited. Whole blood zinc concentration could be directly related to T2DM only at an
early phase of the diabetes disease, as suggested by results from the same cohort study. This hypothesis
could not be examined for serum/plasma zinc concentration. Nevertheless, a positive relationship was
found between this biomarker of zinc status and T2DM in population-based studies.
Our results suggest that a diet moderately elevated in zinc could help to prevent the development
of T2DM. We tried to determine the cut-oﬀ point or range of dietary zinc intake with a protective
eﬀect against type 2 diabetes mellitus (T2DM); however, data were imprecise, heterogeneous, and not
reported in all the studies. Despite these limitations in the data of the selected studies, it was notable
that when the lowest quantiles (reference) did not reach the dietary reference intakes (DRI) according to
the Institute Of Medicine (IOM) for adult men (11 mg/day) and women (8 mg/day) [43], those quantiles
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of dietary zinc intake that reached or moderately exceeded the DRI showed a protective eﬀect, even in
the intermediate quantiles [4,5]. Furthermore, when the highest quantiles of dietary zinc intake did not
reach the DRI, no signiﬁcant association was observed [10]. Interestingly, when the lowest quantiles of
dietary zinc intake reached the DRI, the highest quantiles (>23.34 mg/day) did not show a protective
eﬀect on T2DM, and could even have a harmful impact on the risk of T2DM as observed in a model
not fully adjusted [11]. These data seem to suggest that a dietary zinc intake within or slightly above
the DRI could have a protective role on the risk of T2DM, but not when intake is very high. Consistent
with our ﬁndings, several observational studies have shown a protective eﬀect of a moderately high
dietary zinc intake on cardiometabolic conditions, such as metabolic syndrome [44,45] and gestational
hyperglycemia [46], and mortality by cardiovascular disease [47] and all causes [48]. Conversely, other
studies have found no signiﬁcant [10,49], or even direct associations [50,51] between dietary zinc intake
and some of these cardiometabolic events. The ﬁrst systematic review of prospective cohort studies on
the association between zinc status, including dietary zinc intake, and risk of cardiovascular disease and
T2DM [13] revealed a limited number of studies on this topic, as well as the inconsistence of their results.
As the authors themselves suggested, the eﬀect of confounding factors may have played an important
role in the observed ﬁndings. In our meta-analysis we have evaluated a large number of confounding
factors in order to identify and quantify those that could impact on the relationship between dietary
zinc intake and T2DM. Gender is one of the confounding factors most reported in the above mentioned
studies on the relationship between dietary zinc intake and metabolic syndrome [44,45], cardiovascular
disease [13], and mortality [47]. Our results showed a similar signiﬁcant inverse association between
dietary zinc intake and T2DM in both men and women, suggesting that gender does not seem to have
a relevant role in this relationship.
Interestingly, we observed that the covariate “area of residence” of participants (rural versus
urban) had a key eﬀect on our ﬁndings. While a strong inverse association was observed in studies
conducted on participants living in rural areas, a null relationship was observed in those studies
carried out on urban subjects (Figure 3). Interestingly, when we addressed these ﬁndings also taking
into account the design of the studies, we observed a 41% reduction in the risk of T2DM in both
cross-sectional and prospective studies conducted in rural areas (Figure 4). Conversely, the eﬀect size
was reduced to 12% in cross-sectional studies performed in urban areas, and in prospective cohort
studies, the association was not signiﬁcant. These observations support the hypothesis that living in
urban areas may counteract the beneﬁcial eﬀect of an elevated dietary zinc intake on risk of T2DM.
Accumulating evidence strongly suggests that the change from rural to urban environments may have
a marked impact on lifestyle [52,53], resulting in the increase of certain risk factors, such as unhealthy
diets, sedentary behavior, and smoking, among others, that account for a large contribution to global
burden of major disease [54,55]. Thus, it has been revealed that T2DM risk factors are more common
in urban than in rural areas [56]. The greater exposure to risk factors in urban environments could
explain the small or null protective eﬀect of the intake of zinc from diet against the risk of T2DM.
Indeed, it is known that there is higher prevalence of T2DM in urban compared to rural areas [2,56].
According to the International Diabetes Federation (IDF) Diabetes ATLAS edition 2017, the global
prevalence of diabetes in urban areas was 10.2%, i.e., 279.2 million people aged between 20–79 years,
meanwhile in rural areas was notably lower, 6.9% (145.7 million) [2]. In addition, the number of people
living with diabetes in urban areas is expected to increase to 472.6 million in 2045, due mainly to global
urbanization [2].
It is interesting that the covariate which had the greatest impact on the association between dietary
zinc intake and T2DM was the proportion of T2DM cases identiﬁed in each study, both as a continuous
and categorized variable. When we conducted a meta-regression introducing the percentage of T2DM
as a continuous variable, we found that for each percentage point that increased this covariate, the
protective eﬀect of a moderately high dietary zinc intake, relative to the DRI, against T2DM decreased
0.04 (95% CI: 0.01, 0.07, p = 0.010). Through a meta-regression equation represented in a bubble
plot, we observed that when the proportion of T2DM subjects reached 10%, the protective eﬀect
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from dietary zinc intake was nulliﬁed (Figure 6). Consistently, the three studies with a proportion
of T2DM subjects of 10% or more, did not ﬁnd a signiﬁcant association between dietary zinc intake
and T2DM [6,10,11]. In addition, stratiﬁed analysis based on the percentage of T2DM in each study
(<5%, 5%–9.9%, and ≥10%) showed an undetectable heterogeneity in all the three subgroups (I2 = 0.0%,
p > 0.100), which provides high reliability to the results. Furthermore, a signiﬁcant inverse association
was found between intake of zinc from diet and T2DM when the percentage of T2DM was lower than
10%, and with the highest eﬀect size when that was less than 5% (Figure 5). It should be noted that
the studies with less proportion of T2DM subjects (<5%) were those carried out in rural areas, while
those with the highest percentage of diabetics (5%–9.9%, and ≥10%) were the studies conducted in
urban areas. In addition, among studies of urban areas, those with a moderate proportion of T2DM
(5%–9.9%) retained a signiﬁcant association between dietary zinc intake and T2DM, although it was
more attenuated than those in rural areas. Nevertheless, the studies with higher percentage of T2DM
did not ﬁnd any signiﬁcant relationship (Figure 5). These results suggest that in rural areas, with
less T2DM risk factors, and consequently, less T2DM prevalence, the association between dietary
zinc intake and T2DM is signiﬁcant and the eﬀect size is strong; meanwhile, in urban areas, with a
greater exposure to T2DM risk factors and a higher T2DM prevalence, the association is still signiﬁcant
but with a low eﬀect size when T2DM prevalence is moderate, and not signiﬁcant when the T2DM
prevalence is high.
Only two studies have evaluated the eﬀect of a high total zinc intake on the risk of T2DM [4,6],
and the overall pooled estimates showed no signiﬁcant association (Figure 8). The NHS cohort showed
a moderate protective eﬀect of total zinc intake, while the MDCS cohort did not ﬁnd a relationship.
Consistent with results from the meta-analysis of the dietary zinc intake, the NHS cohort [4] had a
moderate proportion of T2DM (7.3%), meanwhile theMDCS cohort [6] presented the highest percentage
of T2DM of all included studies in this systematic review (14.1%). This supports the hypothesis
previously raised regarding the impact of the T2DM prevalence on the association between zinc intake
and risk of T2DM.
Although, there is currently some evidence of the beneﬁcial eﬀect of zinc supplementation on
glycemic control in T2DM patients [9,57], scarce studies support the use of zinc supplements in the
prevention of this disease [8]. A recent clinical trial based on zinc supplementation has found a reduction
in the progression to T2DM in prediabetic subjects, in addition to an improvement in blood glucose and
insulin levels, insulin resistance, and β–cell function [9]. Observational studies that have assessed the
association between supplementary zinc intake and risk of T2DM are also scarce [4,6,12]. The overall
pooled estimates did not show any signiﬁcant relationship, neither comparing zinc supplement users
versus non-users, nor comparing the highest versus lowest quantile of supplementary zinc intake
(Figure 7). Those studies that compared zinc supplement users versus non-users against the risk
of T2DM, failed to diﬀerentiate between participants who obtained zinc from multivitamin/mineral
supplements from those taking individual zinc supplements [6,12]. Thus, a synergistic eﬀect or an
interaction between minerals and vitamins supplemented, along with zinc, could have aﬀected the
relationship between supplementary zinc intake and the risk of T2DM. Interestingly, the NHS cohort
reported a signiﬁcant inverse association in participants with low dietary zinc intake, but not in those
with high dietary zinc intake [4]. In addition, dietary zinc intake was more strongly associated with a
lower risk of T2DM among those participants with low zinc intakes from supplements. This seems
to suggest that only when the zinc intake is insuﬃcient, zinc supplementation may have beneﬁts.
However, when dietary intake is adequate, additional zinc intake from supplementation may not
confer further beneﬁt.
To the best of our knowledge, only two cross-sectional studies, conducted within the same
population-basedHUNT3 study, have evaluated the associationbetweenwhole bloodzinc concentration
and T2DM [18,19]. However, the results were dissimilar, likely due to characteristics of participants
selected during the sampling. Interestingly, Hansen et al. [18] reported a signiﬁcant and positive
association between whole blood zinc concentration and T2DM, in previously undiagnosed diabetic
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patients and control subjects [18]. Meanwhile, Simic et al. [19], did not ﬁnd a signiﬁcant relationship in
previously diagnosed T2DM patients and control subjects. These results seem to suggest that when
T2DM is in the early stages, i.e., newly diagnosed, zinc levels are more elevated than non-diabetic
subjects, and progressively they are reduced as the disease progresses, which is consistent with our
previous systematic review and meta-analysis [20]. That meta-analysis which aimed to compare whole
blood zinc concentration between T2DM patients and non-diabetic subjects, showed that duration
of T2DM had a relevant inﬂuence on concentration of zinc in whole blood [20]. In addition, we
found a lower whole blood zinc concentration in T2DM patients; however, this group had, at least,
10.2 ± 8.6 years of duration of diabetes, and diﬀerences between cases and controls in that study were
not observed [58], in concordance with the study of Simic et al. [19], among previously diagnosed
T2DM participants [19].
Since the use of whole blood zinc concentration may be not representative of the total zinc
body burden [56], we also assessed the association between zinc and T2DM, through a more reliable
biomarker of zinc status, the serum/plasma zinc concentration [59]. We wanted to contrast the
hypothesis regarding the impact of the T2DM phases on serum/plasma zinc concentration; however,
datawere limited to carry out that analysis. Only six studies evaluated this relationship, and resultswere
inconsistent [14–17,40,41], which was highlighted by high heterogeneity observed after the results were
combined. Two of the included studies were responsible for 44.5% of the heterogeneity detected [16,17].
After both studies were excluded, the combined result was more reliable (OR = 1.47, 95% CI: 1.11–1.95;
I2 = 53.9%, p = 0.090). Curiously, these two studies, together with the third that contributed more
to the global heterogeneity, were conducted on non-population or community-based studies, i.e.,
hospital-based settings [16], retired employees of amotor company [15] and postmenopausal women on
a voluntary basis [17], so the results could not be extrapolated to the general population. However, the
other three studies were carried out on population [14] or community-based [40,41] studies. Stratiﬁed
analysis according to the “sample base” (Figure 9) showed a high heterogeneity in the “non-population
or community-based studies” group (I2 = 98.0%, p < 0.001), and a low heterogeneity in the “population
or community-based studies” group (I2 = 22.5%, p = 0.275). The pooled estimates for this last subgroup
revealed a direct and signiﬁcant association between serum/plasma zinc concentration and T2DM
(OR = 1.64, 95% CI: 1.25–2.14). This ﬁnding is not consistent with a previous meta-analysis that
compared serum/plasma zinc levels between T2DM patients and healthy controls [60]. Results of this
previousmeta-analysis showed signiﬁcantly lower serum/plasma zinc concentration in diabetic subjects
compared to healthy controls, but with high heterogeneity. The high heterogeneity suggests that
results were inﬂuenced by confounding factors, but its source was not analyzed in that meta-analysis.
Finally, a recent cross-sectional study reported that urinary zinc levels were positively associated with
T2DM [61]. These ﬁndings suggest this is a response mechanism against zinc excess in serum/plasma in
diabetic patients, and it seems to be in concordance with the direct relationship between serum/plasma
and T2DM that we observed in our meta-analysis.
Several limitations in the present systematic review and meta-analysis should be considered.
First, the number of results and studies included in meta-analyses was small, and stratiﬁed analyses
might have insuﬃcient power to identify potential confounding factors, as well as to detect potential
sources of heterogeneity. To correct this weakness, random eﬀects meta-regressions were carried
out. Furthermore, our ﬁndings were likely to be inﬂuenced by imprecise measurement of zinc intake.
However, VFFQ and VDHQ were used to assess dietary, supplementary, and/or total zinc intake, in all
but two studies. In addition, diﬀerences in diagnostic criteria for the ascertainment of T2DM over the
years could have introduced misclassiﬁcation bias and could aﬀect results. Finally, meta-analyses were
based on observational studies, which are prone to confounding and reverse causation. Nevertheless,
for meta-analyses of dietary, supplementary and/or total zinc intake, all but one of the included studies
were prospective cohort studies, which allows stronger inferences than cross-sectional studies [62].
Our study has also several strengths. Firstly, the comprehensive and robust search strategy within
the framework of the EURRECA Network of Excellence was designed to avoid the loss of relevant
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studies. Moreover, there were no studies that were excluded for reasons of language, avoiding language
bias. In addition, standard tests and visual inspection of funnel plots did not show any evidence for
risk of publication bias in any meta-analysis. Furthermore, included studies were of high quality,
according to the STROBE Statement [42]. The meta-analyses included 575,851 subjects, had a wide
geographical spread, and a diverse ethnicity, giving more validity to the results. Finally, heterogeneity
was low or moderate in most of the meta-analyses, which also contributes to the study validity.
The important role of zinc on carbohydrate metabolism via several mechanisms is well established,
and this could explain the protective eﬀect of dietary zinc intake on risk of T2DM observed in our
meta-analysis. Zinc is involved in synthesis, storage, crystallization, and secretion, as well as the
action of insulin and translocation of insulin into the cells [21–24]. In addition, zinc seems to play
a role in insulin sensitivity through the activation of the phosphoinositol-3-kinase/protein kinase B
cascade [25]. It has also a role insulin–mimetic, being involved in the regulation process of glucose
homeostasis [26]. Moreover, zinc may participate in the suppression of proinﬂammatory cytokines,
such as interleukin-1β [27] and nuclear factor kβ [28], avoiding β-cells’ death and protecting insulin.
The underlyingmechanismwhereby higher serum/plasma and/orwhole blood zinc concentration could
be related to T2DM is unclear. However, strong evidence supports disturbances in zinc homeostasis
associated with T2DM, that could not be linked to zinc status [63,64]. In recent years, it has been
proposed that the cellular zinc transport system may play a key role in the pathophysiology of
T2DM [65,66]. Thus, diﬀerences between diabetic patients and healthy controls in gene expressions for
most zinc transporters has been observed [63]. This zinc dyshomeostasis may be caused in the early
stages of T2DM, as observed in a trend of increased serum zinc levels from healthy to prediabetic and
diabetic postmenopausal women [67].
5. Conclusions
Findings from this systematic review and meta-analysis revealed a potential protective eﬀect of a
moderately high dietary zinc intake, related to the DRI, on the risk of T2DM. The relationship seems to
be stronger and more evident in rural compared to urban areas. In addition, T2DM prevalence may be
also a confounding factor for this association, being stronger when the prevalence is low, weak when it
is moderate, and disappearing with a high prevalence. Conversely, no associations were observed
between total or supplementary zinc intake and T2DM. However, more data are required to explore
this relationship more fully.
In addition, an elevated serum/plasma zinc concentration is associated with an increased risk of
T2DM in the general population. Meanwhile, high whole blood zinc concentration could be associated
with T2DM, likely only at an early phase of the diabetes disease. Additional studies are required to
conﬁrm these results, and determine the role of serum/plasma and whole blood zinc concentration in
the pathophysiology of T2DM.
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Abstract: The role of the concomitant intake of zinc, potassium, calcium, and magnesium in the
glycemic control of individuals with type 2 diabetes mellitus (T2DM) has not been extensively
discussed. We evaluated the relationship between the dietary intake of these micronutrients and
glycemic markers in 95 individuals with T2DM (mean age 48.6 ± 8.4 years). Hierarchical grouping
analysis was used to divide the individuals into two clusters according to their micronutrient intake,
and differences between clusters were statistically assessed. Effects of individual and combination
intake of micronutrients on glycated hemoglobin percentage (%HbA1c) were assessed using multiple
linear regression and binary logistic regression analysis. We observed a high likelihood of inadequate
intake of the four micronutrients. The group with lower micronutrient intake (cluster 1) displayed
higher %HbA1c (p = 0.006) and triglyceride (p = 0.010) levels. High %HbA1c showed an association
with cluster 1 (odds ratio (OR) = 3.041, 95% conﬁdence interval (CI) = 1.131; 8.175) and time of T2DM
diagnosis (OR = 1.155, 95% CI = 1.043; 1.278). Potassium (β = −0.001, p = 0.017) and magnesium
(β = −0.007, p = 0.015) intakes were inversely associated with %HbA1c. Reduced concomitant
intake of the four micronutrients studied proved to be associated with risk of increased %HbA1c in
individuals with T2DM, which was particularly predicted by magnesium and potassium intakes.
Keywords: micronutrients; trace elements; food; glycated hemoglobin A; hyperglycemia
1. Introduction
Type 2 diabetes mellitus (T2DM) is characterized by failures in blood glucose homeostasis
and is considered a global public health problem [1]. Chronic hyperglycemia leads to increased
oxidative stress and production of proinﬂammatory cytokines, disrupting insulin signaling pathways,
lipid metabolism, protein synthesis, and cell differentiation, and may alter body concentrations of
micronutrients [2–5]. The maintenance of the glycemic control in individuals with T2DM involves
strategies for lifestyle changes, drug therapy, and adoption of healthy eating habits [1,2]. A balanced
Nutrients 2018, 10, 1948; doi:10.3390/nu10121948 www.mdpi.com/journal/nutrients134
Nutrients 2018, 10, 1948
diet with adequate nutrient content can reduce the glycated hemoglobin percentage (%HbA1c) in
subjects with T2DM by 0.3–2% [6]. Over the last few years, studies have veriﬁed the participation of
minerals in the synthesis, secretion, and action of insulin. Among them, the minerals zinc, potassium,
calcium, and magnesium are considered essential for the homeostasis of glucose metabolism [5,7,8].
Zinc plays a key role in the insulin biosynthesis as part of the hexameric structure of this hormone,
and in the sensitivity to insulin in target tissues through stimulation of insulin receptors [9,10].
Calcium and potassium regulate voltage-dependent channels in pancreatic β-cells, which are essential
for insulin exocytosis [11,12]. Magnesium is important for β-cell functioning and acts as a cofactor of
many enzymes involved in the glucose metabolism, like tyrosine kinase enzymes, which phosphorylate
insulin receptors and trigger the signaling cascade [4,12,13].
Thus, an inadequate intake of these micronutrients may impair the insulin synthesis, secretion,
and signaling pathways [4,11,14]. It is possible to observe in the literature studies that associate the
low intake and serum concentration of these minerals with risk of T2DM development [2,13,15–18].
Nevertheless, studies that evaluate the relationship between the dietary intake of these minerals in
glycemic control in subjects with established disease are not widely found. In addition, no studies
have assessed the relationship of the concomitant intake of these four micronutrients with the
glycemic control, insulin biosynthesis, and insulin sensitivity of individuals with T2DM. In this
scenario, the present study aimed to evaluate the relationship of the dietary intake of zinc, potassium,
calcium, and magnesium with glycemic markers in individuals with T2DM in order to expand the
understanding of these relationships in glycemic control.
2. Materials and Methods
2.1. Study Design and Participants
In this cross-sectional study, to be eligible for enrollment, individuals had to be 19–59 years
old and have diagnosis of T2DM. Thus, 102 individuals with T2DM who visited the Family Health
Units in the state of Sergipe, Brazil, were evaluated. Exclusion criteria adopted were the use of
vitamin–mineral supplements, pregnancy, status as a current smoker, and the presence of the following
diseases: rheumatoid arthritis, cancer, chronic renal failure, thyroid dysfunction, and acute infections
or inﬂammatory processes such as inﬂuenza and urinary tract infection. The study followed the
guidelines of the Declaration of Helsinki and all participants provided written informed consent.
The study was approved by the Ethical Committee of the Federal University of Sergipe (Approval
number 1.370.831).
Venous blood samples were obtained, after an overnight fast for at least 10 hours, in ethylenediamine
tetra-acetic acid (EDTA) tubes for estimation of concentration of glycated hemoglobin (HbA1c) in whole
blood, and in gel tubes for the determination of fasting glucose, lipid proﬁle, insulin, and C-peptide in
serum. Measurements of anthropometric parameters, body fat percentage, and blood pressure were
performed. All the measurements were realized by trained technicians, and the individuals were
instructed to avoid physical activity or effort one day before the tests. In combination, dietary intake
assessments of macro and micronutrients was performed. Information about socioeconomic conditions,
medical history, and lifestyle were obtained using a questionnaire.
2.2. Anthropometric Parameters, Bioelectric Impedance and Blood Pressure Measurements
Weight and height measurements were performed to calculate the body mass index (BMI).
The BMI was calculated by dividing the body weight value (in kilograms) by the square value of
the body height (in meters). The participants were classiﬁed as malnourished (BMI < 18.5 kg/m2),
normal weight (BMI 18.5–24.9 kg/m2) or overweight/obese (BMI ≥ 25 kg/m2), assessed according to
the cut-off values proposed by the World Health Organization [19]. Waist circumference was measured
with a non-extendable tape positioned at the midpoint between the last ﬂoating rib and the top of
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the iliac crest. The cut-off point used for waist circumference was ≥80 cm for women and ≥94 cm
for men [20].
Measurement of body fat percentage was performed using the BIA 310 Bioimpedance Analyzer
(Biodynamics Corporation, Shoreline, WA, USA), following the manufacturer’s instructions.
Blood pressure was measured using aneroid sphygmomanometers and a stethoscope according
to the recommendations of the Brazilian Society of Cardiology [21] at rest in a sitting position.
2.3. Biochemical Analyses
Serum concentrations of glucose, triglycerides, total cholesterol, and high-density lipoprotein
cholesterol (HDL-c) were measured by an enzymatic colorimetric method using commercial kits
(Labtest®, Lagoa Santa/MG, Brazil). The HbA1c was measured by immunoturbidimetric inhibition.
All biochemical tests were performed using an automatic biochemical analyzer CMD 800i (Wiener Lab
Group®, Rosario, Argentina). Serum insulin and C-peptide concentrations were measured by
chemiluminescence using commercial kits (Abbott®, Abbott Park, IL, USA) and the automatic
immunoassay analyzer Architect i1000SR (Abbott®, Abbott Park, IL, USA). The homeostasis model
assessment (HOMA) was used to assess insulin sensitivity, based on C-peptide and glucose levels.
Calculations were made using the HOMA calculator (University of Oxford, United Kingdom).
2.4. Food Intake
The 24-h dietary recalls over three days (including two weekdays and one weekend day) were
obtained by Multiple-Pass method [22], and analyzed using the NutWin software (Department
of Informatics, Paulista School of Medicine/UNIFESP, São Paulo/SP, Brazil), which includes the
updated versions of the Brazilian Table of Food Composition (TACO), the Table of Nutritional
Composition of Food Consumed in Brazil, the United States Department of Agriculture (USDA)
Food Composition Databases, and food labels. The adequacy of usual dietary intake of nutrients
by each group was evaluated according to the estimated average requirement (EAR) and adequate
intake (AI) for potassium values proposed by the dietary reference intakes [23,24]. The probability of
inadequate food intake by group was evaluated by z-score, which was calculated from the difference
between the EAR corresponding to each nutrient and the mean ingestion of the group divided by the
standard deviation of the intake. Potassium intake values were compared with AI values [24].
2.5. Statistical Analyses
The Kolmogorov–Smirnov test was used to evaluate data homogeneity. Non-homogeneous data
were subjected to logarithmic transformation. The identiﬁcation of individuals with inaccurate report
of energy intake was performed using the methodology proposed by Mccrory et al. [25], based on the
ratio between the reported energy intake and the total energy expenditure predicted, calculated by the
equation of Vinken et al. [26] and considering the cut-off value of ± one standard deviation. The usual
dietary intake was calculated using the Multiple Sources Method (MSM) (https://msm.dife.de/) [27].
Micronutrient intake values were adjusted for total energy intake according to residual method
proposed by Willett et al. [28].
To verify associations between response variables, and to characterize individuals according
to dietary intake of zinc, magnesium, calcium, and potassium, a hierarchical cluster analysis was
used. From this analysis, the mean values corresponding to the energy-adjusted dietary intake of
the four minerals were auto-scaled, and the similarities between the individuals calculated according
to the Euclidean squared distance, while the Ward’s method was used for the formation of clusters.
Differences between the two clusters formed was assessed using the Student’s t-test (for normal data
distribution) or the Mann–Whitney test (for non-normal data distribution).
Regression models were used to assess the effect of the micronutrient intake on the glycemic
control. Independent variables with p ≤ 0.20 in the bivariate analyses were included in the models
using the enter method. p ≤ 0.20 was adopted according to the criterion of Wang et al. [29], established
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for the testing of a greater number of predictor variables in the model. Thus, a binary logistic regression
model was applied using %HbA1c values above 7.0 [30] and cluster 1 (lower micronutrient intake)
as risk variables. In addition, multiple regression models were applied to assess the effect of each
micronutrient intake on%HbA1c separately.Multicollinearity was assessed by variance inﬂation factors
(VIF) and no correlation was identiﬁed between the independent variables (VIF <10). Both regression
models used sex, age, and time of T2DM diagnosis as adjustment variables.
The results were expressed as means and standard deviations, and as absolute and relative
frequencies. A signiﬁcance level of 5% was adopted for all tests. All statistical analyses were performed
using SPSS for Windows Version 17.0 (SPSS Inc., Chicago, IL, USA).
3. Results
After exclusion of participants with missing dietary information, 95 individuals with T2DM were
ﬁnally evaluated; 69.5% of them were female and mean age was 48.6± 8.4 years. Most individuals were
overweight or obese (81.0%), and mean BMI and body fat percentage values were 30.22 ± 6.78 kg/m2
and 34.98 ± 7.94%, respectively. Waist circumference measurement showed 85.3% of the participants
at increased risk of obesity-associated metabolic diseases (Table 1).
Deﬁcient glycemic control was observed, as indicated by values of fasting glucose and %HbA1c
above the cut-off point for disease control (fasting glucose < 154 mg/dL; %HbA1c < 7.0) [30]. Regarding
lipid proﬁle, 73.7% of the participants presented low HDL-c levels, and 37.9%, 10.5%, and 3.1%
presented hypertriglyceridemia, mixed hyperlipidemia, and hypercholesterolemia, respectively.
Table 1. Clinical, biochemical and nutrient intake variables of individuals with type 2 diabetes mellitus (T2DM).
Variables T2DM (n = 95)
Age, years 48.6 ± 8.4
Sex
Men, n (%) 29 (30.5)
Women, n (%) 66 (69.5)
Time of T2DM diagnosis 1, years 7.3 ± 6.2
Insulin therapy 2, n (%) 21 (22.1)
Oral antidiabetic agents 2, n (%) 70 (73.7)
Lipid-lowering agents 2, n (%) 24 (25.3)
Antihypertensive agents 2, n (%) 46 (48.4)
Weight, kg 78.9 ± 19.3
BMI, kg/m2 30.2 ± 6.8
Fat mass 2, % 35.0 ± 7.9
Waist circumference, cm 99.8 ± 14.3
Men, n (%)
<94 cm 8 (27.6)
≥94 cm 21 (72.4)
Women, n (%)
<80 cm 6 (9.1)
≥80 cm 60 (90.9)
SBP 3, mmHg 129.2 ± 17.0
DBP 3, mmHg 83.5 ± 15.3
Fasting glucose, mg/dL 180.1 ± 84.1
%Hb1Ac 8.1 ± 2.1
Insulin, μU/mL 13.8 ± 13.5
C-peptide, ng/mL 2.7 ± 0.8
HOMA2-%B 77.0 ± 56.2
HOMA2-%S 42.8 ± 20.9
HOMA2-IR 3.3 ± 2.9
Total cholesterol, mg/dL 193.4 ± 47.3
HDL-c, mg/dL 41.1 ± 10.4
LDL-c, mg/dL 117.4 ± 39.8
Triglycerides, mg/dL 174.3 ± 117.1
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Table 1. Cont.
Variables T2DM (n = 95)
Energy intake, kcal/day 1469.4 ± 478.5
Protein intake, g/day 80.0 ± 20.2
Carbohydrate intake, g/day 210.1 ± 73.6
Lipid intake, g/day 37.1 ± 15.6
Zinc intake, mg/day 5.2 ± 1.5
Potassium intake, mg/day 1848.5 ± 543.4
Calcium intake, mg/day 469.0 ± 195.3
Magnesium intake mg/day 218.4 ± 68.1
Results presented in mean ± standard deviation and absolute frequency; 1 n = 91; 2 n = 93; 3 n = 89. %HbA1c:
glycated hemoglobin percentage; BMI: body mass index; DBP: diastolic blood pressure; HDL-c: high-density
lipoprotein cholesterol; HOMA: Homeostasis Assessment Model; LDL-c: low-density lipoprotein cholesterol; T2DM:
type 2 diabetes mellitus; SBP: systolic blood pressure. Micronutrients adjusted for total energy intake using the
residual method [28].
Energy intake was found to be underreported by 84.2% of the individuals. A prevalence of
inadequacy in energy-adjusted zinc intake of 99.9% in males and 82.6% in females was observed.
The prevalence of inadequate energy-adjusted magnesium intake for males and females was 96.4% and
74.9%, respectively. The energy-adjusted calcium intake showed a prevalence of inadequacy of 95.5%.
All the individuals evaluated had energy-adjusted potassium intake below the AI values (Figure 1).
Figure 1. Histogram of energy-adjusted intake of zinc (A), magnesium (B), calcium (C), and potassium
(D), and prevalence of inadequate intake in individuals with type 2 diabetes mellitus (T2DM) (n = 95).
(A) Group intake (mean ± SD): 5.23 ± 1.53 mg/day; Z-score: 3.06 (men) and 0.94 (women). (B) Group
intake (mean ± SD): 218.36 ± 68.13 mg/day; Z-score: 1.80 (men) and 0.67 (women). (C) Group
intake (mean ± SD): 468.95 ± 195.3 mg/day; Z-score: 1.96 (group). (D) Group intake (mean ± SD):
1848.45 ± 543.43 mg/day. SD: Standard deviation.
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When energy-adjusted micronutrient (zinc, potassium, calcium, and magnesium) intake was
compared between clusters, the group with lower micronutrient intake (cluster 1) showed signiﬁcantly
higher %HbA1c (p = 0.006) and serum triglyceride concentration (p = 0.01) in comparison with the
group with higher intake (cluster 2). No statistical differences were seen with regard to the other
variables studied (Table 2).
Table 2. Clinical, biochemical and nutrient intake variables of individuals with type 2 diabetes mellitus (T2DM).
Variables Cluster 1 (n = 65) Cluster 2 (n = 30) p-value
Age, years 48.6 ± 8.6 48.9 ± 7.9 0.866 ¥
Time of T2DM diagnosis, years 7.2 ± 6.4 7.4 ± 6.0 0.909
BMI, kg/m2 30.4 ± 6.9 29.9 ± 6.7 0.762 ¥
Waist circumference, cm 100.8 ± 13.7 97.7 ± 15.5 0.332
Fat mass, % 34.6 ± 8.0 35.8 ± 7.8 0.483
Total cholesterol, mg/dL 198.8 ± 49.7 181.5 ± 40.0 0.097
HDL-c, mg/dL 41.9 ± 10.5 39.2 ± 10.3 0.247
LDL-c, mg/dL 117.9 ± 42.2 116.4 ± 34.5 0.867
Triglycerides, mg/dL 194.9 ± 131.1 129.6 ± 58.5 0.010
%Hb1Ac 8.3 ± 2.1 7.2 ± 1.7 0.006
C-peptide, ng/mL 2.7 ± 0.9 2.7 ± 0.7 0.963
Fasting glucose, mg/dL 190.3 ± 88.2 158.1 ± 70.7 0.082 ¥
Insulin, μU/mL 13.2 ± 11.7 15.1 ± 16.8 0.525
HOMA2-%B 73.7 ± 59.4 84.0 ± 48.8 0.407 ¥
Energy intake, kcal/day 1452.3 ± 471.4 1506.3 ± 499.7 0.611
Lipid intake, g/day 37.4 ± 15.1 36.5 ± 16.8 0.796
Protein intake, g/day 80.2 ± 19.7 79.4 ± 21.4 0.856
Carbohydrate intake, g/day 203.6 ± 74.1 224.2 ± 71.7 0.207
Zinc intake, mg/day 4.8 ± 1.4 6.1 ± 1.5 <0.001
Potassium intake, mg/day 1556.5 ± 344.3 2480.9 ± 301.4 <0.001
Calcium intake, mg/day 400.6 ± 136.4 616.9 ± 222.4 <0.001
Magnesium intake mg/day 191.5 ± 54.2 276.6 ± 58.5 <0.001
Results presented in mean ± standard deviation. p-value <0.05 was considered statistically signiﬁcant. Student’s
t-test for independent samples and ¥ Mann–Whitney test. %HbA1c: glycated hemoglobin percentage; BMI: body
mass index; HDL-c: high-density lipoprotein cholesterol; HOMA: Homeostasis Assessment Model; LDL-c:
low-density lipoprotein cholesterol; T2DM: type 2 diabetes mellitus. Micronutrients adjusted for total energy
intake using the residual method [28].
Considering the signiﬁcant difference in %HbA1c between clusters, a binary logistic regression
model was applied in order to investigate the risk factors for increased %HbA1c (Table 3). We found
that alterations in the %HbA1cwere dependent of the time (in years) taken to diagnose T2DM (p = 0.005)
and lower micronutrient intake (cluster 1) (p = 0.028).
Table 3. Binary logistic regression model of glycated hemoglobin percentage (%HbA1c) and clusters
formed from energy-adjusted mineral intake by individuals with type 2 diabetes mellitus (T2DM).
Dependent Variable Covariables OR (95% CI) p-value
%Hb1Ac §
Age (years) £ 0.987 (0.931; 1.046) 0.661
Sex § 1.598 (0.580; 4.405) 0.365
Time of T2DM diagnosis (years) £ 1.155 (1.043; 1.278) 0.005
Cluster 1 § 3.041 (1.131; 8.175) 0.028
p-value <0.05 was considered signiﬁcant. p-value of model: 0.003 and r2: 0.221. Hosmer and Lemeshow test: 0.591. §
Variables included in the model in the dichotomous format. £ Variables included in the model in continuous format.
Model adjusted by sex, age, and time of T2DM diagnosis. %HbA1c: glycated hemoglobin percentage; CI: conﬁdence
interval; OR: odds ratio; T2DM: type 2 diabetes mellitus. Risk classiﬁcation used %HbA1c >7% [30] and cluster 1
with lower combined intake of zinc, potassium, calcium, and magnesium.
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Multiple regression analyses showed that, for every 1 g of potassium and 100 mg of magnesium
ingested, there was 1% and 0.7% reduction in %HbA1c, respectively. These results were inﬂuenced by
sex and time taken to diagnose T2DM (Table 4).
Table 4. Multiple linear regression models of glycated hemoglobin percentage (%HbA1c; dependent
variable) and energy-adjusted mineral intake by individuals with type 2 diabetes mellitus (T2DM).
Independent Variables β (95%CI) p-value r2 Adjusted
Model 1 1
Age (years) −0.032 (−0.082; 0.019) 0.216
0.143
Sex § 1.069 (0.209; 1.930) 0.015
Time of T2DM diagnosis (years) 0.117 (0.051; 0.183) 0.001
Zinc intake (mg/day) −0.017 (−0.283; 0.250) 0.902
Model 2 2
Age (years) −0.028 (−0.077; 0.021) 0.259
0.198
Sex § 0.925 (0.086; 1.765) 0.031
Time of T2DM diagnosis (years) 1.118 (0.054; 0.182) <0.001
Potassium intake (mg/day) −0.001 (−0.002; 0.000) 0.017
Model 3 2
Age (years) −0.029 (−0.079; 0.021) 0.253
0.151
Sex § 1.025 (0.163; 1.887) 0.020
Time of T2DM diagnosis (years) 0.119 (0.053; 0.184) 0.001
Calcium intake (mg/day) −0.001 (−0.003; 0.001) 0.377
Model 4 2
Age (years) −0.031 (0.080; 0.017) 0.206
0.201
Sex § 1.009 (0.177; 1.840) 0.018
Time of T2DM diagnosis (years) 0.117 (0.053; 0.181) <0.001
Magnesium intake (mg/day) −0.007 (−0.012; −0.001) 0.015
1 p-value of model: 0.002. 2 p-value of model: <0.001. β non-standardized. Variables included in the models in the
continuous format and in the § dichotomous format. All models adjusted by sex, age and time of T2DM diagnosis.
%HbA1c: glycated hemoglobin percentage; CI: conﬁdence interval; T2DM: type 2 diabetes mellitus.
4. Discussion
After assessing the effect of the energy-adjusted dietary intake of zinc, potassium, calcium,
and magnesium on the glycemic control of individuals with T2DM, we found a three-fold increased
risk of high %HbA1c when dietary intake was reduced. In addition, potassium and magnesium intakes
were predictive of %HbA1c decrease. It is noteworthy that most evaluated individuals were likely to
have inadequate ingestion of these micronutrients.
The association between low micronutrient intake and deﬁcient glycemic control is well known
and poor intake of these micronutrients is widely documented in T2DM [2,3,12,31]. However,
most studies looked at the intake of each micronutrient individually, and studies evaluating the
concomitant intake thereof are scarce.
Epidemiological studies have shown a signiﬁcant association between low daily zinc intake and
risk of T2DM [10,18,32], and the risk can be reduced by 20% upon daily intake of more than 13 mg
of zinc [33]. Kanoni et al. [34] found a signiﬁcant correlation between zinc intake and fasting glucose
values, where the daily intake of every 1 mg of zinc was able to reduce the glucose concentration
by 0.02 mg/dL. The same study was included in a recent systematic review, which reported that the
serum zinc concentration has been negatively correlated with %HbA1c and fasting glucose values in
T2DM [16].
The role of zinc in the functioning and maintenance of pancreatic β-cell mass, insulin biosynthesis,
and maturation of secretory granules is well documented [9,10]. In addition, zinc inhibits tyrosine
phosphatases by stimulating auto phosphorylation of insulin receptors [14,16]. Moreover, it is essential
in the redox mechanisms as a component of the superoxide dismutase enzyme, thus being helpful
against the oxidative stress generated by hyperglycemia [10,14].
The role of magnesium in the glycemic control has been shown in experimental studies on
rats with induced T2DM. Magnesium supplementation improved insulin secretion and sensitivity,
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lipid proﬁle, and inﬂammatory status [35,36]. Morakinyo et al. [36] also showed that rats supplemented
with magnesium improved GLUT4 translocation and, consequently, the metabolic control.
Previous evidence also points to an inverse association between magnesium intake and T2DM
risk [13,37]. Hypomagnesemia and low magnesium intake are very prevalent in individuals diagnosed
with T2DM, especially in those with poor glycemic control [12,31,38]. In addition, reduced plasma
concentration of magnesium may lead to changes in the glycemic control, since the body distribution
of this micronutrient has an impact on insulin secretion and action [12].
However, studies addressing the effect of magnesium supplementation on glycemic control
are controversial. Some studies have shown positive effects of magnesium supplementation on blood
glucose and %HbA1c lowering, and on the increased insulin sensitivity [8,39–41]. However, other studies
did not observe such effects, which may be explained by the presence of normomagnesemia, time of
supplementation, and reduced number of individuals assessed [42–47]. Two meta-analyses studies
showed reduction of 0.56 mmol/L (95% confidence interval (CI) = −1.10; −0.01) [48] and 0.37 mmol/L
(95% CI = −0.74; −0.00) [4], respectively, in the fasting glucose levels upon magnesium supplementation.
Magnesium is an important cofactor of enzymes involved in the glucose metabolism, in which
it binds to an ATP molecule, yielding the Mg–ATP complex that acts in phosphate transfer
reactions [4,12,37]. Thus, magnesium participates in the autophosphorylation of the β-subunit of
insulin receptors, proliferation and maintenance of pancreatic β-cells, activity of tyrosine kinases,
and stimulation of proteins and substrates of the insulin signaling cascade [12,13].
Enhanced intakes of calcium and potassium are also associated with reduced risk of T2DM [5,15],
due to the combined action of these minerals in the process of insulin release [7]. Within the pancreatic
β-cells, the intracellular ATP/ADP ratio that follows the glucose metabolism leads to the closure
of ATP-sensitive potassium channels, and subsequent depolarization of the plasma membrane.
Calcium channels are then opened, allowing the calcium inﬂux to the cells and subsequent activation
of exocytosis of the insulin granules [7,11].
The fundamental role of calcium in body weight control and, consequently, in the maintenance
of insulin sensitivity in the adipose tissue, is observed in animal models. Dietary calcium induces
suppression of calcitriol, thus reducing lipogenesis and increasing lipolysis. In addition, it increases the
uncoupling protein-2 (UCP2) expression in the adipose tissue. UCP2 is responsible for the transport
and oxidation of mitochondrial fatty acids, which reduces lipid storage and adiposity [49].
Few studies have assessed the effect of calcium intake on the glycemic control. In an eight-week
study, calcium supplementation (1500 mg per day) improved the insulin sensitivity in individuals
with T2DM [50]. However, insulin sensitivity was not changed after non-diabetic obese individuals
underwent 24 weeks of supplementation with 1000 mg of calcium per day [49].
Furthermore, magnesium intake is likely to be a confounding factor as it is highly correlated
with calcium metabolism as observed in studies addressing the association between intake of both
minerals and the risk of T2DM [51,52]. A relationship between calcium and vitamin D intakes was
also observed as the interaction of these nutrients leads to reduced fasting insulin and %HbA1c levels
in individuals with T2DM [53].
The relation between potassium intake and variables of glycemic control in individuals with
T2DM is not widely addressed in the literature. Both low potassium intake and reduced potassium
concentration in serum were shown to be signiﬁcantly associated with reduced insulin sensitivity and
with a compensatory increase in insulin secretion [5], as well as with risk of T2DM [17,54].
Considering that the adoption of healthy dietary and body weight control patterns is fundamental
for the T2DM management [1,6], a high rate of underreported energy intake is observed among
individuals with T2DM in this study, and this can be the main reason for the high prevalence
of overweight and obesity here documented. Underreporting is a commonly observed practice
among obese individuals and can affect the estimation of nutrient intake, consequently impairing
nutritional and disease assessments [55,56]. In addition, the analysis of food intake that relies on
24-hour recalls may have limitations, since this method is susceptible to inaccurate reports about both
141
Nutrients 2018, 10, 1948
the food consumed and the size of its portions [25]. However, these limitations were mitigated after
calculation of intra and interindividual variability, in combination with the adjustment for energy
intake of nutrients.
Furthermore, food evaluation involves data of tables of food composition, and such tables can be
different depending on where the food is produced. Therefore, similar to the present study, the use of
region or country-speciﬁc food composition tables may help to correct this confounding factor.
5. Conclusions
Overall, studies evaluating the effect of the concomitant intake of micronutrients on variables of
glycemic metabolism in individuals with T2DM are scarce, especially when it comes to zinc, potassium,
calcium, and magnesium. This highlights the importance of our results for a better evaluation of usual
food intake in this population, which is a simple and low-cost procedure, as %HbA1c is routinely
measured in individuals with T2DM and it is the gold standard for glycemic control evaluation.
Therefore, inadequate concomitant intake of zinc, potassium, calcium, and magnesium is related
to poor glycemic control in individuals with T2DM, and the intakes of magnesium and potassium are
predictors of %HbA1c reduction. Further studies on dietary intake of individuals with T2DM and their
relation with glucose metabolism are needed.
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Abstract: We aimed to examine whether dietary patterns that explain the variation of triglyceride
(TG) to high-density lipoprotein cholesterol (HDL-C) ratio were associated with the incidence of type
2 diabetes in Korean adults. We included a total of 5097 adults without diabetes at baseline with
a mean follow-up of 11.54 years. Usual diet was assessed by a validated food frequency questionnaire,
and serum levels of TG and HDL-C were measured at baseline. We derived dietary pattern scores
using 41 food groups as predictors and the TG/HDL-C ratio as a response variable in a stepwise
linear regression. We calculated the odds ratio (OR) with the 95% conﬁdence interval (CI) of type
2 diabetes according to pattern scores using multivariate logistic regression. A total of 1069 incident
cases of type 2 diabetes were identiﬁed. A list of foods characterizing the dietary pattern differed
by sex. Higher dietary pattern scores were associated with an increased risk of type 2 diabetes; ORs
(95% CIs) comparing extreme quintiles were 1.53 (1.12–2.09; p for trend = 0.008) for men and 1.33
(0.95–1.86; p for trend = 0.011) for women. Our study suggests the evidence that dietary patterns
associated with low levels of TG/HDL-C ratio may have the potential to reduce the burden of type
2 diabetes.
Keywords: dietary pattern; triglyceride; high-density lipoprotein cholesterol; type 2 diabetes
1. Introduction
The estimated global prevalence of diabetes mellitus has increased about 50% over the last
decade, increased from 5.9% in 2007 to 8.8% in 2017 according to the International Diabetes
Foundation [1,2] Over 90% of diabetes cases are of type 2 [2], and the rapid increase is largely attributed
to changes in lifestyle factors, such as being overweight or obese, physical inactivity, unhealthy diet,
and smoking [3,4]. To reduce the burden of diabetes and its complications, the early detection and
treatment of diabetes and evidence-based guideline for diabetes prevention or management are
important [5]. The World Health Organization (WHO) and the Food and Agriculture Organization
(FAO) provide dietary recommendations for type 2 diabetes prevention, which include limiting
saturated fat and obtaining an adequate ﬁber intake [6]. In addition, WHO recommends reducing the
free sugar intake to prevent non-communicable diseases (NCDs), including type 2 diabetes [7].
Because nutrients and foods are consumed in combination, dietary pattern analysis can provide
more practical evidence than single-nutrient analysis [8,9]. In addition, the consumption of dietary
factors associated with the risk of type 2 diabetes may correlate with each other; therefore, dietary
pattern analysis that reﬂects the complexity of diets may provide scientiﬁc insight and practical
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strategies for disease prevention. Approaches to assess the effects of dietary patterns on the risk of
diabetes have been implemented in epidemiologic studies [10,11]. Several previous studies have found
signiﬁcant associations between the risk of type 2 diabetes and posteriori-derived dietary patterns that
explain the variation in diabetes-related biomarkers, such as blood glucose, lipids, or inﬂammatory
markers [12–21].
Insulin resistance, a phenomenon involving the resistance to insulin-stimulated glucose uptake,
is involved in the pathogenesis of type 2 diabetes, hypertension, and coronary heart disease [22,23].
Indices derived from fasting glucose and insulin including homoeostasis model assessment-insulin
resistance (HOMA-IR) and quantitative insulin-sensitivity check index (QUICKI) are widely used to
quantify insulin resistance [24]. In addition, the triglyceride (TG) to high-density lipoprotein cholesterol
(HDL-C) ratio has been suggested as a simple measure of insulin resistance [25–28]. Vega et al. [29]
found that a high TG/HDL-C ratio was associated with an increased risk of type 2 diabetes and
cardiovascular disease (CVD) mortality among men participating in the Cooper Center Longitudinal
Study (CCLS). In the Korean population, the TG/HDL-C ratio was also signiﬁcantly associated with
insulin resistance [30,31], and the risk of type 2 diabetes [32].
The aim of our study was to identify posteriori-dietary patterns that explain variation in the
TG/HDL-C ratio and to examine their association with the risk of type 2 diabetes in Korean adults.
Given the sex-differences in TG and HDL-C levels [33] and dietary behavior [34], we identiﬁed the
dietary patterns among men and women separately.
2. Materials and Methods
2.1. Study Population
The Ansan and Ansung study is part of the Korean Genome and Epidemiology Study (KoGES),
which was designed to prospectively investigate the genetic and environmental inﬂuences on chronic
disease in Korean adults [35]. The Ansan and Ansung study included 10,030 adults (4758 men and
5272 women) aged 40–69 years from the general population of urban (Ansan) and rural (Ansung) areas
in 2001–2002. Clinical examination and interviewer-administered questionnaires were conducted at
baseline and at biennial follow up. The follow-up rate was 62.8% at the 6th follow-up in 2013–2014
from baseline [35]. All participants provided informed consent. This study was approved by the Seoul
National University Institutional Review Board (IRB No. E1811/001-009).
Of 10,030 participants at baseline, we excluded participants who had been diagnosed with or
treated for diabetes (n = 683), cancer (n = 247), CVD (n = 408) or had missing data on relevant
information (n = 7); those who had used insulin treatment (n = 93), an oral hypoglycemic drug (n = 360)
or stroke medication (n = 21). We further excluded participants who did not have baseline fasting
plasma glucose, 2-h plasma glucose after a 75 g oral glucose tolerance test (OGTT), or hemoglobin A1c
(HbA1c) measurements (n = 67) as well as undiagnosed diabetes cases who met the American Diabetes
Association (ADA) criteria for the diagnosis of diabetes (n = 692). We also excluded participants who
did not have serum TG or HDL measurements (n = 1) or had outlier values for TG or HDL-C levels as
determined by a box-plot method (greater than 3*interquartile range; n = 4).
KoGES provided food frequency questionnaires (FFQs) data after excluding individuals who:
1) did not answer any questions on the FFQs, 2) left more than 12 blanks for frequency questions,
3) did not answer any questions about rice intake, or 4) had extremely low (<100 kcal/day) or high
(≥10,000 kcal/day) energy intake [36], resulting in exclusion of 255 participants. Furthermore, we
excluded individuals who reported implausible energy intake (<500 or >3500 kcal/day for women
and <800 or >4200 kcal/day for men; n = 230) or did not have data on alcohol consumption (n = 247).
Among those participants who met the inclusion criteria at baseline (n = 7338), we excluded those who
were not followed at the 5th (2011–2012) or 6th (2013–2014) follow up (n = 2228) as well as for those
whose information on the ascertainment of type 2 diabetes during the follow-up (n = 754) was not
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available. As a result, a total of 5097 participants (2410 men and 2687 women) were included in the
current study. Flow diagram of inclusion for study participants is presented in Figure S1.
2.2. Dietary Assessment
Usual dietary intake was assessed using an interviewer-administered semi-quantitative 103 item
FFQ at baseline. The questionnaire was previously validated using 12-day dietary records among
124 participants of KoGES; Pearson’s correlation coefﬁcients for energy-adjusted nutrient intakes
ranged from 0.23 (vitamin A) to 0.64 (carbohydrate) [37]. Daily energy and nutrient intake were
estimated based on the seventh edition of the Food Composition Tables of the Korean Nutrition
Society [38]. Participants were asked to report the frequency and portion size of each food item during
the previous year. Nine frequency categories ranging from “never or seldom” to “three times or more
a day” and three portion sizes (small, medium, or large) were given as options. Alcoholic beverage
consumption was assessed separately at baseline and at each biennial follow up. Alcohol drinking
status was deﬁned as nondrinker, past drinker, or current drinker. Current alcohol drinkers were asked
to report the amount and frequency of alcohol beverage consumption in the previous month, and total
alcohol consumption (g/day) was calculated based on the alcohol content of one standard drink.
2.3. Ascertainment of Type 2 Diabetes and Biomarker Assessment
A diagnostic test for diabetes and interviewer-administered questionnaires on diabetes diagnosis
or treatment were repeated at biennial follow up. We deﬁned incident type 2 diabetes cases as those
who had: 1) a diagnosis of diabetes according to the ADA criteria including HbA1c ≥ 6.5% or fasting
plasma glucose ≥ 126 mg/dl or 2-h plasma glucose ≥ 200 mg/dl after a 75 g OGTT [39]; or 2)
a diagnosis of type 2 diabetes by physicians or treatment with insulin or oral hypoglycemic medication.
Participants who developed type 2 diabetes after baseline were classiﬁed as diabetes cases and were
otherwise categorized as non-cases.
Blood samples were collected after an overnight fast (at least 8 h) at baseline and at each biennial
follow-up examination. Fasting plasma glucose, 1-h and 2-h plasma glucose after a 75 g OGTT were
measured enzymatically using an automatic analyzer (ADIVA 1650; Siemens, USA). Whole blood
HbA1c level was measured by high-performance liquid chromatography (BIO-RAD Variant II—Turbo;
BIORAD, Japan). Serum TG and HDL-C were measured enzymatically using an automatic analyzer
(ADIVA 1650; Siemens, USA). The TG/HDL-C ratio was calculated as the ratio of TG to HDL-C.
2.4. Covariate Assessment
Trained interviewers administered a questionnaire regarding sociodemographic factors,
lifestyle factors, disease history or current treatment, medication history, family disease history,
and reproductive factors. Smoking status was categorized into nonsmoker, past smoker, or current
smoker. Pack-years of smoking were calculated using detailed information on smoking history among
past or current smokers. When information regarding age at menopause was missing (n = 326), we
considered the participant postmenopausal if they had been diagnosed after the age of 50, which
was the median age of menopause in Korean postmenopausal women aged 40–69 years in 2001 [40].
Participants were asked to report: 1) the hours per day spent on four-intensity physical activity levels
(sedentary, light, moderate, and vigorous activity) and 2) the frequency of leisure time spent on
physical activity per week and the hours spent on each activity (aerobic, jogging, walking, swimming,
tennis, golf, bowling, health club exercise, and mountain climbing). Physical activity was expressed
as metabolic equivalents (METs) hours per week by multiplying the hours per week engaged in
that activity by the activity’s corresponding MET value [41,42]. Anthropometric factors of body
weight, height, waist circumference, hip circumference, and blood pressure were obtained by trained
examiners. Body mass index (BMI) was calculated as weight (kg) divided by height-squared (m2).
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2.5. Statistical Analysis
We derived dietary patterns that explained the variation in TG/HDL-C ratio using reduced
rank regression (RRR) [43]. RRR is a posteriori method used to derive linear combinations of
predictor variables (food groups) that explain as much as possible of the variation of response variables
(disease-related markers) [43]. When using only one response variable, RRR is identical to multiple
linear regression [12,44].
When we derived the dietary patterns of the participants at baseline, we included participants
who had never been diagnosed with dyslipidemia and used hyperlipidemia drugs, and participants
who had normal HbA1c and plasma glucose levels according to the ADA criteria to avoid the effect
of these symptoms on their diet. As a result, 3630 participants (1716 men and 1914 women) were
included in the study to derive dietary patterns.
We grouped 103 food items from FFQ and alcohol consumption into 41 groups (g/day) on the
basis of similarities in food composition or nutrient content, and these were used as predictor variables
to derive dietary patterns. As a response variable, the TG/HDL-C ratio was log-transformed for
normality and adjusted for age using a residual method. We then derived dietary patterns that
explained as much as possible of the variation of age-adjusted TG/HDL-C using a stepwise linear
regression model in men and women separately. A signiﬁcance level of 0.05 was used for entry and
retention in the model. We calculated dietary pattern scores by summing the intakes of selected food
groups that were weighted by the regression coefﬁcients for all the study participants.
We used Spearman’s correlation coefﬁcients to assess the correlations of dietary pattern and
selected foods with the TG/HDL-C ratio. We divided the study participants according to the quintiles
of dietary pattern scores and identiﬁed the intakes of selected food groups as well as demographic,
lifestyle, and clinical characteristics. We used multivariate logistic regression models to calculate
the odds ratio (OR) and 95% conﬁdence interval (CI) of type 2 diabetes in each quintile of dietary
pattern scores using the lowest quintile as the reference group. In multivariate models, we adjusted
for age (continuous, years), living area (Ansan and Ansung), energy intake (continuous, kcal/day),
menopausal status (pre and postmenopausal status for women), smoking status (0, >0 and <15, 15–<30,
and 30≤ pack-years for men; ever and never smoking for women), alcohol consumption (0, >0 and <5,
5–<15, 15–<30, and 30≤ g/day for men; ever and never drinking for women), family history of diabetes
(yes, no), chronic disease status at baseline (yes, no; diagnosis or use of medication for hypertension or
hyperlipidemia), and physical activity (continuous, METs-hours/week). We further adjusted for BMI
(kg/m2), which may be an intermediate factor in the causal pathway between dietary patterns related
to TG/HDL-C ratio and the risk of type 2 diabetes. We calculated the p value for the trend across
quintiles by assigning the median value of each quintile to corresponding participants and treating
this value as a continuous variable in the model. We tested for effect modiﬁcation by age, menopausal
status, and BMI at baseline by performing stratiﬁed analyses and the likelihood ratio test (LRT) for
each variable. We also conducted a sensitivity analysis by excluding incident cases of type 2 diabetes
during 2 years of follow up when we examined the association between dietary pattern scores and the
risk of type 2 diabetes. All statistical analyses were performed using SAS statistical software version 9.4
(SAS Institute Inc., Cary, NC). All hypothesis tests were evaluated using two-tailed tests of signiﬁcance
at p < 0.05.
3. Results
When we derived dietary patterns associated with TG/HDL-C ratio, the list of selected food items
differed by sex (Table 1). A high dietary pattern score was characterized in men by higher intakes of
noodles, fruits, fermented salted seafood and lower intakes of candy and chocolate, nuts, and pork,
whereas that in women was characterized by higher intakes of organ and other meats and lower
intakes of dairy products and nuts. The calculated dietary pattern scores were positively associated
with TG/HDL-C ratio; the Spearman’s correlation coefﬁcients were 0.15 for men and 0.13 for women.
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Table 1. Spearman correlation coefﬁcients between dietary pattern scores, selected foods, and the
TG/HDL-C ratio, and the mean intake of selected food groups (g/day) according to the quintile of
dietary pattern scores.
Spearman’s Correlation with
Dietary Pattern Scores
Quintile of TG/HDL-C Ratio-Related
Dietary Pattern Scores
Dietary
Pattern Scores
TG/HDL-C
Ratio Quintile1 Quintile3 Quintile5
Men (n = 2410)
Diet pattern scores 1.00 0.15 a
Positive associations Mean ± SD
Noodles 0.37 a 0.07 a 63.24 ± 54.12 68.18 ± 47.97 152.57 ± 120.93
Fruits 0.33 a 0.03 156.68 ± 150.35 154.63 ± 145.63 426.23 ± 382.61
Fermented salted seafood 0.23 a 0.03 1.26 ± 2.66 0.88 ± 1.58 4.91 ± 8.12
Inverse associations
Candy and chocolate −0.30 a −0.06 a 5.02 ± 8.62 0.68 ± 1.42 0.69 ± 1.90
Nuts −0.29 a −0.06 a 2.46 ± 4.40 0.39 ± 1.02 0.36 ± 1.08
Pork −0.26 a −0.03 69.70 ± 55.90 32.44 ± 29.14 37.11 ± 34.88
Women (n = 2687)
Diet pattern scores 1.00 0.13 a
Positive associations Mean ± SD
Organ and other meats 0.10 a −0.01 0.94 ± 3.11 0.97 ± 2.44 3.62 ± 16.72
Inverse associations
Dairy products −0.88 a −0.12 a 292.40 ± 173.30 75.75 ± 40.48 9.51 ± 32.10
Nuts −0.42 a −0.09 a 2.50 ± 5.02 0.33 ± 0.57 0.04 ± 0.17
Abbreviations: TG, triglyceride; HDL-C, high-density lipoprotein cholesterol. a Spearman’s correlation coefﬁcient
was statistically signiﬁcant (p < 0.05).
The baseline characteristics of men and women are presented in Table 2 according to the quintiles
of sex-speciﬁc dietary pattern associated with TG/HDL-C ratio. Men who had higher dietary pattern
scores were more likely to live in a rural area, have a higher energy intake, and be a current smoker.
Women who had higher dietary pattern scores were more likely to be older and postmenopausal, live
in a rural area, and have a lower energy intake and physical activity. Participants who had higher
dietary pattern scores were more likely to have a higher TG/HDL-C ratio, higher TG levels and lower
HDL-C levels than those who had lower dietary pattern scores.
Table 2. Baseline characteristics of the study participants according to the quintiles for TG/HDL-C
ratio-related dietary pattern scores.
Quintile of TG/HDL-C Ratio-Related Dietary Pattern Scores
Quintile1 Quintile3 Quintile5
Men (n = 2410) 482 482 482
Age (years), mean ± SD 50.38 ± 8.08 50.50 ± 7.99 51.10 ± 8.19
Residential area, n (%)
Rural (Ansung) 148 (30.71) 209 (43.36) 260 (53.94)
Urban (Ansan) 334 (69.29) 273 (56.64) 222 (46.06)
Energy intake (kcal/day), mean ± SD 2095.97 ± 527.68 1802.31 ± 437.21 2289.32 ± 603.02
BMI (kg/m2), mean ± SD a 24.02 ± 2.88 24.27 ± 2.77 24.37 ± 2.90
Physical activity (METs h/week), mean ± SD 9.65 ± 14.83 8.06 ± 12.29 8.76 ± 12.05
Smoking status, n (%) a
Non-smoker 116 (24.07) 97 (20.12) 99 (20.54)
Past smoker 175 (36.31) 165 (34.23) 130 (26.97)
Current smoker 191 (39.63) 220 (45.64) 253 (52.49)
Alcohol consumption status, n (%)
Non-drinker 94 (19.50) 101 (20.95) 80 (16.60)
Past drinker 48 (9.96) 32 (6.64) 51 (10.58)
Current drinker 340 (70.54) 349 (72.41) 351 (72.82)
Family history of diabetes, n (%)
No 434 (90.04) 433 (89.83) 437 (90.66)
Yes 48 (9.96) 49 (10.17) 45 (9.34)
TG/HDL-C ratio, mean ± SD 3.66 ± 2.79 4.14 ± 2.95 4.97 ± 4.06
TG (mg/dL), mean ± SD 150.52 ± 92.96 166.22 ± 92.86 191.56 ± 123.95
HDL-C (mg/dL), mean ± SD 44.88 ± 9.96 43.69 ± 9.27 42.73 ± 10.10
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Table 2. Cont.
Quintile of TG/HDL-C Ratio-Related Dietary Pattern Scores
Quintile1 Quintile3 Quintile5
Women (n = 2687) 538 531 512
Age (years), mean ± SD 50.02 ± 8.06 50.24 ± 8.26 54.41 ± 8.97
Menopausal status, n (%) a
Pre-menopause 243 (52.83) 263 (55.96) 165 (35.71)
Post-menopause 217 (47.17) 207 (44.04) 297 (64.29)
Residential area, n (%)
Rural (Ansung) 199 (36.99) 236 (44.44) 358 (69.92)
Urban (Ansan) 339 (63.01) 295 (55.56) 154 (30.08)
Energy intake (kcal/day), mean ± SD 2081.36 ± 513.71 1818.15 ± 480.73 1679.94 ± 517.76
BMI (kg/m2), mean ± SD a 24.21 ± 2.97 24.72 ± 2.97 25.13 ± 3.23
Physical activity (METs h/week), mean ± SD 11.72 ± 16.47 9.46 ± 14.56 6.69 ± 10.16
Smoking status, n (%) a
Non-smoker 510 (96.05) 511 (96.78) 481 (95.06)
Past smoker 4 (0.75) 5 (0.95) 10 (1.98)
Current smoker 17 (3.20) 12 (2.27) 15 (2.96)
Alcohol consumption status, n (%)
Non-drinker 368 (68.40) 378 (71.19) 371 (72.46)
Past drinker 10 (1.86) 14 (2.64) 18 (3.52)
Current drinker 160 (29.74) 139 (26.18) 123 (24.02)
Family history of diabetes, n (%)
No 467 (86.80) 469 (88.32) 461 (90.04)
Yes 71 (13.20) 62 (11.68) 51 (9.96)
TG/HDL-C ratio, mean ± SD 3.08 ± 2.24 3.27 ± 2.64 3.74 ± 2.59
TG (mg/dL), mean ± SD 133.63 ± 74.45 136.19 ± 81.17 153.49 ± 82.92
HDL-C (mg/dL), mean ± SD 47.72 ± 10.1 45.59 ± 9.76 45.11 ± 9.95
Abbreviations: BMI, body mass index; METs, metabolic equivalents; TG, triglyceride; HDL-C, high-density
lipoprotein cholesterol. a Some participants did not provide relevant information (among men, 1 missing for
BMI; and among women, 326 missing for menopausal status and 27 missing for smoking status).
A total of 1069 (560 men and 509 women) cases of type 2 diabetes were identiﬁed over a mean
follow up of 11.54 years. Multivariate adjusted OR (95% CIs) comparing extreme quintiles was 1.53
(1.12–2.09; p for trend = 0.008) among men and 1.33 (0.95–1.86; p for trend = 0.011) among women
(Table 3). For women, OR (95% CI) comparing the 3rd versus the 1st quintile was 1.45 (1.06–1.99).
After further adjustment for BMI, the association was slightly attenuated in both men and women.
We examined whether the associations between dietary pattern scores and incident type 2 diabetes
varied by age (≤median, >median), menopausal status, and BMI (<25, ≥25 kg/m2) at baseline
regarding the risk of type 2 diabetes (Table 4). The associations appeared to be stronger among older or
postmenopausal women than among younger or premenopausal women; the ORs (95% CI) comparing
the extreme quintiles were 1.10 (0.65–1.86) for younger women and 1.61 (1.03–2.54) for older women.
For BMI, the association appeared to be stronger among men with lower BMI than among those with
higher BMI; the ORs (95% CI) comparing the extreme quintiles were 1.82 (1.19–2.80) for men with lower
BMI and 1.17 (0.74–1.85) for men with higher BMI. However, there were no signiﬁcant interactions by
these factors.
In the sensitivity analysis, we excluded incident cases that were identiﬁed during 2 years of
follow-up (n = 193), and the estimates of the association between the dietary pattern scores and the
incidence of type 2 diabetes were similar to those found in the main analysis (Table S1).
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4. Discussion
We derived dietary patterns that explain the variation in the diabetes-related biomarker,
the TG/HDL-C ratio, in men and women separately. The dietary pattern was characterized by
high intakes of noodles, fruits, fermented salted seafood and low intakes of candy and chocolate, nuts,
and pork among men and by high intakes of organ and other meats and low intakes of dairy products
and nuts among women. Dietary pattern scores were positively associated with the TG/HDL-C ratio.
High dietary pattern score was associated with an increased risk of type 2 diabetes. The associations
appeared to be stronger among older or postmenopausal women, albeit without statistical signiﬁcance.
Insulin resistance is a major risk factor for the development of type 2 diabetes [22,23,
45]. The consequences of insulin resistance and its compensatory hyperinsulinemia include
glucose intolerance, dyslipidemia (increased TG and/or decreased HDL-C), high blood pressure,
hyperuricemia, and increased plasminogen activator inhibitor (PAI)-1 activity [23]. Several studies
have examined the association between risk of type 2 diabetes and dietary patterns that explain
the variation of biomarkers that are linked to diabetes [12–21]. Biomarkers linked to diabetes
that have been used to derive dietary patterns include inﬂammatory markers (e.g., PAI-1, tumor
necrosis factor-α receptor 2, C-reactive protein (CRP), and Interleukin 6) [12,13,19,21], glucose (e.g.,
HbA1c, HOMA-IR, and fasting glucose) [12,14,16,20], lipid-related metabolites (e.g., TG, HDL-C,
adiponectin, and leptin) [12,16,18,21], and uric acids [17]. Food groups that have been frequently
reported to be associated with an increased risk of type 2 diabetes have been characterized by high
intakes of sugar-sweetened beverages or soft drinks [12–14,16,17,21], processed meats [12,13,16,21],
red meats [12,15,16,21], reﬁned grains [13,16], white rice [21] or bread [14,19] and low intakes of
wine [13,15,16], whole grains [16,21], and yellow [13,16,21] and green [16,21] vegetables. In our study,
noodles positively contributed to the dietary pattern scores among men. Batis et al. [20] also identiﬁed
a positive association of wheat noodles with dietary pattern scores that explained variations of HbA1c,
HOMA-IR, and fasting glucose levels among Chinese men and women. Additionally, consistent with
previous studies that identiﬁed a positive contribution of red meats to diabetes-related dietary pattern
scores [12,15,16,21], we found a positive contribution of organ and other meats to dietary pattern
scores among women.
The estimates of the association between dietary pattern scores and the risk of type 2 diabetes
are comparable to those found in previous studies. Jannasch et al. [11] conducted meta-analyses of
the association between posteriori-dietary patterns associated with diabetes-related biomarkers and
risk of type 2 diabetes [12–14,16,46]; combined relative risks (95% CIs) were 0.51 (0.27–0.98) for dietary
pattern related to HbA1c, HDL-C, CRP, and adiponectin [12,16,46], 2.53 (1.56–4.10) for dietary pattern
related to inﬂammatory markers [13,16,46] and 1.39 (1.25–1.54) for dietary patterns associated with
HOMA-IR [14,16,46].
Previous studies have identiﬁed the TG/HDL-C ratio as a clinically useful surrogate estimate
of insulin resistance [25–28]. Methods for estimating TG and HDL-C concentrations are well
standardized [26], and the ratio of the two values provides information on the atherogenic lipoprotein
proﬁle associated with the risk of CVD [47] as well as insulin resistance. A high TG/HDL-C ratio
is associated with an increased risk of type 2 diabetes [29,32,48,49] and with CHD and/or CVD
events [50,51] and mortality [29,52]. Tabung et al. [53] developed an empirical dietary index for
insulin resistance using the TG/HDL-C ratio as a response variable and food groups as explanatory
variables in a stepwise linear regression model in a female cohort, the Nurses’ Health Study (NHS).
An empirical dietary index for insulin resistance was characterized by high intakes of low-calorie
beverages, margarine, red meat, reﬁned grains, processed meats, tomatoes, other vegetables, other
ﬁsh, fruit juice, and creamy soups and low intakes of coffee, wine, liquor, beer, green leafy vegetables,
high-fat dairy products, dark yellow vegetables, and nuts [53]. Consistent with a previous study
that developed a dietary index for insulin resistance, our study also found that dietary pattern was
positively associated with organ and other meats and negatively associated with dairy products and
nuts among women. According to the meta-analysis of prospective cohort studies for individual food
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groups, a higher consumption of red meats was associated with an increased risk of type 2 diabetes [54],
whereas higher consumption of dairy products [55,56] and nuts [57] were associated with a reduced
risk of type 2 diabetes.
There were unexpected inverse associations of dietary pattern scores with pork and
candy/chocolate among men. Even though we used an age-adjusted TG/HDL-C ratio, a difference
in pork by age may exist. Low consumption of pork among older men may explain our ﬁnding;
mean intake of pork among men aged 40s, 50s, and 60s was 47.19 g/day, 42.25 g/day, and 37.65
g/day, respectively. Further study is needed to examine dietary patterns associated with various
biomarkers that have been linked to diabetes and their prediction of type 2 diabetes risk in different
study populations.
This study has several limitations. We did not use person-years of follow-up to analyze the
association because we did not have information on type 2 diabetes incidence for more than 20% of
the original study participants. Therefore, we included participants whose fasting plasma glucose, 2-h
plasma glucose after a 75 g OGTT, and HbA1c were available during the follow-up. This may limit the
generalizability of our ﬁndings; however, we tried to remove the potential bias that could occur from
loss to follow-up. We also cannot rule out the possibility of the presence of measurement error in the
dietary assessment or residual or unknown confounding factors.
The strengths of our study include the measurement of biomarkers to detect the incidence of type
2 diabetes. Fasting plasma glucose, 2-h plasma glucose after a 75 g OGTT, and HbA1c were measured
at baseline and at every biannual follow up. This is the ﬁrst cohort study in Korea to examine the
association between biomarker-related dietary pattern and type 2 diabetes incidence. We were able
to examine a temporal relationship between dietary patterns and the risk of type 2 diabetes, given
a cohort study design. Information on sociodemographic and lifestyle factors as well as medical status
allowed us to adjust for potential confounders. Last, we additionally derived the dietary patterns of
men and women separately. Providing sex-speciﬁc ﬁndings is important because of the sex difference
in biological and behavioral characteristics and sex-speciﬁc results may provide appropriate evidence
on modiﬁable factors that contributing to disease prevention in men and women [58]. We found that
the components of dietary patterns differed by sex, and the results were consistent with previous
studies that examined the association in a sex-speciﬁc way.
5. Conclusions
The present study derived posteriori-dietary patterns using the TG/HDL-C ratio as a biomarker
that is linked to type 2 diabetes, and examined the associations between the dietary pattern scores
and the risk of type 2 diabetes among Korean men and women. Among men, dietary pattern was
characterized by higher intakes of noodles, fruits, fermented salted seafood and lower intakes of candy
and chocolate, nuts, and pork; and the dietary pattern for women was characterized by higher intakes
of organ and other meats and lower intakes of dairy products and nuts. Higher dietary pattern scores
were associated with an increased risk of type 2 diabetes. Our study provides sex-speciﬁc evidence
on dietary patterns associated with the risk of type 2 diabetes, which may partly be mediated by the
TG/HDL-C ratio. Consideration of TG/HDL-C ratio related dietary patterns to reduce the burden of
type 2 diabetes may be needed and our study warrants further replication.
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Abstract: A low carbohydrate diet (LCD), with some staple food being replaced with nuts, has been
shown to reduce weight, improve blood glucose, and regulate blood lipid in patients with type 2
diabetes mellitus (T2DM). These nuts include tree nuts and ground nuts. Tree nut consumption is
associated with improved cardio-vascular and inflammatory parameters. However, the consumption of
tree nuts is difficult to promote in patients with diabetes because of their high cost. As the main ground
nut, peanuts contain a large number of beneficial nutrients, are widely planted, and are affordable
for most patients. However, whether peanuts and tree nuts in combination with LCD have similar
benefits in patients with T2DM remains unknown; although almonds are the most consumed and
studied tree nut. This study sought to compare the effect of peanuts and almonds, incorporated into a
LCD, on cardio-metabolic and inflammatory measures in patients with T2DM. Of the 32 T2DM patients
that were recruited, 17 were randomly allocated to the Peanut group (n = 17) and 15 to the Almond
group (n = 15) in a parallel design. The patients consumed a LCD with part of the starchy staple food
being replaced with peanuts (Peanut group) or almonds (Almond group). The follow-up duration
was three months. The indicators for glycemic control, other cardio-metabolic, and inflammatory
parameters were collected and compared between the two groups. Twenty-five patients completed
the study. There were no significant differences in the self-reported dietary compliance between the
two groups. Compared with the baseline, the fasting blood glucose (FBG) and postprandial 2-h blood
glucose (PPG) decreased in both the Peanut and Almond groups (p < 0.05). After the intervention,
no statistically significant differences were found between the Peanut group and the Almond group
with respect to the FBG and PPG levels. A decrease in the glycated hemoglobin A1c (HbA1c) level from
the baseline in the Almond group was found (p < 0.05). However, no significant difference was found
between the two groups with respect to the HbA1c level at the third month. The peanut and almond
consumption did not increase the body mass index (BMI) and had no effect on the blood lipid profile
or interleukin-6 (IL-6).In conclusion, incorporated into a LCD, almonds and peanuts have a similar
effect on improving fasting and postprandial blood glucose among patients with T2DM. However,
more studies are required to fully establish the effect of almond on the improvement of HbA1c.
Keywords: type 2 diabetes mellitus; peanut; almond; glycemic control; body mass index; lipids;
interleukin-6
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1. Introduction
Type 2 diabetes mellitus (T2DM) is a chronic disease that involves a heterogeneous group of
disorders of the intermediary metabolism, characterized by glucose intolerance [1]. The incidence and
prevalence of T2DM have increased markedly worldwide, and its complications are the leading causes
of morbidity and premature mortality [2]. The use of diet in the prevention, treatment, and control
of T2DM has been recommended, and is one of the strategies for managing the condition. According
to the American Diabetes Association (ADA), the nutritional goals for patients with T2DM are to
achieve normoglycemia and a cardio protective lipid profile that reduces the risk for cardiovascular
disease (CVD) [3].
In recent years, a low carbohydrate diet (LCD) has gained popularity [4],and its effectiveness in
reducing weight, improving blood glucose, and regulating blood lipid in patients with T2DM has been
conﬁrmed by the American Diabetes Association and Diabetes UK [5,6]. ALCD combined with a low
saturated fat intake may be best for patients [7].
Nuts are high in unsaturated fat and are a rich source of bioactive nutrients that have the
potential to provide metabolic and cardiovascular beneﬁts [8]. Bodies concerned with diabetes and
CVD (e.g., the Canadian Cardiovascular Society and the European Atherosclerosis Society) are now
advocating for an increase in nut consumption as part of their dietary recommendations [9–12].
Nuts include tree nuts (almond, walnut, hazelnut, pistachio, pine nut, cashew, pecan, macadamia,
and Brazil nut) and ground nuts (mainly peanut). Almonds are the most studied tree nut. Clinical
trials have shown that the consumption of almonds as well as other tree nuts is associated with
improved glycemic control, insulin sensitivity, decreased inﬂammation, and reduced/sustained body
weight [13–16]. However, tree nuts are difﬁcult to promote in patients with diabetes because of their
high cost, especially in developing and under-developed countries.
As the main ground nut, peanuts have a similar nutrient composition to tree nuts, thus being
nutrient-dense and rich in monounsaturated fatty acid (MUFA) (40% of energy).They are also a good
source of arginine, ﬁber, phytosterols, polyphenols, niacin, folic acid, and vitamin E [17]. In addition,
peanuts are widely planted and are much cheaper than tree nuts, and they are affordable for most
T2DM patients. Randomized controlled and cross-over trials have shown that peanut consumption
helps to moderate glucose concentrations [18], improve the postprandial lipid response, and preserve
endothelial function [19]. However, whether peanuts and tree nuts have similar beneﬁts forT2DM
patients remains unknown.
Almonds are the most consumed tree nut [20]. We aim to compare the effect of peanuts and
almonds incorporated into LCD on cardio-metabolic and inﬂammatory measures in T2DM patients.
2. Materials and Methods
2.1. Subjects
The participants were recruited from a diabetes club and from the Endocrine Division of the First
Afﬁliated Hospital of Soochow University. The inclusion criteria were as follows: The patients were
diagnosed with T2DM, had glycated hemoglobin A1c (HbA1c) of less than 10%, had no change in
oral antidiabetic drugs or in insulin half a month before the intervention, were between 40 to 80 years
old [15,21], were able to communicate, had volunteered to participate in this study, and were willing
to provide informed consent. Those that were excluded were the patients who ate nuts regularly
(≥four per day/week) [22]; were allergic to nuts or other food; had difﬁculty in chewing nuts as
a result of fewer teeth or for other reasons; could not adhere to a LCD strategy; received other
dietary interventions; had severe conditions including indigestion, hepatic failure, renal failure, severe
gallbladder and pancreatic diseases, stroke, malignant tumors, or unstable cardiovascular diseases
(such as myocardial infarction, ketosis, or hyperthyroidism); those who were taking glucocorticoid;
and those whose fasting blood glucose (FBG) was more than 16.7 mmol/L [23] during the intervention.
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2.2. Study Design
This study is a prospective, randomized controlled trial (RCT) that was performed between
December 2015 and April 2016. The recruited patients were randomly allocated to the Peanut and
Almond groups using a table of random numbers. The random numbers were generated by one
researcher, and were concealed to the researcher who was responsible for the allocation, and the
participants were blinded prior to assignment. Before the intervention, all of the subjects underwent
a one-week washout period [23] to diminish the effect of background diets on the study. This study
followed the Declaration of Helsinki and the Guidelines for Good Clinical Practice, and was approved
by the ethics committee of the First Afﬁliated Hospital of Soochow University (no. 2015106). All of the
enrolled participants signed a consent form.
2.3. Sample Size Calculation
Evidence from the literature showed that the mean difference of the changes in the HbA1c
levels were 1.6% between the Peanut group and the Almond group [21,24]. Therefore, we calculated
13 participants for each group, with α = 0.05 and power = 0.80. In light of the sample loss of 10%,
the number for each group was calculated to be 16. Finally, we recruited 15 participants for the Peanut
group and 17 participants for the Almond group in this study.
2.4. Intervention
We incorporated peanuts or almonds into a low-carbohydrate diet (LCD), which is a
dietary strategy that refers to a carbohydrate intake of between 30–200 g/day or calories from
carbohydrates/total calories <45%, being supplemented instead with fat or protein [24]. Our team
developed a LCD education handbook [24] for patients with T2DM based on evidence from the
literature, guidelines regarding T2DM dietary management, consultation with diabetes experts and
nutritionists, and reviews by patients. The researcher and patients reviewed the LCD handbook, and the
researcher trained the patients to restrict their intake of starchy staple food (such as potatoes and broad
beans) to 50 g/meal per day during the one-on-one education session. The reduced staple food/meal
was substituted by consuming 60 g/day peanuts for men and 50 g/day for women in the Peanut
group [25], and 55 g/day almonds for men and 45 g/day for women in the Almond group [25,26].
The peanuts and almonds (without salt and with the skin intact, and free of charge) were prepared in
vacuum packing, according to a daily amount. The patients were instructed to consume nuts between
meals or with breakfast, or when hungry. For those whose fasting plasma glucose were higher than
normal (>6.1 mmol/L), the nuts were required to be consumed before 10:00 a.m. in the morning [27].
The patients were instructed to consume 50% of the nuts before bedtime if there was a risk of a nocturnal
hypoglycemic event. The intervention duration was three months for the two groups.
The follow-ups were conducted once a week in the ﬁrst month of the intervention, and once every
two weeks in the second and third months. The duration of each follow-up session was about 10 min.
The patients’ compliance to the dietary plan was reviewed and those with a poor compliance were
supported in order to adhere to the plan. The data relating to modiﬁcation of hypoglycemic agents and
the occurrence of hypoglycemia were also collected. Those whose diets did not meet the requirements
of the dietary program in the intervention period were excluded from the study.
2.5. Diet Record
The patients maintained a diet record, including details of the diet of any day over the weekend
and two working days, as well as the time of nut consumption. The types and quantities of the food
consumed were assessed to determine the patients’ adherence to a LCD strategy. Among the patients
who met the dietary requirements for a LCD, the number of bags of nuts consumed per week was
assessed to determine the patients’ dietary adherence.
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2.6. Cardio-Metabolic and Anthropometric Parameters
The cardio-metabolic and anthropometric parameters included the FBG, postprandial 2-h
blood glucose (PPG) levels, HbA1c, total cholesterol, low density lipoprotein cholesterol (LDL-C),
high density lipoprotein cholesterol (HDL-C), triglycerides, and body mass index (BMI). The HbA1c,
blood lipids, and BMI were measured at the baseline and at the end of the third month. Venous
blood samples were collected at the School of Nursing of Soochow University after a 12 h overnight
fast. The HbA1c was measured by high-performance liquid chromatography using Aﬁnion AS100
Analyzer (Alere, Inc., Shanghai, China), and the total cholesterol, LDL-C, HDL-C, and triglycerides
were measured using the spectrophotometry method in the molecular laboratory of the School of
Nursing of Soochow University. The height and weight were measured using a calibrated stadiometer,
and the patients were weighed wearing light clothing and without shoes. The BMI was calculated as
the weight (in kilograms) divided by the square of the height (in meters). The FBG and PPG levels
were measured by collecting the peripheral blood from the ﬁngers using a rapid glycemic apparatus
by patients once a week at home. The glycemic meters were checked by the research staff and the
patients were educated to measure the FBG and PPG correctly so as to reduce the subject bias.
2.7. Hypoglycemic Episodes and Antidiabetic Medication Modiﬁcation
Hypoglycemic episodes in this study were determined by the patients’ self-reported hypoglycemic
symptoms, with or without a measured plasma glucose concentration of ≤70 mg/dL (≤3.9 mmol/L),
according to the deﬁnition of hypoglycemia in diabetes, given by the American Diabetes
Association [28]. To assess the modiﬁcation of the hypoglycemic agents, the use and changes of
the doses of oral antidiabetic drugs and insulin were recorded at the baseline and in the third month.
2.8. Interleukin-6
Interleukin-6 (IL-6) was measured to assess the impact of peanuts and almonds on inflammation.
The fasting venous blood was collected and the serum was separated in the molecular laboratory of the
School of Nursing of Soochow University. Human IL-6 ELISA kit (R&D SystemsTM, Emeryville, CA, USA)
was used to determine the IL-6 levels in the Hematology Center of the Cyrus Tang Medical Institute at
Soochow University.
2.9. Ratio of Urinary Albumin/Creatinine
In order to determine the safety of peanuts and almonds in patients with diabetes, a mid-stream
specimen of random urine was collected, and the ratio of urinary albumin/creatinine (ACR) was
measured using a dry immune marker scattering quantitative method [29].
2.10. Statistical Analysis
A statistical analysis was performed using SPSS 18.0 software (SPSS, Inc., Dhicago, IL, USA).
For continuous variables, the results were presented as mean ± standard deviation (SD). Comparisons
were performed using a t-test for the independent samples for general baseline demographic,
and clinical characteristics, and one-way analysis of variance (ANOVA) for the outcomes of interest.
To eliminate the problem of imbalance in the baseline characteristics, the comparisons of anthropometric
and metabolic variables between the groups after the intervention were performed using a covariance
analysis with the baseline measurements adjusted. The trends in the dietary adherence, FBG, and PPG
in the two groups, which were assessed once a week during the intervention, were analyzed using
repeated ANOVA, and have been presented as a fold line diagram. The intention-to-treat (ITT) of
HbA1c was performed so as to ensure the reliability of the research results. For the categorical variables,
the results were presented as numbers and percentages, and comparisons between the groups were
performed using the Chi-squared test or the Fisher’s exact test. A p value of <0.05 was considered
statistically significant.
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3. Results
3.1. Study Participants
On the basis of inclusion and exclusion criteria, 32 T2DM participants were recruited and
randomly allocated to the Peanut group (n = 15) and the Almond group (n = 17). Four participants
in the Peanut group and three participants in the Almond group withdrew from the study. In the
Peanut group, one participant did not like peanuts, one showed abnormally elevated FPG after
the ﬁrst week, one’s uric acid increased during the second week (with a history of increased uric
acid), and one showed a poor adherence (<four per day/week). In the Almond group, one did not
like almonds, one was lost to follow-up, and one could not adhere to the diet program because of
toothache. Finally, the data of 11 patients in the Peanut group and 14 in the Almond group were
analyzed (Figure 1). The mean age of the participants was 69.60 ± 7.25 years, and 15 (60.0%) were
men. The general characteristics of the enrolled participants in each group are shown in Table 1.
There were no statistically signiﬁcant differences in any of the parameters between the two groups
(p > 0.05, Table 1). The time of exercise per week in the two groups did not change signiﬁcantly from
the baseline, and there was no statistically signiﬁcant difference found at the third month.
Figure 1. Flow diagram of the patients included in the study.
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Table 1. Baseline characteristics.
Variables
Peanut (n = 11) Almond (n = 14)
t/χ2 p
¯
x± SD/n (%) ¯x± SD/n (%)
Demographic data
Age (years) 68.00 ± 5.80 70.86 ± 8.21 −0.977 a NS
Gender—male 5 (45.5) 10 (71.4) - b NS
Exercise (min/week) 430.9 ± 222.2 421.4 ± 318.5 0.084 a NS
Exercise habits
Never regular exercise 4 (36.4) 10 (71.4)
- b NSRegular exercise 7 (63.6) 4 (28.6)
Like sweets or rice or noodles—no 1 (9.1) 1 (7.1) - b NS
The amount of staple food, liang/day (1 liang = 50 g) 3.77 ± 1.75 3.61 ± 2.02 0.215 a NS
Consuming nuts—yes 9 (81.8) 13 (92.9) - b NS
Clinical data
Smoking—yes 2 (18.2) 0 (0) - b NS
SBP (mmHg) 130.73 ± 7.56 128.00 ± 13.77 0.589 a NS
DBP (mmHg) 79.55 ± 10.25 75.71 ± 8.89 1.000 a NS
Family history of diabetes—yes 5 (45.5) 6 (42.9) - b NS
Diabetes duration, years 11.27 ± 6.36 15.21 ± 8.82 −1.247 a NS
Complications—yes 4 (36.4) 6 (42.9) - b NS
Accompanying diseases—yes 9 (81.8) 7 (50.0) - b NS
p-value for comparisons between the treatment diets by an independent samples t-test or Chi-square test. a t-test;
b Fisher’s exact test. SBP—systolic blood pressure; DBP—diastolic blood pressure; NS: Differences were not
signiﬁcant. SD—standard deviation. Complications included diabetic retinopathy, nephropathy, neuropathy,
cardiopathy, foot ulcers, and cognitive impairment.
3.2. Dietary Adherence
The dietary adherence was assessed through the bags of nuts consumed by the participants
per week. A fold line diagram was performed to compare the dietary compliance between the two
groups (Peanut versus Almond). The results showed that there were no signiﬁcant differences in the
self-reported dietary compliance per week between the two groups (p > 0.05, Figure 2).
⎯ ⎯
 
Figure 2. The changing trends of dietary adherence in the Peanut and Almond groups. Values are
means, with their standard deviations represented by vertical bars.
3.3. Effect of Peanuts and Almonds on Glycemic Control
3.3.1. Fasting Blood Glucose
Changing Trends of Fasting Blood Glucose
The changing trends of FBG in the two groups during the intervention are described by the fold
line diagram (Figure 3). The results show that, for the Peanut group, the levels of FBG were stable
with a slight decline, down to the tenth week to the lowest level. For the Almond group, the levels
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of FBG decreased signiﬁcantly for the ﬁrst three weeks, and then ﬂuctuated around the level of the
third month.
Figure 3. The changing trends of fasting blood glucose (FBG) in the Peanut and Almond groups.
Values are means, with their standard deviations represented by vertical bars. For the Peanut group,
* FBG was signiﬁcantly lower at the tenth week than that at the sixth week (p = 0.035). For the Almond
group, ** FBG was signiﬁcantly lower at the third week than that at the ﬁrst week (p = 0.001).
Comparison of Fasting Blood Glucose Levels
Compared to the baseline, the FBG levels of the two groups decreased signiﬁcantly (p < 0.05).
However, the differences between the two groups, with respect to FBG, were not statistically signiﬁcant
(p > 0.05) (Table 2).
Table 2. Comparison of fasting blood glucose (mmol/L) between the two groups.
Study Period Peanut (n = 11) Almond (n = 14) F p
Baseline 7.73 ± 1.19 8.28 ± 2.05 0.537 NS
Third month 6.69 ± 0.54 (adjusted: 6.77 ± 0.20) 6.79 ± 0.92 (adjusted: 6.73 ± 0.17) 0.016 NS
F 6.945 5.785 - -
p 0.016 * 0.024 * - -
F-value and p-value for comparisons by one-way analysis of variance or covariance analysis for between-group
differences at the third month, with adjusted data presented as mean ± standard error. * p < 0.05; NS: differences
were not signiﬁcant.
3.3.2. Postprandial Two-Hour Blood Glucose
Trends in Postprandial Two-Hour Blood Glucose
The changing trends of PPG in the two groups during the intervention are described by the fold
line diagram (Figure 4). Both of the groups showed ﬂuctuation, and the amplitude of the ﬂuctuation of
the Peanut group was signiﬁcantly larger than that of the Almond group.
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Figure 4. The changing trends of postprandial 2-h blood glucose in the Peanut and Almond groups.
Values are means, with their standard deviations represented by vertical bars. For the Peanut group, *
PPG was signiﬁcantly lower at the sixth week than that at the third week (p = 0.027).
Comparison of Postprandial Two-Hour Blood Glucose
Compared to the baseline, the PPG in the two groups improved signiﬁcantly (p < 0.05). However,
there were no signiﬁcant differences between the two groups at the third month (p > 0.05) (Table 3).
Table 3. Comparison of postprandial 2-h blood glucose (mmol/L) in the two groups.
Study Period Peanut (n = 11) Almond (n = 14) F p
Baseline 10.36 ± 1.40 10.61 ± 2.83 0.072 NS
Third month 8.94 ± 1.55 (adjusted: 9.03 ± 0.38) 8.91 ± 1.89 (adjusted: 8.85 ± 0.34) 0.115 NS
F 5.011 4.487 - -
p 0.037 * 0.044 * - -
F-value and p-value for comparisons by one-way analysis of variance or covariance analysis for between-group
differences at the third month, with adjusted data presented as mean ± standard error. * p < 0.05; NS: differences
were not signiﬁcant.
3.3.3. Glycated Hemoglobin
At the baseline, the HbA1c levels were not signiﬁcantly different between the Peanut and Almond
groups. Compared with the baseline, the HbA1c decreased signiﬁcantly in the Almond group (p< 0.05,
Table 4). However, there were no signiﬁcant differences between the two groups by the third month.
The intention-to-treat (ITT) in relation to the HbA1c levels were performed so as to ensure the stability
of the above results. The ITT results were found to be in agreement with the earlier ﬁndings (Table 5).
Table 4. Comparison of glycated hemoglobin (%) between the two groups.
Study Period Peanut (n = 11) Almond (n = 14) F p
Baseline 6.81 ± 0.82 7.39 ± 1.16 0.072 NS
Third month 6.76± 0.91 (adjusted: 6.97 ± 0.15) 6.81 ± 0.73 (adjusted: 6.65 ± 0.13) 2.453 NS
F 0.015 4.541 - -
p NS 0.043 * - -
F-value and p-value for comparisons by one-way analysis of variance or covariance analysis for between-group
differences at the third month, with adjusted data presented as mean ± standard error. * p < 0.05; NS: differences
were not signiﬁcant.
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Table 5. Glycated hemoglobin (%) between the two groups in intention-to-treat (ITT).
Study Period Peanut (n = 15) Almond (n = 17) F p
Baseline 6.96 ± 0.89 7.36 ± 1.07 2.119 NS
Third month 6.93 ± 0.96 (adjusted: 6.90 ± 0.18) 6.88 ± 0.71 (adjusted: 6.65 ± 0.11) 2.361 NS
F 0.015 4.210 - -
p NS 0.048 * - -
F-value and p-value for comparisons by one-way analysis of variance or covariance analysis for between-group
difference at the third month, with adjusted data presented as mean ± standard error. * p < 0.05;
ITT—intention-to-treat; NS: differences were not signiﬁcant.
3.4. Effect of Peanuts and Almonds on Other Cardio-Metabolic and Anthropometric Indicators
Compared with the baseline, the BMI, total cholesterol, LDL-C, HDL-C, and triglycerides
in the two groups did not improve signiﬁcantly by the third month. After the intervention,
the cardio-metabolic and anthropometric indicators were not signiﬁcantly different between the
two groups (Table 6).
Table 6. Comparison of other cardio-metabolic indicators between the two groups.
Variables Study Period Peanut (n = 11) Almond (n = 14) F p
BMI
(Kg/m2)
Baseline 22.84 ± 2.48 24.08 ± 3.15 1.141 NS
Third month 22.67 ± 2.44(adjusted: 23.30 ± 0.22)
23.43 ± 2.90
(adjusted: 22.94 ± 0.20) 1.482 NS
F 0.025 1.141 - -
p NS NS - -
Total
cholesterol
(mmol/L)
Baseline 4.48 ± 0.77 4.90 ± 1.00 1.362 NS
Third month 4.25 ± 0.93(adjusted: 4.40 ± 0.21)
4.51 ± 0.86
(adjusted:4.39 ± 0.19) 0.002 NS
F 0.398 1.260 - -
p NS NS - -
LDL-C
(mmol/L)
Baseline 2.48 ± 0.72 2.97 ± 0.84 2.290 NS
Third month 2.51 ± 0.84(adjusted: 2.69 ± 0.15)
2.74 ± 0.63
(adjusted: 2.59 ± 0.14) 0.234 NS
F 0.006 0.653 - -
p NS NS - -
HDL-C
(mmol/L)
Baseline 1.49 ± 0.28 1.36 ± 0.30 1.219 NS
Third month 1.53 ± 0.22(adjusted: 1.49 ± 0.05)
1.34 ± 0.26
(adjusted: 1.38 ± 0.04) 3.123 NS
F 0.197 0.029 - -
p NS NS - -
Triglycerides
(mmol/L)
Baseline 1.05 ± 0.46 1.87 ± 1.19 2.184 NS
Third month 0.96 ± 0.46(adjusted: 0.98 ± 0.23)
1.26 ± 0.87
(adjusted: 1.25 ± 0.20) 0.777 NS
F 0.207 1.317 - -
p NS NS - -
F-value and p-value for comparisons by one-way analysis of variance or covariance analysis for between-group
differences at the third month, with adjusted data presented as mean ± standard error.BMI—body mass index;
LDL-C—low density lipoprotein cholesterol; HDL-C—high density lipoprotein cholesterol; NS: differences were
not signiﬁcant.
3.5. Hypoglycemia and Medication Changes
3.5.1. Incidence of Hypoglycemia
The incidence of hypoglycemia in the two groups showed no signiﬁcant differences during the
three months before the intervention (baseline) and during the intervention period. One patient in the
Almond group and none in the Peanut group sustained a hypoglycemic episode during the trial.
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3.5.2. Antidiabetic Drugs Used
During the study, one subject in the Peanut group and two subjects in the Almond group had a
decrease in the dose of oral hypoglycemic drugs, and one subject in the Almond group had an increase
in the dose of oral hypoglycemic drugs, according to the recommendations of physicians. There were
no signiﬁcant differences in the antidiabetic drugs used between the two groups at baseline and by the
third month (Table 7).
Table 7. Comparison of antidiabetic drugs between the two groups.
Study Period Peanut (n = 11) Almond (n = 14) F/χ2 p
¯
x± SD/n (%) ¯x± SD/n (%)
Baseline
No 1 (9.1%) 2 (14.3%)
0.423 a NS
Oral antidiabetic drugs 7 (63.6%) 9 (64.3%)
Insulin 0 (0%) 0 (0%)
Both 3 (27.3) 3 (21.4%)
Third
month
No 1 (9.1%) 1 (7.1%)
0.581 a NS
Oral antidiabetic drugs 7 (63.6%) 10 (71.4%)
Insulin 0 (0%) 0 (0%)
Both 3 (27.3) 3 (21.4%)
Insulin
dose (IU)
Baseline 28.33 ± 11.59 36.00 ± 24.58 0.239 b NS
Third month 27.00 ± 10.82(adjusted: 30.19 ± 1.18 d)
33.33 ± 20.03
(adjusted: 30.14 ± 1.18 d) 0.001
c NS
a Fisher’s exact test; b one-way analysis of variance; c covariance analysis; d standard error; NS: differences were
not signiﬁcant.
3.6. Effect of Peanuts and Almonds onInterleukins-6
Compared with the baseline, theIL-6 in the two groups did not improve signiﬁcantly by the third
month. After the intervention, the IL-6 was not signiﬁcantly different between the two groups (Table 8).
Table 8. Comparison of interleukin-6 (IL-6) (x ± s, pg/mL) in the two groups.
Study Period Peanut (n = 11) Almond (n = 14) F p
Baseline 12.78 ± 30.62 2.18 ± 1.10 1.696 NS
Third month 10.65 ± 26.91(adjusted: 5.44 ± 0.52)
2.70 ± 1.83
(adjusted: 6.79 ± 0.45) 3.761 NS
F 0.030 0.832 - -
p NS NS - -
p-value for comparisons by one-way analysis of variance or covariance analysis for between-group differences at
the third month, with adjusted data presented as mean ± standard error. NS: differences were not signiﬁcant.
3.7. Effect of Peanuts and Almonds on Ratio of Urinary Albumin/Creatinine
There were no signiﬁcant differences between the two groups at baseline and by the third month
(Table 9).
Table 9. Comparison of albumin/creatinine (ACR) (x ± s, mg/g) in the two groups.
Study Period Peanut (n = 11) Almond (n = 14) F p
Baseline 25.58 ± 26.40 18.53 ± 16.19 0.679 NS
Third month 31.47 ± 48.70 (adjusted: 25.55 ± 5.26) 17.88 ± 21.87 (adjusted: 22.54 ± 4.65) 0.182 NS
F 0.124 0.008 - -
p NS NS - -
p-value for comparisons by one-way analysis of variance or covariance analysis for between-group difference at the
third month, with adjusted data presented as mean ± standard error. ACR—ratio of urinary albumin/creatinine;
NS: differences were not signiﬁcant.
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4. Discussion
This is the ﬁrst study that compared the effect of peanuts and almonds in patients with T2DM,
when incorporated into a LCD diet in order to replace some staple food. The diet diaries revealed that
the participants had a good adherence to the dietary intervention, and no signiﬁcant difference with
respect to nut adherence was found between the two groups. This RCT showed that, in combination
with a LCD diet, peanuts yielded similar reductions in FBG and PPG compared to almonds.
4.1. Effect of Peanuts and Almonds on Glycemic Control
High levels of FBG, PPG, and HbA1c are some of the most difﬁcult challenges faced by patients
with T2DM, and these parameters could be used as the main indicators in order to establish a glycemic
control [30]. This study showed that both peanuts and almonds incorporated into a LCD diet resulted
in reductions in FBG and PPG after the intervention, which is consistent with previous research
results [18,21,31]. The reason might lie in the fact that there is a decrease in the total amount of
carbohydrate rich foods in a LCD. In addition, peanuts and almonds are rich in fat, they possess a
low-glycemic index, and could alter the glycemic index of co-consumed foods [32]. What is more,
the greater fat availability may reduce the gastric emptying rate, and may decrease the carbohydrate
absorption rate [33].
However, the content of unsaturated fatty acids (UFAs) and soluble ﬁber in almonds is higher
than that in peanuts [17]. UFAs could facilitate the movement of the glucose receptor to the cell surface,
thus increasing the insulin sensitivity [34]. UFAs also act through the stimulation of GLP-1 secretion,
which improves the efﬁcacy of the β-cell function [35]. Soluble ﬁber increases the gastric distention,
viscosity in the gastrointestinal tract, and the slower absorption of macronutrients [36]. In this way,
it lowers the speed of carbohydrate absorption and the concentration of PPG [37]. Based on the above
reasons, the glycemic effect of almonds may be more stable than that of peanuts. In our study, although
peanuts and almonds yielded similar reductions in FBG and PPG by the end of the three-months
intervention, the amplitude of the ﬂuctuation of the PPG in the Peanut group was signiﬁcantly larger
than that of the Almond group.
The HbA1c level can reﬂect the mean blood glucose level over the last 8–12 weeks, and can be used
to evaluate the long-term glycemic control of patients [30]. HbA1c has a closer association with PPG
than FPG [38]. In the present study, the effect of peanuts on the HbA1c reduction was not signiﬁcant.
This might be due to the ﬂuctuation of PPG in the Peanut group. The result of our study is in line with
the RCT by Wien et al. [39], which did not ﬁnd that incorporating peanuts into an American Diabetes
Association meal plan had a signiﬁcant effect in decreasing HbA1c in adults with T2DM. Although
there was a 0.48% decrease in HbA1c from the baseline caused by almond consumption, the greater
effect of almonds on the improvement of HbA1c was not found by the third month, compared to
peanuts. The short-term duration of the follow-up may be one of the reasons for this. After a 24-week
almond intervention, Gulati et al. [40] found a statistically signiﬁcant improvement in the levels of
HbA1c compared with the control diet.
4.2. Other Cardio-Metabolic Indicators
The consumption of peanuts and almonds has not been associated with increased body weight,
despite their high lipid content. Human feeding trials have shown that nut ingestion moderates
appetite postprandially [41]. The inclusion of peanuts and almonds increases a feeling of satiety
and leads to a strong dietary compensation effect. In addition, because of the inefﬁciency in energy
absorption, nut consumption does not promote a greater energy intake than other foods [41]. In a
randomized cross-over study, after 12 weeks of incorporating high oleic peanuts into the diet, a less than
predicted increase in the body weight was found, despite a large additional amount of energy being
consumed from the peanuts [25]. Similarly, Li et al. [26] and Gulati et al. [40] also reported no changes
in the body weight and BMI with the almond diet, however, a statistically signiﬁcant improvement was
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seen in the body fat [26], waist circumference, and waist-to-height ratio [40]. Sato et al. [42] reported a
signiﬁcant improvement of BMI on a LCD diet on in T2DM patients with higher baseline levels of BMI
(26.5 Kg/m2). Among the subjects with a relative normal baseline BMI, this study did not ﬁnd that
peanuts or almonds incorporated into a LCD diet had a signiﬁcant reduction on the BMI.
The total cholesterol, LDL-C, HDL-C, and triglyceride levels were not altered significantly with an
almond or peanut diet in this study, contrary tomany other studies [14]. However, the cholesterol lowering
effects of nuts are shown to be the greatest in individuals with higher baseline lipids [43]. The subjects in
this study had an average healthy baseline lipid level. Barbour et al. [25] and Wien et al. [39] also reported
no differences in lipids with peanut consumption in subjects with healthy baseline lipid levels.
4.3. Hypoglycemia and Medication Changes
The antidiabetic drugs and insulin doses used in the Peanut and Almond groups were identical.
There was no interference caused by the agents when comparing the glycemic control effects between
peanuts and almonds in this study.
We used hypoglycemia as a safety indicator. Although there was no signiﬁcant difference in
the between-group comparison, the percentage of hypoglycemia was reduced from 18.2% to zero in
the Peanut group. Nocturnal hypoglycemia occurred in two participants in the Peanut group before
the intervention, and it was recommended that they consume 50% of their prescribed peanuts before
bedtime. The occurrence of hypoglycemia in the morning causes the body to produce a large amount
of glucocorticoids, namely the Somogyi effect, leading to increased blood glucose in the morning [44].
Peanuts and almonds, which are rich in healthy fat, can delay the speed of gastric emptying, and can
continuously supply energy [27] to the body so as to prevent the occurrence of the Somogyi effect.
During the intervention in the Almond group, daytime hypoglycemia occurred in one case because of
strenuous exercise, and there was no nocturnal hypoglycemia found.
4.4. Effect of Peanuts and Almonds on Interleukin-6
IL-6 was chosen as an indicator of inﬂammation. Chronic low-level inﬂammation plays an
important role in the occurrence and development of DM [17,45]. IL-6 is the source of the metabolic
syndrome induced by inflammation, and plays a core regulatory role in the inflammatory response [46,47].
IL-6 can inhibit insulin signaling transduction and could therefore impede the action of insulin [47].
Peanuts are rich in folic acid, which can inhibit the cascade of a reaction in the process of
inﬂammation in vessel wall, and this may reduce the release of vascular inﬂammatory factors [48].
Although the administration of folic acid can cause a decrease in the concentration of homocysteine,
and, as a consequence, could inﬂuence the decrease in the concentration of the indicators of
inﬂammation [49], a decrease of IL-6 caused by peanut consumption was not found in this study.
As an indicator of inﬂammation, the C reactive protein (CRP) did not improve after 12-week of peanut
consumption in the study by Barbour et al. [25]. Contrary to our study, in the study by Gulati et al. [40],
a signiﬁcant improvement in the CRP was found after 24-weeks of almond consumption. Whether
the inconsistency in the improvement of inﬂammation between studies is correlated to the different
intervention duration needs to be further veriﬁed.
4.5. Effect of Peanuts and Almonds on Kidney Burden
ACR is a sensitive indicator of early renal damage [50], which is used to assess the impact of
peanuts and almonds incorporated into a LCD on renal function in this study. Our study found
that peanut and almond consumption with a LCD did not increase the burden on the kidney.
Díaz-López et al. also reported no change in ACR after a one-year Mediterranean diet supplemented
with nuts [51].
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5. Limitation
There are some limitations to this study. Firstly, the sample size was small. There was also an
imbalance in the gender, diabetes duration, and baseline HbA1c level between groups, although
there were no signiﬁcant differences found. The prolonged effect of peanuts and almonds on the
prognosis of T2DM was not observed because of the short follow-up duration. Finally, measurement
differences might exist in the FBG and PPG levels, which were measured by the patients themselves,
using different blood glucose meters at home.
6. Conclusions
Incorporated into a low-carbohydrate diet, both peanuts and almonds can improve the fasting
blood glucose and postprandial 2-h blood glucose in patients with T2DM. The effect of almonds in
promoting long-term glycemic control needs to be conﬁrmed by more studies.
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Abstract: This study aimed to elucidate the effect of an energy restricted and carbohydrate restricted
diet on the management of Japanese diabetes patients. Several databases including MEDLINE,
EMBASE, and the Japan Medical Abstracts Society were searched for relevant articles published prior
to June 2017. The articles identiﬁed were systematically reviewed. We identiﬁed 286 articles on an
energy restricted diet, assessed seven and included two studies in our review. On a carbohydrate
restricted diet, 75 articles were extracted, seven articles assessed and three included in the review,
of which two were the studies that were selected for the energy restricted diet group, since they
compared energy restricted diets with carbohydrate restricted diets. All selected studies were on
Japanese patients with type 2 diabetes. No studies for type 1 diabetes were found in our search.
Two randomized controlled trials on an energy restricted diet were also included in the three studies
for a carbohydrate restricted diet. All the three randomized controlled trials showed better glucose
management with the carbohydrate restricted diet. Our study revealed that there is very little
evidence on diets, particularly in Japanese patients with diabetes, and that the energy restricted
diet, which has been recommended by the Japan Diabetes Society in the sole dietary management
approach, is not supported by any scientiﬁc evidence. Our ﬁndings suggest that the carbohydrate
restricted diet, but not the energy restricted diet, might have short term beneﬁts for the management
of diabetes in Japanese patients. However, since our analysis was based on a limited number of small
randomized controlled trials, large scale and/or long term trials examining the dietary approaches in
these patients are needed to conﬁrm our ﬁndings.
Keywords: energy restricted diet; low energy diet; carbohydrate restricted diet; low carbohydrate
diet; diabetes; Japanese
1. Introduction
Nutrition therapy plays an integral role in the management of diabetes [1]. Several dietary
approaches such as the Mediterranean diet, dietary approaches to stop hypertension (DASH),
a vegetarian diet, and a carbohydrate restricted diet have been recommended by the American Diabetes
Association (ADA) and reviewed by Ley et al. in The Lancet [2,3]. On the other hand, the Japan Diabetes
Society (JDS) has ofﬁcially recommended only an energy restricted diet since 1965 [4], as it believes
that the pathophysiology and food preferences of Japanese patients with diabetes are unique when
compared to patients in Western countries [5]. As per the JDS guidelines, energy restriction was
calculated based on the ideal body weight as follows: total energy intake (kcal) = ideal body weight
(kg = height (m) × height (m) × 22) × physical activity index (obese, 20–25; non-obese sedentary,
25–30; non-obese normal intensity active, 30–35; non-obese high intensity active, 35 and above). In fact,
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a recent study of the trajectory of body mass index (BMI) in Japanese patients with diabetes has shown
it to be continuously normal (approximately 24.4) and not obese [6]. The BMI of Japanese individuals is
very different from that of Americans [7] and Europeans [8], suggesting that there must be differences
in the pathophysiology as well. However, because the European Association for the Study of Diabetes
(EASD) mentioned that energy restriction is not needed in patients whose BMI is lower than 25 [9],
the discrepancy in the position of energy restriction between the JDS and the Western countries seems
more problematic. Although the JDS guidelines [4] on the dietary recommendations are reportedly
based on 86 studies, none of those references support the JDS recommended an energy restriction
diet. Eighty-three of these papers were not studies on dietary approach for Japanese patients with
type 2 diabetes. The remaining three references were on dietary approaches for Japanese diabetic
patients, where one is the ‘eating vegetables before carbohydrate’ diet [10], one is the before-after study
on exercise and energy restriction diet which instructed a deﬁcit of 140 kcal/d from the baseline for
subjects with metabolic syndrome [11], and the last is the carbohydrate restriction diet [12]. Thus, it is
evident that the JDS guidelines are not based on any supportive evidence for energy restriction in
diabetic patients with normal BMI, despite the fact that energy restriction is the basis of the consensus
in preparing the guidelines by the writing committee [4]. However, since the JDS recognizes that an
evaluation of the effectiveness and safety of dietary approaches is needed in their recommendation [5],
in this study we have tried to evaluate the effectiveness of the energy restricted diet in Japanese
patients with diabetes. Furthermore, in recent years, emerging evidence has suggested that a restricted
carbohydrate diet improves glycemic control [13], although it is not yet conclusive, especially in long
term follow-ups [1,14]. We have, therefore, evaluated the effectiveness of the carbohydrate restricted
diet as well.
2. Materials and Methods
2.1. Study Search
Searches of MEDLINE, EMBASE, and Japan Medical Abstracts Society (JAMAS) databases from
their inception (MEDLINE 1966, EMBASE 1947, AND JAMAS 1964) until 30 June 2017, were performed.
To identify studies related to an energy restricted diet, we used a combination of the following
keywords: “low-energy” or “energy-restriction” or “low-calorie” or “caloric-restriction” and “diabetes,”
and “Japanese” in the MEDLINE and EMBASE databases. Similarly, for articles related to a
carbohydrate restricted diet, we used the terms “low-carbohydrate” or “carbohydrate-restriction,”
and “diabetes,” and “Japanese” in the MEDLINE and EMBASE databases. In the JAMAS database,
we used the same combination of keywords in Japanese. Other dietary approaches such as,
the Mediterranean diet, DASH (dietary approaches to stop hypertension), fat restriction (low fat)
diet, low glycemic index (low GI) diet, vegetarian diet, and high-protein diet were excluded because
preliminary searches by one author (S.Y.) found no relevant study in Japanese (partly presented in
60th JDS annual meeting in 2017, Nagoya by S.Y.).
2.2. Study Selection
The following exclusion criteria were applied: (1) non-Japanese data, (2) non-diabetic patient data,
(3) other dietary approaches, (4) unpublished data (including abstracts presented only in scientiﬁc
meetings), and (5) studies not appropriate for our evaluation such as case series and case reports.
After each search, based on the title and abstract, two authors (S.Y. and Y.K.) extracted relevant
reports independently. One author (S.Y.) collected the papers for a full-text evaluation by two
independent authors (S.Y and Y.K). Disagreements were primarily resolved through discussions
and by consulting a third author (H.N.). We did not perform any quantitative data analysis because
our search found few studies that were not enough to perform a meta-analysis.
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2.3. Validity and Quality Assessment
The risk of bias was assessed against the key criteria: random sequence generation; allocation
concealment; blinding of participants, personnel, and assessors; incomplete outcome data; selective
outcomes reporting; and other sources of bias, in accordance with the recommendations of the Medical
Information Network Distribution Service (Minds) [15].
2.4. Data Abstraction
We reviewed each full-text report to determine its eligibility and extracted and tabulated all
the relevant data independently. The extracted data included the characteristics of the subjects
(including age, gender), the study design, publication year, follow-up period, and risk parameters.
Any disagreement was resolved by consensus among the investigators.
3. Results
We identiﬁed a total of 286 articles related to an energy restricted diet, of which seven [16–22]
were assessed for their eligibility for inclusion in our review (Figure 1). All were studies on patients
with type 2 diabetes. No study was identiﬁed for type 1 diabetes. There were no articles outlining
the adverse effects of energy restriction. Five articles were excluded from the systematic review
because (a) counseling [16], (b) meal delivery [17], and (c) periodization [18] were evaluated under
the same level of energy restriction in three studies; one study assessed the effects of very strict
energy restriction under hospitalization (1000 kcal/day) [19]; while another did not evaluate an energy
restricted diet [20]. After excluding these ﬁve studies, the remaining two randomized controlled trials
(RCTs) were appraised in our systematic review [21,22]. The two selected articles were moderately
homogeneous in terms of the level of energy restriction. Both studies adopted a carbohydrate restricted
diet as the control group. The sample sizes in these two studies were 24 [21] and 66 [22].
Both studies were also selected in the carbohydrate restricted diet section. To avoid redundancy,
we created a summary table that included the two studies each on a carbohydrate restricted diet and
an energy restricted diet, and an energy restricted diet was used as the control group (Table 1). In both
studies, the energy restricted diet (Table 1, control group) had inferior effects on HbA1c improvement
when compared to the carbohydrate restriction group (Table 1, intervention group). However, a review
of dietary energy in one study [21] revealed that the levels of energy intake were similar in both
the energy and carbohydrate restriction groups. In the other study [22], the levels of energy intake
were higher in the energy restriction group compared to those in the carbohydrate restriction group.
Thus, we concluded that the net effect of energy restriction on glycemic control could not be assessed
in both studies (Table 2).
We identiﬁed a total of 75 articles related to a carbohydrate restricted diet, of which seven were
assessed for their eligibility to be included in our review (Figure 2) [19–25]. All were studies on
patients with type 2 diabetes. No studies were identiﬁed for type 1 diabetes. There were no articles
that showed adverse effects of carbohydrate restriction. Four articles were excluded from the study
because the same levels of carbohydrate restriction were recommended for all participants, and a
longitudinal change in glycemic control was observed in two studies [20,23]. One study evaluated
the effect of very strict energy restriction under hospitalization (1000 kcal/day) [19]. In one study,
carbohydrate restriction was prescribed only on a single day (admission day 8) [24]. After excluding
these four studies, the remaining three RCTs were appraised in our systematic review [21,22,25].
The three selected articles were moderately homogeneous in terms of the level of carbohydrate
restriction. Among these studies, two had an energy restricted diet as the control groups and were
the same studies selected for the energy restricted diet analysis [21,22], while the third study had a
carbohydrate-rich diet with similar energy intake [25]. The sample sizes in these three studies were
24 [21], 66 [22], and 15 [25].
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Figure 1. Flow diagram of selecting the energy restriction studies included in our study.
Two randomized controlled trials were appraised in our systematic review.
Table 1 shows the summary of each study. A carbohydrate restricted diet had superior effects
on improvement of HbA1c [21,22] or the postprandial glucose levels as determined by continuous
glucose monitoring [25] compared to the control group in all three studies. However, in one study
the energy intake was lower in the intervention (carbohydrate restriction) group than in the control
(energy restriction) group [22] (Table 2). Thus, we concluded that a carbohydrate restriction diet was
supported by limited evidence in Japanese patients with type 2 diabetes.
Figure 2. Flow diagram of selecting the carbohydrate studies included in our study. Three randomized
controlled trials were appraised in our systematic review.
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4. Discussion
The present study was an attempt to elucidate the effects of an energy restricted diet and
carbohydrate restricted diet on the management of diabetes in Japanese patients by reviewing previous
studies from available databases. The ﬁrst and most important ﬁnding of our study is that there is
very little evidence on diets in Japanese patients with diabetes.
Our second ﬁnding was that an energy restricted diet, which has been recommended by the
JDS as the sole dietary management approach, is not supported by any scientiﬁc evidence so far.
The two studies in our review were not appropriate to judge the effects of an energy restricted diet on
glycemic control because the levels of energy intake in the energy restriction group were not lower
than those in the control group [21,22]. While in one study the energy restriction group showed
a non-signiﬁcant reduction of HbA1c (from 7.7 ± 0.6 to 7.5 ± 1.0%, p = 0.45) [18], no change was
seen in HbA1c in another study [22], indicating that an energy restricted diet is not supported by
scientiﬁc evidence in Japan. The available data on the effects of an energy restricted diet are very
limited, which results in difﬁculties in the evaluation and recommendation of such a diet. Furthermore,
the CALERIE (Comprehensive Assessment of Long term Effects of Reducing Intake of Energy) study
revealed that energy restriction in non-obese subjects leads to loss of bone mineral density [26] and
lean body mass [27] in a two year period. In light of these ﬁndings, a multi-faceted evaluation might
be required for patients with diabetes in terms of examining the effects and safety of energy restriction.
If the JDS continues to adopt dietary guidelines [4] different from those in Western countries, it should
be backed by sufﬁcient evidence that can be critically evaluated. Well-designed, multi-centered RCTs
to establish dietary evidence should be actively encouraged.
The third ﬁnding of our study was that as a short-term management approach a carbohydrate
restricted diet is more effective than an energy restricted diet. All three RCTs in our review were
small but well-designed [21,22,25]. Although observational studies have presented safety concerns
regarding the carbohydrate restricted diet in Western countries [28,29], a similar study in Japan was
in favor of carbohydrate restriction [30]. Furthermore, recently the PURE (Prospective Urban and
Rural Epidemiological) study, which was held in 18 countries, showed that carbohydrate intake was
positively correlated with mortality [31], suggesting the safety of carbohydrate restriction.
Regarding the long-term effects of carbohydrate restriction, Sato et al. have recently reported
that the statistical superiority of a carbohydrate restricted diet receded in an 18-month follow-up
study. In their cohort, the median HbA1c level changed from 8.3% at baseline to 8.2% at 18 months
in the energy restriction group and from 8.0% to 7.7% in the carbohydrate restriction group [32].
Hence, Sato et al. concluded that well-constructed nutrition therapy, including both energy and
carbohydrate restricted diets, might be equally effective in improving HbA1c levels in the long
term [32]. However, improvement in HbA1c have not yet been observed with energy restricted
diets. Furthermore, although it was a non-RCT, Haimoto et al. [33] have previously shown that
the carbohydrate restriction group had better HbA1c, BMI, and tapering of sulfonylureas during a
24-month period. Sanada et al. [34] have reported that a carbohydrate restriction diet was effective
during a 36-month period. Thus, we cannot exclude the possibility that a carbohydrate restricted
diet is effective in the long term. Unlike other carbohydrate restriction studies, the study by Sato
et al. [22,32], showed that the carbohydrate restriction group consumed less energy than the energy
restriction group. This reduced energy intake in the energy non-restricted group may explain the
rebound in the carbohydrate restriction group in the study by Sato et al. [32]. Our ﬁndings therefore
point towards the possibility that a carbohydrate restricted diet could potentially be an option as a ﬁrst
line dietary approach for Japanese patients with diabetes. However, longer-term and larger RCTs are
needed to conﬁrm this hypothesis.
Our study has some limitations. First, all three studies included in our review were small and
short term. Second, the included studies all have a potential performance bias because the subjects and
healthcare providers were not blinded. However, it might be difﬁcult to solve this problem in studies
evaluating dietary effects on glycemic control under actual clinical situations.
181
Nutrients 2018, 10, 1080
5. Conclusions
Our systematic review revealed that there are only a few dietary studies in Japanese patients
with diabetes. Large-scale trials are needed to more fully evaluate the risks and beneﬁts of an
energy restricted diet, which is recommended by JDS. On the other hand, the effectiveness of a
carbohydrate restricted diet is supported by limited evidence, at least in the short term. Well-designed
and more sophisticated trials are needed to establish evidence-based dietary approaches speciﬁcally
for these patients.
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Abstract: Diet quality inﬂuences glycemic control in people with type 2 diabetes (T2D), impacting
their risk of complications. While there are many cross-sectional studies of diet and diabetes, there is
little understanding of the extent to which people with T2D change their diet after diagnosis and
of the factors that impact those changes. This paper describes the rationale for and design of the
3D longitudinal Study which aims to: (i) describe diet quality changes in the 12 months following
T2D diagnosis, (ii) identify the demographic, physical and psychosocial predictors of sustained
improvements in diet quality and glycemic control, and (iii) identify associations between glycemic
control and diet quality in the 12 months following diagnosis. This cohort study will recruit adults
registered with the Australian National Diabetes Services Scheme who have been recently diagnosed
with T2D. Participants will be involved in ﬁve purposefully developed telephone surveys, conducted
at 3 monthly intervals over a 12-month period. Diet quality will be determined using a 24-h dietary
recall at each data collection point and the data will be scored using the Dietary Approaches to
Stop Hypertension (DASH) diet-quality tool. This study is the ﬁrst dedicated to observing how
people newly diagnosed with T2D change their diet quality over time and the predictors of sustained
improvements in diet and glycemic control.
Keywords: type 2 diabetes mellitus; nutrition; DASH; diet quality; diabetes management; dietary
intake; longitudinal analysis; lifestyle management
1. Introduction
Diet quality plays a vital role in helping people with type 2 diabetes (T2D) to achieve and maintain
optimal glycemic control, thereby lowering their risk of developing diabetes-related complications [1].
Diet quality can be described as the extent to which food intake complies with national or international
dietary guidelines or a priori diet quality score [2]. Investigating diet quality based on dietary patterns,
deﬁned as multiple dietary components operationalized as a single exposure [3], provides valuable
information, beyond analyzing speciﬁc nutrients (e.g., protein) or food groups (e.g., dairy) [4]. This is
because dietary patterns closely reﬂect actual dietary behavior and have a stronger inﬂuence on
disease risk than speciﬁc nutrients or foods [5]. Findings from dietary pattern analyses may facilitate
the translation of useful recommendations to health professionals and the general population [5,6].
A dietary pattern rich in whole-grains, fruits, vegetables, legumes, and nuts; moderate in alcohol;
and low in reﬁned grains, red or processed meats, and sugar-sweetened beverages has been shown to
improve glycemic control in people with T2D [7]. Consequently, a key feature of international T2D
management recommendations is to eat healthy foods that provide a high-quality diet [8–10].
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However, evidence has shown that people with T2D have low-quality diets, despite these
recommendations [10–15]. Our recent systematic review identiﬁed that internationally, people with
T2D do not adhere to food group recommendations outlined in dietary guidelines [15]. Qualitative
studies examining lived experiences report that people with T2D ﬁnd it challenging to adopt and
maintain healthy dietary behaviors after diagnosis [13,14]. Our previous qualitative study that
investigated the experiences and perceptions of Australian adults newly diagnosed with T2D found
that while participants reported making immediate, widespread changes to dietary behaviors that led
to improvements in diet quality initially, they found it challenging to maintain dietary change [13].
Participants described feeling restricted in food choice, being uncertain of ideal dietary behaviors
and felt unheard and rushed when speaking about their diet with health professionals [13]. Similar
results were obtained in a qualitative study in Mexico where people reported making only short-term
adherence to improvements in dietary intake due to difﬁculties with controlling appetite and eating
with others [14]. While these qualitative ﬁndings of experiences raise concerns, it is important to also
investigate quantitative aspects of diet quality change following diagnosis.
Cross-sectional research has assessed the diet quality of people with T2D at a single-point in
time [15], however, no research has quantitatively explored changes in diet quality after diagnosis.
Consequently, there is no evidence as to whether diet quality remains ﬁxed once an individual
is diagnosed with T2D, or whether there are periods of marked increases or decreases in diet
quality. Prospective, observational studies are valuable as they measure events in temporal sequence
and can distinguish causes from effects [16,17]. Many factors inﬂuence diet quality. These include
non-modiﬁable factors such as age and sex, and modiﬁable factors such as self-efﬁcacy, perception of
current diet, environmental factors such as marketing and food availability, and relationships with
health professionals [11,13]. There is currently no data on the demographic and health characteristics
inﬂuencing diet quality change for people with T2D [13,18]. There is a clear need to investigate how
diet changes over time so targeted strategies can be developed to facilitate improved glycemic control.
This paper describes the methodological protocol of the 3D Longitudinal Study, so named
because seeing something in three dimensions adds clarity. In this case it refers to the 3D’s of Diet,
after Diagnosis with Diabetes. The study aims are to:
(i) Describe diet quality changes in the 12 months following T2D diagnosis.
(ii) Identify the demographic, physical and psychosocial predictors of improvements in diet quality
and glycemic control.
(iii) Identify associations between glycemic control and diet quality in the 12 months
following diagnosis.
2. Theoretical Framework
The ability to predict and explain health-related behavior is important for developing strategies
to change those behaviors [19]. The theory of planned behavior (TPB) is among the most inﬂuential
and widely applied theories of the factors inﬂuencing health-related behavior [19]. According to the
TPB, the single best predictor of a person’s behavior is the intention to perform that behavior [20].
This is predicted by three constructs: attitude, subjective norm, and perceived behavioral control (PBC).
The greater the PBC and more favorable the attitude and subjective norms, the stronger the intent
will be to perform the behavior [20]. According to the TPB, people with T2D will intend to improve
their diet quality to the extent that they believe the likely outcomes of consumption to be favorable,
perceive social pressure from those who are important to them and feel capable of improving their diet
quality without difﬁculty [21]. The constructs of the TPB are considered strong predictors of healthful
eating and are commonly applied in the development of dietary behavior change interventions [21,22].
This study will integrate the TPB into its design in order to explore the factors that may serve as
moderators in inﬂuencing the TPB constructs, thus affecting dietary behaviors and T2D management.
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3. Materials and Methods
3.1. Study Design
The 3D Longitudinal Study is a prospective observational cohort study that will be conducted in
Australia between 2018–2019. The study will recruit people newly diagnosed with T2D and monitor
their dietary intake over 12 months. The Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) checklist for cohort studies was used to guide the development of the research
protocol [23]. The 3D Longitudinal Study is registered with the Australian New Zealand Clinical
Trials Registry (ANZCTR) (ref: ACTRN12618000375257) and was approved by the Grifﬁth University
Human Research Ethics Committee (ref: 2017/951). Study results will be published in peer-reviewed
journals and presented at scientiﬁc conferences.
3.2. Potential Participants
Eligible participants will be adults aged 18 years or older who have been recently diagnosed
with T2D (<6 months prior to recruitment contact), are registered with the Australian National
Diabetes Service Scheme (NDSS) and have indicated their willingness to be contacted for research
purposes. The NDSS is an initiative of the Australian Government and is administered with the
assistance of Diabetes Australia [24]. In 2017, there were approximately 1.1 million people registered
with the NDSS [25]. Registration is part of usual care for people diagnosed with T2D, therefore this
potential participant pool provides broad representation of the target population. People with T2D
are authorized to register for free if they live in Australia or are visiting from a country with which
Australia has a Reciprocal Health Care Agreement on an applicable visa [24]. Registering with the
NDSS enables individuals to access a range of government approved diabetes-related products and
information services [24]. All registrants have the option of consenting to being contacted for research
purposes. Upon registration, patients are required to register their personal details on a form signed by
a registered Australian medical practitioner, nurse practitioner or a credentialed diabetes educator [24].
The majority of T2D diagnoses in Australia are made by general practitioners (GPs), who are the usual
coordinators of management [7]. A detailed participant inclusion and exclusion criteria is listed in
Table 1.
Table 1. Inclusion and exclusion criteria for the 3D Longitudinal Study.
Inclusion Criteria Exclusion Criteria
Adults aged >18 years Individuals aged <18 years.
Diagnosed with T2D <6 months prior to recruitment contact Diagnosed with LADA, T1D, gestational diabetes orpre-diabetes
Registered with the Australian NDSS and indicated their
willingness to be contacted for research purposes.
Individuals who have been placed on a special diet
due to a co-morbidity (e.g., renal disease)
Able to communicate in English
LADA, Latent Autoimmune Diabetes in Adults; NDSS, National Diabetes Service Scheme; T1D, Type 1 diabetes;
T2D, Type 2 diabetes.
3.3. Participant Recruitment and Screening
A convenience sample of all individuals registered with the NDSS with a new diagnosis of
T2D over the previous 6-month period will be sent an initial invitation letter and a plain-language
summary of the research project via email by Diabetes Australia. Interested individuals will be invited
to contact the research team via email or telephone to conﬁrm eligibility, provide informed consent and
arrange data collection. Participants will be informed they can withdraw from the study at any stage.
This recruitment method has been trialed in a feasibility study conducted in 2016–2017 (unpublished)
which successfully recruited 22 participants from 1000 email invitees. Of these 22, 17 completed
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baseline data collection, six participants had left the study by 3 months, however all participants
remaining at 3 months were retained to 12 months.
3.4. Data Collection
Data will be collected using a purpose-developed, interviewer-administered telephone surveys
at ﬁve-time points; baseline, and then at 3, 6, 9, and 12 months after commencing the study. Surveys
will be conducted by Accredited Practicing Dietitians (APDs). The feasibility study found each survey
takes approximately 30 min to complete. A measuring tape will be posted to all participants within
two working days of recruitment to provide enough time to measure their waist circumference before
data collection begins. Strategies including contact and scheduling methods have been shown to
improve cohort retention in longitudinal studies [26]. Participants will be contacted 2 weeks prior to
their next anticipated data collection round to schedule a time. All participants will be sent a reminder
via their preferred contact method (email or text message) one day prior to the date of their next survey.
The recruitment and contact process is outlined in Figure 1.
Figure 1. Recruitment and contact process for the 3D Longitudinal Study.
3.5. Survey Design
Data from all secondary outcome measures will be recorded in an online survey management
system: www.limesurvey.org [27]. Item wording and response options were composed to align with
the Australian Bureau of Statistics (ABS) 2016 Census and the Australian Longitudinal Study on
Women’s Health (ALSWH) to allow for comparison of outcomes [28,29]. Survey questions were
generated using a developmental model [30] that employs ﬁve stages of questionnaire design and
testing: conceptualization, design, testing, revision, and data collection. The feasibility study allowed
testing of questions to ensure they were comprehendible, relevant and appropriate to participants
and to conﬁrm the survey length was suitable. Revisions were then made based on the feedback
provided. For example, some participants in the feasibility study felt they were being asked the same
question twice in the Healthy Eating Belief Scale. Therefore, the interviewer’s scripted introduction
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and description of the Healthy Eating Belief Scale was modiﬁed to notify participants that there would
be some repetition. The second draft was then pilot tested on three adults outside of the research team
to ensure comprehensibility, suitability and ﬂow.
3.6. Outcome Measures
Table 2 provides an overview of the primary (diet quality) and secondary outcomes and when
they will be collected.
Table 2. Overview of data collection points in the 3D Longitudinal Study.
Data Collection Methods
Time Collected
0 Months 3 months 6 Months 9 Months 12 Months
Diet quality     
Glycemic control     
Medication use     
Baseline demographic factors 
Physical factors     
Psychosocial factors     
Exposure to allied healthcare support     
3.6.1. Primary Outcome Measure: Change in Diet Quality (measured by DASH score)
Diet quality can be measured by a variety of purpose developed tools [31]. These are constructed
by assigning higher scores within sub-scales based on more frequent or higher intakes of foods,
nutrients or both [31]. Dietary Approaches to Stop Hypertension (DASH) is a dietary pattern high in
whole-grains, fruits, and vegetables; moderate in low-fat dairy; and low in red and processed meats,
added sugars, and sodium [32]. While originally developed to assist people in the prevention and
management of hypertension, DASH is now recommended for the dietary management of T2D [18,33].
Adherence to DASH positively impacts on glycemic control, weight, and hypertension, which are
key indicators of risk for diabetes-related complications [5,18,32]. A randomized controlled trial
(RCT) conducted in adults with T2D showed that adherence to DASH improved glycated hemoglobin
(HbA1c) (−1.2%), fasting blood glucose (−0.92 mmol/L), weight (−3 kg) and waist circumference
(−4.8 cm) over 8 weeks when compared with a control diet [34,35]. Those following the DASH dietary
pattern, also had a greater reduction in LDL cholesterol (difference from the control diet, −7.7 ± 3.3%).
A systematic review and meta-analysis of 20 RCTs found DASH signiﬁcantly reduced systolic
(−5·2 mmHg) and diastolic blood pressure (−2·6 mmHg) in adults with and without diabetes [36].
Another systematic review andmeta-analysis of 13 RCTs revealed that adults without T2Dwho adhered
to DASH achieved greater weight loss (−1.42 kg), reduced Body Mass Index (BMI) (−0.42 kg/m2) and
decreased waist circumference (−1.05 cm) compared with controls [37]. Considering the recognized
impact on glycemic control, weight and hypertension, DASH was chosen as the dietary pattern used
to assess diet quality in the present study. Participant DASH scores will be calculated using the DASH
diet-quality tool which has been shown to have the highest correlation with health outcomes related to
T2D compared to other tools that measure diet quality [38,39].
Change in DASH score from baseline to 3 months will be used to categorize participants as diet
quality improvers or diet quality maintainers. Participants will be split into 2 groups; those who
improved their DASH score by at least 3 DASH points (Diet quality improvers) and those who
maintained their DASH score within 2.99 points or decreased their DASH score by at least 3 points
(Diet quality maintainers). A change in DASH score of 3 points was selected based on ﬁndings from
previous literature [40]. In a 20-year longitudinal study of over 40,000 adults, an average DASH score
of 23.8 out of 40 was observed, and a change in score of approximately 3 points or more was sufﬁcient
to signiﬁcantly inﬂuence long-term glycemic control [40].
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Dietary intake data will be obtained through the Australian version of the Automated
Self-Administered 24-h Dietary Assessment Tool (ASA-24). The ASA-24 is based on the validated
Automated Multiple-Pass Method (AMPM) which is considered the optimal method for obtaining
24-h recall data due to its numerous probes, standardization of interviewer administration and
validation against recovery biomarkers [41,42]. This method is also consistent with the methodology
of the most recent population nutrition survey in Australia (the National Nutrition Survey) and has
been shown to be a valid measure of dietary behavior at a given time point [43,44]. The ASA-24 is
an online automated questionnaire that guides the individual through a system designed to maximize
respondents’ opportunities for remembering and reporting foods eaten in the previous 24 h [45].
The questionnaire is divided into ﬁve phases in line with published methodological guidelines;
‘quick list’, ‘forgotten foods’, ‘time and occasion’, ‘detail cycle’, and ‘ﬁnal probe’ [45]. These phases
encourage respondents to think about their intake in different ways and from several perspectives
which has been shown to reduce bias in the estimation of dietary intake [45]. Once a speciﬁc food or
beverage is reported, systematic questions are asked to capturemore precise information about the food,
cooking methods and quantity consumed. The ASA-24, usually a self-completed tool, will be adapted
for use in a telephone survey; a researcher will ask the questions and enter the data. This will reduce
participant burden and help decrease any bias associated with participant information technology
literacy levels. This process was carried out successfully in a feasibility study with patients newly
diagnosed with T2D. The data from the feasibility study was able to be used to assess changes in diet
quality over a 12-month period.
Following data collection, participant 24-h dietary recall data will be sent from the ASA-24
program to the research team. This data will then be manually entered into FoodWorks by
an experienced dietitian to allow determination of participant DASH scores. FoodWorks is a dietary
analysis software program using standardized serve sizes that allows for quantiﬁcation of speciﬁc food
groups (e.g., vegetables) and nutrients (e.g., sodium) obtained from reported dietary intakes, recipes
and meals [46]. FoodWorks draws on the national AUSNUT database [47]. AUSNUT was developed
by Food Standards Australia and New Zealand and includes complete nutrient data sets of Australian
foods designed speciﬁcally for nutrition surveys and is therefore suitable for use in this project [47].
DASH scores will be calculated using the standard scoring tool created by Fung et al [39].
Every tenth DASH score will be cross-checked by a second member of the research team to ensure
accuracy. The standard scoring tool determines a score between 8 and 40 points, with 40 points
representing optimal accordance with the DASH dietary pattern [39]. The DASH score is calculated
by summing the number of daily servings of seven dietary components; fruits, vegetables, nuts and
legumes, whole-grains, low-fat dairy, red and processed meats, added sugar, and sodium intake.
For each of the components, participants are classiﬁed according to their intake ranking. Higher
intakes of fruits, vegetables, low-fat dairy, whole-grains, and nuts and legumes receive higher scores.
For example, quintile 1 is assigned 1 point and quintile 5 is assigned 5 points. Intake of sodium,
red and processed meats and added sugars are scored in reverse as these are less desirable foods [39].
The lowest quintile is given a score of 5 points and the highest quintile is given a score of 1 point.
The components scores are then summed to give an overall DASH score [39]. The scoring criteria for
the DASH-style diet is outlined in Table 3.
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Table 3. Dietary Approaches to Stop Hypertension (DASH) dietary pattern scoring criteria.
Component Foods Scoring Quintiles (Q) *
Fruits All fruits and fruit juices Q1 = 1 point
Q2 = 2 points
Q3 = 3 points
Q4 = 4 points
Q5 = 5 points
Vegetables All vegetables except potatoes and legumes
Nuts and legumes Nuts and peanut butter, dried beans, peas, tofu
Whole-grains Brown rice, dark breads, cooked cereal, whole-graincereal, other grains, popcorn, wheat germ, bran
Low-fat dairy Skim milk, yogurt, cottage cheese
Sodium Sum of sodium content of all foods Q1 = 5 points
Q2 = 4 points
Q3 = 3 points
Q4 = 2 points
Q5 = 1 point
Red and processed meats Beef, pork, lamb, deli meats, organ meats,hot dogs, bacon
Added sugar Foods and beverages with added sugars (i.e., sugarsweetened beverages)
* Q1 represents low consumption and Q5 represents high consumption.
3.6.2. Secondary Outcome Measures
Secondary outcome measures will include: glycemic control, medication use, demographic factors,
physical factors, psychosocial factors, and exposure to health provider support.
Glycemic Control
HbA1c reﬂects average plasma glucose over the previous six to eight-week period [48,49].
In Australia, it is best practice for GPs to conduct HbA1c testing on people with T2D every 3 months [8].
The test is subsidized by Medicare, the Australian Government’s universal health scheme, up to four
times in a 12-month period [50]. The GP on the research team will retrospectively obtain participants’
HbA1c results over the 12-month study period from the relevant pathology laboratory. Other blood
results collected will include; fasting blood glucose, high-density lipoprotein cholesterol, low-density
lipoprotein cholesterol, and C-reactive protein.
Medication Use
Information on all medication use (name of medication and dosage) will be collected, including
over-the-counter, and complementary medicines.
Demographic Factors
Demographic factors collected at baseline including; age, gender, highest education level, living
arrangement, self-selected social class, household income, ability to manage on income, and smoking
status. Response options will be dichotomous (e.g., gender), continuous (e.g., age) or categorical (e.g.,
highest educational level), consistent with categories used in the national consensus by the ABS.
Age and Gender
Participants’ age at last birthday and gender will be collected. Sex response options will include
three categories in line with the ABS 2016 Census; male, female and other [51].
Highest Education Level
Collecting data on highest educational level helps generate a single measure of an individual’s
overall educational attainment, whether it be a school or non-school qualiﬁcation [51]. Participants
will be asked to report their highest education level from eight categories in line with the ABS 2016
Census; postgraduate degree, graduate diploma and graduate certiﬁcate, bachelor degree, advanced
diploma, diploma, certiﬁcate, year 12, or year 11 and below [51].
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Living Arrangement
Data on participants’ current living arrangement will be collected. In line with the ALSWH,
response options will include; no one, partner/spouse, own children, someone else’s children, parents,
or other adults [29].
Self-Selected Social Class
Requesting information on self-selected social class allows class designation to be meaningful to
participants and is more likely to reﬂect their actual class identity [52]. Participants will be asked to
self-select their social class from one of four response options in line with the ALWHS; ‘upper class’,
‘middle class’, ‘working class’, or ‘don’t know’ [52].
Household Income and Ability to Manage on Income
Gross income refers to the sum of income received from all sources before any deductions (income
tax, the Medicare Levy or salary sacriﬁced amounts) are taken out [51]. Participants will be asked to
report their average yearly gross household income from six response options in line with the ALSWH;
less than $20,000, $20,001–$30,000, $30,001–$50,000, $50,001–$100,000, more than $100,000 or ‘don’t
know/would rather not say’. Details on participants’ ability to manage on their current income will
also be collected. Seven response options in line with the ALSWH will include; ‘impossible’, ‘difﬁcult’,
‘always difﬁcult’, ‘sometimes difﬁcult’, ‘not too bad’, ‘easy’, or ‘not sure’ [53].
Smoking Status
Participants will be asked to report their smoking status. Wording of the question has been
developed to correspond with the ABS 2016 Census and response categories will include ‘yes’ or
‘no’ [51].
Physical Factors
Self-reported anthropometric data is valid and recommended for monitoring prevalence of obesity,
particularly for large-scale studies because of its simplicity and low cost [54–56]. Physical factors will
include; self-reported waist circumference, weight, and height. All response options will be continuous.
Waist Circumference
Waist circumference is a better indicator of central obesity than BMI or waist-to-hip ratio and
is more strongly correlated with intra-abdominal fat content and cardiovascular risk factors [57].
Participants will be asked to self-report their waist circumference to the nearest centimeter. Participants
will be asked to report results of two measures at each round of data collection, which will be
averaged during data analysis. Measuring instructions adapted from the ALSWH will be provided to
participants in the postal envelope [58]. Instructions will request participants to measure mid-central
adiposity using the tape to measure at the level of the mid-point between the lower costal border and
the iliac crest [58].
Weight
Weight will be self-reported at each data collection point to the nearest decimal point. If the
participant can only report the amount in stones and pounds, a conversion factor of 2.203 will be used
to convert pounds into kilograms in line with the ALSWH [52]. Participants will be asked to describe
where and how their weight was measured to assess the accuracy of the information.
Height
Height will be self-reported to the nearest centimeter at baseline only. If the participant can only
report the information in feet or inches, a factor of 2.54 will be used to convert inches to centimeters in
line with the ALSWH [52].
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BMI
BMI provides the most useful population-level measure of obesity [58,59]. Participants’ BMI will
be calculated after each round of data collection using the standard equation (weight (kg)/height
(m)2) [58]. Participants will be grouped into BMI categories for analysis according to the World
Health Organization guidelines; underweight (<18.50 kg/m2), normal weight (18.50–24.99 kg/m2),
overweight (≥25.00 kg/m2) and obese (≥30.00 kg/m2) [59].
Physical Activity
Regular physical activity is a key feature of international T2D management guidelines [9,60].
This is because it has been shown to improve glycemic control (regardless of whether weight loss has
occurred), lipid levels, and blood pressure in people with T2D [61–63]. Participants’ physical activity
levels will be measured through the IPAQ-SF which is one of the most widely used physical activity
assessment questionnaires and has been shown to be a valid measure of obtaining internationally
comparable physical activity data [64,65]. It measures self-reported physical activity in the previous
seven days and includes seven items that collect information on walking time, moderate and vigorous
physical activity time and sitting time [66]. Data obtained in the IPAQ-SF will be used to estimate total
metabolic equivalent (MET)-minutes per week for each participant [67].
Psychosocial Factors
Healthful Eating Beliefs
Healthy eating beliefs will be investigated at each of the ﬁve data collection points to better
understand their beliefs, attitudes and intentions towards making positive dietary behaviors and how
these impact on diet quality change over time. Participants’ healthy eating beliefs will be assessed
through the Healthful Eating Beliefs Scale. This scale is based on the TPB [68]. Standardized questions
have been selected from previous Healthful Eating Beliefs Scales to suit the current study. Table 4
provides an outline of the rationale for investigation behind the questions and modes of responses.
Participant scores will be generated for each of the seven subscales of the Healthful Eating Beliefs Scale
by calculating the mean of the 5-point Likert scale items, with higher scores representing more positive
beliefs, attitudes, and intentions towards improving dietary behaviors.
Mental Health
Mental health data will be collected at baseline, 6 and 12 months using the internationally
validated K10 questionnaire [69]. This 10-item questionnaire yields a global measure of distress based
on questions about anxiety and depressive symptoms experienced in the most recent four-week
period [70]. It is scored using a ﬁve-level response scale based on the frequency of symptoms reported
for each question. One is the minimum score for each item (none of the time) and ﬁve is the maximum
score (all of the time). The maximum score is 50 indicating severe distress, the minimum score is 10
indicating no distress [70].
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Table 4. Healthful Eating Beliefs Scale rationale for investigation and modes of responses.
Category Rationale forInvestigation Area of Enquiry
Standardized Questions and Response
Options Source
Healthful Eating
Beliefs Scale
To better understand
healthy eating beliefs
among participants
and determine if they
change over time.
Behavioral
intention
“I intend to eat a healthful diet each day in the
next 2 months,” 5-pt Likert
“I will try to eat a healthful diet each day in the
next 2 months,” 5-pt Likert
“I plan to eat a healthful diet each day in the
next 2 months,” 5-pt Likert
[68]
Perceived
behavioral control
“I have the self-discipline to eat a healthful
diet” 5-pt Likert
“I have the ability to eat a healthful diet”
5-pt Likert
“Me eating a healthful diet would be
easy/difﬁcult” 5-pt Likert
“Whether I do or do not follow the
recommendations for my diet is entirely up to
me” 5-pt Likert
[71]
Subjective norm
“People important to me think I should not/I
should eat a healthful diet” 5-pt Likert
“Other people expect me to follow the daily
recommendations for diet” 5-pt Likert
“People important to me want me to eat a
healthful diet” 5-pt Likert
“Other people with diabetes follow the daily
recommendations for diet” 5-pt Likert
[71,72]
Attitudes towards
self-care
“Following the recommendations for my diet
would be harmful/beneﬁcial” 5-pt Likert
“It would be worthless/valuable for me to
follow the daily recommendations for my diet”
5-pt Likert
“Following daily recommendations for diet is
unnecessary/necessary” 5-pt Likert
Following daily recommendations for diet is
unpleasant/pleasant” 5-pt Likert
[72]
Exposure to GP and Allied Healthcare Support
Interactions with health professionals may help facilitate positive changes in dietary behaviors [73].
At each data collection point, participants will be asked about their concurrent and previous exposure
to healthcare provider support (e.g., dietitian, diabetes educator). Participants will also be asked
to report how useful they found the advice on a 5-point Likert scale (1 being ‘not at all useful’,
2 being ’slightly useful’, 3 being ‘neutral’, 4 being ‘somewhat useful’ and 5 being ‘extremely useful’).
Question wording has been modiﬁed from previously conducted qualitative research that explored
the experiences of dietary change in people with T2D [13].
3.7. Participant Conﬁdentiality
All study related information will be de-identiﬁed and stored securely online with
password-protected access systems. Daily back-ups of all electronic data will occur to minimize
any risk of lost data. Only members of the research team who need to contact study patients, enter data
or perform data quality control will have access to participant information.
3.8. Statistical Modeling and Sample Size
The longitudinal aspect of diet quality change will be analyzed using regression models [74].
Diet quality at 12 months (measured by the DASH score) will be the primary outcome, with glycemic
control, interim diet changes (primarily at 3 months), medication use, demographic measures, physical
measures, psychosocial measures, and exposure to healthcare provider support as the explanatory
variables. This model will determine the relative importance of diet quality change both immediately
after diagnosis and in the medium term with regards to a 12-month outcome towards sustained
healthy eating.
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Sample size calculations, such as those provided in Diggle et al. [74] are not readily computed for
complex regression models and assessment using simulation studies would be more appropriate [75].
However, due to the relatively small participation rate in the feasibility study (22 participants/1000
invited) credible model parameters are currently unable to be formulated, and the effect differences
over time cannot be reliably inferred. Additionally, current research of diet quality change post diabetes
is lacking [15], therefore effects cannot be competently elicited. As a result, rather than determining
an initial sample size for the study, a Bayesian updating procedure will be used to collect data. In this
manner, sample size will be calculated during the early stages of data collection to yield an idea of
how many samples should be collected. Additionally, using a Bayesian framework, the parameter
estimates of the mixed model will be sequentially updated as batches of data are obtained, a process
known as Bayesian learning [76,77].
4. Discussion
The study described in this paper, the 3D Longitudinal Study, will be the ﬁrst to observe
changes in diet quality in people with T2D after diagnosis and the factors (demographic, physical,
and psychosocial) that inﬂuence those changes. Longitudinal studies help highlight differences or
changes in the values of one or more variables between different time periods, describe participants’
intra-individual and inter-individual changes over time and monitor the magnitude and patterns of
those changes [78]. This is important for the proposed research because it is necessary to understand
the extent to which people change their diet after a T2D diagnosis and why some people are able to
sustain these changes over time and others are not. Understanding this will help to develop targeted
strategies and facilitate enhanced dietary behavior support important to assist all people with T2D
to have long-term success in improving their diet quality and help reduce the risk of complications.
The results of this study will signiﬁcantly add to the body of literature on the diet quality changes of
people diagnosed with T2D, which is an under-researched area.
Limitations of the 3D Longitudinal Study are acknowledged. Recruitment through the NDSS is
the most suitable way to access a large number of potential participants with T2D, however selection
bias cannot be excluded as registration is voluntary, so participants may have greater diabetes
self-management motivation. Self-reported dietary intake data and physical measurements may
introduce misreporting bias and social desirability responses. Measurement errors associated with
dietary assessment methods are also acknowledged. However, use of the ASA-24 h dietary recall
(Australian version) which is a validated tool speciﬁcally designed for the Australian population,
reduces risk of bias [43]. A feasibility study for this project has already determined that its recruitment
capability, data collection and analysis procedures are achievable and appropriate.
Author Contributions: E.B., L.B., H.M. and L.T.W. identiﬁed the research question. All authors developed
the research protocol. All authors have been involved in drafting the manuscript and revising it critically for
intellectual content. All authors read and approved the ﬁnal manuscript.
Funding: This research received no external funding.
Conﬂicts of Interest: The authors declare no conﬂict of interest.
References
1. Coppell, K.J.; Kataoka, M.; Williams, S.M.; Chisholm, A.W.; Vorgers, S.M.; Mann, J.I. Nutritional intervention
in patients with type 2 diabetes who are hyperglycaemic despite optimised drug treatment—Lifestyle Over
and Above Drugs in Diabetes (LOADD) study: Randomised controlled trial. BMJ 2010, 341, c3337. [CrossRef]
[PubMed]
2. Leech, R.M.; Worsley, A.; Timperio, A.; McNaughton, S.A. Understanding meal patterns: Deﬁnitions,
methodology and impact on nutrient intake and diet quality. Nutr. Res. Rev. 2015, 28, 1–21. [CrossRef]
[PubMed]
195
Nutrients 2019, 11, 158
3. Lockheart, M.S.K.; Steffen, L.M.; Rebnord, H.M.; Fimreite, R.L.; Ringstad, J.; Thelle, D.S.; Pedersen, J.I.;
Jacobs, D.R., Jr. Dietary patterns, food groups and myocardial infarction: A case–control study. Br. J. Nutr.
2007, 98, 380–387. [CrossRef] [PubMed]
4. Drehmer, M.; Odegaard, A.O.; Schmidt, M.I.; Duncan, B.B.; Cardoso, L.D.; Matos, S.M.A.; Molina, M.D.C.B.;
Barreto, S.M.; Pereira, M.A. Brazilian dietary patterns and the dietary approaches to stop hypertension
(DASH) diet-relationship with metabolic syndrome and newly diagnosed diabetes in the ELSA-Brasil study.
Diabetol. Metab. Syndr. 2017, 9. [CrossRef]
5. Sievenpiper, J.L.; Dworatzek, P.D.N. Food and dietary pattern-based recommendations: An emerging
approach to clinical practice guidelines for nutrition therapy in diabetes. Can. J. Diabetes 2013, 37, 51–57.
[CrossRef] [PubMed]
6. Mozaffarian, D.; Ludwig, D.S. Dietary guidelines in the 21st century–A time for food. JAMA 2010, 304,
681–682. [CrossRef]
7. Ley, S.H.; Hamdy, O.; Mohan, V.; Hu, F.B. Prevention and management of type 2 diabetes: Dietary
components and nutritional strategies. Lancet 2014, 383, 1999–2007. [CrossRef]
8. The Royal Australian College of General Practitioners (RACGP). General Practice Management of Type 2
Diabetes: 2016–2018; RACGP: East Melbourne, VIC, Australia, 2016.
9. National Institute for Health and Care Excellence (NICE). Type 2 Diabetes in Adults: Management United
Kingdom; NICE: London, UK, 2017.
10. Vitolins, M.Z. Action for Health in Diabetes (Look AHEAD) trial: Baseline evaluation of selected nutrients
and food group intake. J. Am. Diet Assoc. 2009, 109, 1367–1375. [CrossRef]
11. Nelson, K.M.; Reiber, G.; Boyko, E.J. Diet and exercise among adults with type 2 diabetes: Findings from
the third national health and nutrition examination survey (NHANES III). Diabetes Care 2002, 25, 1722–1728.
[CrossRef]
12. Jarvandi, S.; Gougeon, R.; Bader, A.; Dasgupta, K. Differences in food intake among obese and nonobese
women and men with type 2 diabetes. J. Am. Coll. Nutr. 2011, 30, 225–232. [CrossRef]
13. Ball, L.; Davmor, R.; Leveritt, M.; Desbrow, B.; Ehrlich, C.; Chaboyer, W. Understanding the nutrition
care needs of patients newly diagnosed with type 2 diabetes: A need for open communication and
patient-focussed consultations. Aust J Prim Health 2016, 22, 416–422. [CrossRef] [PubMed]
14. Castro-Sanchez, A.E.; Avila-Ortiz, M.N. Changing dietary habits in persons living with type 2 diabetes. J.
Nutr. Educ. Behav. 2013, 45, 761–766. [CrossRef] [PubMed]
15. Burch, E.; Ball, L.; Somerville, M.; Williams, L.T. Dietary intake by food group of individuals with type 2
diabetes mellitus: A systematic review. Diab. Res. Clin. Prac. 2018, 10, 160–172. [CrossRef] [PubMed]
16. Mann, C.J. Observational research methods. Research design II: Cohort, cross sectional, and case-control
studies. Emerg. Med. J. 2003, 20, 54–60. [CrossRef] [PubMed]
17. Mariani, A.W.; Pego-Fernandes, P.M. Observational studies: Why are they so important? Sao Paulo Med. J.
2014, 132, 1–2. [CrossRef] [PubMed]
18. Evert, A.B.; Boucher, J.L.; Cypress, M.; Dunbar, S.A.; Franz, M.J.; Mayer-Davis, E.J.; Neumiller, J.J.;
Nwankwo, R.; Verdi, C.L.; Urbanski, P.; et al. Nutrition therapy recommendations for the management of
adults with diabetes. Diabetes Care 2013, 36, 3821–3842. [CrossRef] [PubMed]
19. McEachan, R.R.C.; Conner, M.T.; Taylor, N.J.; Lawton, R. Prospective prediction of health-related behaviors
with Theory of Planned Behavior: A meta-analysis. Health Psych. Rev. 2011, 5, 97–144. [CrossRef]
20. Ajzen, I. The theory of planned behavior. Organ. Behav. Hum. Decis. Process 1991, 50, 179–211. [CrossRef]
21. Kothe, E.J.; Mullan, B.A. Interaction effects in the theory of planned behavior: Predicting fruit and vegetable
consumption in three prospective cohorts. Br. J. Health Psych. 2015, 20, 549–562. [CrossRef]
22. Hardeman, W.; Johnston, M.; Johnston, D.W.; Bonetti, D.; Wareham, N.; Kinmonth, A.L. Application of the
theory of planned behavior in behavior change interventions: A systematic review. Psych. Health 2002, 17,
123–158. [CrossRef]
23. von Elm, E.; Altman, D.G.; Egger, M.; Pocock, S.J.; Gotzsche, P.C.; Vandenbroucke, J.P.; STROBE Initiative.
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines
for reporting observational studies. Int. J. Surg. 2014, 12, 1495–1499. [CrossRef]
24. National Diabetes Service Scheme (NDSS): Registration. Available online: https://www.ndss.com.au/
registration (accessed on 20 May 2018).
196
Nutrients 2019, 11, 158
25. National Diabetes Services Scheme (NDSS): Type 2 Diabetes. Available online: https://www.ndss.com.au/
data-snapshots (accessed on 1 July 2018).
26. Abshire, M.; Victor, D.D.; Cajita, M.I.A.; Eakin, M.N.; Needham, D.M.; Himmelfarb, C.D. Participant retention
practices in longitudinal clinical research studies with high retention rates. BMC Med. Res. Method 2017, 17,
1–10. [CrossRef]
27. LimeSurvey Organisation. Available online: https://www.limesurvey.org/ (accessed on 1 September 2018).
28. Australian Bureau of Statistics (ABS). Available online: http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/
bySubject/2008.0~{}2016~{}MainFeatures~{}Age~{}99 (accessed on 1 September 2018).
29. Elstgeest, L.E.M.; Mishra, G.D.; Dobson, A.J. Transitions in living arrangements are associated with changes
in dietary patterns in young women. J. Nutri. 2012, 142, 1561–1567. [CrossRef] [PubMed]
30. Brancato, G.; Macchia, S.; Murgia, M.; Signore, M.; Simeoni, G.; Blanke, K.; Körner, T.; Nimmergut, A.;
Lima, P.; Paulino, R.; et al. Handbook of Recommended Practices for Questionnaire Development and Testing in the
European Statistical System; Eurostat: Luxembourg city, Luxembourg, 2004.
31. Collins, C.E.; Burrows, T.L.; Rollo, M.E.; Boggess, M.M.; Watson, J.F.; Guest, M.; Duncanson, K.;
Pezdirc, K.; Hutchesson, M.J. The comparative validity and reproducibility of a diet quality index for
adults: The Australian recommended food score. Nutrients 2015, 7, 785–798. [CrossRef] [PubMed]
32. Campbell, A.P. DASH eating plan: An eating pattern for diabetes management. Diabetes Spectrum 2017, 30,
76. [CrossRef] [PubMed]
33. Clark, A.L. Use of the Dietary Approaches to Stop Hypertension (DASH) eating plan for diabetes
management. Diabetes Spectrum 2012, 25, 244–252. [CrossRef]
34. Salehi-Abargouei, A.; Maghsoudi, Z.; Shirani, F.; Azadbakht, L. Effects of Dietary Approaches to Stop
Hypertension (DASH)-style diet on fatal or nonfatal cardiovascular diseases-incidence: A systematic review
and meta-analysis on observational prospective studies. Nutrition 2013, 29, 611–618. [CrossRef]
35. Azadbakht, L.; Surkan, P.J.; Esmaillzadeh, A.; Willett, W.C. The dietary approaches to stop hypertension
eating plan affects C-reactive protein, coagulation abnormalities, and hepatic function tests among type 2
diabetic patients. J. Nutr. 2011, 141, 1083–1088. [CrossRef]
36. Siervo, M.; Lara, J.; Chowdhury, S.; Ashor, A.; Oggioni, C.; Mathers, J.C. Effects of the Dietary Approach to
Stop Hypertension (DASH) diet on cardiovascular risk factors: A systematic review and meta-analysis. Brit.
J. Nutri. 2015, 113, 1–15. [CrossRef]
37. Soltani, S.; Shirani, F.; Chitsazi, M.J.; Salehi-Abargouei, A. The effect of dietary approaches to stop
hypertension (DASH) diet on weight and body composition in adults: A systematic review and meta-analysis
of randomized controlled clinical trials. Obesi. Rev. 2016, 17, 442–454. [CrossRef]
38. Alkerwi, A.; Vernier, C.; Crichton, G.E.; Sauvageot, N.; Shivappa, N.; Hebert, J.R. Cross-comparison of diet
quality indices for predicting chronic disease risk: Findings from the Observation of Cardiovascular Risk
Factors in Luxembourg (ORISCAV-LUX) study. Briti. J. Nutri. 2015, 113, 259–269. [CrossRef] [PubMed]
39. Fung, T.T.; Chiuve, S.E.; McCullough, M.L.; Rexrode, K.M.; Logroscino, G.; Hu, F.B. Adherence to
a DASH-Style diet and risk of coronary heart disease and stroke in women. Arch. Intern. Med. 2008,
168, 713–720. [CrossRef] [PubMed]
40. de Koning, L.; Chiuve, S.E.; Fung, T.T.; Willett, W.C.; Rimm, E.B.; Hu, F.B. Diet-quality scores and the risk of
type 2 diabetes in men. Diabetes Care 2011, 34. [CrossRef]
41. National Institute of Health (NIH). Available online: https://epi.grants.cancer.gov/asa24/respondent/
validation.html (accessed on 1 June 2018).
42. Moshfegh, A.J.; Rhodes, D.G.; Baer, D.J.; Murayi, T.; Clemens, J.C.; Rumpler, W.V.; Paul, D.R.; Sebastian, R.S.;
Kuczynski, K.J.; Ingwersen, L.A.; et al. The US department of agriculture automated multiple-pass method
reduces bias in the collection of energy intakes. Amer. J. Clin. Nutri. 2008, 88, 324–332. [CrossRef] [PubMed]
43. Kirkpatrick, S.I.; Subar, A.F.; Douglass, D.; Zimmerman, T.P.; Thompson, F.E.; Kahle, L.L.; George, S.M.;
Dodd, K.W.; Potischman, N.; et al. Performance of the automated self-administered 24-hour recall relative
to a measure of true intakes and to an interviewer-administered 24-h recall. Amer. J. Clin. Nutri. 2014, 100,
233–240. [CrossRef] [PubMed]
44. Thompson, F.E.; Dixit-Joshi, S.; Potischman, N.; Dodd, K.W.; Kirkpatrick, S.I.; Kushi, L.H.; Alexander, G.L.;
Coleman, L.A.; Zimmerman, T.P.; Sundaram, M.E.; et al. Comparison of interviewer-administered and
automated self-administered 24-hour dietary recalls in 3 diverse integrated health systems. Amer. J. Epidem.
2015, 181, 970–978. [CrossRef]
197
Nutrients 2019, 11, 158
45. Australian Bureau of Statistics (ABS). Available online: http://www.abs.gov.au/ausstats/abs@.nsf/mf/
4363.0.55.001 (accessed on 31 May 2018).
46. Xyris Software: FoodWorks 9 Professional. Available online: https://xyris.com.au/products/foodworks-9-
professional/ (accessed on 1 June 2018).
47. Food Standard Australia New Zealand (FSANZ): Food Nutrient Database FSANZ. Available
online: http://www.foodstandards.gov.au/science/monitoringnutrients/ausnut/foodnutrient/Pages/
default.aspx (accessed on 1 May 2018).
48. Nathan, D.M.; Turgeon, H.; Regan, S. Relationship between glycated haemoglobin levels and mean glucose
levels over time. Diabetologia 2007, 50, 2239–2244. [CrossRef]
49. Schifreen, R.; Hickingbotham, J.M.; Bowers, G.N. Accuracy, precision and stability in measurement of
hemoglobin A1c by "high-performance" cation-exchange chromatography. Clin. Chem. 1980, 26, 466.
50. Australian Government: Medicare Beneﬁts Schedule online. Available online: http://www.mbsonline.gov.
au (accessed on 15 June 2018).
51. Australian Bureau of Statistics (ABS). Available online: http://www.abs.gov.au/ausstats/abs@.nsf/mf/
2901.0 (accessed on 28 May 2018).
52. Williams, L.; Germov, J.; Young, A. The effect of social class on mid-age women’s weight control practices
and weight gain. Appetite 2011, 56, 719–725. [CrossRef]
53. Australian Longitudinal Study on Women’s Health (ALSWH). Australian Longitudinal Study on Women’s
Health, 1946–1951 Cohort Summary 1996–2013; ALSWH: New South Wales, Australia, 2015.
54. Spencer, E.A.; Appleby, P.N.; Davey, G.K.; Key, T.J. Validity of self-reported height and weight in 4808
EPIC–Oxford participants. Public Health Nutri. 2002, 5, 561–565. [CrossRef]
55. Booth, M.L.; Hunter, C.; Gore, C.J.; Bauman, A.; Owen, N. The relationship between body mass index and
waist circumference: Implications for estimates of the population prevalence of overweight. Intern. J. Obesity
2000, 24, 1058–1061. [CrossRef]
56. Chan, N.P.T.; Choi, K.C.; Nelson, E.A.S.; Sung, R.Y.T.; Chan, J.C.N.; Kong, A.P.S. Self-reported waist
circumference: A screening tool for classifying children with overweight/obesity and cardiometabolic
risk factor clustering: Self-reported waist circumference. Pediatr. Obesity 2012, 7, 110–120. [CrossRef]
[PubMed]
57. Ma, W.Y.; Yang, C.Y.; Shih, S.R.; Hsieh, H.J.; Hung, C.S.; Chiu, F.C.; Lin, M.S.; Liu, P.H.; Hua, C.H.; Hsein, Y.C.;
et al. Measurement of Waist Circumference: Midabdominal or iliac crest? Diabetes Care 2013, 36, 1660–1666.
[CrossRef] [PubMed]
58. Williams, L.; Hollis, J.; Collins, C.; Morgan, P. The 40-Something randomized controlled trial to prevent
weight gain in mid-age women. BMC Public Health 2013, 13, 1007. [CrossRef]
59. World Health Organization (WHO). Obesity: Preventing and Managing the Global Epidemic; WHO: Geneva,
Switzerland, 2000.
60. International Diabetes Federation (IDF). IDF Clinical Practice Recommendations for Managing Type 2 Diabetes in
Primary Care; IDF: Brussels, Belgium, 2017.
61. Colberg, S.R.; Sigal, R.J.; Fernhall, B.; Regensteiner, J.G.; Blissmer, B.J.; Rubin, R.R.; Chasan-Taber, L.;
Albright, A.L.; Braun, B.; American College of Sports Medicine; et al. Exercise and type 2 diabetes:
The American College of Sports Medicine and the American Diabetes Association: Joint position statement.
Diabetes Care 2010, 33, e147–e167. [CrossRef] [PubMed]
62. Balducci, S.; Zanuso, S.; Nicolucci, A.; De Feo, P.; Cavallo, S.; Cardelli, P.; Fallucca, S.; Alessi, E.; Fallucca, F.;
Pugliese, G.; et al. Effect of an intensive exercise intervention strategy on modiﬁable cardiovascular risk
factors in subjects with type 2 diabetes mellitus. Arch. Internal. Med. 2010, 20, 1794–1803. [CrossRef]
[PubMed]
63. Umpierre, D.; Ribeiro, P.A.; Kramer, C.K.; Leitão, C.B.; Zucatti, A.T.; Azevedo, M.J.; Gross, J.L.; Ribeiro, J.P.;
Schaan, B.D. Physical activity advice only or structure exercise training and association with HbA1c levels in
type 2 diabetes: A systematic review and meta-analysis. JAMA 2011, 17, 1790–1799. [CrossRef] [PubMed]
64. van Poppel, M.N.; Chinapaw, M.J.; Mokkink, L.B.; van Mechelen, W.; Terwee, C.B. Physical activity
questionnaires for adults: A systematic review of measurement properties. Sports Med. 2010, 565–600.
[CrossRef]
198
Nutrients 2019, 11, 158
65. Craig, C.L.; Marshall, A.L.; Sjostrom, M.; Bauman, A.E.; Booth, M.L.; Ainsworth, B.E. International Physical
Activity Questionnaire: 12-country reliability and validity. Med. Sci. Sports Exercise 2003, 35, 1381–1395.
[CrossRef]
66. International Physical Activity Group. Available online: https://sites.google.com/site/theipaq/
questionnaire_links (accessed on 1 June 2018).
67. International Physical Activity Group. Available online: https://sites.google.com/site/theipaq/scoring-
protocol (accessed on 1 June 2018).
68. Blue, C.L. Does the theory of planned behavior identify diabetes-related cognitions for intention to be
physically active and eat a healthy diet? Pub. Health Nurs. 2007, 24, 141–150. [CrossRef]
69. Beyond Blue. Available online: https://www.beyondblue.org.au/the-facts/anxiety-and-depression-
checklist-k10 (accessed on 1 June 2018).
70. Tan, L.S.; Khoo, E.Y.; Tan, C.S.; Griva, K.; Mohamed, A.; New, M.; Lee, Y.S.; Lee, J.; Tai, E.S.; Wee, H.L.
Sensitivity of three widely used questionnaires. Qual. Life Res. 2015, 24, 153–162. [CrossRef] [PubMed]
71. Watanabe, T.; Berry, T.R.; Willows, N.D.; Bell, R.C. Assessing intentions to eat low-glycemic index foods by
adults with diabetes using a new questionnaire based on the theory of planned behaviour. Can. J. Diabetes
2015, 39, 94–100. [CrossRef] [PubMed]
72. Gatt, S.; Sammut, R. An exploratory study of predictors of self-care behaviour in persons with type 2 diabetes.
Intern. J. Nursing Studies 2008, 45, 1525–1533. [CrossRef] [PubMed]
73. Agborsangaya, C.B.; Gee, M.E.; Johnson, S.T.; Dunbar, P.; Langlois, M.F.; Leiter, L.A.; Pelletier, C.; Johnson, J.A.
Determinants of lifestyle behavior in type 2 diabetes: Results of the 2011 cross-sectional survey on living
with chronic diseases in Canada. BMC Pub. Health 2013, 13, 451. [CrossRef] [PubMed]
74. Diggle, P. Analysis of Longitudinal Data, 2nd ed.; Oxford University Press: New York, NY, USA, 2002.
75. Green, P.; MacLeod, C.J.; Nakagawa, S. SIMR: An R package for power analysis of generalized linear mixed
models by simulation. Methods Ecol. Evol. 2016, 7, 493–498. [CrossRef]
76. Gill, J. Bayesian Methods: A Social and Behavioral Sciences Approach, 3rd ed.; CRC Press: Boca Raton, FL, USA,
2015.
77. Spiegelhalter, D.J.; Abrams, K.R.; Myles, J.P. Bayesian Approaches to Clinical Trials and Health-Care Evaluation,
1st ed.; John Wiley & Sons: Chichester, UK, 2004.
78. Ruspini, E. Introduction to Longitudinal Research, 1st ed.; Routledge: London, UK, 2002.
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
199
nutrients
Review
Polyunsaturated Fatty Acids and Glycemic Control in
Type 2 Diabetes
Vibeke H. Telle-Hansen, Line Gaundal and Mari C.W. Myhrstad *
Faculty of Health Sciences, Oslo Metropolitan University, Postbox 4, St. Olavsplass, 0130 Oslo, Norway;
vtelle@oslomet.no (V.H.T.-H.); linega@oslomet.no (L.G.)
* Correspondence: mmyhrsta@oslomet.no; Tel.: +47-9139-2176
Received: 1 April 2019; Accepted: 10 May 2019; Published: 14 May 2019
Abstract: The impact of dietary fat on the risk of cardiovascular disease (CVD) has been extensively
studied in recent decades. Solid evidence indicates that replacing saturated fatty acids (SFAs) with
polyunsaturated fatty acids (PUFAs) decreases blood cholesterol levels and prevents CVD and CVD
mortality. Studies indicate that fat quality also may aﬀect insulin sensitivity and hence, the risk of
type 2 diabetes (T2D). A high intake of SFAs has shown to increase the risk of T2D in prospective
studies, while a high intake of PUFAs reduces the risk. Whether PUFAs from marine or vegetable
sources aﬀect glycemic regulation diﬀerently in T2D remains to be elucidated. The aim of the present
review was therefore to summarize research on human randomized, controlled intervention studies
investigating the eﬀect of dietary PUFAs on glycemic regulation in T2D. About half of the studies
investigating the eﬀect of ﬁsh, ﬁsh oils, vegetable oils, or nuts found changes related to glycemic
control in people with T2D, while the other half found no eﬀects. Even though some of the studies
used SFA as controls, the majority of the included studies compared PUFAs of diﬀerent quality.
Considering that both marine and vegetable oils are high in PUFAs and hence both oils may aﬀect
glycemic regulation, the lack of eﬀect in several of the included studies may be explained by the use
of an inappropriate control group. It is therefore not possible to draw a ﬁrm conclusion, and more
studies are needed.
Keywords: PUFA; polyunsaturated fatty acids; glycemic control; nuts; ﬁsh; ﬁsh oil; vegetable oil;
type 2 diabetes
1. Introduction
The most important public health challenge in the world today is premature morbidity
and mortality from non-communicable diseases (NCDs) like cancer, type 2 diabetes (T2D), and
cardiovascular disease (CVD) [1]. Globally, the prevalence of T2D has increased from 108 million in
1980 to 422 million individuals in 2014 [2]. The WHO has estimated that diabetes will be the seventh
most important cause of death in the world by 2030 [3]. Relative risk of CVD is increased two to four
times in people with T2D compared with non-diabetic subjects, and is the primary cause of death in
people with T2D [4].
The health impact of diet is well recognized, and even small dietary changes may contribute to
signiﬁcant health eﬀects [5–7]. Lifestyle and diet can be highly eﬀective in preventing and treating
T2D [8–11]. A high intake of saturated fatty acids (SFAs) increases the risk of CVD due to increased
low-density lipoprotein (LDL) cholesterol in the blood, while polyunsaturated fatty acids (PUFAs)
have the opposite eﬀect [5,12–15]. Studies indicate that dietary fat quality also may aﬀect insulin
sensitivity and hence, the risk of T2D. As early as 1959, Kinsell et al. reported on fat quality and insulin
regulation [16]. Several studies on fat quality and glycemic regulation have been published since
then [17–20]. According to observational studies, both intake of PUFAs and replacement of SFAs with
Nutrients 2019, 11, 1067; doi:10.3390/nu11051067 www.mdpi.com/journal/nutrients200
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PUFAs reduce the risk of T2D [21,22]. Imamura and colleagues recently performed a comprehensive
meta-analysis and systematic review of dietary fat and glycemic regulation in randomized controlled
trials (RCTs). They found that replacing the intake of SFAs with PUFAs improved glycemia and insulin
resistance [19]. These results are in accordance with a systematic review from 2014 [13]. However,
none of these reviews distinguished between PUFAs derived from marine or vegetable sources, and
both people with and without T2D were included.
In addition to the opposing health eﬀects of saturated versus unsaturated fat, speciﬁc PUFAs
may diﬀer in their health eﬀects. Some studies have indicated that n-6 PUFAs, but not n-3 PUFAs,
may improve insulin sensitivity [13]. In a meta-analysis from 2008, n-3 PUFA supplementation in
people with T2D had no signiﬁcant eﬀect on glycemic control [23], whereas vegetable PUFAs were
found to reduce fasting insulin and Homeostasis Assessment Model-Insulin Resistance (HOMA-IR) in
a more recent meta-analysis in healthy subjects [24]. To what degree PUFAs from diﬀerent sources
aﬀect glycemic regulation in people with T2D remains unknown.
The aim of the present review was therefore to summarize the literature on human intervention
studies investigating the eﬀect of marine- and vegetable-derived PUFAs on glycemic regulation in T2D.
2. Materials and Methods
To summarize the eﬀects of PUFAs on glycemic control in people with T2D we performed
a literature search in PubMed in August 2018. Only original articles on RCTs in humans were
included. Furthermore, only studies with information about glycemic control and/or T2D and/or
dietary unsaturated fat were included. The search words were: “glycemic control” AND “type 2
diabetes” AND “PUFA” AND/OR “unsaturated fats” AND/OR “nuts” AND/OR “oils” AND/OR “fatty
ﬁsh” AND/OR “omega 3” AND/OR “omega 6”. We included studies which clearly or possibly fulﬁlled
the following criteria: glycemic control, T2D and dietary interventions, and intake of unsaturated fat.
In addition, studies with subjects referred to as non-insulin dependent diabetes mellitus (NIDDM)
were also included, and hence these subjects are referred to as NIDDM in the present review. Moreover,
we excluded studies that clearly fulﬁlled at least one of the following criteria: Non original study (for
example editorial, review or conference paper), studies that did not compare the criteria measurements
to a control group, animal study, articles written in languages other than English, or lack of inclusion
criteria measurements (as deﬁned previously). Interventions with ethyl esters and not available articles
were excluded, and duplicate articles were removed. In addition to the literature search, two articles
were included based on other reviews. In total, 31 articles were identiﬁed as eligible and included in
the present article. Figure 1 shows the ﬂow chart of the study selection.
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Figure 1. Flow chart of the study selection. RCT: randomized controlled trial; T2D: type 2 diabetes.
3. Results and Discussion
In the present review, we identiﬁed 31 RCTs (postprandial and short- and long-term intervention
trials (lasting from 30 days to 30 weeks), parallel and crossover design) investigating the eﬀects of
PUFAs as dietary components in glycemic regulation in people with T2D or NIDDM (Tables 1–3). Of
the 31 included studies, 14 studies investigated the eﬀect of ﬁsh, ﬁsh oil, eicosapentaenoic acid (EPA)
and/or docosahexaenoic acid (DHA) on glycemic regulation [25–38]; 12 studies investigated vegetable
oils [39–50]; and ﬁve studies investigated the eﬀect of nuts [51–55]. All participants were adults, male
and females in the age range between 34 and 84 years (min–max), with T2D or NIDDM.
3.1. Fish and Fish Oil
A relationship between ﬁsh and/or marine n-3 fatty acids consumption and reduced risk of CVD
was originally suggested by epidemiological studies among Greenland Inuits and Danes [56]. The
eﬀects of both the amount and quality of dietary fat and ﬁsh oil have since been studied intensively.
Suggestedmechanisms of the cardiovascular beneﬁts frommarine n-3 PUFAs include decreased plasma
triglyceride levels andbloodpressure, aswell as anti-thrombotic, antiarrhythmic, and anti-inﬂammatory
eﬀects [57–59]. The eﬀect of ﬁsh oil on glycemic regulation in T2D is less studied. In the present review,
14 intervention studies with ﬁsh or ﬁsh oil in people with T2D or NIDDM were included (Table 1).
Balfegó and coworkers investigated the eﬀect of a standard diet with sardines on metabolic
control [27]. Thirty-ﬁve subjects were randomized to follow either a T2D standard diet (control group),
or a T2D standard diet enriched with 100 g of sardines per day, 5 days a week (sardine group) for
6 months. The changes in fasting glucose, glycated hemoglobin A1c (HbA1c), fasting insulin and
HOMA-IR values were similar between the two groups [27]. The eﬀects of moderate aerobic exercise
and the incorporation of ﬁsh into a low-fat diet (30 energy (E) % fat) on glycemic control were examined
in 49 subjects [34]. The subjects were randomly assigned to a low fat diet (30 E% fat) with or without
one ﬁsh meal per day (3.6 g n-3 fatty acids) and further randomized to a moderate (55–65% VO2
max) or light (heart rate <100 bpm) exercise program for eight weeks. While fasting insulin levels
decreased in the ﬁsh and light exercise group compared with light exercise alone (control), there were
no diﬀerences in fasting blood glucose concentration after any of the interventions compared with the
control group. In the ﬁsh and light exercise group, they also demonstrated a signiﬁcant rise in HbA1c
compared with the control group [34].
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The eﬀects of the marine n-3 fatty acids EPA/DHA in a liquid diet on glycemic control was
investigated in a multicenter randomized trial with 30 elderly [29]. The subjects were divided into two
groups receiving either an EPA/DHA-rich diet (EPA 25 mg/100 kcal and DHA 17 mg/100 kcal) or a diet
without EPA/DHA (control group). A signiﬁcant reduction in fasting blood glucose and HbA1c was
observed after intake of EPA/DHA compared with the control diet [29]. Sarbolouki et al. included 67
men and women in a double blind, placebo-controlled randomized study to investigate the eﬀects
of EPA on glycemic regulation [28]. The participants received either EPA (2 g/day, 95% pure EPA) or
placebo (2 g corn oil/day) for three months. EPA treatment reduced fasting plasma glucose, HbA1c, and
HOMA-IR compared with the control group [28]. In a randomized, double blind, placebo-controlled
trial, Wang and colleagues investigated the eﬀect of 4 g ﬁsh oil per day (1.34 g EPA and 1.07 g DHA) or
corn oil (control) on glucose metabolism in 99 subjects [25]. There were no signiﬁcant eﬀects on fasting
serum glucose, insulin, HbA1c, or HOMA-IR after ﬁsh oil treatment for six months compared with
corn oil [25]. Zhen et al. investigated the eﬀects of n-3 PUFA from marine or vegetable sources on
glycemic control in 166 subjects [26]. The study was a double blind RCT and the participants received
either ﬁsh oil (2 g/day EPA + DHA), ﬂaxseed oil (2.5 g/day alpha linolenic acid (ALA)), or corn oil
(control group) for 180 days. Intake of ﬁsh oil, but not ﬂaxseed oil, reduced HbA1c compared with
corn oil. There were no eﬀect on fasting insulin or glucose [26]. In order to determine the eﬀects of n-3
fatty acids, a randomized, double blind, placebo-controlled trial was conducted in 81 subjects [31]. The
subjects received capsules with either n-3 fatty acids (1.6 g/day EPA and 0.8 g/day DHA) or sunﬂower
oil (control group) for two months. Treatment with n-3 fatty acids signiﬁcantly decreased HbA1c,
while fasting blood glucose was not signiﬁcantly altered [31]. In line with these results, 6 g/day of
either ﬁsh oil (1.8 g n-3 PUFAs) or sunﬂower oil (control) given to 10 men for two months did not show
any signiﬁcant changes in fasting blood glucose, insulin, or HbA1c between the groups [33]. The study
had a randomized, double blind crossover design. In the same study, supplementation with ﬁsh oil
did not alter basal hepatic glucose production and there were no diﬀerence in insulin suppression of
hepatic glucose production nor in insulin stimulation of whole-body glucose disposal measured by the
euglycemic-hyperinsulinemic clamp between the groups [33]. In a double blind RCT, Pedersen and
colleagues investigated the impact of vitamin E-enriched ﬁsh oil in 44 subjects [32]. The participants
received a daily dose of 4 g of either ﬁsh oil (2.6 g/day EPA + DHA) or corn oil (control) for eight
weeks, in addition to an equal amount of vitamin E (53.6 g/day). There were no signiﬁcant changes in
fasting blood glucose or HbA1c between the groups. However, within the ﬁsh oil group, fasting blood
glucose was increased [32]. In a double blind, randomized crossover study, 10 g of ﬁsh oil (1.8 g EPA
+ 1.2 g DHA) or olive oil (control) were given daily to eight male subjects for two weeks [37]. There
were no signiﬁcant changes in fasting blood glucose, average daily blood glucose, hyperglycemic
clamp, nor insulin sensitivity [37]. In a double blind, randomized, crossover study, 11 subjects received
supplements with ﬁsh oil, linseed oil, or olive oil (control) for three months in a dose corresponding to
35 mg fatty acids per kilogram body weight [35]. Neither ﬁsh oil nor linseed oil modulated glycemic
control (fasting glucose and insulin, HbA1c, insulin sensitivity, glucose eﬀectiveness, acute insulin
response to glucose) compared with the control group [35]. Morgan and colleagues gave 40 subjects
(18 men and 22 women) 9 g of ﬁsh oil, 18 g of ﬁsh oil, 9 g of corn oil, or 18 g of corn oil daily as a
supplement for 12 weeks [36]. They did not detect any eﬀect within (9 g versus 18 g) nor between (ﬁsh
oil groups combined versus corn oil groups combined) the intervention groups on fasting glucose or
HbA1c [36]. In a study by Borkman et al., 10 subjects were included in a three week blinded crossover
study [38]. Subjects were given a standard diabetic diet supplemented with a daily dose of 10 g ﬁsh oil
concentrate (30% n-3 fatty acids), 10 g saﬄower oil, or no supplementation (control). Fasting blood
glucose increased with 14% during ﬁsh oil and 11% during saﬄower oil supplementation compared
with control, whereas fasting insulin level remained unchanged [38].
Taken together, about half of the included studies (eight out of 14) found no signiﬁcant changes
related to markers of glycemic regulation such as fasting glucose, insulin, HbA1c or markers related
to insulin resistance or sensitivity [25,27,30,32,33,35–37] after intervention with ﬁsh or ﬁsh oil when
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compared with a control group. In ﬁve of the studies a reduction in glucose [28,29], insulin [28,34]
and/or HbA1c [26,28,29,31] was observed. Impaired glycemic regulation was observed in two studies,
where intake of ﬁsh or ﬁsh oil increased fasting glucose [38] and an increase in HbA1c [34] was observed
after intake of ﬁsh in combination with light exercise. In addition to the between groups eﬀects, two of
the studies found an additional eﬀect on glycemic regulation within groups, in which Dunstan et al.
observed increased HbA1c [34], while Balfego et al. found decreased eﬀect on fasting insulin, HbA1c,
and HOMA-IR [27]. In a recent meta-analysis of 11 RCTs including people with T2D, overweight
individuals, or healthy individuals, Akinkuolie et al. showed that consumption of n-3 PUFAs did not
aﬀect insulin [60]. In line with this, a lack of association between n-3 PUFAs in blood and risk of T2D
was the conclusion in the Uppsala Longitudinal Study of Adult Men (ULSAM) [61].
Since about half of the studies in the present review reported improved glycemic regulation while
the other half reported no or impaired eﬀects, it is diﬃcult to draw a ﬁrm conclusion about ﬁsh and
ﬁsh oil and glycemic regulation.
3.2. Vegetable Oils
Vegetable oils are rich in PUFAs, the main constituent being n-6 fatty acids, and in particular
linoleic acid (LA). There is convincing evidence that partial replacement of SFAs with monounsaturated
fatty acids (MUFAs) or PUFAs lowers fasting blood total- and LDL-cholesterol [5,13–15] and thereby
reduces the risk of developing CVDs [5,6,13,14,62–64]. In addition to the cholesterol-lowering eﬀects
of PUFAs, some studies indicate that PUFAs may improve glycemic regulation [13,19]. Twelve studies
investigating the eﬀect of vegetable oils on glycemic control in people with T2D or NIDDM were
included in this review (Table 2).
Foster and colleagues examined markers of glycemic control in 43 postmenopausal women
after intake of ﬂaxseed oil (high in alpha-linolenic acid (ALA)) for 12 weeks [40]. The study was a
randomized, double blind, placebo-controlled trial, and the participants received either 40 mg/day
zinc, 2 g/day ﬂaxseed oil, both zinc and ﬂaxseed oil, or olive oil (control). There were no signiﬁcant
changes in blood glucose, insulin, HbA1c or HOMA-IR between the intervention groups after 12 weeks.
However, insulin and HOMA-IR decreased within the control group [40]. In a study by Jenkins et al.,
the combined eﬀect of ALA, MUFAs, and low glycemic load on glycemic control and CVD risk factors
were investigated in 141 subjects [41]. The study was a RCT with a parallel design and the subjects
were provided daily with canola oil-enriched whole-wheat bread (500 kcal/day or 31 g canola oil per
2000 kcal) or whole-wheat bread without canola oil (500 kcal) (control diet). The test diet signiﬁcantly
reduced HbA1c compared with the control diet and the result remained statistically signiﬁcant after
adjustment for body weight change [41]. Barre and coworkers investigated the eﬀect of ﬂaxseed oil
on glycemic control in 32 subjects [44]. The subjects were randomly assigned to receive 10 g/day of
ﬂaxseed oil or saﬄower oil for three months. The amount of ALA was approximately 60 mg/kg body
weight/day in the ﬂaxseed oil group. Flaxseed oil had no impact on fasting blood glucose, insulin, or
HbA1c compared with the control group [44]. Conjugated linoleic acid (CLA), the trans fatty acid of
LA, was compared with saﬄower oil high in cis-LA in 35 obese, postmenopausal women [43]. The
participants consumed 8 g oil per day for 16 weeks in a crossover study, with four weeks washout in
between the intervention periods, giving a total of 36 weeks. The aim of the study was to investigate
weight reduction, and they found a signiﬁcant reduction in BMI after CLA oil intake but not after
saﬄower oil intake. Nevertheless, even though a weight reduction is associated with improved
glycemic regulation, there was a signiﬁcant reduction in fasting blood glucose only within the saﬄower
oil group [43]. To investigate the long-term eﬀects of a diet enriched in LA on insulin sensitivity, Heine
and colleagues conducted a randomized, crossover study in 14 subjects [50]. The PUFA to SFA ratio
(P:S ratio) of the diets were altered by substituting LA-rich fats and oils for products rich in saturated
fats. The participants received a diet (total fat content of 38–39 E%) with a P:S ratio of 0.3 (low P:S
diet) or 1.0 (high P:S diet) in a randomized order for 30 weeks each. Fasting blood glucose, insulin,
HbA1c, glucose incremental area under the curve (iAUC), C-peptide, and insulin responses did not
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diﬀer between the groups after intervention. However, the metabolic clearance rate of glucose was
higher in the high P:S diet compared with the control group. This diﬀerence was only observed at
the lowest infusion rate (6 mg/kg/min) [50]. A 12-week intervention with bakery products containing
ﬂaxseed oil (13 g/day), milled ﬂaxseed (32 g/day), or no ﬂaxseed (control group) investigated the eﬀects
on fasting blood glucose, insulin, and HbA1c in 34 adult males and females [42]. The ﬂaxseed and
ﬂaxseed oil groups received equivalent amounts of 7.4 g ALA per day. There were no diﬀerences in
fasting HbA1c, glucose and insulin after the intervention period [42]. Isocaloric diets with diﬀerent
fatty acid composition was investigated in a randomized crossover trial with 16 obese subjects for six
weeks [48]. The energy content of carbohydrate, protein and fats were kept constant, but the diets
diﬀered in fat composition. There were no signiﬁcant changes between the diets in HbA1c, fasting
blood glucose, insulin, or postprandial glycemic response. However, serum insulin and C-peptide
responses increased following the trans-MUFA and SAT diets compared with the cis-MUFA diet [48].
In a study by Gerhard et al., the eﬀect of two ad libitum diets on glycemic control was investigated [45].
Eleven subjects were randomly assigned to receive an ad libitum low-fat, high-carbohydrate diet (20
E% total fat, 65 E% carbohydrates, higher in ﬁber), or a high-MUFA diet (40 E% total fat, 26 E% MUFAs,
45 E% carbohydrates), each for six weeks. There were no eﬀect on fasting glucose or HbA1c after
the high-MUFA diet compared with low-fat diet [45]. Brynes and coworkers investigated the eﬀect
of an isoenergetic high-MUFA diet (olive oil) compared with high-PUFA diet (corn oil), on glycemic
regulation in nine overweight subjects [46]. Glycemic control remained stable throughout the study
and there were no change in fasting or postprandial iAUC for glucose or insulin in response to an
identical standard meal after 24 days of intervention [46]. Instead of comparing fat quality, intake of
MUFAs from oil or margarine was compared with intake of carbohydrates from breakfast cereals with
either a high or low glycemic index [47]. After a six-month intervention with 72 subjects there were no
diﬀerences in fasting blood glucose or HbA1c between the groups. After a standard breakfast and
lunch, a reduction in mean 8-h plasma insulin in the group given MUFAs compared with the cereal
group was however observed [47]. During a four-week period, 12 women received an isocaloric diet
high in either MUFAs (HMUFA) or complex carbohydrates (high-CHO). This crossover study had a
four-week washout period during which the subjects followed the American Diabetes Association
(ADA) isocaloric diet. Glycemic control, including fasting blood glucose, insulin and fructosamine
did not signiﬁcantly change with the diﬀerent intervention diets. However, fasting blood glucose and
insulin were reduced within both groups after intervention [49]. The eﬀect of walnut oil on blood
glucose in 90 subjects was investigated in a RCT, lasting for three months [39]. In the experimental
group, walnut oil (15 g/day) was added to the diet, while the control group did not undergo any
intervention. HbA1c level and fasting blood glucose decreased signiﬁcantly in the experiment group
compared with the control group [39].
In summary, six of the 12 studies investigating vegetable oils on glycemic regulation such as
fasting glucose, insulin, HbA1c or markers related to insulin resistance or insulin sensitivity did not
ﬁnd any eﬀects in people with T2D [40,42,44–46,49], although two of the studies found within group
changes [40,49]. In the other six studies however, there were changes in glycemic regulation either
between or within groups [39,41,43,47,49,50]. In contrast to the studies showing a decreasing eﬀect on
glycemic regulation after intervention, the study by Norris et al. found increased fasting glucose levels
and HOMA-IR after intervention with CLA compared with saﬄower oil (control group). However,
saﬄower oil reduced both fasting glucose levels and HOMA-IR within the control group [43]. Even
though CLA, a trans fatty acid, is debated for its possible health eﬀects [65], trans fatty acids in general
are well known for their cholesterol increasing eﬀects [66] and may explain the impaired eﬀects related
to glycemic regulation. Vegetable oils mainly consist of n-6 PUFAs and in particular LA, and other
studies have shown a beneﬁcial eﬀect of n-6 PUFAs on glycemic regulation. A recent pooled analysis
from prospective cohort studies demonstrated that higher levels of LA in blood were associated with a
43% reduced relative risk for T2D [67]. This is in line with the results from the ULSAM study. Men
who developed T2D had a lower proportion of LA and a higher proportion of SFAs (C:14 and C:16) in
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serum cholesterol esters compared with those who did not develop T2D [61]. Summers et al. showed
that switching from a diet rich in SFAs to a diet rich in PUFAs for 5 weeks improved insulin sensitivity
in people with T2D, non-obese and obese subjects [68]. Even though others have found improved
glycemic regulation after intervention with PUFAs, we are not able to draw ﬁrm conclusions based on
the studies included in the present review.
3.3. Nuts
Nuts are high-energy, nutrient-dense foods that are rich in PUFAs and other bioactive components,
including ﬁber, antioxidants, vitamins and minerals [69]. Epidemiological studies have found an
inverse relationship between nut consumption and reduced risk of T2D [70,71]. In the present review,
ﬁve RCTs intervening with diﬀerent nuts (cashew, pistachio, peanuts or mixed nuts) in people with
T2D were included (Table 3).
In the study by Mohan and coworkers, they investigated the eﬀect of a standard diabetic diet
with 30 g cashew nuts per day for 12 weeks on glycemic regulation in 300 subjects [51]. They did not
ﬁnd any signiﬁcant diﬀerences in glycemic regulation (fasting blood glucose, insulin, HbA1c, and
HOMA-IR) after the intervention [51]. In another study, by Parham et al., the eﬀect of pistachio nut
supplementation on glycemic control and inﬂammatory markers was investigated [53]. The study
included 48 subjects in a double blind, randomized, placebo-controlled crossover trial. The subjects
received either 25 g pistachio nuts twice a day or a control diet without nuts for 12 weeks, followed by
an eight-week washout period, before switching interventions. A decrease in HbA1c and fasting blood
glucose was observed after intake of pistachio nuts compared with the control group. There were no
eﬀects on HOMA-IR after intake of pistachio nuts [53]. Also, Sauder and coworkers investigated the
eﬀect of pistachio nuts on glycemic control [52]. They included 30 subjects in a randomized, controlled,
crossover study. After a two-week run-in period, participants consumed diets with pistachio nuts
(contributing with 20% of total energy) or without pistachio nuts (control group) for four weeks
each, separated by a two-week washout period. Glycemic measures were assessed both fasted and
during a 75-g oral glucose tolerance test. There were no eﬀect on fasting glucose, insulin, HbA1c,
HOMA-IR or glucose area under the curve (AUC) or insulin AUC after intake of nuts compared
with control group [52]. Wien and colleagues investigated the eﬀect of incorporating peanuts into
the American Diabetes Association (ADA) meal plan on cardio-metabolic parameters [54]. They
performed a 24-week parallel RCT with 60 subjects. The intervention group received an ADA meal
plan containing about 20% of energy from peanuts, while the control group followed a peanut-free
ADA meal plan. After 24 weeks of intervention, there were no diﬀerences in fasting blood glucose or
HbA1c between the groups. [54]. In a study by Kendall and colleagues, the eﬀect of nut consumption
alone or in combination with white bread on postprandial glycaemia in 14 healthy compared with
10 people with T2D were examined [55]. The participants consumed 30, 60, and 90 g of mixed nuts
alone or in combination with white bread (50 g available carbohydrate). All three doses of mixed
nuts consumed alone signiﬁcantly reduced the glycemic response compared with the control group.
Adding nuts (60 g and 90 g) to white bread signiﬁcantly reduced the glycemic response in healthy
subjects however, signiﬁcant reduction in glycemic response were only observed after adding 90 g
nuts to white bread in people with T2D [55].
Taken together, three of the ﬁve studies investigating intake of nuts and glycemic regulation such
as fasting blood glucose, insulin, HbA1c or markers related to insulin resistance or sensitivity found
beneﬁcial eﬀects in T2D. Pistachio nuts reduced both fasting blood glucose levels and HbA1c [53]
or fructosamine [52], and intervention with mixed nuts led to reduction in postprandial glycemic
response [55]. In these studies, nut consumption beneﬁts glycemic regulation regardless of the
type of nuts, study design or duration. These results are in line with the The Prevención con Dieta
Mediterránea (PREDIMED)-study, in which 30 g nuts per day (almonds, hazelnuts, and walnuts),
given as supplements to a Mediterranean diet, signiﬁcantly reduced the incidence of T2D compared
with a low-fat diet without nut supplementation in high risk subjects [72].
211
Nutrients 2019, 11, 1067
4. Discussion
In the present summary, improvements related to glycemic control in people with T2D were
observed in about half of the studies investigating the eﬀect of ﬁsh, ﬁsh oil, or vegetable oil. Intake of
nuts may however indicate a more beneﬁcial eﬀect, even though the number of studies are limited.
The present review also demonstrates that the studies investigating the eﬀect of PUFAs on glycemic
control in subjects with T2D or NIDDM are quite diﬀerent in design with respect to type of dietary
intervention, study duration, and measurements of glycemic control, and hence the results are diﬃcult
to compare. Most importantly, the intervention and the control food diﬀer largely between the studies.
Of the included studies, mainly vegetable oils (corn, sunﬂower, linseed, and olives) functioned as
control for both ﬁsh and ﬁsh oil interventions, and for diﬀerent vegetable oils. Hence, the studies are
comparing PUFAs of diﬀerent quality. Considering that vegetable oils are high in PUFAs and therefore
may aﬀect glycemic regulation, the lack of eﬀect in several of the included studies may be explained by
the use of an inappropriate control group. It is therefore not possible to conclude whether intake of
marine- or vegetable-derived PUFAs will have a positive eﬀect on glycemic regulation in people with
T2D. In the previous mentioned meta-analysis performed by Imamura et al., intake of PUFAs was
compared with intake of SFAs. Changing the intake of SFAs with PUFAs improved glycaemia and
insulin resistance [19]. SFAs may therefore represent a better control group when investigating the
eﬀect of PUFAs on glycemic regulation. The study by Imamura et al. was however not unique to T2D,
as both healthy and people with T2D were included. This may explain the discrepant ﬁndings between
previous studies and the present review. In addition, Coelho et al. conclude that supplementation
of 0.42–5.2 g PUFAs per day for at least eight weeks may become an alternative treatment for T2D.
However, only six studies were included in the review [20]. In contrast, a meta-analysis from 2011
did not ﬁnd any eﬀect of n-3 PUFA consumption on insulin sensitivity. The study included 11 studies
investigating the eﬀect in both healthy and people with T2D [60]. In addition, ALA-enriched diets did
not aﬀect HbA1c, fasting blood glucose, or insulin in a meta-analysis conducted in people with T2D.
The study included eight interventions [73]. In conclusion, the reported discrepancies between other
studies and this review regarding PUFAs and glycemic control are probably due to the heterogeneity
of the studies.
Even though fat quality has been shown to aﬀect glycemic regulation, it is possible that also fat
quantity will be of importance. Vessby and coworkers reported that a total fat intake of more than 37
E% increases the risk of insulin resistance independent of fat quality [74]. Total fat intake were not
consistently reported in the present reviewed studies, and hence we cannot rule out that a high total
fat intake may have aﬀected the results.
Limitations of the current review includes the search strategy. To ensure that the included studies
had focus on glycemic regulation, the search words “glycemic control” were used. This may have
aﬀected the number of articles and we cannot rule out the possibility that some relevant studies have
not been included. We did however include two studies from other reviews.
5. Conclusions
In the present review, we have identiﬁed studies that show beneﬁcial eﬀects of both marine and
vegetable-derived PUFAs on glycemic control in people with T2D. The studies are however diﬀerent
in design and no ﬁrm conclusions can be drawn. In order to understand the role of PUFAs in the
management of T2D, we suggest more well designed RCTs where the eﬀect of PUFAs speciﬁcally is
compared with the eﬀect of SFAs.
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Abstract: The prevalence of diabetes is increasing globally, and its eﬀect on patients and the healthcare
system can be signiﬁcant. Gestational diabetesmellitus (GDM) and type 2 diabetes arewell established
risk factors for cardiovascular disease, and strategies for managing these conditions include dietary
interventions, such as the use of a low glycemic index (GI) diet. Aims: This review aimed to
evaluate the eﬀects of a low GI diet on the cardio-metabolic and inﬂammatory parameters in patients
with type 2 diabetes and women with GDM and assess whether the eﬀects are diﬀerent in these
conditions. Methods: This review was based on the preferred reporting items for systematic reviews
and meta-analyses (PRISMA) guidelines. Three databases (EMBASE, Pubmed, and PsycINFO)
were searched from inception to 20 February 2019 using search terms that included synonyms and
Medical Subject Headings (MeSH) in line with the population, intervention, comparator, outcomes,
and studies (PICOS) framework. Studies were evaluated for the quality and risk of bias. Results:
10 randomised controlled studies were included in the systematic review, while 9 were selected for
the meta-analysis. Two distinct areas were identiﬁed: the eﬀect of a low GI diet on lipid proﬁle and
the eﬀect of a low GI diet on inﬂammatory parameters. The results of the meta-analysis showed
that there were no signiﬁcant diﬀerences (p > 0.05) between the low GI and higher GI diets with
respect to total cholesterol, HDL, and LDL cholesterol in patients with type 2 diabetes. However,
there was a signiﬁcant diﬀerence (p = 0.027) with respect to triglyceride which increased by a mean of
0.06 mmol/L (0.01, 0.11) in patients with type 2 diabetes on higher GI diet. With respect to the women
with GDM, the ﬁndings from the systematic review were not consistent in terms of the eﬀect of a
low GI diet on the lipid proﬁle. The results of the meta-analysis did not show signiﬁcant diﬀerences
(p > 0.05) between low GI and higher GI diets with respect to adiponectin and C-reactive proteins
in patients with type 2 diabetes, but a signiﬁcant diﬀerence (p < 0.001) was observed between the
two groups in relation to interleukin–6. Conclusion: This systematic review and meta-analysis have
demonstrated that there were no signiﬁcant diﬀerences (p > 0.05) between the low GI and higher GI
diets in relation to total cholesterol—HDL and LDL cholesterol—in patients with type 2 diabetes.
However, a signiﬁcant diﬀerence (p < 0.05) was observed between the two groups with respect to
triglyceride in patients with type 2 diabetes. The results of the eﬀect of a low GI diet on the lipid
proﬁle in patients with GDM were not consistent. With respect to the inﬂammatory parameters, the
low GI diet signiﬁcantly decreased interleukin–6 in patients with type 2 diabetes compared to the
higher GI diet. More studies are needed in this area of research.
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1. Introduction
Globally, there is an increasing prevalence of diabetes, with over 420 million people living with
the condition. This number has signiﬁcant implications for health care provisions due to the impact
of diabetes and its complications on those who have the condition [1,2]. Type 2 diabetes is usually
characterised by insulin deﬁciency due to beta cell dysfunction and often involves insulin resistance [3].
On the other hand, hyperglycaemia ﬁrst detected at any time during pregnancy is classiﬁed either as
diabetes in pregnancy or Gestational Diabetes Mellitus (GDM), and are usually diagnosed based on
the fasting and/or 2 h plasma glucose following a 75 g oral glucose load [4].
Both type 2 diabetes and GDM have implications for carbohydrate, protein and fat metabolism
and may predispose individuals to acute and long-term complications [5]. About half of the women
diagnosed with GDM proceed to develop type 2 diabetes within 5 to 10 years after giving birth [6]. Due
to changing lifestyles, type 2 diabetes is increasingly diagnosed in children [7]. In 2013, over 3.2 million
adults were diagnosed with diabetes in England and Wales, with prevalence rates of 6% and 6.7% in
England and Wales, respectively [7]. In addition, about 90% of adults who are currently diagnosed
with diabetes have type 2 diabetes, with the burden of the disease disproportionally aﬀecting ethnic
minorities, particularly Africans, African-Caribbeans, and South Asians [7].
GDM presents adverse risks to the mother and child during the pre- and post–natal period [4]. It
was estimated that 21.3 million live births had some form of raised blood glucose or hyperglycaemia
in 2017, and about 85.1% of these were due to GDM [6]. This represented about one in every seven
births aﬀected by GDM [6]. In England and Wales, of the estimated 700,000 women who give birth
every year, about 5% have either pre-existing diabetes or GDM [8]. About 87.5% of these women who
have diabetes during pregnancy have GDM [8]. Therefore, management strategies, including dietary
interventions such as the use of a low glycemic index (GI) diet, have been recommended instead of
a higher GI diet, in order to manage hyperglycaemia and mitigate related complications [8]. In our
previous review on the eﬀect of a low GI diet in patients with type 2 diabetes, Ojo et al. [9] found
that a low GI diet was more eﬀective in controlling glycated haemoglobin and fasting blood glucose
compared with a higher GI diet in these patients. Therefore, this current review builds on the earlier
systematic review and meta-analysis [9] by assessing the impact of a low GI diet on lipid proﬁle and
inﬂammatory markers.
Why is it important to do this review? GDM is closely associated with type 2 diabetes, as they
share many key pathophysiological characteristics including progressive insulin resistance [3,10].
In addition, people who develop either type 2 diabetes or GDM have similar risk factors, such as
ethnicity (South Asian or Afro–Caribbean), a high body mass index (BMI), family history, and advanced
age [5,10].
Although low grade inﬂammation and insulin resistance are part of normal physiological
adaptation of pregnancy, these processes are exacerbated in patients with GDM and obesity [11].
Elevated levels of inﬂammatory components, such as tumour necrosis factor alpha (TNF-α), have
been shown to correlate with progressive insulin resistance in pregnancy and are associated with
hyperinsulinaemia in obesity and in patients with type 2 diabetes [10]. The risks associated with GDM,
including postpartum type 2 diabetes, increase with progressive hyperglycaemia [8,12]. Furthermore,
both GDM and type 2 diabetes are well established risk factors for cardiovascular diseases [3,5,13].
This calls for scrutiny and a greater understanding of the role of low GI diets on inﬂammatory
parameters and lipid proﬁles (cardiometabolic parameters) in these patients, as the biomarkers
have implications for insulin resistance and cardiovascular mortality. We know this based on the
knowledge that dietary interventions are useful approaches to managing type 2 diabetes and GDM.
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Therefore, a study should involve an evaluation of the eﬀect, and quality and quantity of the macro
and micronutrients in the foods consumed. Of particular interest is the quality of carbohydrate in the
diets of people with type 2 diabetes or GDM, often linked to its glycemic index (GI). Foods with low
GI may improve glycemic control including the reduction in glycated haemoglobin (HbA1c) through
improvement in peripheral insulin sensitivity [14–19]. However, the evidence regarding the eﬀect of a
low GI diet on lipid proﬁles is still conﬂicting.
Bouchie et al. [20] revealed that 5 weeks of a low GI diet was useful in improving plasma lipids in
non-diabetic men who were moderately overweight. However, in normolipidemic well controlled
patients with type 2 diabetes, Brand et al. [21] observed that low GI diets did not provide improvement
in plasma lipids. Clar et al. [22], in their meta–analysis, noted that there is, presently, no compelling
evidence that shows that low GI diets have signiﬁcant beneﬁcial eﬀects on blood lipids. On the
other hand, Schwingshacki and Hoﬀman [23] demonstrated that a low GI diet has beneﬁcial eﬀects
with respect to pro–inﬂammatory markers, such as C–reactive protein (CRP) which may be useful in
preventing obesity associated diseases. This study involved both patients who had type 2 diabetes and
participants who were non–diabetic. The systematic reviews by Goﬀ et al. [13], Clar et al. [22], and
Fleming and Godwin [24] were based on assessing the eﬀect of low GI diets on lipid proﬁles on either
general participants or those with cardiovascular diseases. No previous review has assessed the eﬀect
of a low GI diet on both lipids and the inﬂammatory proﬁle of patients with type 2 diabetes and/or
GDM. Therefore, the current review evaluates the impact of a low GI diet on the cardio-metabolic and
inﬂammatory parameters in patients with type 2 diabetes and GDM. This is based on the understanding
that the control of cardio-metabolic parameters is a useful approach in managing patients with type 2
diabetes and women with GDM [4,25].
Objectives:
This is a systematic review and meta-analysis which:
• Evaluates the eﬀect of a low GI diet on cardio-metabolic and inﬂammatory parameters in patients
with type 2 diabetes and women with GDM.
2. Methods
This systematic review and meta-analysis was written according to the preferred reporting items
for systematic reviews and meta-analyses (PRISMA) guidelines [26]. The eligibility criteria for paper
inclusion according to type of study, participants, intervention, and outcomes are described below.
Types of Studies:
Randomised controlled studies were the only studies included in this review (Tables 1 and 2).
Type of Participants:
Patients with type 2 diabetes or pregnant women with gestational diabetes were the participants
of interest in all the studies selected (Table 2).
Type of Interventions:
Diets with low GI were compared with diets with higher GI in patients with type 2 diabetes and
in women with GDM. The classiﬁcation of diets as having either low GI or higher GI was based on the
lower GI values of the intervention diets (low GI diet).
2.1. Outcomes of Interest
The primary measures of interest were:
• Cardio-metabolic parameters: total cholesterol (TC) mmol/L, low density lipoprotein (LDL)
cholesterol mmol/L, high density lipoprotein (HDL) cholesterol mmol/L, and triglycerides
(TG) mmol/L.
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The secondary outcome measures were:
• Inﬂammatory parameters: C–reactive protein (CRP) mg/L, Adiponectin mg/L, and Interleukin–6
(IL-6) mg/L.
2.2. Search Terms and Search Strategy
The process of searching for articles for this review relied on the Population, Intervention,
Comparator, Outcome, and Study design (PICOS) approach [27] and involved electronic databases
(EMBASE, Pubmed, and PsycINFO) from inception to 20 February 2019. A number of articles were
identiﬁed through this process by using search terms, including Medical Subject Headings (MeSH)
and synonyms. Boolean operators (AND/OR) were used to combine words and search terms (Table 1).
The reference lists of included articles were manually searched for relevant papers.
2.3. Inclusion and Exclusion Criteria
The criteria for selecting studies are outlined in Table 2. No time or language restriction was
applied. Only primary research studies that were randomised controlled trials were selected for this
review. In addition, studies involving patients with type 2 diabetes or GDM and the use of low GI
diets across the world were included. Those studies not meeting the criteria set out in Table 2 and
the text were excluded from this review. In this regard, studies that had animals, patients with type 1
diabetes, children with diabetes, or healthy adults without diabetes were excluded from the current
review (Table 2). In addition, observational studies and those involving dietary supplements were
excluded. Therefore, a total of 9 studies were included in the meta-analysis (Figure 1).
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2.4. Quality Assessment and Risk of Bias of Included Studies
The Critical Appraisal Skills Programme (CASP) checklist for randomised controlled trials [28]
was used to evaluate the studies. In addition, the Cochrane risk of bias tool [29,30] was used to assess
the methodological quality of the included studies. A grade (or score) was allocated to each trial on
the basis of selection bias, performance bias, detection bias, attrition bias, and reporting bias. This
process involved reviewing details about the similarity at baseline of the groups being compared, the
blindness of the outcome measurement and participants, the randomisation method, dropout rates,
selective reporting, and compliance with the intervention. On the basis of this information, studies
were categorised into three groups: (a) low risk of bias, (b) unclear risk of bias, and (c) high risk of bias.
2.5. Data Extraction and Management
Statistical Analysis
Treatment eﬀects were summarized as the weighted mean diﬀerence (WMD) with standard
deviation by using the absolute change values from baseline to post-intervention for control and
intervention groups. Themeta-analysiswas performed in stata (version 15.0, Stata Corp, College Station,
TX, USA). Fixed-eﬀects models were applied to estimate the overall weighted mean diﬀerence.
All results were presented with a 95% conﬁdence interval (CI) and displayed on a forest plot and
table, and the null hypothesis of no eﬀect was rejected at p ≤ 0.05. In addition to the forest plots, I2
statistics were assessed to quantify the degree of heterogeneity. Values <25% were considered to be
low, 25%–50% moderate, and >50% high. Q statistics was also used to assess heterogeneity. The null
hypothesis of homogeneity was rejected if p < 0.1, given the low power of the test [29].
2.6. Data Inclusion Decisions
Gomes et al. [31] expressed their results as the median and interquartile ranges, which were
converted to means and standard deviations [29]. In addition, for the meta-analysis, the units of
measurements for the lipid parameters were converted to mmol/L, while for the inﬂammatory markers,
they were converted to mg/L. The Grant et al. [32] study was not included in the meta-analysis, as the
information provided showed that there were no signiﬁcant diﬀerences (p > 0.05) between the low GI
and the higher GI groups in terms of lipids and inﬂammatory markers. However, these results were
not expressed in quantitative terms.
3. Results
Ten studies were selected for the systematic review (Table 3), and nine studies were included in
the meta-analysis (Table 4). In addition, while four of the studies were conducted in Canada, two
were carried out in China and one study each was carried out in Brazil, Greece, Malaysia, and the
USA.The total number of subjects in the eight studies included in the meta-analysis in patients with
type 2 diabetes involved 394 participants in the low GI group and 388 participants in the higher GI
group. There were 41 subjects in the low GI group compared with 42 participants in the higher GI
group in the only study on women with GDM.
Based on the systematic review (Tables 3 and 4) and meta-analysis, two distinct areas have
been identiﬁed: the eﬀect of a low GI diet on lipid proﬁles and the eﬀect of a low GI diet on
inﬂammatory parameters.
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3.1. Evaluation of the Risk of Bias of the Studies Selected
Most of the studies demonstrated either a low risk of bias or an unclear risk of bias in all the
domains evaluated (selection bias, performance bias, detection bias, attrition bias, and reporting bias)
(Figure 2). However, Jenkins et al. [34] showed high risk of bias in the area of selection bias (Figure 3).
 
Figure 2. A summary risk of bias graph of included studies.
 
Figure 3. A risk of bias graph for each included study.
3.2. The Eﬀect of a Low GI Diet on Lipid Proﬁle
Grant et al. [32] found no signiﬁcant diﬀerences (p > 0.05) between the low GI group compared to
the higher GI group, with respect to the lipid proﬁle in women with GDM (Table 3). In their study,
Ma et al. [33] observed that the increases in total cholesterol (0.12 versus 0.23 mmol/L) and triglyceride
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(0.41 versus 0.56 mmol/L), and the decrease in HDL cholesterol (−0.01 versus −0.11), were signiﬁcantly
lower (p < 0.05) than the higher GI group in women with GDM (Table 4).
In patients with type 2 diabetes, the results of the meta-analysis showed no signiﬁcant diﬀerences
(p > 0.05) between the low GI and higher GI groups with respect to HDL with a mean diﬀerence of
0.00 mmol/L (−0.02, 0.02) and LDL cholesterol with a mean diﬀerence of −0.14 mmol/L (−0.37, 0.09)
(Figures 4 and 5, respectively).
Figure 4. A forest plot showing the eﬀects of a low GI diet on HDL cholesterol (mmol/L).
Figure 5. A forest plot showing the eﬀect of a low GI diet on LDL cholesterol (mmol/L).
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In addition, the ﬁndings from the meta-analysis found no signiﬁcant diﬀerence (p > 0.05) between
the two groups in relation to the total cholesterol which decreased by a mean of −0.08 mmol/L (−0.31,
0.16) (Figure 6) in the lowGI group. The results showed that there was a signiﬁcant diﬀerence (p = 0.027)
with respect to triglycerides, which increased by a mean of 0.06 mmol/L (0.01, 0.11) in patients with
type 2 diabetes in the higher GI group (Figure 7).
Figure 6. A forest plot depicting the eﬀect of a low GI diet on Total Cholesterol (mmol/L).
Figure 7. A forest plot depicting the eﬀect of a low GI diet on Triglyceride (mmol/L).
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3.3. The Eﬀect of a Low GI Diet on Inﬂammatory Parameters
According to Grant et al. [32], there was no signiﬁcant diﬀerence (p > 0.05) between the low GI
and higher GI groups in relation to the C–reactive protein in women with GDM. In patients with
type 2 diabetes, Gomes et al. [31] and Cai et al. [40] found that a low GI diet can reduce or prevent
the inﬂammatory responses induced by a high GI diet. In addition, a low GI diet has been shown to
reduce C–reactive protein levels signiﬁcantly compared to a high GI diet [37,39].
With respect to serum interleukin–6 and adiponectin, Argiana et al. [39] did not ﬁnd signiﬁcant
diﬀerences in both groups between week 0 and week 12 in patients with type 2 diabetes. The results of
the meta-analysis did not show signiﬁcant diﬀerences (p > 0.05) between low GI and higher GI diets
with respect to adiponectin and C-reactive protein in patients with type 2 diabetes (Table 5). However,
a signiﬁcant diﬀerence (p < 0.001) was observed between the two groups in relation to interleukin–6
(Table 5), with the low GI diet decreasing interleukin–6 by a mean of −1.01 mg/L (−1.55, −0.48). A
meta-analysis was not conducted for the patients with GDM with respect to inﬂammatory parameters
due to the limited number of studies.
Table 5. Results of a meta-analysis of the eﬀect of a low GI diet on inﬂammatory parameters.
Outcomes
Patients with Type 2 Diabetes
N Studies Weighted Mean Diﬀerence (95% CI) mg/L p-Value I2 %
Interleukin–6 2 −1.01 (−1.55, −0.48) 0.001 0.0
C–eactive Protein 5 −0.32 (−1.17, 0.53) 0.467 0.0
Adiponectin 2 0.01 (−0.00, 0.03) 0.072 0.0
4. Discussion
The results of the two studies [32,33] that evaluated the eﬀects of low GI diets on lipid proﬁles
in women with GDM were not consistent. While Grant et al. [32] did not ﬁnd signiﬁcant diﬀerences
(p > 0.05) between the low GI and higher GI groups in relation to lipids, Ma et al. [33] found signiﬁcant
diﬀerences (p < 0.05) between the two groups with respect to total cholesterol, triglycerides, and HDL
cholesterol. On the other hand, the results of the meta-analysis showed that there were no signiﬁcant
diﬀerences (p > 0.05) between the low GI diet and higher GI group with respect to total cholesterol,
HDL, and LDL cholesterol in patients with type 2 diabetes (although the diﬀerence was statistically
signiﬁcant (p < 0.05) in relation to triglycerides, with higher GI diet increasing triglyceride levels). The
diﬀerences observed between the eﬀects of a low GI in patients with GDM compared to patients with
type 2 diabetes in some of the metabolites may due to the limited number of studies in the current
review and the diﬀerences in the pathophysiology of both conditions. In a previous meta-analysis,
Fleming and Godwin [24] revealed that a low GI diet may help lower total cholesterol and LDL
cholesterol. In addition, Goﬀ et al. [13] found that low GI diets reduced total and LDL cholesterol
and had no eﬀect on HDL cholesterol and triglycerides. It is possible that the diﬀerences between
the current review and the previous reviews in relation to some of the metabolites may be due to the
participants included in the studies. While this review was based only on patients with GDM and
type 2 diabetes, the earlier reviews were based on the general population [24] or included participants
without diabetes [13].
The results of the eﬀect of a low GI diet on inﬂammatory markers were variable in the studies
selected in patients with GDM. However, the results of the meta-analysis showed that diﬀerences
between low GI and higher GI groups were only signiﬁcant (p < 0.05) in relation to interleukin–6, which
decreased in the low GI group in patients with type 2 diabetes. These results are discussed below.
4.1. The Eﬀect of a Low GI Diet on Lipid Proﬁle
There appears to be controversy regarding the role of low GI diets in the prevention of
cardiovascular diseases. The eﬀect of GI on total cholesterol, LDL, and HDL cholesterol is not
quite clear [39,41]. For example, in women with GDM, Grant et al. [32] reported no signiﬁcant
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diﬀerences (p > 0.05) between the low GI and higher GI groups with respect to the lipids in women
with GDM. However, Ma et al. [33] found that low GI diets improved blood lipids.
In patients with type 2 diabetes, Gomes et al. [31] found that a low GI diet reduced body fat. In the
study by Jenkins et al. [34], it was observed that HDL cholesterol increased by 1.7 mg/dL in the low GI
group and decreased by −0.2 mg/dL in the higher GI group (p = 0.005). In contrast, Wolever et al. [37]
noted that HDL cholesterol was 4% lower in the low GI group, while the higher GI values were
intermediate. Other studies [35,36,38] demonstrated no signiﬁcant diﬀerence between the low GI and
higher GI groups in relation to HDL cholesterol.
According to Jenkins et al. [35], low GI legumes produced signiﬁcant decreases in total cholesterol
level (p < 0.001) in patients with type 2 diabetes. The relative reduction in total cholesterol level
was greater in the low GI legume diet group compared with the higher GI group [35]. However,
Ma et al. [36] and Wolever et al. [37] did not ﬁnd a signiﬁcant diﬀerence between low GI and higher GI
diets with respect to the total cholesterol in patients with type 2 diabetes.
Jenkins et al. [35] demonstrated that a lowGI legumeproduced signiﬁcant decreases in triglycerides
(p < 0.001) in patients with type 2 diabetes. Decreases in triglycerides in the low GI group were also
reported by Yusof et al. [38], although Wolever et al. [37] showed increased levels of triglycerides in the
low GI group. On the other hand, Ma et al. [36] found no signiﬁcant diﬀerence between low GI and
higher GI with respect to triglycerides.
The mechanism by which dietary GI inﬂuences blood lipids has not been entirely elucidated [42].
This may explain the diﬀerences in the ﬁndings of the various studies. However, it has been suggested
that high GI diets increase non esteriﬁed fatty acid concentrations after intervention compared to
baseline, and increased levels of non-esteriﬁed fatty acids can cause beta cell dysfunction, insulin
resistance, and reduced glucose uptake [31]. In other words, elevated levels of blood glucose, insulin,
and free fatty acids following a high GI diet can induce insulin resistance, which could lead to increased
triglyceride, a greater inﬂammatory response, and a decrease in HDL cholesterol [43,44].
Hyperinsulinaemia and insulin resistance are signiﬁcantly correlated to dyslipidaemia and
contribute to the changes in the plasma lipid proﬁle [45]. Therefore, the potential eﬀects of a low GI diet
on cardiometabolic parameters may be caused by a reduction of hyperglycaemia, hyperinsulinaemia
and levels of free fatty acids, which could lead to a reduced risk of insulin resistance, beta cell
dysfunction, dyslipidaemia, and inﬂammatory response [45,46].
4.2. The Eﬀect of a Low GI Diet on Inﬂammatory Parameters
Based on the ﬁndings of the meta-analysis in relation to the inﬂammatory parameters, low GI diets
signiﬁcantly decreased (p < 0.05) levels of interleukin-6 compared with the higher GI diets in patients
with type 2 diabetes. Diﬀerences between the two groups were not statistically signiﬁcant (p > 0.05)
with respect to C-reactive proteins. The mechanism for this ﬁnding, with respect to interleukin-6, may
due to hyperglycaemia in the higher GI group, which induces the release of inﬂammatory cytokines
from monocytes [47]. Furthermore, the exposure of endothelial cells to varying levels of glucose
concentration can increase the risk of oxidative stress and apoptosis and thus lead to the production of
pro-inﬂammatory cytokines [39,48,49]. The results of this review conﬁrm the ﬁndings of a previous
study by Juanola-Falgaroma et al. [50], which found that subjects allocated a low GI diet showed
signiﬁcantly higher decreases in interleukin–6 after intervention.
This review has both clinical and public health implications in terms of our understanding of the
role low GI diets in the management of cardiometabolic and inﬂammatory parameters in patients
with diabetes.
5. Limitations
Although a total of nine studies were included in the meta-analysis, this number was limited
by the two sub-groups of GDM and type 2 diabetes. More studies in each of the sub-groups would
have further enhanced the wider application of the ﬁndings of this review. In addition, the lack of a
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consensus on what constitutes a low GI diet, and the variation in the GI levels of dietary interventions
in the studies included, may have impacted the analysis of the ﬁndings of this review.
6. Conclusions
This systematic review and meta-analysis have demonstrated that there were no signiﬁcant
diﬀerences (p > 0.05) between low GI and higher GI diets in relation to total cholesterol, HDL, and LDL
cholesterol in patients with type 2 diabetes. However, a signiﬁcant diﬀerence (p < 0.05) was observed
between the two groups with respect to triglycerides in patients with type 2 diabetes. The results of
the eﬀect of a low GI diet on the lipid proﬁle in patients with GDM were not consistent. With respect
to the inﬂammatory parameters, the low GI diet signiﬁcantly decreased interleukin–6 in patients with
type 2 diabetes than the higher GI diet. More studies are needed in this area of research.
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Abstract: The aim of this review was to investigate existing guidelines and scientiﬁc evidence on
determining insulin dosage in people with type 1 and type 2 diabetes, and in particular to check
whether the prandial insulin dose should be calculated based on glycemia or the meal composition,
including the carbohydrates, protein and fat content in a meal. By exploring the effect of the meal
composition on postprandial glycemia we demonstrated that several factors may inﬂuence the
increase in glycemia after the meal, which creates signiﬁcant practical difﬁculties in determining
the appropriate prandial insulin dose. Then we reviewed effects of the existing insulin therapy
regimens on glycemic control. We demonstrated that in most existing algorithms aimed at calculating
prandial insulin doses in type 1 diabetes only carbohydrates are counted, whereas in type 2 diabetes
the meal content is often not taken into consideration. We conclude that prandial insulin doses in
treatment of people with diabetes should take into account the pre-meal glycemia as well as the size
and composition of meals. However, there are still open questions regarding the optimal way to
adjust a prandial insulin dose to a meal and the possible beneﬁts for people with type 1 and type 2
diabetes if particular parameters of the meal are taken into account while calculating the prandial
insulin dose. The answers to these questions may vary depending on the type of diabetes.
Keywords: carbohydrate counting; protein and fat counting; insulin dosage; glucose monitoring;
diabetes mellitus; type 1 diabetes; type 2 diabetes
1. Introduction
In healthy people, fasting plasma glucose rarely reaches 5.5 mmol/L (100 mg/dL) and the highest
values after meals do not exceed 7.8 mmol/L (140 mg/dL), and quickly return to the starting level [1].
Hyperglycemia deﬁnes diabetes, and glycemic control plays an important role in the treatment of
diabetes. Type 1 and type 2 diabetes are the two main types of the disease, which affects more
than 425 million people worldwide [2]. Consistent hyperglycemia can lead to serious micro- and
macrovascular complications, which cause diseases affecting the heart and blood vessels, kidneys,
eyes, nerves and teeth. In addition, people with diabetes also have a higher risk of developing
infections. In almost all high-income countries, diabetes is a leading cause of cardiovascular disease,
blindness, kidney failure, and lower limb amputation. The premature morbidity, mortality, reduced
life expectancy, and ﬁnancial and social costs of diabetes make it one of the most important public
health conditions [3]. The goals of treatment for diabetes are to prevent or delay complications,
decrease mortality and maintain quality of life. An adequate glycemic control is a way of achieving
these goals. In the American Diabetes Association (ADA) recommendations [4] for the majority of
adults with diabetes (excluding pregnant women), the glycated hemoglobin A1c (HbA1c) below 7.0%
(53 mmol/mol), preprandial blood glucose concentration in the range from 4.4 to 7.2 mmol/L (from
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80 to 130 mg/dL) and after meals—below 10.0 mmol/L (180 mg/dL) were accepted as target values.
At the same time, the recommendations underline that more or less stringent targets may be taken into
account. They should be individualized depending on the duration of diabetes, age, life expectancy,
co-morbid medical conditions, cardiovascular complications or advanced microvascular complications,
occurrence of the hypoglycemic unawareness, as well as the individual expectations of the person
with diabetes. It should be noted that in recent years, organizations such as The National Institute for
Health and Care Excellence (NICE) [5], Institute for Clinical Systems Improvement (ICSI) [6], American
Association of Clinical Endocrinologists and American College of Endocrinology (AACE/ACE) [7,8],
Scottish Intercollegiate Guidelines Network (SIGN) [9], and the U.S Veterans Affairs/Department of
Defense (SIGN) [10] have indicated that the target values of HbA1c are differentiated depending on
the individual characteristics of people with diabetes. In its recently published recommendations,
the American College of Physicians proposed target values of HbA1c for most people with type 2
diabetes in the range of 7.0% to 8.0% (53 to 64 mmol/mol) [11]. In a commentary from Diabetes
Care, Matthew C. Riddle and colleagues [12] indicate the necessity to evaluate established and newer
therapeutic options based on many years of observation, which will optimize the individualization of
both goals and methods of therapy. The therapeutic goals set by ADA seem balanced and reasonable,
they are broadly in line with the guidelines of other scientiﬁc societies. The HbA1c concentration below
7.0% (53 mmol/mol) is the accepted target value for the majority of patients with diabetes, excluding
pregnant women. The possibility of achieving a more stringent goal of treatment, i.e., HbA1c below
6.5% (48 mmol/mol) for a group of patients who can achieve this goal without an increased risk of
hypoglycemia or other adverse effects of the treatment as well as taking into account less stringent
values of HbA1c, e.g., below 8.0% (64 mmol/mol) for older people are good examples of individualized
therapeutic goals. Recommendations of the Polish Diabetes Association include similar individualized
therapeutic goals [13]. Therapy adjustments should be made to maximize the proportion of time that
glycemia is within the optimal range, i.e., between 3.9 and 10.0 mmol/L (70 and 180 mg/dL) for most
patients [14]. A study of Bode et al. in people with type 1 and type 2 diabetes with HbA1c of 7.5%
(58 mmol/mol) showed that 29% of blood glucose values exceeded 10.0 mmol/L (180 mg/dL) [15].
The postprandial blood glucose testing and evaluation is particularly important if the HbA1c target is
not achieved despite satisfactory pre-meal glycemia. The postprandial glucose measurements should
be made 1–2 h after the beginning of the meal and using treatments aimed at reducing postprandial
plasma glucose values to <10.0 mmol/L (180 mg/dL) may help to lower HbA1c [4].
What is the real effect of the diet on the postprandial glycemia? Can we assess the effect of
carbohydrates, fat and protein, and meals with a high or low glycemic index (GI) on postprandial
glycemia? Are there differences that are related to the type of diabetes? In this review, we have
attempted to answer these questions, based on the existing guidelines and available scientiﬁc evidence,
to see if the prandial insulin dose should be calculated based on glycemia or the size and composition
of a meal including carbohydrates, protein and fat content in the meal. We investigated the effect of
macronutrient content in a meal on postprandial glycemia and we identiﬁed factors that may make it
difﬁcult to determine the appropriate dose of insulin to compensate for food intake in people with
diabetes. Then we reviewed effects of the existing insulin therapy regimens on glycemic control and
we assessed existing algorithms aimed at calculating prandial insulin doses in people with type 1
and type 2 diabetes. Finally, we concluded the work and asked questions which are still waiting
for answers.
2. Effect of Fat, Protein and Carbohydrates in a Meal on Postprandial Glycemia
In type 1 diabetes, fat reduces the early glucose response (the ﬁrst 2–3 h after the meal) and
delays the peak blood glucose due to the delayed gastric emptying. In type 1 diabetes, fat leads to
late post meal (>3 h) hyperglycemia [16]. In children with type 1 diabetes, adding 35 g of fat to the
meal can increase the blood glucose level by 2.3 mmol/L (41 mg/dL) [17]. Fat consumption increases
the need for insulin and requires an individual increase of the insulin dose with caution, and the
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calculation of the necessary insulin dose should take into account the duration of insulin action [18].
While paying attention to prevent late after-meal hyperglycemia, one should remember the risk of
early hypoglycemia immediately after the meal. Campbell et al. demonstrated in type 1 diabetic
patients that increasing the mealtime insulin is not an efﬁcient strategy alone because it may increase
the risk of early postprandial hypoglycemia [19].
Total and saturated fat intake were associated with a higher risk of type 2 diabetes, but these
associations were not independent of obesity [20]. Dietary fat and free fatty acids (FFA) are known to
impair insulin sensitivity and enhance hepatic glucose production [21]. Limited results are available
on the fat effects on gastric emptying and postprandial glycemia in people with type 2 diabetes.
Gentilcore et al. demonstrated that ingestion of fat before a carbohydrate meal resulted in slower gastric
emptying and attenuated postprandial rises in glucose, insulin, and glucose-dependent insulinotropic
polypeptide but it stimulated glucagon-like peptide-1 (GLP-1) in type 2 diabetes [22].
Protein consumption affects the blood glucose concentration in the late postprandial period. In
people with type 1 diabetes using intensive insulin therapy 75 g or more of protein alone signiﬁcantly
increases postprandial glycemia from 3 to 5 h in people with type 1 diabetes [23]. Moreover, protein
has different effects when consumed with and without carbohydrates, e.g., 30 g of protein with
carbohydrates will affect blood glucose [16,17].
In type 2 diabetes, protein when consumed without carbohydrates has a very small effect on the
level of glucose in the blood. In people with type 2 diabetes, after ingesting 50 g of protein the glucose
response to protein remains stable for 2 h and then begins to decline [24]. Protein does not result in
an increase of the blood glucose concentration, and it results in only a modest increase in the rate of
glucose disappearance [25].
Meals with a high GI cause a rapid increase in glycemia. An inadequate insulin dose that does
not take into account the rapid absorption of carbohydrates after consuming foods with a high GI may
lead to a rapid increase in the blood glucose concentration.
Foods with a low GI cause a smaller increase in the glucose level, reducing the peak of glycemia,
but at the same time it was demonstrated that such foods increase the risk of hypoglycemia after the
meal in people with type 1 diabetes if taken with inadequate doses of insulin [16]. Three studies in
people with type 1 diabetes suggested that the risk of mild hypoglycemia is greater with low GI than
with high GI foods when the usual carbohydrate-to-insulin ratio is used [26–28]. However, low GI
diets can signiﬁcantly improve metabolic control in less than optimally controlled people with type 1
and type 2 diabetes, as indicated by the results of a meta-analysis reported by Thomas and Elliott [29].
The twelve included studies in this meta-analysis involved a total of 612 participants. Three studies
had participants with type 1 diabetes, 8 studies had participants with type 2 diabetes, and one study
had participants with either type 1 or type 2 diabetes. Low GI diets lower HbA1c levels by 0.4%
compared with comparison diets, i.e., high GI diet in 10 studies, measured carbohydrate exchange
diet in one study, and a high-cereal ﬁber diet in another study. Nevertheless, it should be remembered
that eating a large amount of high carbohydrate foods with a low GI can lead to a signiﬁcant increase
in glycemia. A similar effect is observed after eating foods with a low GI but with a high content of
fructose or sucrose, e.g., fruit juices.
The following questions should be asked: what do we know about the effects of individual
components of the diet on postprandial glycemia in people with diabetes and is this knowledge
necessary for us to effectively control it?
In a study reported in 2004, the effect of two diets on a 24-h glycemia and insulinemia proﬁles was
compared in people with untreated type 2 diabetes [30]. The control diet was developed in accordance
with the recommendations of the American Heart Association and the US Department of Agriculture,
and it consisted of 55% carbohydrates with emphasis on products containing starch, 15% protein
and 30% fat, including 10% monounsaturated, 10% polyunsaturated and 10% saturated fatty acids.
The test diet was designed to consist of 20% carbohydrates, 30% protein and 50% fat. The content
of saturated fatty acids in this diet was ~10% of the total food energy. Mean blood glucose values
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determined after 5 weeks of the dietary treatment were signiﬁcantly lower in patients using the test
diet compared to those using the control diet, 7.0 mmol/L (126 mg/dL) vs. 10.5 mmol/L (190 mg/dL).
The control diet caused a higher increase of the insulin concentration in the blood. Thus, the diet
with the carbohydrate restriction consumed for 5 weeks dramatically reduced blood glucose levels
in people with type 2 diabetes. However, it should be emphasized that the study was conducted in
people with untreated diabetes. Studies on the effect of various diets on glycemic control in people
with type 2 diabetes treated with insulin have not been conducted so far, and thus—are required.
Low-carbohydrate diets (LCD) are recognized as “no side effects” diets in the newest consensus report
of ADA and the European Association for the Study of Diabetes (EASD) [31]. However, in the same
consensus report the systematic literature review and meta-analysis of Sainsbury et al. is cited, which
indicates that LCDs (26% of total energy) in people with type 1 and type 2 diabetes produce substantial
reductions in HbA1c at 3 months and 6 months, with diminishing effects at 12 and 24 months and that
no beneﬁt of moderate carbohydrate restriction (26%–45%) was observed in 25 randomized controlled
trials involving 2415 participants that were included in the meta-analysis [32]. Moreover, Mizidi et al.
demonstrated the unfavorable effect of LCDs on total and cause-speciﬁc mortality, based on both
individual data and pooling previous cohort studies. These authors concluded that given the fact that
LCDs may be unsafe, it would be currently preferable not to recommend such diets [33]. On the other
hand, several cohort studies showed that high carbohydrate diets (HCD) might be associated with
higher risk of total mortality and cardiovascular disease [34,35].
The composition of the diet isn’t the only factor that affects the blood glucose after a meal.
In people with poorly controlled type 2 diabetes, reducing consumption of carbohydrates during
breakfast and increasing it during lunch helps to improve glycemic control. By choosing one of
meals with the highest carbohydrate content, while keeping the same daily intake of carbohydrates, a
different therapeutic effect can be obtained [36].
The order in which foods containing various amounts of carbohydrates, protein and fat are
consumed also affects the postprandial glucose level. Shukla et al. studied people with type 2 diabetes,
who have been receiving the same meal consisting of carbohydrates, protein and vegetables for three
days and consumed it in a random order: ﬁrst carbohydrates, then after 10 min protein and vegetables
or ﬁrst protein and vegetables, then after 10 min carbohydrates or all components of the meal at the
same time. It was shown that peaks of the glucose rise after the meal were more than 50% lower, with
a simultaneously lower increase of insulinemia and higher secretion of GLP-1 when carbohydrates
had been consumed as the last part of the meal in comparison with consumption of carbohydrates
at the beginning of the meal [37]. The order of consuming food products affects also concentration
of ghrelin—the “hunger hormone” which has orexigenic and adipogenic properties and is thought
to play an important role in regulating food intake and body weight. Shukla et al. showed that the
intake of carbohydrates at the beginning of the meal led to the restoration of postprandial ghrelin
concentration in the postprandial period [38]. This effect was not found when the meal was started
by serving protein and vegetables. Ghrelin secretion is suppressed immediately after a meal, the
depth and duration of the suppression being proportional to the energy intake. Insulin may suppress
circulating ghrelin independently of glucose [39]. Taking carbohydrates at the beginning of a meal
shortens the period of suppression of ghrelin, which may result in shortening the period of feeling
satiety, speeding up the next meal, and consequently leading to weight gain.
All these data indicate that a few factors may inﬂuence the increase in glycemia after the meal,
which creates signiﬁcant practical difﬁculties in determining the appropriate dose of insulin to
compensate for food intake in people with diabetes.
3. Automatic Bolus Calculators in People with Type 1 Diabetes
People with type 1 diabetes treated with insulin pumps may use an automatic bolus calculator
that allows them to determine the insulin dose based on the amount of carbohydrates consumed
in the meal and an individual insulin sensitivity. The use of the bolus calculator in patients treated
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with multiple insulin injections resulted in a signiﬁcant improvement of the metabolic control while
the number of hypoglycemic episodes was slightly reduced [40]. There are some promising new
applications of the emerging technologies in this ﬁeld like the expert system using the automatic
speech-to-text conversion, which is able to determine the caloricity, the content of carbohydrates, fat
and protein in the meal in a fairly accurate way based on its voice description provided by the user.
Such a system is an easy-to-use support tool in the type 1 diabetes treatment that makes it possible to
improve the postprandial glycemic control [41,42]. This system can also be useful in people with type 2
diabetes to control the amount of food consumed or adjust insulin dosage. Other systems that attempt
to calculate the meal content based on its digital image [43,44] or the monitoring of activities related to
consumption of the meal, e.g., swallowing or chewing [45] are also under development and testing.
Regardless of how the meal content is determined and entered, each automatic bolus calculator must
implement an algorithm determining the insulin dose, which should be able to control postprandial
glucose concentration. The review of such algorithms for people with type 1 diabetes can be found for
example in a report of Krzymien et al. [46].
In people with type 1 diabetes, prandial insulin doses are individualized using parameters such
as the insulin-to-carbohydrates ratio, and much less frequently, the circadian ﬂuctuations of this
parameter. However, in most algorithms the meal is characterized just by carbohydrate content despite
the fact that new insights concerning the effect of dietary macronutrients on postprandial glycemia
conﬁrm that fat and protein content should be taken into consideration while calculating prandial
insulin doses [16,47,48]. Pankowska and Blazik showed that the insulin bolus calculator with an
algorithm accounting for carbohydrates and protein and/or fat in the meal could effectively suggest a
normal or a square-wave bolus and indicate the timing of the square-wave bolus in the insulin pump
users [49]. The same authors demonstrated in a 3-month open label randomized control study that the
use of this system by educated children and adolescents with type 1 diabetes was safe and reduced 2-h
postprandial blood glucose level and glucose variability [50].
Summing up, the improvement in the postprandial plasma glucose control in people with type 1
diabetes depends primarily on properly adjusting the insulin dose to the meal being consumed.
4. Inter-Subject Variability of a Response to Meals
The algorithms that have been implemented in automatic bolus calculators so far have not
accounted for variability in the response to meals with identical carbohydrate content. In 2015, Zeevi
et al. demonstrated on an 800-person cohort of individuals aged 18–70 not previously diagnosed
with diabetes that people eating identical meals presented high variability in post-meal blood glucose
responses. These authors showed that personalized diets created with the help of an accurate predictor
of the blood glucose response integrating parameters such as dietary habits, physical activity, and
gut microbiota might successfully lower postprandial blood glucose concentration and its long-term
metabolic consequences [51]. In the same report authors developed a machine-learning algorithm
accurately predicting personalized postprandial glycemic responses to real-life meals based on blood
parameters, dietary habits, anthropometrics, physical activity, and the gut microbiota. These results
indicate that it may be beneﬁcial to incorporate such a personalized meal-dependent predictor of the
postprandial glycemia into automatic insulin bolus calculators. However, we must emphasize that in
the work of Zeevi et al., the study group consisted of a healthy population and it should be conﬁrmed
that the ﬁndings are equally valid in people with diabetes before they can be used to optimize the
diabetes treatment. Recently, Rozendaal et al. demonstrated that the large variability in postprandial
glycemic response dynamics to different types of food is inadequately predicted by existing glycemic
measures such as the Glycemic Index, the Glycemic Load and the Glycemic Glucose Equivalents [52].
They quantitatively described the postprandial glycemic response dynamics using a physiology-based
dynamic model. Although both these reports were based on data of people without diabetes, their
conclusions admittedly should be applicable also to people with type 1 diabetes. The conclusions from
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the recent studies on variability of postprandial glucose response, if conﬁrmed in people with diabetes,
should result in more personalized algorithms for prandial insulin dose calculation in the future.
5. Insulin Therapy in People with Type 2 Diabetes
Insulin therapy in people with type 2 diabetes is signiﬁcantly different from that used to treat
people with type 1 diabetes. Typically, the treatment starts with the basal insulin and is directed to
the fasting blood glucose control [53]. The fasting glucose is closely controlled by regulating hepatic
glucose production with variable release of insulin into the portal vein, and with modulation of
insulin action in the liver by glucagon and FFA [54,55]. In type 2 diabetes, the basal insulin secretion
is impaired, and FFA and the fasting glucagon levels are high. An injection of long-acting insulin
inhibits glucose production in the liver by acting directly on the liver and indirectly by reducing the
release of FFA from adipose tissue [56,57]. In untreated type 2 diabetes, the HbA1c level depends
primarily on fasting glycemia. The postprandial glucose concentration is less inﬂuential, especially
in cases where the HbA1c level is greater than 8.0% (64 mmol/mol) [58]. In type 2 diabetes, most
of the hypoglycemic agents used allow effective control of the fasting blood glucose. Metformin,
sulfonylureas, thiazolidinediones and basal insulins (human NPH and insulin glargine, detemir,
degludec) have little effect on postprandial hyperglycemia. Starting the basal insulin therapy is very
simple. Normally, oral medications that have been used before initiation of the insulin therapy are
given with insulin at a dose of 10 U or 0.1–0.2 U/kg of the body weight. The daily dose is then adjusted
based on the fasting glycemia to obtain an individually determined fasting glucose target by increasing
it in steps of 10% to 15% or 2 to 4 U once or twice a week. In the case of hypoglycemia, the dose is
usually reduced by 4 U or 10% to 15% [59]. Yki-Järvinen et al. performed a study in patients with
type 2 diabetes treated with one or two oral preparations with an average baseline HbA1c value of
9.5% (80 mmol/mol). After 36 weeks of active administration of insulin glargine and metformin, a
signiﬁcant improvement in metabolic control and a reduction in the fasting glucose was achieved.
During the last 12 weeks the fasting plasma glucose averaged 5.8 mmol/L (104 mg/dL), and the
mean HbA1c value was 7.14% (54 mmol/mol) at the end of the study period implying that half of the
study group remained inadequately controlled (HbA1c > 7%), mainly due to hyperglycemia during
the day [60]. The insulin treatment of people with type 2 diabetes requires normalization of both
fasting and postprandial glycemia [61]. Failure to achieve HbA1c targets requires intensiﬁcation of the
therapy by choosing one of two therapeutic options, administering insulin mixtures twice a day, or
administering fast-acting insulin before the largest meal.
For the treatment with insulin mixtures, the following principles established by ADA should be
followed in the majority of people with type 2 diabetes [59]:
• Initially, the usual dose of the basal insulin should be divided, and 2/3 of the dose should be
administered before the morning and 1/3 of the dose before the evening meal.
• The insulin dose should be adjusted by adding 1 to 2 U or 10% to 15% once or twice a week until the
target values in the glucose self-monitoring are obtained. In case of 4 blood glucose measurements
per day, the insulin dose before the breakfast should be adjusted to control the blood glucose
concentration after lunch and before supper, and the dose administered before the dinner should
be changed to control the blood glucose measured before bedtime and before breakfast.
• If hypoglycemia occurs, the appropriate insulin dose should be reduced by 2 to 4 U or 10% to 20%.
Recommendations for choosing dosage of insulin mixtures are similar to those of basal insulin,
and dose adjustments depend on the results of blood glucose measurements. It is assumed that patients
treated with insulin mixtures should eat meals at a similar rate of calories. It should also be noted
what part of the mixture is short-acting or fast-acting insulin. A randomized study performed by
Chen et al. showed that insulin mixtures containing 50% of the fast-acting analogue are much more
effective in treating patients using higher carbohydrate diets [62]. This is reﬂected in the summary of
clinical recommendations on the use of insulin mixtures in the treatment of type 2 diabetes, indicating
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that in some patients Mix50 mixtures may be more appropriate than Mix25/30 mixtures, and clinicians
should consider not only efﬁcacy and safety, but also traits and patient preferences during insulin
treatment of people with type 2 diabetes [63].
In healthy people after eating a meal, insulin releases quickly and signiﬁcantly increases, which
is accompanied by an increase in the secretion of amylin (another hormone besides insulin, which is
produced by β cells), which inhibits the secretion of glucagon, slows gastric emptying and causes a
feeling of satiety. An important role is also played by various gastro-intestinal peptides, including
GLP-1, which also inhibit the release of glucagon, such as amylin, and slow the emptying of the
stomach and lead to a feeling of fullness. In people with type 2 diabetes, the release of insulin after
a meal is slower, no increase is observed as in healthy people, the peak of insulin secretion occurs
90 to 120 min after starting the meal whereas in healthy people it is observed within the ﬁrst 30 min.
The increase in amylin secretion is also delayed and reduced, which, as a consequence, does not lead
to suppression of glucagon, slowing gastric emptying and limiting food intake (no feeling of fullness).
The secretion or action of GLP-1 may also be impaired [64]. Many individuals with type 2 diabetes
may require mealtime bolus insulin dosing in addition to basal insulin. The dose and duration of
action of prandial insulin should correspond to the need for adequate glycemic control. In many cases,
meals vary greatly in terms of composition, size and time of consumption. Inappropriate therapeutic
decisions regarding insulin dosing may lead to signiﬁcant hyperglycemia or hypoglycemia. It should
also be remembered that the exogenous insulin injection leads to inhibition of endogenous insulin and
amylin secretion, reducing the feeling of satiety, leading to increased food intake and the body weight
gain. In the case of a signiﬁcant reduction in endogenous insulin and amylin secretion, treatment with
insulin administered before meals is very difﬁcult.
A lack of ability to achieve adequate glycemic control (HbA1c) during the treatment with basal
insulin is a signal, besides the possibility of treatment with insulin mixtures, for administration of a
fast-acting analogue before the largest meal, i.e., the use of the basal-plus insulin regimen. Usually
an analogue is administered at a dose of 4 U, 0.1 U/kg or 10% of the basal insulin dose. If HbA1c is
lower than 8.0% (64 mmol/mol) during this period, a reduction in the basal insulin dose should be
considered. Then the dose should be adjusted by 1 to 2 U or 10% to 15% once or twice a week until
the target values in self- control are achieved. In the presence of hypoglycemia and the diagnosis of
the cause, the dose is reduced by 2 to 4 U or by 10% to 20%. It is a simple treatment that is easily
accepted by patients [59]. On average, after adding a single dose before one meal, a reduction of
HbA1c by 0.3 to 0.5% (3.3 to 5.5 mmol/mol) is observed. At the beginning of the treatment, the
addition of a single injection of insulin is usually just as effective as using two injections, but with a
lower risk of hypoglycemia and similar glycemic control is achievable as in the case of insulin delivery
in multiple injections [65,66]. A good therapeutic effect can be obtained regardless of the rate of
change in adjusting insulin doses [67]. Hence, just like in the case of insulin mixtures, the dose setting
depends on the results of glycemic measurements and it is not based on adjusting the doses to the
meal. Along with the time from the diagnosis of type 2 diabetes, the postprandial hyperglycemia
control becomes more and more difﬁcult. Many patients require early signiﬁcant intensiﬁcation of
therapy to ensure further decades of active life. In particular, earlier intensiﬁcation of the treatment
due to a rapid deterioration of metabolic control is required in relatively young people with type
2 diabetes [68]. However, intensiﬁcation of insulin therapy increases the risk of weight gain and
hypoglycemia. Many patients reach a state where further insulin dose increase does not improve
glycemic control. In addition, as demonstrated in studies evaluating the results of intensiﬁcation
of insulin therapy in people with type 2 diabetes, the basal-bolus regimen provides a small further
improvement in HbA1c levels compared to simpler insulin delivery regimens [69,70].
The ADA states in its recommendations that the postprandial glucose increase may be better
controlled by adjusting the time of insulin administration before a meal, indicating that the type of
insulin used (short acting insulin or a fast-acting analog) should be taken into account while adjusting
the time of insulin administration. Insulin doses set before meals should depend on the measured
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blood glucose levels and meal times. In this case, ADA also draws attention to the adjustment of the
dose according to the carbohydrates consumed. However, this is only a note, because in the published
recommendations the results of glycemia have a major impact on the setting of insulin doses [59].
For over a dozen years, research has been undertaken to assess the effectiveness of insulin therapy
in people with type 2 diabetes based on adjusting insulin doses to meals. In 2008, Bergenstal et al.
published the results of a multicenter, controlled, open label, randomized study that compared the use
of two algorithms, i.e., Simple Algorithm vs. Carbohydrates Count, for adjusting mealtime insulin
along with a simple algorithm for adjusting glargine insulin in a group of people with type 2 diabetes.
The study involved 273 participants aged 18–70 years, with type 2 diabetes for at least 6 months, with
HbA1c in the range of 7.0 to 10.0% (53 to 86 mmol/mol), taking at least 2 insulin injections per day for
at least 3 months before the study. All patients recorded results of the self-monitored blood glucose
before meals and at bedtime, insulin doses, menus, information on hypoglycemia, physical activity
levels as well as the results of a 7-point blood glucose proﬁle performed on week 0, 12, 18, and 24.
The study established fairly stringent blood glucose targets that were as follows: fasting < 5.3 mmol/L
(95 mg/dL), preprandial (before lunch and dinner) < 5.6 mmol/L (100 mg/dL) and before sleep <
7.2 mmol/L (130 mg/dL). In the Carbohydrates Count group, depending on the sensitivity to insulin,
from 1 U per 20 g of carbohydrates to 3 U per 15 g of carbohydrates were given. In this group, a
slightly greater but not statistically signiﬁcant reduction in HbA1c, i.e., −1.59 vs. −1.46% (−17.5 vs.
−16.1 mmol/mol) was obtained, lower daily doses of insulin were used, and a tendency towards
less weight gain was observed [71]. In AACE/ACE Consensus Statement it has been declared that
“carbohydrate counting was not more effective than a simpliﬁed bolus insulin dosage algorithm based
on pre-meal and bedtime glucose patterns” based on results of this trial [8]. However, Hirose et al.
conducted tests in a hospital setting in a small group of patients comparing the results of dose setting
based on glycemia and based on carbohydrate content counting. After 14 days of treatment, better
glycemic control was obtained in the carbohydrate counting group (p < 0.001) [72]. These results were
not conﬁrmed by the authors of another randomized study, which compared the ﬁxed meal insulin
dosing with ﬂexible meal dosing based on carbohydrate counting in hospitalized people with type 2
diabetes requiring at least 20 U of insulin per day. In the ﬂexible meal dosing group, the algorithm
used to treat type 1 diabetes with insulin pumps was adopted. The constant dose group required much
larger amounts of basal insulin, but both groups achieved similar glycemic control [73]. During the last
EASD meeting in Berlin (2018), a group of Danish researchers announced the results of the evaluation
of efﬁcacy of advanced carbohydrate counting and the use of an automated bolus calculator compared
with mental insulin bolus calculation in people with type 2 diabetes on the basal-bolus insulin therapy.
In conclusion they stated that the advanced carbohydrate counting and insulin bolus calculation is
an efﬁcient, low cost tool to reduce HbA1c in people with type 2 diabetes on the basal-bolus insulin
regimen. Similar effects were observed regardless of whether the automated bolus calculator or the
mental bolus calculations were used. The blinded continuous glucose monitoring revealed decreased
glycemic variability with both options, whereas only the group using the automated bolus calculator
increased the time in the euglycemic range [74].
Practically, the system based on the results of both glycemic and glycemic-after-prone tests is a
combined treatment with GLP-1 agonist and the basal insulin. However, this treatment is effective
only in those people with type 2 diabetes who have preserved endogenous insulin secretion.
6. Conclusions
It seems reasonable to conclude that in the insulin treatment of people with diabetes prandial
doses of insulin should take into account the result of pre-meal glycemia as well as the composition
and size of meals. There are still open questions regarding the optimal way to adjust a prandial
insulin dose to a meal and the possible beneﬁts for people with type 1 and type 2 diabetes if particular
parameters of the meal are taken into account while calculating the prandial insulin dose (e.g., content
of all macronutrients in a meal, the proportion and order of consumption of various foods during
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a meal, inter-subject variability of response to the meal in respect to the postprandial blood glucose
etc.). It should be emphasized that the answers to these questions may vary depending on the type
of diabetes. In type 1 diabetes, it is generally accepted and considered to be beneﬁcial to take into
account the carbohydrate content of the meals when adjusting the prandial insulin doses. There is
also evidence that protein and fat counting is advantageous in children and adolescents with type
1 diabetes treated with insulin pumps. However, there is no data available on this topic for adults
with type 1 diabetes or people with type 2 diabetes. Hence, we should emphasize that the following
questions are still waiting for answers:
• Is the calculation of carbohydrate exchangers sufﬁcient to achieve improved postprandial glycemic
control in adults with type 1 diabetes and people with type 2 diabetes or should the intake of
protein and fat be also taken into account?
• What other factors should be taken into consideration when determining doses of insulin
administered before meals in people with diabetes?
• Is it possible to develop a simple algorithm for prandial insulin dose adjustment based on the
blood glucose measurements and counting all macronutrients in the meal?
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Abstract: Hedychium coronarium has a long history of use worldwide as a food and in folk
medicine. In this study, we aimed to investigate the effect of an aqueous extract of H. coronarium
leaves (HC) on type 2 diabetes mellitus (T2DM). Two types of animal models were used in this
study: Streptozotocin (STZ)-induced T2DM (Wistar rats; N = 8) and C57BKSdb/db mice (N = 5).
After treatment with HC for 28 days, glucose tolerance improved in both of the diabetic animal
models. As signiﬁcant effects were shown after 14 days of treatment in the STZ-induced T2DM model,
we carried out the experiments with it. After 28 days of treatment with HC, the levels of cholesterol,
triglyceride, high-density lipoprotein, and low-density lipoprotein were signiﬁcantly improved
in the STZ-induced T2DM model. The lesions degree of islet β-cells was decreased after the HC
treatment. Although the insulin level increased moderately, the aldosterone level was signiﬁcantly
decreased in the HC-treated groups, suggesting that aldosterone might play an important role in this
effect. In summary, HC is a natural product and it is worth exploring its effect on T2DM.
Keywords: Hedychium coronarium; type 2 diabetes; aldosterone; streptozotocin; metabolic syndrome;
folk medicine
1. Introduction
Diabetes is a chronic progressive disease and one of the ten leading causes of death worldwide [1].
In the past three decades, the prevalence of type 2 diabetes mellitus (T2DM) has increased dramatically
in countries of all income levels. Over time, diabetes causes various complications: It starts
by damaging blood vessels, reducing the blood ﬂow, with sequelae that may be macrovascular
(heart attack, stroke, and heart failure) [2–4], or microvascular (blindness [5–7] and kidney failure [8]),
or causing neuropathies (lower limb amputation). When diabetes is not controlled, not only is
the patient quality of life affected and present a burden on medical resources, but the condition
may also lead to death. In 2015, the World Health Organization (WHO) declared diabetes as one
of the four priority noncommunicable diseases (NCDs) and established a diabetes program to
reduce the impact of diabetes by 2020. The management of diabetes consists of two main
Nutrients 2019, 11, 629; doi:10.3390/nu11030629 www.mdpi.com/journal/nutrients248
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steps: Preventing (decreasing the possible risk factors) and stabilizing the disease progress (early
diagnosis, medication, and intake management) [9]. To stabilize the disease, it is crucial to adopt
effective measures for surveillance and treatment strategies (pharmacologic and non-pharmacologic
interventions) [10,11]. In addition to the development of novel drugs, the use of traditional medicine
and food supplements for the treatment of T2DM should be investigated.
Traditional medicine (also known as folk medicine) has been used globally for centuries.
Although the medicinal properties of resources such as mollusks and plants rely on the inheritance
of experience, they have been gradually accepted in modern medicine. A food supplement is
a dosed formulation of food and herbs, and provides medical beneﬁts through its biologically
active components [12]. Therefore, both traditional medicine and food supplements can be part
of the treatment strategies for diabetes.
Extensive research has focused on the rhizome of Hedychium coronarium.
However, the pharmacological benefits of H. coronarium leaf appear overlooked. H. coronarium is
highly accessible and its leaf is a common vegetable in Taiwan. Therefore, in this study, two types of
animal models were used to evaluate the lowering blood glucose level benefits of an aqueous extract of
H. coronarium leaves (HC). A new supplement was developed, called SugarOut (SO), which contained 15%
red yeast rice (RYR) and 7.2% H. coronarium. Red yeast rice (RYR) is a fermentation product that is
traditionally used in East Asia to dye and preserve food. Its main pharmacologically active compound is
monacolin-K (also called lovastatin).
H. coronarium (also called ginger lily), a plant approximately 1–3 m in height and has a long history
of use in food and traditional folk medicine. For example, it is used in beauty products in Hawaii
and Japan, as an essential oil in Vietnam, and as a vegetable in Malaysia. It can help ease indigestion,
inﬂammation, insomnia, and pain in the muscles, joints, and abdomen [13,14]. In Brazil, H. coronarium
leaf is considered a diuretic [15] and is used for the treatment of hypertension [16]. In India, the rhizome
is used for the treatment of diabetes [17]. Many different bioactive compounds have been isolated from
H. coronarium and their pharmacological effects have been established. For example, diterpenoids and a
diarylheptanoid showed anti-angiogenic activity and suppressed the growth of different cancer cell
types [18]. Coronarin D shows active resistance to Gram-positive bacteria and fungi [19], induces G2/M
arrest, apoptosis, and autophagy [20]. Hedychilactones A, B, and C inhibit increases in nitric oxide
(NO) production and the induction of inducible NO synthase [21]. Quercetin-3-O-glucuronide (Q3GA)
has been reported to show beneﬁcial effects in the reduction and prevention of various diseases,
including neurodegenerative diseases, and to exert anti-inﬂammatory and antioxidant activities [22].
2. Material and Methods
2.1. Preparation of Aqueous Extract of Hedychium coronarium and SugarOut
The HC (containing 1.4% Q3GA) was a deep brown powder. Fresh overground parts
(leaves and stems) of H. coronarium were collected in Pingtung, Taiwan. The dried leaves and stems of
H. coronarium (100 kg) were extracted in 100% water at room temperature (25–35 ◦C). The 100% water
extracts were concentrated in vacuo and then lyophilized to obtain a dark brown powder (8.4% yield).
SO was a prototype supplement (dark red powder) developed from H. coronarium that assisted
with blood glucose regulation. It contained twomain extracts: The RYR extract (15%) and the HC (7.2%).
The two main bioactive compounds were monacolin K 1.8 mg (±20%) and Q3GA 0.6 mg (±20%).
Both test substances were provided by Vinovo Inc. The HC was stored at 4 ◦C and the SO
was stored at room temperature. Both test substances were freshly dissolved in distilled water
and administered by oral gavage daily to all rodents in the morning.
2.2. Animal Study
The Streptozotocin (STZ)-induced T2DM model was established in Wistar rats obtained from
BioLASCO Ltd. (Taipei, Taiwan) and C57BKSdb/db mice (termed db/db here) were obtained from
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the National Laboratory Animal Center (Taipei, Taiwan). All procedures involving the use of animals
were in compliance with the Guide for the Care and Use of Laboratory Animals (Press, 1996)
and approved by the Institutional Animal Care and Use Committee at our institution (Approval
no. LAC-2016-0168). The preliminary data suggested that the effective dose of SO was 246 mg/kg
in the db/db model. As bioavailability differs between rodent species, based on FDA Guidance,
the conversion factors for the rat Wistar STZ model and the mouse db/db model were 6.2 and 12.3,
respectively [23]. Therefore, 124 mg/kg SO was administered to the STZ-T2DM rats and 246 mg/kg
was administered to the C57BKSdb/db mice by oral gavage.
2.2.1. C57BKSdb/db Mice (db/db Model)
The C57BKSdb/db mouse is a model of diabetes with a spontaneous mutation (Leprdb) resulting
in morbid obesity, chronic hyperglycemia, pancreatic beta cell atrophy, and low insulin [24].
The diabetes model is determined to be well-established when the blood glucose level is >230 mg/dL
after 18 h fasting. Fifteen male mice (25–30 g) were divided into the following three groups (N = 5):
Control (treated with distilled water); HC (17.71 mg/kg); and SO (246 mg/kg) [23] (Figure 1).
Figure 1. Study procedure for the C57BKSdb/db mice (termed db/db here). Fifteen male db/db mice
were randomly divided into three groups (N = 5): Control, treatment with Hedychium coronarium leaves
(HC), or SugarOut (SO) supplement. FBG, fasting blood glucose; OGTT, oral glucose tolerance test;
B.W., Body Weight.
2.2.2. STZ-Induced Type 2 Diabetes Model
T2DM was induced in 24 6-week-old male Wistar rats by the administration of 65 mg/kg
STZ in 0.1 M citrate solution 15 min after nicotinamide injection (230 mg/kg in saline;
intraperitoneally) [25–28]. The rats were caged (two animals per cage) in a controlled environment
(12 h light/dark cycle, 23 ± 1 ◦C, and 39–43% relative humidity). The fasting glucose level was
measured 1 week after the injections. The T2DM model was determined to be well-established
when the blood glucose level was >230 mg/dL after 18 h of fasting. After T2DM was established,
the rats were randomly divided into three groups of eight rats: Control; HC (8.928 mg/kg); and SO
(124 mg/kg). An additional eight Wistar rats were used as the sham control (Figure 2).
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Figure 2. Study procedure for Streptozotocin (STZ)-induced type 2 diabetes rats. Diabetes was induced in 24
male Wistar rats, which were then randomly divided into three groups (Control, HC, and SO; N = 8).
2.3. Fasting Blood Glucose and Oral Glucose Tolerance Test
All rodents were administered the test substances daily. The body weight and fasting blood
glucose (FBG) was measured on day 0, 14, and 28. The oral glucose tolerance test (OGTT)
was performed on day 14 and 28. Each rodent fasted for 16 h before the FBG measurement. The test
substances were administered 30 min before glucose challenge (1 g/kg), and then the blood glucose
was tested 0, 30, 60, 90, and 120 min after the challenge by using IME-DC glucose test strips
(IME-DC, Berlin, Germany).
2.4. Aldosterone and Insulin Levels
Serum samples were collected on day 29 after the T2DM rats were sacriﬁced. Insulin was
quantiﬁed through the measurement of the optical density at 450 nm by using a Mercodia Ultrasensitive
rat insulin ELISA kit (Mercodia AB, Uppsala, Sweden) and aldosterone was quantiﬁed through
the measurement of the optical density at 405 nm corrected by the measurement at 590 nm by using
an aldosterone ELISA kit (ab136933; Abcam, Cambridge, UK).
2.5. Histopathological Analysis
The pancreas was excised from T2DM rats after they were sacriﬁced on day 29. The samples
were ﬁxed in 10% neutral buffered formalin, and then prepared and examined by a professional
pathologist from the Graduate Institute of Veterinary Pathobiology, National Chung Hsing University,
Taichung, Taiwan. The severity of lesions in the islet β-cells of the pancreas was graded according to
the methods described by Shackelford et al. [29]. The degree of lesions was graded from one to ﬁve,
depending on severity: 1 = minimal (<1%); 2 = slight (1–25%); 3 = moderate (26–50%); 4 = moderately
severe (51–75%); 5 = severe/high (76–100%).
2.6. Serum Biochemical Analysis
Blood samples from the T2DM rats were collected at the end of the 28-day oral administration
period and then analyzed by using an Express Plus automatic clinical chemistry analyzer
(Siemens Healthineers, Erlangen, Germany).
2.7. Statistical Analysis
All values are expressed as the mean± standard deviation (SD) in tables and the mean± standard
error (SE) in ﬁgures. The comparisons between groups were performed by one-way analysis of
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variance (ANOVA) followed by Scheffe multiple comparison tests using SPSS Statistical Software
(IBM, New York, NY, USA). Values of p < 0.05 were considered signiﬁcant.
3. Results
3.1. HC Improved Fasting Blood Glucose and Glucose Tolerance in Both Diabetic Animal Models After 28 Days
of Treatment
In the db/db model, after oral gavage of SO and HC, mice gained weight slower than the control
group (Figure 3A). The HC decreased the FBG (Figure 3B) and increased the glucose tolerance
after treatment for 14 days (Figure 3C); a signiﬁcant difference was observed after treatment for 28 days
(Figure 3D). SO also affected the FBG and glucose tolerance, however, the effects of SO were not
as remarkable as those of the HC.
(A) 
 
(B) 
 
(C) 
 
(D) 
Figure 3. Effects of HC and SO in C57BKSdb/db mice (N = 5). (A) Changes in body weight.
(B) Changes in fasting blood glucose (FBG) after treatment with HC and SO for 14 days
and 28 days. (C) Oral glucose tolerance test (OGTT) after administration of HC and SO for 14 days.
(D) OGTT after administration of HC and SO for 28 days. Signiﬁcant difference between
the control-treated group at * p < 0.05, by one-way ANOVA.
In general, the STZ-induced T2DM model shows a signiﬁcant weight reduction [30]. In this
study, after oral gavage of SO and HC for 28 days, the body weights of mice receiving HC and SO
was increased compared to that in the control group (Figure 4A) and the FBG was slightly lower in
the SO group on day 28 (Figure 4B). After 14 days of oral administration of HC and SO, the blood
glucose level in the HC and SO groups was signiﬁcantly decreased compared with that in the control
group at 60, 90, and 120 min after intake of 1 g/kg glucose (Figure 4C; p-value in Supplementary
Table S1). After administration of HC and SO for 28 days (Figure 4D), the glucose level in the SO
group was signiﬁcantly lower than that in control group from 30 to 120 min after the intake of 1 g/kg
glucose (p-value in Supplementary Table S1), however, the HC only resulted in a signiﬁcant difference
at 30 min after glucose intake. The area under the curve (AUC) of both the SO and HC groups was
signiﬁcantly lower than that of the control group (Table 1). These results suggested that HC could
improve the FBG and glucose tolerance after 28 days in the db/db mice. A notable increase in glucose
tolerance was observed in both the HC and SO groups after 14 days of administration, and a signiﬁcant
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increase in glucose tolerance was observed after 28 days of administration in the T2DM model.
Therefore, the following experiments focused on the STZ-induced T2DM model.
(A) 
 
(B) 
(C) 
 
(D) 
Figure 4. STZ-induced type 2 diabetes model (T2DM; N = 8) after the administration of HC and SO
for 14 and 28 days. (A) Changes in body weight. (B) Changes in fasting blood glucose. (C) OGTT
after administration of HC and SO for 14 days. (D) OGTT after administration of HC and SO for 28 days.
Signiﬁcant difference between control-treated group at * p < 0.05, # p < 0.01 by one-way ANOVA.
Table 1. Area under the curve (AUC) of blood glucose in the oral glucose tolerance test (OGTT).
AUC 14 Days 28 Days
Sham 8898.75 ± 1816.12 1666.88 ± 3399.66
Control 23,578.13 ± 9636.76 32,130.00 ± 8133.19
H. coronarium leaves (HC) 11,730.00 ± 5959.70 14,979.38 ± 5656.03 *
SugarOut (SO) 10,301.25 ± 5884.57 11,945.63 ± 13,782.89 **
Sham = wild-type Wistar rats treated with distilled water. N = 8 in each group. The data are expressed
as the mean ± standard deviation (SD). Signiﬁcant difference between the control-treated group at * p < 0.05,
** p < 0.01 by one-way ANOVA.
3.2. H. coronarium Attenuated STZ-Induced Pancreatic Damage and Ameliorated the Markers
of Metabolic Syndrome
The levels of cholesterol, triglyceride, high-density lipoprotein (HDL), and low-density lipoprotein
(LDL) were signiﬁcantly decreased in the STZ-induced T2DM model compared with the control group.
In the HC group, creatinine and blood urea nitrogen (BUN) were lower than the control group
and similar to the sham group. The SO group did not show any signiﬁcant differences compared
with the control group, but the laboratory results tended to be similar to those in the sham group
(Tables 2 and S2). STZ caused a severe decrease in islet β-cells (Figure 5B) and severe atrophy of
acinar cells in the pancreas (Figure 5B; Figure 6B). Biopsy sections of the HC (Figure 5C; Figure 6C)
and SO (Figure 5D; Figure 6D) groups showed that the morphology of the islet β-cells and acinar
cells of the pancreas tended to be similar to the sham group (Figure 5A; Figure 6A). According to
the degree of lesions (Table 3) after 28 days treatment, HC (0.79-fold) and SO (0.68-fold) prevented
the decrease of islet cells and the atrophy of acinar cells (HC, 0.85-fold; SO 0.70-fold). HC and SO had
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moderate protective effects against the damage caused by STZ and regulated lipid markers (Table 2).
However, the mechanism underlying the beneﬁcial effects of HC on T2DM remains to be elucidated.
Table 2. Biochemical analysis of T2DM rat model after treatment with HC and SO for 28 days.
Group Sham Control HC SO
Number of Animals 8 8 8 8
Cholesterol mg/dL 69.28 ± 25.71 161.50 ± 63.79 76.63 ± 15.30 ** 111.63 ± 51.48
Triglycerides mg/dL 58.13 ± 23.93 753.38 ± 434.92 105.13 ± 33.31 ** 480.75 ± 410.14
HDL mmol/L 27.13 ± 12.16 33.38 ± 13.23 42.75 ± 13.10 38.50 ± 12.31
LDL mmol/L 7.63 ± 1.77 37.63 ± 19.83 10.50 ± 2.56 ** 22.25 ± 21.02
HDL: low-density lipoproteins cholesterol; LDL: low-density lipoproteins cholesterol. Data are expressed
as the mean ± SD. Signiﬁcant difference between the control-treated group at ** p < 0.01 by one-way ANOVA.
(A) 
 
(B) 
 
(C) 
 
(D) 
 
Figure 5. Histopathological changes by hemotoxylin and eosin (H & E) staining (400×) of the islets
of the pancreas in rats with STZ-induced β-cell toxicity. (A) Sham control. Normal architecture of
the β-cells in the islets of the pancreas. STZ induced a slight to moderate/severe decrease of β-cells in
the islets of the pancreas in (B) T2DM control model. (C) T2DM model treated with HC for 28 days.
(D) T2DM model treated with SO for 28 days. Scale bar = 50 μm.
(A) 
 
(B) 
 
(C) 
 
(D) 
 
Figure 6. Histopathological changes (H & E staining, 400×) of the acinar cells in the pancreas in rats
with STZ-induced β-cell toxicity. (A) Sham control. Normal architecture of the β-cells in the islets of
the pancreas. STZ induced a slight to moderate/severe decrease of β-cells in the islets of the pancreas
in (B) T2DM control model. (C) T2DM model treated with HC for 28 days. (D) T2DM model treated
with SO for 28 days. Scale bar = 50 μm.
Table 3. Degree of lesions in the pancreas of the T2DM model animals after treatment with HC and SO
for 28 days.
Pancreas Control HC SO
Decrease, β-cell, islet, focal 3.80 ± 0.45 3.00 ± 0.71 2.60 ± 0.55
Atrophy, acinar cell, diffuse 4.00 ± 0.00 3.40 ± 0.89 2.80 ± 1.10
The degree of lesions was graded from one to ﬁve depending on severity: 1 = minimal (<1%); 2 = slight (1–25%);
3 = moderate (26–50%); 4 = moderate/severe (51–75%); 5 = severe/high (76–100%).
3.3. HC Altered Insulin and Aldosterone Content in Blood
Insulin levels in the HC (1.32-fold) and SO (1.29-fold) groups increased moderately compared
with the control group (Figure 7). Much research has shown that the renin-angiotensin-aldosterone
system (RAAS) plays a critical role in diabetes [31–33]. In our previous study, the oral administration
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of H. coronarium aqueous extract (3 g/kg) to Sprague Dawley rats for 90 days, resulted in a decrease of
aldosterone levels in the serum. Therefore, we measured the aldosterone level in the present study.
Aldosterone was signiﬁcantly decreased in both HC (0.59-fold) and SO (0.61-fold) groups compared
with that in the control group (Figure 8).
Figure 7. Insulin level in T2DM model rats after 28 days of treatment. No signiﬁcant difference was
found between the control-treated group by one-way ANOVA.
Figure 8. Aldosterone level in T2DM model rats after 28 days of treatment. Signiﬁcant difference
between the control-treated group at *** p < 0.001 by one-way ANOVA.
4. Discussion and Conclusions
In this study, we aimed to explore a natural product, H. coronarium, and determine if it would
beneﬁt people with diabetes. Two types of diabetic rodent models were used to determine the glycemia
lowering effect of an aqueous extract of H. coronarium leaves. We found that HC signiﬁcantly increased
glucose tolerance in both diabetic models, improved the lipid proﬁle, moderately increased insulin,
beneﬁted β-cell structure, and decreased the aldosterone level in an STZ-induced T2DM model.
Although HC has been used as a folk medicine worldwide—as a diuretic and for the treatment of
inﬂammation, hypertension, and diabetes—its mechanism of action is yet to be elucidated.
Previous studies have reported that the RAAS has played a major role in diabetes; aldosterone is
signiﬁcantly increased in primary hyperaldosteronism, diabetes, and other metabolic syndromes.
An increase in aldosterone causes impaired glucose tolerance, decreased pancreatic β-cell function,
and tissue insulin sensitivity [31,34,35]. Aldosterone is a mineralocorticoid hormone that is produced
from cholesterol in the cortex of the adrenal gland. It interacts with the mineralocorticoid receptor
(MR) to regulate blood pressure, water sodium, and potassium homeostasis [36]. In addition,
it has genomic and non-genomic actions. The genomic actions occur through the binding of
aldosterone to cytoplasmic MR, and the aldosterone-MR complex translocates to the nucleus
and modulates nuclear transcription [37]. As for the rapid non-genomic action, aldosterone
increases intracellular Ca2+ and protein kinase C (PKC) activation. In addition, aldosterone activates
and stimulates Na+/K+-ATPase, Na+/K+/2Cl+, NHE1, and NBCe1 [38–40], and other pathways,
such as the Mitogen-activated protein (MAP) kinases pathway, adenylate cyclase, tyrosine kinase,
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and cAMP-dependent protein kinase. Therefore, understanding the complete regulation of aldosterone
biosynthesis will allow medicinal interventions for the management of hypertension, congestive heart
failure, renal disease, and diabetes mellitus [41]. In this study, both HC and SO signiﬁcantly decreased
aldosterone levels and increased glucose tolerance in the STZ-induced T2DM model. These ﬁndings
suggest that T2DM may be improved by alteration of the aldosterone levels, but more studies are
recommended to understand the regulation of this pathway.
Flavonoids may play a role in many metabolic processes involved in T2DM, and Q3GA (also known
as miquelianin) is a flavonol glucuronide. Q3GA has been proven to inhibit the production of reactive
oxygen species (ROS), low-density lipoprotein (LDL) oxidation [42,43], act as an anti-inflammatory,
and improve insulin resistance in skeletal cells [44]. Q3GA also inhibited angiotensin II (Ang II)-induced
increases in the DNA binding activity of activator protein (AP)-1, a downstream transcription factor of
c-Jun N-terminal kinases (JNK), composed of the c-Jun homo/heterodimer [45]. Angiotensin II interacts
with the angiotensin receptor (AT1) membrane receptor that is coupled to cellular second messengers,
it is important in the regulation of aldosterone secretion [46]. As Q3GA can reduce the effect of Ang II,
it may also contribute to the regulation of aldosterone.
As we would like to develop a new supplement containing HC, we also examined the effect of SO
in this study. RYR has been reported to exert anti-inflammatory, hypotensive, cholesterol-lowering,
cardioprotective, anticancer, and osteogenic activities [47]. In a previous study, RYR extract
(300 mg/kg/day) was reported to decrease the FBG, increase insulin secretion, and protect islet cells in
db/db mice [48]. Therefore, we selected RYR for the development of a food supplement containing HC.
When the two compounds were combined, we expected an additional effect. In the present study, we also
tested the efficacy of SO. SO slightly lowered fasting blood glucose after 28 days of treatment in the STZ
-induced T2DM model (Figure 4B). The glucose tolerance (Figure 4C,D) in the SO treatment group was
moderately increased compared with that in the HC group after 28 days. However, no differences in
insulin, aldosterone, and histopathological findings were observed when the SO group was compared
with the HC group. We found that HC exerts beneficial effects in diabetes through modulation of
the aldosterone level in the blood to improve glucose tolerance. SO may slightly assist in the improvement
of glucose tolerance, although the supplement formula requires improvement. SO also showed effects in
two animal models, however, the efficacy of SO in the db/db model was not as strong as HC. The db/db
model is known to have as defects in the leptin receptor, leading to increases in insulin and blood glucose,
insulin resistance, and obesity [49]. In contrast, STZ is a DNA alkylating agent that targets β-cells [25–28].
As shown by the lipid profile in the STZ model, SO has the ability to ameliorate lipid markers, although
not to the same extent as HC (Table 2). This explained how SO lowered the FBG and increased the glucose
tolerance after 14 days of treatment, but was not as effective as HC during day 28 in db/db model
(Figure 3).
In summary, we treated two types of diabetic rodent models with HC and SO, and found that
both HC and SO exerted beneﬁcial effects on T2DM. However, SO treatment did not show a signiﬁcant
difference compared with the HC treatment. The underlying mechanisms of HC, and the interactions
of HC and RYR combined, are not wholly investigated yet. Therefore, we suggest that HC could be
a suitable candidate for the development of drugs and food supplements for the treatment of T2DM,
but more studies should be performed in order to understand the profound mechanism.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/11/3/629/s1,
Table S1: p-Value of oral glucose tolerance test (OGTT) after administrating Hedychium coronarium (HC)
and SugarOut (SO) in STZ-induced type 2 diabetes model (T2DM; N = 8); Table S2: Biochemistry analysis of
STZ-T2DM after treating HC and SO for 28 days.
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Abstract: Elevated blood free fatty acids (FFAs), as seen in obesity, impair muscle insulin action
leading to insulin resistance and Type 2 diabetes mellitus. Serine phosphorylation of the insulin
receptor substrate (IRS) is linked to insulin resistance and a number of serine/threonine kinases
including JNK, mTOR and p70 S6K have been implicated in this process. Activation of the energy
sensor AMP-activated protein kinase (AMPK) increases muscle glucose uptake, and in recent years
AMPK has been viewed as an important target to counteract insulin resistance. We reported
recently that rosemary extract (RE) increased muscle cell glucose uptake and activated AMPK.
However, the effect of RE on FFA-induced muscle insulin resistance has never been examined. In the
current study, we investigated the effect of RE in palmitate-induced insulin resistant L6 myotubes.
Exposure of myotubes to palmitate reduced the insulin-stimulated glucose uptake, increased serine
phosphorylation of IRS-1, and decreased the insulin-stimulated phosphorylation of Akt. Importantly,
exposure to RE abolished these effects and the insulin-stimulated glucose uptake was restored.
Treatment with palmitate increased the phosphorylation/activation of JNK, mTOR and p70 S6K
whereas RE completely abolished these effects. RE increased the phosphorylation of AMPK even
in the presence of palmitate. Our data indicate that rosemary extract has the potential to counteract
the palmitate-induced muscle cell insulin resistance and further studies are required to explore its
antidiabetic properties.
Keywords: muscle; insulin resistance; free fatty acids (FFA); diabetes; rosemary extract; AMPK
1. Introduction
Insulin plays a critical role in maintaining blood glucose homeostasis. The increase in postprandial
glucose levels causes the release of insulin by the β cells of the pancreas which is delivered to
its target tissues via the bloodstream. In skeletal muscle and adipose tissue, insulin promotes the
transport, utilization and storage of glucose [1,2], while in the liver, insulin inhibits endogenous
glucose production. The end result of these actions of insulin is to return the plasma glucose levels to a
physiological range of 4–7 millimolar (mM).
The action of insulin in muscle cells is initiated by binding to its receptor, leading to tyrosine
phosphorylation of the receptor and insulin receptor substrate (IRS-1), activation of the lipid kinase
phosphatidylinositol-3 kinase (PI3K) and the serine threonine kinase Akt resulting in GLUT4 glucose
transporter translocation from an intracellular pool to the plasma membrane and increase in glucose
uptake [3,4]. Impairments in the PI3K-Akt cascade leads to insulin resistance and type 2 diabetes
mellitus (T2DM) [1,2,5].
Skeletal muscle accounts for around 80% of postprandial glucose uptake and is quantitatively the
most important insulin target tissue, and therefore muscle insulin resistance is a major contributor
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to decreased glucose tolerance and T2DM. Insulin resistance is strongly associated with obesity and
increased plasma lipid levels. In vitro studies have shown that exposure of muscle cells to the free fatty
acids (FFA) palmitate induces insulin resistance [6]. In addition, evidence from in vivo animals studies
have shown that lipid infusion [7,8] or increased plasma lipid levels by high fat diet results in muscle
insulin resistance [7,9]. Studies have shown that serine phosphorylation of IRS-1 leads to impairment
in the insulin-signaling pathway and contributes to insulin resistance [6,10,11]. Signaling molecules
such as mammalian target of rapamycin (mTOR) [12,13], ribosomal protein S6 kinase (p70 S6K) [14,15],
glycogen synthase kinase 3 (GSK3) [16], c-Jun N-terminal kinase (JNK) [17] and protein kinase C
(PKCs) [18] have been implicated in the serine phosphorylation of IRS-1 [19].
Adenosine monophosphate (AMP)-activated protein kinase (AMPK) is a serine/threonine
kinase acting as a cellular energy sensor and activated by increased AMP/ATP ratio and/or via
phosphorylation by its upstream kinases, liver kinase B1 (LKB1), calmodulin-dependent protein kinase
(CaMKKs) and transforming growth factor-β (TGF-β)-activated kinase 1 (TAK1) [20,21]. Muscle AMPK
is activated by muscle contraction/exercise [21] and several compounds including metformin [22],
thiazolidineones [23] and polyphenols such as resveratrol [24] and naringenin [25] leading to increased
glucose uptake. In recent years, AMPK activators have been recognized as promising pharmacological
intervention for the prevention and treatment of T2DM [21,26–28].
Rosemary (Rosmarinus ofﬁcinalis L.) is an aromatic evergreen plant reported to have
antioxidant [29,30], anticancer [19,20] and antidiabetic properties [31–36]. Rosemary extract
(RE) contains different classes of polyphenols including phenolic acids, ﬂavonoids and phenolic
terpenes [37]. The polyphenols found in the highest quantity in RE are carnosic acid (CA), carnosol
(COH) and rosmarinic acid (RA) and their production is inﬂuenced by growth conditions such as soil
quality, water availability and sunlight exposure. Furthermore, the choice of solvent and extraction
method affects the chemical composition of the extract with the possibility of losing lipid soluble
chemicals by an aqueous-based extraction method and water-soluble chemicals by non-polar solvent
(ethanol, methanol)-based extraction.
Previous studies by our group found a signiﬁcant increase in muscle glucose uptake and AMPK
activation by RE treatment [38]. In addition, administration of RE decreased plasma glucose levels
in streptozotocin-induced diabetic mice [31], rats [33,35,36], alloxan-induced diabetic rabbits [32],
genetic [34], and dietary [36,39–41] animal models of obesity and insulin resistance.
According to the World Health Organization and the International Diabetes Federation (IDF)
estimates, T2DM is a disease on the rise [42] and with huge economic burden to health care systems
around the globe. Although many different strategies currently exist for the prevention and treatment
of insulin resistance and T2DM, they are lacking in efﬁcacy and, therefore, there is a need for new
preventative measures and targeted therapies. In recent years, chemicals found in plants/herbs have
attracted attention for their use as functional foods or nutraceuticals for preventing and treating insulin
resistance and T2DM.
In the present study, we focused on RE and examined its potential to counteract the
palmitate-induced insulin resistance in muscle cells.
2. Materials and Methods
2.1. Materials
Fetal bovine serum (FBS), dimethyl sulfoxide (DMSO), palmitate, bovine serum albumin (BSA)
and cytochalasin B, were purchased from Sigma Life Sciences (St. Louis, MO, USA). Materials for cell
culture and trypan blue solution 0.4% were purchased from GIBCO Life Technologies (Burlington,
ON, USA). Phospho—and total AMPK (CAT 2531 and 2532, respectively), Akt (CAT 9271 and 9272
respectively), JNK (CAT 9251 and 9252, respectively), mTOR (CAT 2971 and 2972, respectively),
p70 S6K (CAT 9205 and 2708, respectively) and HRP-conjugated anti-rabbit antibodies (CAT 7074)
were purchased from New England BioLabs (NEB) (Missisauga, ON, Canada). Insulin (Humulin R)
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was from Eli Lilly (Indianapolis, IN, USA). Luminol Enhancer reagents, polyvinylidene diﬂuoride
(PVDF) membrane, reagents for electrophoresis and Bradford protein assay reagent were purchased
from BioRad (Hercules, CA, USA). [3H]-2-deoxy-D-glucose was purchased from PerkinElmer (Boston,
MA, USA).
2.2. Preparation of Rosemary Extract (RE)
Following previously established protocols by our group [38] whole dried rosemary leaves
(Rosmarinus ofﬁcinalis L.) (Compliments, Sobey’s Missisauga, ON, Canada) were grounded and passed
through a mesh sieve. 5 grams of ground leaves were steeped for 16 h in dichloromethane-methanol
(1:1) (30 mL). Under a slight vacuum the ﬁltrate was collected followed by methanol (30 mL) extraction
for 30 min. The solvent was removed using rotary evaporator. Aliquots of the extract dissolved in
dimethyl sulfoxide (DMSO) were prepared (100 μg/mL) and were stored at −20 ◦C. All experiments
were performed using the same batch of RE.
2.3. Preparation of Palmitate Stock Solution
Stock palmitate solution was prepared by conjugating palmitate with fatty acid-free BSA as
previously reported [6]. In brief palmitic acid was dissolved in 0.1N NaOH and diluted in 9.7% (w/v)
BSA solution that was previously warmed (45–50 ◦C) to give a stock solution of 8 mM palmitate.
The ﬁnal molar ratio of free palmitate/BSA was 6:1.
2.4. Cell Culture, Treatment and Glucose Uptake
L6 rat muscle cells were used in all experiments. Myoblasts were grown and differentiated
into myotubes, as previously established [5,24]. Brieﬂy, cells were grown in α-Minimum Essential
Medium (MEM) media containing 2% v/v FBS until fully differentiated. Myotube stage was reached
at approximately 6 to 7 days after seeding. All treatments were performed using serum-free
media. The fully differentiated myotubes were treated with 0.2 mM palmitate in the absence or
presence of 5 μg/mL RE for 16 h followed by treatment without or with 100 nM insulin for 0.5 h.
A vehicle-treated control DMSO group was used in parallel with the treated groups. Following the
treatment, the cells were rinsed using HEPES-buffered saline (HBS) and exposed to HBS containing
10 μM [3H]-2-deoxy-D-glucose for 10 min to measure glucose uptake, as previously described [24,43].
Cytochalasin B (10 μM) was used to determine the non-speciﬁc glucose uptake. Cells were seeded
in 12-well plates and 3 wells were used for each treatment group. The ﬁrst two wells were used
to measure the total glucose uptake and the third used to measure the non-speciﬁc (treated with
cytochalasin B). The two total glucose uptake values were averaged, and the non-speciﬁc value was
subtracted to obtain the speciﬁc. At the end of the assay, the cells were rinsed with 0.9% NaCl solution
and lysed using 0.05 N NaOH. The radioactivity was measured by liquid scintillation counter and the
Bradford assay was used to examine the cellular protein content.
2.5. Immunoblotting
After treatment, the cells were quickly washed with ice cold HBS solution and lysed
using cold lysis buffer. Whole cell lysates were prepared using lysis buffer containing
20 mM Tris (PH 7.5), 150 mM NaCI, 1 mM ethylenediaminetetraacetic acid (EDTA), 1 mM
ethylene glycol-bis β-aminoethyl ether/egtazic acid (EGTA), 1% Triton X-100, 2.5 mM sodium
pyrophosphate, 1 mM p-glycerolphosphate, 1mM sodium orthovanadate (Na3VO4), 1 μg/mL
leupeptin. Phenylmethylsulfonyl ﬂuoride (PMSF) was added, to a ﬁnal concentration of 1 mM,
prior to use. The lysates were stored at −20 ◦C. The protein samples (20 μg) were separated using
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) followed by a transfer to a
PVDF membrane. The membranes were blocked using blocking buffer (5% (w/v) dry milk powder in
Tris-buffered saline) followed by overnight incubation at 4 ◦C with the primary antibody. The primary
antibody was detected using HRP-conjugated anti-rabbit secondary antibody followed by exposure to
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LumiGLOW reagent. The corresponding bands were visualized with FluroChem software (Thermo
Fisher, Waltham, MA, USA).
2.6. Statistical Analysis
Statistical analysis was completed using GraphPad Prism software 5.3 manufactured from
Graphpad Software Inc. (La Jolla, CA, USA). The data from several experiments were pooled and
presented as mean ± standard error (SE). The means of all the groups were obtained and compared to
the control group using one-way analysis of variance (ANOVA) which was followed by Tukey’s post
hoc test for multiple comparisons.
3. Results
3.1. Rosemary Extract Restores the Insulin-Stimulated Glucose Uptake in Palmitate-Treated Muscle Cells
All the experiments were performed using L6 cells in their differentiated myotube stage (Figure 1).
In our lab we have used L6 myotubes for different studies extensively for more than 20 years and
differentiation of the cells is assessed microscopically. We are certain that all experiments were
performed using differentiated cells/myotubes. Upon differentiation of L6 cells, the expression of the
insulin receptor and GLUT4 transporters dramatically increases which results in a 2-fold increase in
insulin responsiveness. We examined routinely the response of the cells to insulin (100 nM for 30 min)
and we got a 2-fold increase in glucose uptake an indirect measurement of differentiation. Altogether
with (1) the microscopic evaluation and (2) the biological evaluation/ insulin responsiveness/glucose
uptake assay we are absolutely sure that the cells used in the present study were at the myotube stage.
Figure 1. L6 muscle cells in the myoblast (A) and fully differentiated myotube (B) stage. L6 cells were
seeded and cultured in 2% fetal bovine serum (FBS)-containing α-MEM culture media (day 1, A) and
upon reaching conﬂuency were spontaneously differentiated into myotubes (day 7, B). Photographs
were taken using EVOS XL Core imaging system at magniﬁcation ×10 and ×20.
The effects of the free-fatty acid palmitate in the absence or the presence of RE on the
insulin-stimulated glucose uptake was examined. Acute stimulation of L6 myotubes with insulin
(100 nM, 30 min) signiﬁcantly increased glucose uptake (201 ± 1.21% of control, p < 0.0001,
Figure 2). Exposure of the cells to palmitate (0.2 mM, 16 h) although did not have any effect on
the basal glucose uptake (103 ± 2.7% of control) (Figure 2), it resulted in signiﬁcant reduction
of the insulin-stimulated glucose uptake (117 ± 15.6% of control) indicating insulin resistance.
Most importantly in palmitate-treated cells, exposure to RE resulted in signiﬁcant restoration of
insulin-stimulated glucose uptake (179 ± 10.5% of control, p = 0.0001, Figure 2). Exposure of the
cells to RE (5 μg/mL) alone resulted in signiﬁcant increase in glucose uptake (208 ± 15.6% of control,
p < 0.0001). Treatment with RE and palmitate did not have a signiﬁcant effect on glucose uptake (122 ±
7.6% of control). Moreover, combined treatment with RE and insulin (202 ± 8.0% of control, p < 0.0001)
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did not result in greater response than each treatment alone. These data indicate that the negative
effect imposed by palmitate treatment on insulin responsiveness is abolished by the presence of RE.
Figure 2. Rosemary extract (RE) restores the insulin-stimulated glucose uptake in palmitate treated
muscle cells. Fully differentiated L6 myotubes were treated without (control, C) or with 0.2 mM
palmitate (P) for 16 h in the absence or the presence of 5 μg/mL RE followed by stimulation without
or with 100 nM insulin (I) for 30 min and [3H]-2-deoxy-D-glucose uptake measurements. The results
are the mean ± standard error (SE) of 4–7 independent experiments, expressed as percent of control
(*** p < 0.001 vs. control, ### p < 0.001 vs. insulin alone).
To investigate any potential cell-damaging effects of palmitate and RE treatment, we examined
cell morphology and cell viability. No changes in cell morphology was seen with any of the treatments.
Additionally, we utilized the trypan blue exclusion assay to examine cell viability. No effect on cell
viability (RE: 98%, P: 97%, P + RE: 99% of control) was seen.
3.2. Rosemary Extract Prevents the Palmitate-Induced Ser307 and Ser636/639 Phosphorylation of IRS-1
Previous studies conducted in L6 muscle cells in vitro and rat muscle in vivo have indicated that
increased phosphorylation levels of Ser307 and Ser636/639 of IRS-1 leads to impairment in the insulin
signaling leading to insulin resistance [44,45]. Therefore, next we investigated the effects of palmitate
and RE downstream of the insulin receptor and examined IRS-1 phosphorylation and expression.
Exposure of L6 myotubes to 0.2 mM palmitate resulted in signiﬁcant increase in Ser307 and Ser636/639
phosphorylation of IRS-1 (199.4 ± 24.98%, 162 ± 6.74% of control, p = 0.0005, p < 0.0091 respectively)
(Figure 3A,B). Treatment with 5 μg/mL RE did not have any effect on the basal Ser307 or Ser636/639
phosphorylation (118 ± 11.24%, 105 ± 3.51% of control respectively) but completely abolished the
palmitate-induced increase in Ser307 and Ser636/639 phosphorylation of IRS-1 (108 ± 16.91% of
control and 107 ± 7.32% of control, respectively), (Figure 3A,B). The total levels of IRS-1 were not
impacted by any treatment (P: 103.3 ± 8.63, RE: 98.82 ± 13.21, RE + P: 108 ± 9.33) (Figure 3C). The ratio
of phosphorylated levels of IRS-1 (Ser307 and Ser636/639) over the total levels of IRS-1 is shown on
Figure 3D. Treatment with palmitate signiﬁcantly increased the ratio of phosphorylated Ser307 and
Ser636/639 /total IRS-1(202.2 ± 43.7, 157.7 ± 7.7% of control, p < 0.0009 respectively). RE did not have
an effect on the ratio of basal Ser307 and Ser636/639 phosphorylation of IRS-1/ total IRS-1 (123.8 ± 20
and 111.4 ± 19.4% of control respectively) but completely abolished the palmitate-induced response
(101.1 ± 12.6 and 99.3 ± 5.1% of control, p = 0.0008 and p = 0.0086 respectively).
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Figure 3. Effects of palmitate and RE on IRS-l expression and Ser307, Ser636/639 phosphorylation. Fully
differentiated myotubes were treated without (control, C) or with 0.2 mM palmitate (P) in the absence
or the presence of 5 μg/mL RE for 16 h. After treatment, the cells were lysed, and sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was performed, followed by immunoblotting
with speciﬁc antibodies that recognize phosphorylated (Ser307, Ser636/639) or total IRS-1 (T-IRS-1).
Representative immunoblots are shown (A). The densitometry of the bands was measured and
expressed in arbitrary units (B–D). The data are the mean ± SE of three separate experiments
(*** p < 0.001, ** p < 0.01 vs. control, ### p < 0.001 vs. palmitate alone).
3.3. Rosemary Extract Restores the Insulin-Stimulated Akt Phosphorylation in Palmitate Treated Myotubes
Next, we investigated the effect of palmitate and RE treatment on insulin-stimulated Akt
phosphorylation and expression. Treatment of L6 myotubes with insulin resulted in a signiﬁcant
increase in Akt Ser473 and Thr308 phosphorylation (I: 312 ± 19.21 and 289 ± 23.12% of control,
p = 0.0006, p = 0.0009, respectively) (Figure 4A,B). Treatment of the cells with palmitate abolished
the insulin-stimulated Akt phosphorylation on Ser473 and Thr308 residues (P + I: 121.9 ± 31.30 and
131 ± 35.90% of control respectively, p = 0.0008) (Figure 4A,B). Palmitate and RE each alone or in
combination did not have any effect on the basal Ser473 or Thr308 Akt phosphorylation (P: 98.2 ± 3.02,
95 ± 6.20, RE: 103 ± 4.10, 105 ± 6.2%, RE + P: 109.1 ± 9.06, 111 ± 5.92% of control, respectively).
However, in the presence of RE, the decline in the insulin-stimulated Akt phosphorylation on Ser473
and Thr308 seen with palmitate was completely prevented (RE + P + I: 346.7 ± 66 and 312 ± 30.31%
of control respectively, p < 0.001 (Figure 4A,B). The total levels of Akt were not signiﬁcantly affected
by any of the treatments (I: 108 ± 8.4, P: 99 ± 5.9, P + I: 101 ± 11.6, RE: 94 ± 5.72, RE + P: 93.6 ± 7.2,
RE + P + I: 93 ± 15.23% of control) (Figure 4C).
3.4. Rosemary Extract Prevents the Palmitate-Induced Phosphorylation of C-Jun N-Terminal Kinase (JNK) in
L6 Myotubes
Following the establishment that chronic exposure to palmitate increases the phosphorylation of
Ser307 and Ser636/639 of IRS-1, we examined the signaling molecules that may be involved. JNK is a
serine/threonine kinase shown to increase serine phosphorylation of IRS-1 and involved in insulin
resistance [46,47]. We hypothesized that the levels of JNK phosphorylation and/or expression would
be increased by palmitate. Indeed, exposure of the cells to palmitate (0.2 mM) signiﬁcantly increased
JNK phosphorylation (250 ± 9.77% of control, p = 0.0007) and treatment with RE completely abolished
the palmitate-induced phosphorylation of JNK (114 ± 12.90% of control, p = 0.0006) (Figure 5A,B).
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RE alone did not affect the phosphorylation of JNK (98 ± 7.44% of control). Moreover, the total levels
of JNK were not signiﬁcantly changed by any treatment: P: 107 ± 7.21, RE: 104 ± 7.53 and RE + P:
105 ± 8.76% of control (Figure 5C).
Figure 4. Effects of palmitate and RE on Akt expression and Ser473 and Thr308 phosphorylation.
Fully differentiated L6 myotubes were treated without (control, C) or with 0.2 mM palmitate (P) for
16 h in the absence or the presence of 5 μg/mL RE followed by stimulation without or with 100 nM
insulin (I) for 15 min. After treatment, the cells were lysed, and SDS-PAGE was performed, followed
by immunoblotting with speciﬁc antibodies that recognize phosphorylated Ser473, Thr308 or total
Akt. Representative immunoblots are shown (A). The densitometry of the bands was measured
and expressed in arbitrary units (B,C). The data are the mean ± SE of three separate experiments
(*** p < 0.001 vs. control, ### p < 0.001 vs. insulin alone).
3.5. Rosemary Extract Prevents the Palmitate-Induced Phosphorylation of mTOR and p70 S6K in L6 Myotubes
Another kinase implicated in serine phosphorylation of IRS-1 is mTOR and, therefore,
we examined the effects of palmitate on mTOR phosphorylation/activation and expression. Exposure
of the cells to 0.2 mM palmitate signiﬁcantly increased mTOR and p70 S6K phosphorylation
(403 ± 85.60 and 200 ± 42.55% of control, p < 0.0001, respectively) (Figure 6A–C). Treatment with RE
alone did not affect the basal mTOR or p70 S6K phosphorylation (104 ± 13.71 and 82.12 ± 6.04% of
control, respectively) while completely abolished the palmitate-induced phosphorylation of mTOR and
p70 S6K (60 ± 20.53% and 90 ± 7.11% of control, p = 0.0002 and p = 0.0005, respectively), (Figure 6A–C).
The total levels of mTOR and p70 S6K were not signiﬁcantly changed by any treatment: P: 104 ± 3.01,
105 ± 5.83, RE: 93 ± 2.44, 97 ± 2.21 and RE + P: 88 ± 3.85, 92.22 ± 4.23% of control, respectively
(Figure 6A–C).
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Figure 5. Effects of palmitate and RE on JNK expression and phosphorylation. Fully differentiated
myotubes were treated without (control, C) or with 0.2 mM palmitate (P) for 16 h in the absence or
the presence of 5 μg/mL RE. After treatment, the cells were lysed, and SDS-PAGE was performed,
followed by immunoblotting with speciﬁc antibodies that recognize phosphorylated Thr183/Tyr185 or
total JNK. Representative immunoblots are shown (A). The densitometry of the bands was measured
and expressed in arbitrary units (B,C). The data are the mean ± SE of three separate experiments
(*** p < 0.001 vs. control, ### p < 0.001 vs. palmitate alone).
Figure 6. Effects of palmitate and RE on mTOR and p70 S6K expression and phosphorylation.
Fully differentiated myotubes were treated without (control, C) or with 0.2 mM palmitate (P) for
16 h in the absence or the presence of 5 μg/mL RE. After treatment, the cells were lysed, and SDS-PAGE
was performed, followed by immunoblotting with speciﬁc antibodies that recognize phosphorylated
Ser2448 or total mTOR or phosphorylated Thr389 or total p70 S6K. Representative immunoblots are
shown (A). The densitometry of the bands was measured and expressed in arbitrary units (B,C).
The data are the mean ± SE of three separate experiments (*** p < 0.001 vs. control, ### p < 0.001 vs.
palmitate alone).
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3.6. Rosemary Extract increases the Phosphorylation of AMPK in the Presence of Palmitate
Previous studies by our group showed that rosemary extract and rosemary extract polyphenols
increased glucose uptake and phosphorylated/activated AMPK in L6 muscle cells [38,48–50]. Here we
investigated the chronic effect of RE on AMPK as well as the effect of RE on AMPK in an environment
of elevated FFA. Treatment with 5 μg/mL RE signiﬁcantly increased the phosphorylation of AMPK
(295 ± 26.94% of control, p < 0.0001) (Figure 7A,B). Most importantly, RE increased phosphorylation of
AMPK even in the presence of 0.2 mM of palmitate (270 ± 22.54% of control, p < 0.0001), (Figure 7A,B).
Treatment with palmitate alone did not have any signiﬁcant effect on the phosphorylation of AMPK
(150 ± 14.32% of control). Furthermore, the total levels of AMPK were not affected by any treatment
(P: 103 ± 8.63, RE: 99 ± 13.21, RE + P: 108 ± 9.33% of control) (Figure 7C).
Figure 7. Effects of palmitate and RE on AMPK expression and phosphorylation. Fully differentiated
myotubes were treated without (control, C) or with 0.2 mM palmitate (P) for 16 h in the absence or
the presence of 5 μg/mL RE. After treatment, the cells were lysed, and SDS-PAGE was performed,
followed by immunoblotting with speciﬁc antibodies that recognize phosphorylated Thr172 or total
AMPK. Representative immunoblots are shown (A). The densitometry of the bands was measured
and expressed in arbitrary units (B,C). The data are the mean ± SE of three separate experiments
(*** p < 0.001 vs. control).
4. Discussion
Obesity and elevated FFAs are highly correlated with insulin resistance and are major risk factors
for the development of type 2 diabetes mellitus [19], a disease affecting millions of people globally.
The search of compounds with the potential to counteract insulin resistance is the focus of many
research groups worldwide and such compounds will provide huge beneﬁts.
In the present study, we found that exposure of L6 myotubes to palmitate, to mimic the elevated
plasma FFA levels seen in obesity in vivo, signiﬁcantly decreased the insulin-stimulated glucose uptake
indicating the induction of insulin resistance. These data are in agreement with previous studies
showing that exposure of skeletal muscle cells to similar concentrations of palmitate induced insulin
resistance [6,51–53]. Most importantly, in the presence of rosemary extract the palmitate-induced
insulin resistance was prevented and the insulin-stimulated glucose uptake was restored to levels
comparable to the response seen with insulin alone. These ﬁndings are the ﬁrst to show that RE
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can counteract the palmitate-induced insulin resistance. It should be noted that although all the
experiments in the present study were performed using the same batch of RE, in our lab we prepared
a total of 3 different batches of RE using the same source of whole dried rosemary leaves (compliments
of Sobey’s Mississauga, ON, Canada) and we tested them; all 3 batches gave us the same response,
signiﬁcantly increased L6 muscle cell glucose uptake and activated AMPK. We found that exposure of
L6 cells to palmitate for 16 h increased Ser307 and Ser636/639 phosphorylation of IRS-1 in agreement
with other studies showing increased Ser307 and Ser636/639 phosphorylation of IRS-1 by palmitate
exposure in L6 [52,54] and C2C12 [55]. Our data are in agreement with in vivo animal studies
showing increased serine phosphorylation of muscle tissue IRS-1 by high fat diet [15,17,56]. Increased
phosphorylation of these serine residues of IRS-1 lead to a decreased PI3K-Akt downstream signaling
and reduced glucose uptake [57]. Importantly our data show that treatment with RE prevented the
palmitate-induced serine phosphorylation of IRS-1. This effect of RE is similar to metformin, the ﬁrst
line of treatment for T2DM, found to decrease the palmitate-induced Ser307 phosphorylation of IRS-1
in L6 muscle cells [58].
Furthermore, our data showed that exposure of the cells to palmitate signiﬁcantly attenuated the
insulin-stimulated phosphorylation of Akt. These data are in agreement with other in vitro studies
using L6 [59], or C2C12 [60] cells and in vivo studies showing attenuation of the insulin-induced
phosphorylation of Akt in isolated soleus muscle from animals fed a high-fat diet [61]. Interestingly,
in the presence of RE the insulin-induced phosphorylation of Akt was restored indicating that RE has
a potential to counteract the deleterious effects of palmitate and act similarly to metformin shown
to counteract the effects of palmitate and restore insulin-induced Akt phosphorylation in L6 muscle
cells [62].
Exposure of L6 muscle cells to palmitate signiﬁcantly increased the phosphorylation of JNK in
agreement with other studies in L6 [63] and C2C12 [64] muscle cells as well as ﬁndings from in vivo
studies showing increased phosphorylation of JNK in muscle tissue from animals fed a high-fat
diet [46,65]. Our data show that treatment with RE prevented the palmitate-induced phosphorylation
of JNK in L6 muscle cells and are in agreement with a study showing quercetin, a polyphenol from
the ﬂavonoid group, to signiﬁcantly attenuate the palmitate-induced phosphorylation of JNK in L6
muscle cells and in muscles obtained from ob/ob mice [63].
Furthermore, exposure of L6 cells to palmitate signiﬁcantly increased the phosphorylation of
mTOR and its downstream effector p70 S6K and treatment with RE abolished the palmitate effects.
Although increased mTOR and p70 S6K phosphorylation by palmitate has been reported previously in
L6 [66] and C2C12 cells [67] and in muscle tissue from animals fed a high-fat diet [66,68], our study is
the ﬁrst to show that RE has the potential to block these effects. Our data indicate the potential of RE,
similar to metformin, to block the palmitate-induced mTOR and p70 S6K phosphorylation in C2C12
muscle cells [69].
Furthermore, we investigated the total and phosphorylated levels of AMPK. Previously, we found
that treatment of L6 myotubes with RE [38] and the RE polyphenols carnosic acid (CA) [48], rosmarinic
acid [49] and carnosol [50] signiﬁcantly increased the phosphorylation of AMPK. In the present study,
we found that 0.2 mMpalmitate for 16 h did not affect AMPK phosphorylation or expression. Treatment
with RE increased the phosphorylation/activation of AMPK even in the presence of palmitate, an
effect similar to metformin which has been shown to phosphorylate/activate AMPK in the presence
of palmitate in C2C12 and L6 muscle cells [62,69]. Studies have indicated that activation of AMPK
signiﬁcantly lowers the activity of mTOR and its downstream effector p70 S6K [70,71] and, therefore,
the inhibition of mTOR and p70 S6K phosphorylation by RE treatment, seen in our study, may be
mediated by AMPK. Studies using strategies to inhibit AMPK such as using an inhibitor of AMPK
(Compound C) or siRNA techniques should be performed in the future to explore this further. To our
surprise, exposure of the cells to RE and palmitate did not have a signiﬁcant effect on the glucose
uptake, indicating that in the presence of palmitate not only the acute insulin response was abolished
but also the effect of RE is attenuated (Figure 2). It should be noted that RE in the presence of palmitate,
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resulted in a signiﬁcant increase in AMPK phosphorylation and our data indicate that this increase was
enough to abolish the palmitate-induced phosphorylation of mTOR and p70 S6K leading to a decrease
in serine phosphorylation of IRS-1 but not sufﬁcient to increase the glucose uptake in the cells (Figure 7,
RE + P increased AMPK phosphorylation; Figure 2: RE + P no signiﬁcant increase in glucose uptake).
We have investigated previously the effects of RE, CA and RA on glucose transporters in GLUT4 and
GLUT1 overexpressing cells and found no effect on glucose transporter translocation [38,48,49], and we
had proposed that RE may increase glucose uptake by affecting GLUT3 translocation or by affecting
glucose transporter activity. The lack of a signiﬁcant increase in glucose uptake by RE in the presence
of palmitate (Figure 2: RE + P) indicates that palmitate may affect a signaling step downstream of
AMPK such as TBC1D1 that prevents the increase in glucose transporter activity/glucose uptake.
A limited number of studies have also examined the antidiabetic effects of RE and its polyphenols
in vivo. In high-fat diet-induced diabetic mice, the administration of RE signiﬁcantly decreased
the fasting plasma glucose levels (72%), decreased total cholesterol (68%), total fat fecal excretion
(1–2 fold) and body weight, thereby improving the lipid proﬁle of the mice [39]. Another study
found that RE enriched with CA signiﬁcantly ameliorated high-fat diet-induced obesity and metabolic
syndrome in mice [72]. The administration of RE enriched with CA in obese rats resulted in signiﬁcant
attenuation of TNFα and interleukin 1α indicating the anti-inﬂammatory effects of RE [73]. Additional
studies showed that dietary supplementation of RE enriched with CA resulted in body weight and
epidydimal fat reduction [74], as well as suppression of hepatic steatosis [75]. In high-fat diet-induced
diabetic rats, the administration of RA dose-dependently ameliorated hyperglycemia and insulin
resistance in addition to increasing GLUT4 translocation to the plasma membrane in muscle [36].
Moreover, a recent study conducted in humans administered dried rosemary leaf powder have shown
signiﬁcant improvement in the blood lipid proﬁle, antioxidant levels, and decrease in fasting plasma
glucose levels [76]. These studies demonstrate that RE and its polyphenols exhibit antihyperglycemic
and antidiabetic properties in vivo and are in agreement with our ﬁndings. However, there are
currently no studies that elucidate the mechanism involved in the effects of RE and its polyphenols.
The present study found increased serine phosphorylation of IRS-1, and increased phosphorylation of
mTOR, p70 S6K and JNK by palmitate and an effect of RE treatment to inhibit them and restore the
insulin-stimulated Akt phosphorylation and the insulin-stimulated glucose uptake.
5. Conclusions
The prevalence of T2DM is constantly increasing and according to the International Diabetes
Federation it is expected to affect 420 million people worldwide by the year 2040 [42]. Additionally,
insulin resistance and T2DM are highly correlated with the development of other pathological states
including cardiovascular disease and cancer [19]. As a result, new strategies to aid in the prevention
and management of T2DM will provide huge beneﬁts to our society. As previously indicated, increased
levels of FFA and obesity mediate insulin resistance in muscle cells. The present study has shown
that the exposure of muscle cells to the FFA palmitate, to mimic the elevated FFA levels seen in
obesity, induced insulin resistance. Palmitate increased the serine phosphorylation of IRS-1 and
phosphorylation of JNK, mTOR and p70 S6K, while the insulin-stimulated Akt phosphorylation
and the insulin-stimulated glucose uptake were signiﬁcantly reduced. Importantly, these effects of
palmitate were attenuated by rosemary extract and the insulin-stimulated glucose uptake was restored.
In addition, rosemary extract increased the phosphorylation/activation of the energy sensor AMPK,
the activation of which has recently been recognized as a targeted approach to counteract insulin
resistance and T2DM. Our study is the ﬁrst to show that rosemary extract has the potential to counteract
the palmitate-induced muscle cell insulin resistance, and further studies are required to explore its
antidiabetic properties and to elucidate the exact cellular mechanisms involved.
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Abstract: The increased consumption of high fat-containing foods has been linked to the prevalence of
obesity and abnormal metabolic syndromes. Rhizopus oligosporus, a fungus in the family Mucoraceae,
is widely used as a starter for homemade tempeh. Although R. oligosporus can prevent the growth
of other microorganisms, it grows well with lactic acid bacteria (LAB). Lactobacillus plantarum can
produce β-glucosidase, which catalyzes the hydrolysis of glucoside isoﬂavones into aglycones (with
greater bioavailability). Therefore, the development of a soybean-based functional food by the
co-inoculation of R. oligosporus and L. plantarum is a promising approach to increase the bioactivity of
tempeh. In this study, the ameliorative effect of L. plantarum in soy tempeh on abnormal carbohydrate
metabolism in high-fat diet (HFD)-induced hyperglycemic rats was evaluated. The co-incubation
of L. plantarum with R. oligosporus during soy tempeh fermentation reduced the homeostatic model
assessment of insulin resistance, HbA1c, serum glucose, total cholesterol, triglyceride, free fatty acid,
insulin, and low-density lipoprotein contents, and signiﬁcantly increased the high-density lipoprotein
content in HFD rats. It also increased the LAB counts, as well as the bile acid, cholesterol, triglyceride,
and short-chain fatty acid contents in the feces of HFD rats. Our results suggested that the modulation
of serum glucose and lipid levels by LAB occurs via alterations in the internal microbiota, leading to
the inhibition of cholesterol synthesis and promotion of lipolysis. Tempeh, which was produced with
both L. plantarum and R. oligosporus, might be a beneﬁcial dietary supplement for individuals with
abnormal carbohydrate metabolism.
Keywords: tempeh; lactic acid bacteria; short chain fatty acids; metabolic syndrome; high fat
diet; feces
1. Introduction
The consumption of fast food, fried food, and high-fat foods is increasing along with changes
in lifestyle. Therefore, the incidence of metabolic syndrome is increasing and is expected to
become a major issue worldwide. It is characterized by high blood pressure, high blood sugar,
hypertriglyceridemia, obesity, and low high-density lipoprotein (HDL) levels in the blood. In addition,
metabolic syndrome is associated with an increased risk of type II diabetes and cardiovascular
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diseases. Therefore, the WHO predicts that the prevalence of diabetes mellitus (DM) will increase to
5.92 billion individuals by 2035, and Asia is one of the regions with the highest patient population [1].
Preliminary estimates are predicted to increase to 42.3 million for patients with diabetes mellitus in
Asia in 2080 from 20.8 million populations in 2000, and economic development, high-fat foods, fried
food, etc., are likely to be the primary underlying causes [1].
Lactobacillus has wide applications in probiotics and has many advantages among humans and
animals. It will be beneﬁcial to administer active microorganisms to hosts when probiotics are supplied
in sufﬁcient quantity [2]. The study also shows that probiotics play an important role in preventing
and treating chronic metabolic diseases or immune-related diseases. Many studies have shown that
lactic acid bacteria (LAB) are beneﬁcial for human health, e.g., they could decrease the total cholesterol
in blood and they have favorable effects in patients with type II diabetes [2]. It remarkably increased
fecal and bile acid cholesterol levels after administration of Lactobacillus plantarum. Furthermore, it
helped decrease the total blood cholesterol levels after moderate intake of Lactobacillus plantarum [2,3].
Recently, numerous phytochemicals have been reported in soybeans and fermented soybean products.
In particular, isoﬂavones genistein and daidzein are beneﬁcial for humans and isoﬂavones can prevent
cardiovascular diseases, cancers, metabolic syndrome, or help to treat osteoporosis because it canmimic
estrogen in humans [2,4]. Furthermore, certain animal studies reported that isoﬂavones can either
decrease body weight or increase insulin levels; moreover, it plays an important role in modulating
serum glucose levels in diabetic rats [2]. Numerous complex compounds are metabolized/decomposed
by microorganisms to generate compounds of higher nutritional value, such as increasing aglycone
during soybean fermentation [4].
Tempeh is a fermented soybean product that originated in Indonesia. Tempeh is rich in soy
protein and genistein, which have beneﬁcial effects on the regulation of high blood sugar and
prevent diabetes [5]. The processing of tempeh involves the addition of Rhizopus spp. to cooked,
peeled soybeans for fermentation at 37 ◦C for ﬁve days. The weather in Indonesia is wet and hot,
and accordingly, tempeh can be made at room temperature [6]. Some studies have reported that
tempeh, which prevents diarrhea and anemia and is richer in vitamins and minerals than unfermented
soybean, contains many vitamins B12 and antioxidants [4]. Furthermore, genistein, daidzein, and
β-sitosterol in tempeh prevent cancers, cardiovascular diseases, type II diabetes, and blood glucose
regulation [7]. Tempeh also signiﬁcantly decreases phytic acid and trypsin (antinutritive factors) levels
during fermentation. This is one of the reasons why tempeh is popular, especially among vegetarians,
in Asia, Europe, and the Americas because of its beneﬁcial functions [4,7,8].
Many studies have shown that fermented soybean and LAB are effective for the prevention of type
II diabetes [9,10]. However, the effects of the co-fermentation of Lactobacillus plantarum and Rhizopus
oligosporus on type II diabetes have not been evaluated. Therefore, we prepared tempeh while using
both L. plantarum and R. oligosporus (a common fungus used as a starter for tempeh) and administered
it to rat models of diabetes, with HFD-induced high serum glucose and cholesterol. The objective of
this study was to develop a strategy to improve the quality of life in patients with metabolic syndrome
based on alternative food therapy.
2. Materials and Methods
2.1. Sample Preparation
Kaohsiung Number 9 soybeans were used for co-fermented tempeh. Soybeans were washed and
soaked for 12 h and the outer membranes were removed. After drying, water (twice the weight of
soybeans) and 1% lactic acid were added, followed by cooking at 100 ◦C for 30 min. Next, L. plantarum
and R. oligosporus were inoculated at 30 ◦C in a fermentative environment for 48 h after samples were
cooled. Normal tempeh was prepared according to the same procedure with only R. oligosporus. All of
the samples were stored at −20 ◦C in a refrigerator until the central temperature reached −18 ◦C,
and samples were then freeze-dried for 48 h. After the water was removed, samples were milled and
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stored at −20◦C. In addition, normal diet (LabDiet 5001) was purchased from Young Li Trading Co.,
Ltd. (New Taipei, Taiwan) The composition of the HFD was normal diet: cholesterol: coconut oil =
73:2:25 [11].
2.2. Animals and Diets
Eight-week-old male Sprague–Dawley (SD) rats were obtained from BioLASCO Taiwan Co., Ltd.
(Taipei, Taiwan). The animals were housed in a room with an alternate light/dark cycle (12 h), a
temperature of 25 ± 2 ◦C, and a relative humidity of 55−60%. All rats were fed experimental diets
ad libitum with free access to drinking water at all times. After two weeks of adaptive feeding, the
rats were randomly assigned to groups of eight animals each and fed different experimental diets as
follows: rats in the control group were fed a normal chow diet with 13.5% kcal fat (Laboratory Rodent
Diet 5001; Lab Diet/PMI Nutrition International, Purina Mills LLC, Gray Summit, MO, USA) and rats
in the negative control group and treatment groups were fed the HFD (coconut oil 25%, cholesterol 2%,
feed powder 73%) modiﬁed, as described in Gandhi et al. [11]. Diabetes was induced by treatment
with 30 mg/kg STZ and 45 mg/kg nicotinamide for four weeks. Rats were induced by 20 mg/kg
STZ again if their serum glucose levels did not reach 150 mg/dL after one week of induction. Rats
in the treatment groups (8 rats/group) were separated into the normal diet group (control group),
negative control group (HFD, SH group), and positive control group fed pioglitazone (10 mg/kg
body weight/day, SHP group) in the last four weeks. The other rats were orally administered cooked
soybean (40 mg/kg body weight/day, SHS group), tempeh (40 mg/kg body weight/day, SHL group),
or probiotic fermented tempeh (40 mg/kg body weight/day, SHTL group) in the last four weeks.
The total study period was 14 weeks for all groups. Food intake and body weight were measured
weekly for the duration of the experiment. The animals were maintained in accordance with the
National Pingtung University of Science and Technology and Tajen University guidelines for the care
and use of laboratory animals. The animal study protocols were approved by the Ethics Committee at
the Tajen University (Approval No. 105-10).
2.3. Serum Samples
All blood samples were solidiﬁed at room temperature for 30 min after collection. Centrifugation
at 3000× g for 20 min, the supernatant was obtained and stored at −80◦C before analysis.
2.4. Fasting Serum Glucose
Before the fasting serum glucose test, all rats were fasted overnight (14–16 h). Blood from the tail
artery was collected (0.1 mL/rat) and analyzed while using a blood-glucose meter.
2.5. Oral Glucose Tolerance Test (OGTT)
The OGTT assay followed a similar protocol to that of the fasting serum glucose test. All of
the rats were fasted overnight (14–16 h) and weighed. Blood was then collected from the tail artery
(0.1 mL/rat) and analyzed using a blood-glucose meter. All animals received 1.5 g of glucose/kg body
weight. Blood was sampled from the tail vessels of conscious animals before the load (t = 0) and 30, 60,
90, and 120 min after glucose administration. The samples were allowed to clot for 30 min, centrifuged
(3000× g, 20 min), and evaluated while using a blood-glucose meter.
2.6. Biochemical Measurements
Commercial kits for determining the levels of free fatty acids (FFA), HbA1c,
high-density-lipoprotein-cholesterol (HDL-C), insulin, and low-density-lipoprotein-cholesterol
(LDL-C) in rats were obtained from Randox Laboratories (Crumlin, Co., Antrim, UK). The biochemical
assays were performed according to the protocols provided by Randox Laboratories.
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2.7. Homeostasis Model Assessment-Insulin Resistance (HOMA-IR)
The homeostasis model assessment for insulin resistance (HOMA-IR) was calculated via the
following equation: fasting serum insulin (mU/L) × fasting glucose (mmol/L)/22.5 [12].
2.8. Stool Assay
Total LAB in stool samples were determinedwhile using a 1.0-g stool sample diluted 10–1000 times
with double distilled endotoxin-free water. Next, 1.0 mL of the sample was added to Lactic Acid
Bacteria Count Plates 6461 (3M Petriﬁlm, St. Paul, MN, USA). Samples were analyzed after incubation
for 48 h at 37 ◦C. For short chain fatty acid (SCFA) detection, the protocol described by Holben [13]
was used, with modiﬁcations. First, 910 μL of absolute alcohol and 90 μL of pivalic acid (5 mg/mL)
were added to 0.5 g of the stool sample and vortexed for 2 min. Next, 500 μL of 0.8 M perchloric
acid was added and vortexed for 5 min, followed by centrifugation for 1 min at 13,000 rpm. Then,
0.5 mL of the supernatant was mixed with 50 μL of 4 M KOH for 5 min, and 250 μL of oxalic acid
solution was added at 4 ◦C for 60 min. Finally, the sample was centrifuged for 1 min at 13000 rpm
again and the supernatant was passed through a 0.22-μm ﬁlter. All of the samples were analyzed while
using Mass Selective Detector 5973Network, HP-INNOWax (Capillary column: 30 m, inner diameter:
0.25 mm, particle size: 0.25 μm, detector: Mass Selective Detector 5973Network, gas: Helium, split
rate: 5:1, column ﬂow rate: 2 mL/min, total ﬂow rate: 15 mL/min, injector temperature = 200 ◦C,
oven temperature = 100 ◦C, detector temperature = 200 ◦C, initial temperature = 100 ◦C for 1 min,
heating procedure of 2 ◦C/min until reaching 110 ◦C for 2 min, then 3 ◦C/min until reaching 170 ◦C
for 1 min, ﬁnal heating at 10 ◦C/min until reaching 200 ◦C for 2 min). Each sample (1 μL) was used for
gas chromatography injection for 32 min, and then a mass spectrometer was used to compare acetic
acid, propionate, and butyrate, as described previously [13]. Cholesterol, triglycerides, and cholic acid
were analyzed while using ELISA kits (BioVision Inc., Milpitas, CA, USA). All tests were performed
according to the protocols provided by BioVision Inc.
2.9. Next-Generation Sequencing Analysis of Stool Samples
2.9.1. Amplicon Library Construction and Sequencing
Total bacterial DNA from 5 g of rat feces was isolated and puriﬁed using the PowerSoil® DNA
Isolation Kit (Mo Bio, Qiagen, Hilden, Germany). A 16S rDNA region (V3–V5 hypervariable region)
from puriﬁed total bacterial DNA was ampliﬁed via PCR to produce 400-bp DNA fragments for
further puriﬁcation. The speciﬁc PCR primers were as follows: forward primer overhang adaptor
(5′–TCGTCGGCAGCGTCAGATGTGTATAA GAGACAG–3′) and reverse primer overhang adaptor
(5′–GTCTCGTGGGCTCGGAGATGTG TATAAGAGACAG–3′). Amplicons were generated while
using a high-ﬁdelity polymerase (AccuPrime; Invitrogen, Carlsbad, CA, USA), puriﬁed using a
Magnetic Bead Capture Kit (Ampure; Agencourt, Beverly, MA, USA), and quantiﬁed using a
ﬂuorometric kit (QuantIT PicoGreen; Invitrogen, Carlsbad, CA, USA). PCR conditions were 30 cycles
of 30 s at 95 ◦C, 30 s at 55 ◦C, and 30 s at 72 ◦C, and a ﬁnal extension for 5 min at 72 ◦C. The puriﬁed
amplicons were then pooled in equimolar concentrations using a SequalPrep Plate Normalization Kit
(Invitrogen, Carlsbad, CA, USA). The ﬁnal concentration of the library was determined using an SYBR
Green Quantitative PCR (qPCR) assay and the size distribution of the library was determined using
Caliper LabChip. 16S rRNA-speciﬁc regions were then sequenced using a MiSeq sequencer (Illumina,
San Diego, CA, USA).
2.9.2. Bioinformatic Analysis
Raw reads from the MiSeq sequencer for the metagenomic workﬂow were analyzed while
using QIIME (http://qiime.org/). Reference sequences in Greengenes gg_13_8 (99_otus.fasta) were
used in the analysis (Greengenes database, http://greengenes.lbl.gov/). The Ribosomal Database
Project (RDP) classiﬁer (http://rdp.cme.msu.edu/classiﬁer/) was used to classify the 16S rDNA
279
Nutrients 2018, 10, 1143
sequences into distinct taxonomic categories that are based on sequence alignments. The operational
taxonomic units (OTUs) for Lactobacillus species were determined by BLAST searches and groups
were preliminarily assigned by alignments with the NCBI genome database. All 16S rDNA sequences
were mapped to the RDP database while using QIIME and divided into groups corresponding to their
taxonomy at the level of order and were then assigned to OTUs. A sequence similarity exceeding 0.95
was the threshold for OTUs, according to the value for species distinction in microbiology.
2.10. Statistical Analysis
All results are reported as means± SD and the differences between the control and tempeh-treated
groups were analyzed by one-way analysis of variance (ANOVA) and Duncan’s multiple range tests
(IBM SPSS Statistics 19, North Castle, NY, USA) with a signiﬁcance threshold of p < 0.05.
3. Results
3.1. Hyperglycemic Rat Model
We induced DM in rats by STZ after 10 weeks of feeding on the HFD. The fasting serum glucose
level was signiﬁcantly higher (p < 0.05) in the STZ treatment group than in normal rats provided the
chow diet (Figure 1).
 
Figure 1. Oral glucose tolerance test (OGTT) for streptozotocin (STZ)-induced diabetic rats fed a
high-fat diet for 14 weeks and administered Lactobacillus plantarum co-fermented tempeh orally during
the last 4 weeks. Control: normal diet; SH: Streptozotocin (STZ 30 mg/kg, Nicotinamide 45 mg/kg)
+ High fat diet (Coconut oil 25%, Cholesterol 2%, Feed powder 73%); SHP: Streptozotocin (STZ
30 mg/kg, Nicotinamide 45 mg/kg) + High fat diet (Coconut oil 25%, Cholesterol 2%, Feed powder
73%) + Pioglitazone (10 mg/kg body weight); SHS: Streptozotocin (STZ 30 mg/kg, Nicotinamide
45 mg/kg) + High fat diet (Coconut oil 25%, Cholesterol 2%, Feed powder 73%) + Unfermented soybean
(40 mg/kg body weight); SHT: Streptozotocin (STZ 30 mg/kg: Nicotinamide 45 mg/kg) + High fat
diet (Coconut oil 25%, Cholesterol 2%, Feed powder 73%) + Tempeh (40 mg/kg body weight); SHTL:
Streptozotocin (STZ 30 mg/kg, Nicotinamide 45 mg/kg) + High fat diet (Coconut oil 25%, Cholesterol
2%, Feed powder 73%) + Tempeh + Lactobacillus plantarum (40 mg/kg body weight). * Indicates a
signiﬁcant difference (p < 0.05) compared with the control group at the same time point. Results are
expressed as mean values ± SD. (n = 8/group).
3.2. Oral Glucose Tolerance Test
In the treatment groups, serum glucose levels were ameliorated in DM rats after 14 weeks of
HFD feeding (Figure 1). The serum glucose levels in the SH group (HFD) after the oral administration
of glucose at 30, 60, 90, and 120 min were signiﬁcantly higher than those of other treatment groups
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(p < 0.05). In addition, the OGTT showed that 40 mg/kg soybean (SHS group) and 40 mg/kg tempeh
(SHT group) reduced the serum glucose level in STZ-induced DM rats. Moreover, the SHTL treatment
group (40 mg/kg) exhibited signiﬁcantly lower serum glucose levels than those in other treatment
groups that are based on the OGTT (p < 0.05).
3.3. Effects of Various Treatments on Serum Biochemistry in DM Rats
In our serum biochemistry analysis, we observed signiﬁcantly increased TG, cholesterol, LDL,
FFA, serum glucose, HbA1C, and insulin levels, but reduced HDL levels in DM rats in the SH group
after 14 weeks of the HFD (p < 0.05) (Table 1). The SH group achieved insulin resistance based on the
HOMA-IR values. However, the SHS (40 mg/kg), SHT (40 mg/kg), and SHTL (40 mg/kg) treatments
resulted in signiﬁcant decreases in TG, cholesterol, LDL, FFA, serum glucose, HbA1C, and insulin
levels, but increased HDL levels in DM rats (p < 0.05). In addition, the SHTL (40 mg/kg) treatment
group exhibited the greatest improvements in all serum biochemical parameters, indicating that it
could alleviate the symptoms of DM in rats; this group also exhibited improved insulin-resistance
based on the HOMA-IR calculation.
Table 1. Selected serum biochemical parameters for STZ-induced diabetic rats fed a high-fat diet for
14 weeks and administered Lactobacillus plantarum co-fermented tempeh orally during the last 4 weeks.
Items/Groups Control SH SHP SHS SHT SHTL
Triglyceride (mg/dL) 55.11 ± 20.0 bcd 118.1 ± 35.8 a 49.30 ± 8.52 cd 71.50 ± 17.2 bc 76.40 ± 24.7 b 47.90 ± 9.95 d
Cholesterol-total (mg/dL) 53.50 ± 6.86 c 90.33 ± 11.1 a 66.50 ± 13.4 bc 79.67 ± 14.4 ab 69.67 ± 14.4 bc 65.50 ± 9.98 bc
HDL-cholesterol (mg/dL) 40.56 ± 7.78 ab 35.71 ± 4.59 b 34.20 ± 6.16 b 45.13 ± 10.3 a 40.29 ± 4.08 ab 40.14 ± 3.42 ab
Cholesterol/HDL-C 1.41 ± 0.07 b 2.12 ± 0.35 a 2.04 ± 0.36 a 2.02 ± 0.15 a 1.94 ± 0.16 a 2.01 ± 0.17 a
LDL-cholesterol (mg/dL) 7.89 ± 2.23 c 36.00 ± 8.68 a 23.63 ± 7.20 b 28.75 ± 9.77 b 24.78 ± 6.29b 25.00 ± 5.24 b
Free-fatty acid (mmol/L) 1.43 ± 0.61 b 2.31 ± 0.25 a 1.16 ± 0.06 b 1.55 ± 0.23 b 1.36 ± 0.31 b 1.41 ± 0.24 b
Glucose AC (mg/dL) 100 ± 8.4 c 199 ± 42.3 a 125 ± 34.6 bc 151 ± 25.5 b 141 ± 24.8 b 109 ± 17.3 c
HbA1C (%) 4.02 ± 0.13 d 6.96 ± 1.05 a 5.17 ± 0.97 bc 5.58 ± 1.42 b 5.51 ± 1.25 b 4.42 ± 0.32 cd
Insulin (ng/mL) 2.48 ± 2.11 b 9.99 ± 5.46 a 1.61 ± 0.81 b 2.11 ± 0.67 b 2.61 ± 0.53 b 1.65 ± 0.53 b
HOMA-IR 0.55 ± 0.18 c 4.46 ± 0.95 a 0.54 ± 0.19 c 0.89 ± 0.17 bc 1.07 ± 0.36 b 0.59 ± 0.16 c
Control: normal diet; SH: Streptozotocin (STZ 30 mg/kg, Nicotinamide 45 mg/kg) + High fat diet (Coconut oil 25%,
Cholesterol 2%, Feed powder 73%); SHP: Streptozotocin (STZ 30 mg/kg, Nicotinamide 45 mg/kg) + High fat diet
(Coconut oil 25%, Cholesterol 2%, Feed powder 73%) + Pioglitazone (10 mg/kg body weight); SHS: Streptozotocin
(STZ 30 mg/kg, Nicotinamide 45 mg/kg) + High fat diet (Coconut oil 25%, Cholesterol 2%, Feed powder 73%) +
Unfermented soybean (40 mg/kg body weight); SHT: Streptozotocin (STZ 30 mg/kg: Nicotinamide 45 mg/kg)
+ High fat diet (Coconut oil 25%, Cholesterol 2%, Feed powder 73%) + Tempeh (40 mg/kg body weight); SHTL:
Streptozotocin (STZ 30 mg/kg, Nicotinamide 45 mg/kg) + High fat diet (Coconut oil 25%, Cholesterol 2%, Feed
powder 73%) + Tempeh + Lactobacillus plantarum (40 mg/kg body weight). a~d letters are signiﬁcantly different
from all samples tested (p < 0.05). Results are expressed as mean values ± SD. (n = 8/group).
3.4. Changes in Total Lactic Acid Bacteria in Diabetes Mellitus (DM) Rat Stools
There were no signiﬁcant differences in the total LAB content in the rat stool samples before
treatment among groups (Table 2). However, the total LAB content was lower in the SH group than in
the Normal group. The total LAB contents were signiﬁcantly higher in the SHT and SHTL groups than
in the SH group in DM rats (p < 0.05). The total LAB content in the stool sample in the SHTL group
was higher than those in other groups. However, the total LAB content in stool samples in the SHP
group was signiﬁcantly lower than those in all DM rats (p < 0.05).
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Table 2. Lactic acid bacteria counts (Log CFU/g) in STZ-induced diabetic rats in different
treatment groups.
Items/Groups Control SH SHP SHS SHT SHTL
Week 0 7.66 ± 0.04 a 7.65 ± 0.09 a 7.64 ± 0.01 a 7.59 ± 0.05 a 7.75 ± 0.08 ab 7.67 ± 0.05 a
Week 4 8.91 ± 0.07 a 8.09 ± 0.06 c 7.71 ± 0.27 d 8.04 ± 0.16 c 8.31 ± 0.04 bc 8.44 ± 0.05 b
Control: normal diet; SH: Streptozotocin (STZ 30 mg/kg, Nicotinamide 45 mg/kg) + High fat diet (Coconut oil 25%,
Cholesterol 2%, Feed powder 73%); SHP: Streptozotocin (STZ 30 mg/kg, Nicotinamide 45 mg/kg) + High fat diet
(Coconut oil 25%, Cholesterol 2%, Feed powder 73%) + Pioglitazone (10 mg/kg body weight); SHS: Streptozotocin
(STZ 30 mg/kg, Nicotinamide 45 mg/kg) + High fat diet (Coconut oil 25%, Cholesterol 2%, Feed powder 73%) +
Unfermented soybean (40 mg/kg body weight); SHT: Streptozotocin (STZ 30 mg/kg: Nicotinamide 45 mg/kg)
+ High fat diet (Coconut oil 25%, Cholesterol 2%, Feed powder 73%) + Tempeh (40 mg/kg body weight); SHTL:
Streptozotocin (STZ 30 mg/kg, Nicotinamide 45 mg/kg) + High fat diet (Coconut oil 25%, Cholesterol 2%, Feed
powder 73%) + Tempeh + Lactobacillus plantarum (40 mg/kg body weight). a~d letters are signiﬁcantly different
from all samples tested (p < 0.05). Results are expressed as mean values ± SD. (n = 8/group).
3.5. Changes in Short Chain Fatty Acids (SCFAs) in DM Rat Stools
For STZ-induced DM rat groups within two weeks, there were no signiﬁcant differences in acetic
acid, propionic acid, and butyric acid in comparison with those in the SH group in DM rats (data not
shown). However, the DM rats had higher SCFA contents than the rats fed a normal diet (Table 3).
After four weeks of oral administration, the SHTL group exhibited signiﬁcantly increased acetic acid,
propionic acid, butyric acid, and valeric acid in stool samples compared with those in the SH group in
DM rats (p < 0.05). The increases in acetic acid, propionic acid, and butyric acid in the SHTL group
were the greatest when compared with those of other treatment groups.
Table 3. Changes in short- and medium-chain fatty acid in the feces in STZ-induced diabetic rats fed a
high-fat diet for 14 weeks and administered Lactobacillus plantarum co-fermented tempeh orally during
the last four weeks.
Week Items
Groups
Control SH SHP SHS SHT SHTL
4
Acetic acid_C2 4.16 ± 0.41 d 5.21 ±0.11 c 5.30 ± 0.29 c 5.93 ± 0.31 c 6.86 ± 0.28 b 7.86 ±0.64 a
Propanoic acid_C3 0.55 ± 0.11 c 0.70 ± 0.17 bc 0.84 ± 0.19 abc 1.01 ± 0.16 ab 0.87 ± 0.07 ab 1.13 ± 0.07 a
Butyric acid_C4 0.51 ± 0.06 abc 0.27 ± 0.02 c 0.45 ± 0.06 bc 0.70 ± 0.21 ab 0.57 ± 0.28 abc 0.83 ± 0.11 a
Isobutyic acid_C4t 0.00 ± 0.01 a 0.04 ± 0.05 a 0.02 ± 0.01 a 0.01 ± 0.02 a 0.04 ± 0.02 a 0.05 ± 0.01 a
Valeric acid_C5 0.03 ± 0.01 ab 0.00 ± 0.00 b 0.01 ± 0.02 b 0.09 ± 0.07 ab 0.05 ± 0.03 ab 0.11 ± 0.04 a
Isovaleric acid_C5t 0.02 ± 0.01 a 0.05 ± 0.06 a 0.05 ± 0.01 a 0.05 ± 0.01 a 0.06 ± 0.03 a 0.08 ± 0.02 a
Caproic acid_C6 0.00 ± 0.00 a 0.00 ± 0.00 a 0.00 ± 0.00 a 0.00 ± 0.00 a 0.01 ± 0.01 a 0.01 ± 0.02 a
Control: normal diet; SH: Streptozotocin (STZ 30 mg/kg, Nicotinamide 45 mg/kg) + High fat diet (Coconut oil 25%,
Cholesterol 2%, Feed powder 73%); SHP: Streptozotocin (STZ 30 mg/kg, Nicotinamide 45 mg/kg) + High fat diet
(Coconut oil 25%, Cholesterol 2%, Feed powder 73%) + Pioglitazone (10 mg/kg body weight); SHS: Streptozotocin
(STZ 30 mg/kg, Nicotinamide 45 mg/kg) + High fat diet (Coconut oil 25%, Cholesterol 2%, Feed powder 73%) +
Unfermented soybean (40 mg/kg body weight); SHT: Streptozotocin (STZ 30 mg/kg: Nicotinamide 45 mg/kg)
+ High fat diet (Coconut oil 25%, Cholesterol 2%, Feed powder 73%) + Tempeh (40 mg/kg body weight); SHTL:
Streptozotocin (STZ 30 mg/kg, Nicotinamide 45 mg/kg) + High fat diet (Coconut oil 25%, Cholesterol 2%, Feed
powder 73%) + Tempeh + Lactobacillus plantarum (40 mg/kg body weight). a~d letters are signiﬁcantly different
from all samples tested (p < 0.05). Results are expressed as mean values ± SD. (n = 8/group).
3.6. Changes in Total Cholesterol, Bile Acid, and TG in DM Rat Stools
As shown in Table 4, there were no signiﬁcant differences in stool weight, cholesterol (TC), bile
acid, and TG before treatment among samples. However, the SH group had the lowest weights
and excretion of TC and bile acid from the stool at 14 weeks among all the DM groups (p < 0.05).
The SHT and SHTL groups exhibit greater bile acid contents than those of other groups in stool samples
(p < 0.05), especially the SHTL group, which exhibited the highest bile acid excretion at 14 weeks in
the DM rats (p < 0.05). The TG content in the SH group was signiﬁcantly lower than those in the
control, SHP, SHT, and SHTL groups. The excretion of TC, bile acid, and TG in the SHTL group was
signiﬁcantly higher than that in the SH group (p < 0.05).
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Table 4. Changes in weight, cholesterol, bile acid, and triglyceride contents in feces in STZ-induced
diabetic rats fed a high-fat diet for 14 weeks and administered Lactobacillus plantarum co-fermented
tempeh orally during the last 4 weeks.
Week Items
Groups
Control SH SHP SHS SHT SHTL
Week 0
Feces weight (g) 81.7 ± 1.75 81.0 ± 5.00 81.7 ± 3.06 80.7 ± 3.73 80.3 ± 4.30 81.7 ± 4.16
cholesterol content (mg/g) 1.56 ± 0.31 1.47 ± 0.57 1.67 ± 0.16 1.66 ± 0.34 1.60 ± 0.26 1.43 ± 0.18
Bile acid content (μg/g) 6.35 ± 0.51 6.22 ± 0.49 6.54 ± 0.41 6.84 ± 0.59 6.48 ± 0.35 6.56 ± 0.36
Triglyceride content (μg/g) 57.52 ± 2.85 57.14 ± 3.48 58.12 ± 4.98 58.28 ± 2.78 57.04 ± 4.62 57.28 ± 2.14
Week 4
Feces weight (g) 81.7 ± 3.80 c 79.7 ± 3.06 c 83.0 ± 9.8 bc 96.7 ± 4.16 ab 100.0 ± 6.00 a 104.0 ± 6.27 a
cholesterol content (mg/g) 4.90 ± 1.32 d 27.5 ± 0.93 c 29.2 ± 2.62 bc 29.0 ± 3.13 bc 32.1 ± 2.44 b 35.6 ± 1.34 a
Bile acid content (μg/g) 4.63 ± 0.55 d 176.4 ± 0.44 b 247.7 ± 3.73 a 115.9 ± 2.76 c 173.0 ± 6.78 b 248.2 ± 3.86 a
Triglyceride content (μg/g) 68.97 ± 1.76 a 47.63 ± 3.45 c 57.48 ± 2.01 b 43.11 ± 0.24 c 67.16 ± 3.15 a 72.29 ± 8.87 a
Control: normal diet; SH: Streptozotocin (STZ 30 mg/kg, Nicotinamide 45 mg/kg) + High fat diet (Coconut oil 25%,
Cholesterol 2%, Feed powder 73%); SHP: Streptozotocin (STZ 30 mg/kg, Nicotinamide 45 mg/kg) + High fat diet
(Coconut oil 25%, Cholesterol 2%, Feed powder 73%) + Pioglitazone (10 mg/kg body weight); SHS: Streptozotocin
(STZ 30 mg/kg, Nicotinamide 45 mg/kg) + High fat diet (Coconut oil 25%, Cholesterol 2%, Feed powder 73%) +
Unfermented soybean (40 mg/kg body weight); SHT: Streptozotocin (STZ 30 mg/kg: Nicotinamide 45 mg/kg)
+ High fat diet (Coconut oil 25%, Cholesterol 2%, Feed powder 73%) + Tempeh (40 mg/kg body weight); SHTL:
Streptozotocin (STZ 30 mg/kg, Nicotinamide 45 mg/kg) + High fat diet (Coconut oil 25%, Cholesterol 2%, Feed
powder 73%) + Tempeh + Lactobacillus plantarum (40 mg/kg body weight). a~d letters are signiﬁcantly different
from all samples tested (p < 0.05). Results are expressed as mean values ± SD. (n = 8/group).
3.7. Microbiota Analysis of DM Rats
We evaluated the distribution of gut bacteria by next-generation sequencing. The SH, SHP, SHS,
and SHT groups exhibited a change in the dominant bacteria to Bacteroides in STZ-induced DM
rats, and the second most dominant bacteria changed to Prevotella (Figure 2). Interestingly, in the
SHTL group, the dominant bacteria in the stool samples was Lactobacillus (36.29%) after the oral
administration of tempeh co-fermented with L. plantarum (40 mg/kg) in DM rats. The second most
dominant bacterium in the SHTL group was Bacteroides (29.58%). The Lactobacillus content in the
SHTL group was greater than that in the SH group by 34.2%.
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Figure 2. Changes in bacterial distribution in feces in STZ-induced diabetic rats fed a high-fat diet
for 14 weeks and administered Lactobacillus plantarum co-fermented tempeh orally during the last
4 weeks. Control: normal diet; SH: Streptozotocin (STZ 30 mg/kg, Nicotinamide 45 mg/kg) + High
fat diet (Coconut oil 25%, Cholesterol 2%, Feed powder 73%); SHP: Streptozotocin (STZ 30 mg/kg,
Nicotinamide 45 mg/kg) + High fat diet (Coconut oil 25%, Cholesterol 2%, Feed powder 73%) +
Pioglitazone (10 mg/kg body weight); SHS: Streptozotocin (STZ 30 mg/kg, Nicotinamide 45 mg/kg) +
High fat diet (Coconut oil 25%, Cholesterol 2%, Feed powder 73%) + Unfermented soybean (40 mg/kg
body weight); SHT: Streptozotocin (STZ 30 mg/kg: Nicotinamide 45 mg/kg) + High fat diet (Coconut
oil 25%, Cholesterol 2%, Feed powder 73%) + Tempeh (40 mg/kg body weight); SHTL: Streptozotocin
(STZ 30 mg/kg, Nicotinamide 45 mg/kg) + High fat diet (Coconut oil 25%, Cholesterol 2%, Feed
powder 73%) + Tempeh + Lactobacillus plantarum (40 mg/kg body weight). Results are expressed as
mean values ± SD. (n = 8/group).
4. Discussion
High serum glucose is a symptom of diabetes, and postprandial hyperglycemia is a metabolic
phenomenon in type II diabetes [14,15]. Therefore, the objective of diabetes therapy is to control
the fasting and postprandial serum glucose concentrations. Soybean isoﬂavones can be transformed
from glycosides to aglycones by probiotics, and aglycone-isoﬂavones have better bioavailability in
humans [16]. After treatment for four weeks, rats in each group were fasted for 12 h and then evaluated
by OGTT (Figure 1). In our study, the SHTL group had better OGGT results in the late stage, and this
was attributed to the high bioavailability of isoﬂavones from L. plantarum fermented with Rhizopus
oryzae in tempeh in DM rats. Although the SHS and SHT groups had isoﬂavones, they exhibited
decreased serum glucose in the OGTT. The higher serum glucose levels that were observed in the
SHTL group than in other groups may reﬂect the higher aglycone-isoﬂavone content in the SHTL
group. These results are consistent with previous ﬁndings [17].
The syndromes of insulin resistance are caused by abnormal responses of human tissues (such
as the muscle, liver, adipocyte, and central nervous system tissues) to insulin, thereby inducing
dysfunctions in glucose and lipid metabolism [18–22]. Insulin resistance normally co-exists with high
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blood pressure, hypertriglyceridemia, decreased HDL, increased LDL, and multiple metabolic disorder
syndromes in animals. Hence, these syndromes could induce severe complications in patients with
type II diabetes [23,24]. Animal and human studies consistently demonstrate that Lactobacillus can
reduce the total cholesterol and LDL levels in the blood [25–27]. In addition, epidemiological and
other studies have shown that isoﬂavonoids (genistein) in soybean could improve type II DM by
regulating the metabolism of glucose and lipids [28,29]. Many studies have shown that isoﬂavonoids
and daidzein of the soybean could reduce serum glucose levels in animals with DM [30–32]. As shown
in Table 1, the SHLT co-fermentative group had better bioavailability, decreased TG and LDL levels,
and increased HDL levels in the serum. Additionally, serum glucose and HbA1C levels were effectively
regulated in the SHLT group. However, isoﬂavonoids (genistein) not only improved the metabolism
of serum glucose, but also reduced the HOMA-IR value in DM rats. Our results were similar to those
of Kwon (2010), who showed that fermented soybean can decrease TC and TG levels in the liver and
can regulate the metabolism of serum glucose in SD rats [33].
Microbes that are beneﬁcial to hosts are referred to as probiotics [34]. These probiotics, including
LAB, need to survive in gastric acid and bile acid conditions in animals [35]. LAB can inhibit potential
pathogen proliferation, decrease serum cholesterol levels, and regulate the immune system [36].
Furthermore, LAB in the stool can protect against gastric acid and bile acid damage. The consumption
of soybean products also increases SCFAs, lactic acid bacteria, and the volume of stool [37]. Table 2
shows that total LAB increased signiﬁcantly in soybean-fed groups. In particular, the SHLT group had
the highest total LAB count in the stool. These ﬁndings are consistent with those of Panasevich [37].
Many studies have shown that increased dietary ﬁber intake can improve stool excretion, stimulate
segmented colon movement, and improve blood sugar control [38–43]. Probiotics can produce active
metabolites, such as SCFAs, in the gut. SCFAs are also a product of dietary ﬁber fermentation.
They include acetate, propionate, and butyrate [44,45]. Some studies have shown that acetate is the
most abundant SCFA in the serum and it can regulate inﬂammation and protect against the invasion
of pathogens [46–48]. Propionate can decrease total cholesterol levels [49]. Butyrate can improve
HFD-induced obesity and insulin sensitivity [50,51]. Table 3 demonstrates that the SHLT group
exhibited increased acetate, propionate, and butyrate in the stool when compared with the levels in
other groups. The results of Schneider (2006) supported our results for stool SCFAs [52].
Protein, isoﬂavones, or dietary ﬁber in soybeanswould affect themetabolism of cholesterol [53–55].
LAB can improve the absorption of isoﬂavones by regulating β-galactosidase and glucosidase
activity [56]. Glucosides of isoﬂavones are transformed to aglycone-isoﬂavones with better
bioavailability via Lactobacillus [57]. In addition, increased consumption of aglycone-isoﬂavones
improves fatty liver diseases [58]. Some results have demonstrated that the intake of soy products with
dietary ﬁber can decrease serum total cholesterol and LDL-C levels, and the interaction of bile acid and
microbes also regulates liver fat and the metabolism of cholesterol [59–61]. Recent studies have shown
that the gut microbiota can affect intestinal-liver circulation and bile acid metabolism because it can
produce new bile acid via decarboxylation, replacing the bile acid that is consumed by intestinal-liver
circulation and decreasing the serum cholesterol level [62,63]. The consumption of dietary soy
products can increase Lactobacillus spp. in the stool and promotes the activity of bile hydrolase [64].
Nagata (1982) also found that soy products could increase the bile acid content in rat feces and affects
the metabolism of liver cholesterol, since bile acid synthesis requires cholesterol [65,66]. These results
may be explained by the stimulation of bile acid secretion and the activity of 7α-hydroxylase cholesterol
synthesis induced by LAB and isoﬂavones [67–69].
Prebiotics are a good source of probiotics and regulate cholesterol and blood sugar. They are
typically derived from cereal ﬁbers, such as β-dextran, arabinoxylan, inulin, galactose, and
fructooligosaccharides [70,71]. Wang (2012) found that hemicellulose from cereals is composed of
β-dextran, which can compete with cholesterol binding sites on LDL. Therefore, the consumption of
dietary cereal ﬁber can decrease the serum levels of LDL and cholesterol [72,73]. Moreover, LAB can
reduce blood cholesterol by various mechanisms, e.g., the inhibition of cholesterol synthesis enzymes,
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stimulation of cholesterol excretion in feces, and inhibition of cholesterol recycling, which can increase
the synthesis of cholic acid [74]. Table 4 shows that the SHLT group exhibited dramatically increased
levels of stool cholesterol and triglycerides. It is possible that LAB decreased cholesterol by each of
these mechanisms, but it decreases blood cholesterol by increasing bile acid synthesis.
The gut microbiota is substantially inﬂuenced by the diet and it affects human health via microbial
metabolism [75]. The gut microbiota in the human colon is also affected by the diet and induces
metabolic diseases, like type II diabetes. In other words, dietary changes can improve physiological
metabolism in humans by modifying microbial metabolic processes [76,77]. In a comparison of the gut
microbiota, 53% of children in the African countryside, but not in Europe, had Prevotella. This may
be explained by dietary differences since children in the African countryside consume cereal, soy,
and vegetables and European children consume more protein and animal fat (and exhibit abundant
Bacteroides in the gut) [78]. Prevotella and Bacteroides are major microbes in the human colon, and
their distribution and metabolic activity are related to the diet. For example, Prevotella is abundant in
those who eat a high ﬁber diet, but Bacteroides is abundant in those who eat high protein and high-fat
diets [77]. Figure 2 also shows that the dominant bacteria in our HFD group were Bacteroides, but
those in the normal control group were Prevotella.
Stool samples of children in the African countryside have four times higher levels of propionate
and butyrate than those of samples from European children [78], and this difference might reﬂect
the consumption of soy products, which increases Lactobacillus in stool samples [79]. Probiotics can
increase SCFA production [79]. As shown in Figure 2, Lactobacillus was more abundant in the SHTL
group than in other groups. Accordingly, the acetate, propionate, and butyrate contents were the
highest in the stool samples of the SHTL group. These ﬁndings suggest that the SHTL group exhibits
decreased serum glucose via increases in the proliferation of Lactobacillus and improvements in
SCFA excretion.
5. Conclusions
The effects of L. plantarum co-incubated with R. oligosporus to produce soy tempeh on diabetes
have not been evaluated. The present results demonstrate that L. plantarum co-incubation in soy
tempeh ameliorates hyperglycemia, hyperlipidemia, and hyperinsulinemia by altering the intestinal
bacterial distribution and increasing intestinal SCFA release in HFD-fed rats. These ﬁndings suggest
that soy tempeh that is produced by co-incubation with L. plantarum has therapeutic effects and is a
potential dietary supplement for preventing the progression of DM.
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Abstract: The combination of freeze-dried aronia, red ginseng, ultraviolet-irradiated shiitake
mushroom and nattokinase (AGM; 3.4:4.1:2.4:0.1) was examined to evaluate its effects on insulin
resistance, insulin secretion and the gut microbiome in a non-obese type 2 diabetic animal model.
Pancreatectomized (Px) rats were provided high fat diets supplemented with either (1) 0.5 g AGM
(AGM-L), (2) 1 g AGM (AGM-H), (3) 1 g dextrin (control), or (4) 1 g dextrin with 120 mg metformin
(positive-control) per kg bodyweight for 12 weeks. AGM (1 g) contained 6.22mg cyanidin-3-galactose,
2.5 mg ginsenoside Rg3 and 244 mg β-glucan. Px rats had decreased bone mineral density in the
lumbar spine and femur and lean body mass in the hip and leg compared to the normal-control
and AGM-L and AGM-H prevented the decrease. Visceral fat mass was lower in the control group
than the normal-control group and its decrease was smaller with AGM-L and AGM-H. HOMA-IR
was lower in descending order of the control, positive-control, AGM-L, AGM-H and normal-control
groups. Glucose tolerance deteriorated in the control group and was improved by AGM-L and
AGM-H more than in the positive-control group. Glucose tolerance is associated with insulin
resistance and insulin secretion. Insulin tolerance indicated insulin resistance was highly impaired
in diabetic rats, but it was improved in the ascending order of the positive-control, AGM-L and
AGM-H. Insulin secretion capacity, measured by hyperglycemic clamp, was much lower in the
control group than the normal-control group and it was improved in the ascending order of the
positive-control, AGM-L and AGM-H. Diabetes modulated the composition of the gut microbiome
and AGM prevented the modulation of gut microbiome. In conclusion, AGM improved glucose
metabolism by potentiating insulin secretion and reducing insulin resistance in insulin deﬁcient
type 2 diabetic rats. The improvement of diabetic status alleviated body composition changes and
prevented changes of gut microbiome composition.
Keywords: aronia; ginseng; mushroom; pancreatectomy; type 2 diabetes; gut microbiome;
insulin secretion
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1. Introduction
The prevalence of type 2 diabetes is markedly increasing in Asian countries, including Korea
and reached 8.7% of the Asian population by 2014; it is expected to reach 12–5% by 2025 [1].
This is associated with ethnic differences in the etiology of type 2 diabetes [1]. Type 2 diabetes
generally develops as a consequence of the imbalance between insulin resistance and insulin
secretion [2]. When insulin resistance increases due to obesity, inﬂammation, oxidative stress, aging,
less physical activity, etc., insulin secretion is elevated to overcome insulin resistance and to maintain
normoglycemia. Increased inﬂammation and oxidative stress may accelerate the development of type 2
diabetes especially in Asians. However, Asians are more susceptible to type 2 diabetes under the insulin
resistant condition since their insulin secretory capacity and β-cell mass are low [3]. The Westernization
of diets mostly elevate insulin resistance in Asians which that is not compensated due to low insulin
secretion capacity. Thus, Westernization of diets can increase the prevalence of type 2 diabetes in many
cases although obesity is much less in Asian than Caucasians.
Type 2 diabetes is prevented and treated by reducing insulin resistance and increasing insulin
capacity in both Asians and non-Asians, although the disease has a somewhat different etiology
in Asians than non-Asians. Asians with type 2 diabetes are usually not obese, although they
are insulin resistant [3]. Thus, the proper animal model for Asian type 2 diabetes needs to be
non-obese, have lower insulin secretion capacity, and higher insulin resistance than the non-diabetic
rats. Partially pancreatectomized rats are an optimal model for studying Asian type 2 diabetes [4].
They have about 60% insulin secretion capacity and about 50% of the pancreatic mass of the rats with
intact pancreas [4]. The Px rats gradually develop insulin resistance. A high fat diet accelerates the
increase of insulin resistance in Px rats [5]. Anti-diabetic interventions for Asians can be examined
for improvements in both insulin resistance and insulinotropic activity in Px rats fed with a high fat
diet [6].
Previous studies have supported that the gut microbiome produces microbial metabolites
including short-chain fatty acids (SCFAs), bile acids (BAs) and lipopolysaccharides (LPS) that modulate
host glucose metabolism, mainly in the liver [7]. This is called the gut liver axis. These metabolites
directly inﬂuence metabolic diseases including type 2 diabetes [7]. Low-grade peripheral inﬂammation
also promotes the development of type 2 diabetes. Patients with a low bacterial α- diversity in the
gut microbiome are at greater risk of metabolic diseases than are patients with high α-diversity [8].
Herbs rich in ﬁber, polyphenols and polysaccharides increase the abundance of the phylum Bacteroidetes,
and genera Akkermansia, Biﬁdobacteria, Lactobacillus, Bacteroides and Prevotella [7]. However, it reduces
the number of phylum Firmicutes and Firmicutes/Bacteroidetes ratio in the intestines. It is well known
that some herbal compounds improve glucose metabolism by modulating insulin resistance and
insulin secretion. The changes in some of the microbial metabolites from consuming plant compounds
are correlated with changes to the gut microbiome that modulate glucose metabolism [9].
Aronia melanocarpa, red ginseng and shiitake mushroom have been reported to improve glucose
metabolism. Aronia and its anthocyanins have anti-inﬂammatory and antioxidant properties that
improve insulin sensitivity and prevent type 2 diabetes [10]. Red ginseng and ginsenoside Re, Rb1,
and Rb2, its active ingredients, have demonstrated an antidiabetic action in in vitro, animal, and clinical
studies [11–14]. Ultraviolet-irradiated shiitake mushroom (Lentinus edodes), polysaccharides,
has antioxidant activity and it is a good source for vitamin D (V-D) in humans [5]. The dosage
of 100–400 mg shiitake mushroom/kg bw is effective for anti-oxidant properties because it increases
the content of the reduced form of glutathione, but at higher dosages it has an adverse effect on
immunity [15]. Anti-diabetic effects of V-D are still controversial. V-D may exert anti-diabetic
activity by improving insulin secretion and insulin sensitivity [5]. However, some placebo-controlled
clinical studies of vitamin D administration have not shown that it improves insulin release and
sensitivity [16]. Type 2 diabetes increases the thrombotic risk to develop cardiovascular diseases [17].
Although nattokinase has not been shown shown to possess anti-diabetic activity, it is reported
to improve blood ﬂow by inhibiting platelet aggregation and thrombosis to reduce cardiovascular
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events [18]. The water or ethanol extracts of aronia, red ginseng and shiitake mushroom have been
well studied, but the whole foods, including dietary ﬁber, may be better for inducing changes to the
gut microbiome that inﬂuence glucose metabolism.
Insulin resistance and β-cell function and mass are associated with increased oxidative stress
and inﬂammation [1,10,19]. Aronia and shiitake mushrooms improve insulin resistance [5,10],
red ginseng potentiates β-cell function and mass [11], and nattokinase prevents thrombosis [18].
The combination of aronia, red ginseng, shiitake mushroom and nattokinase, which have anti-oxidative
and anti-inﬂammatory properties, may alleviate type 2 diabetic symptoms and its complications.
However, its direct effects on anti-diabetic activity such as insulin resistance and insulin secretion have
not been examined. The relationship between anti-diabetic activity and the gut microbiome is also
not well characterized. We hypothesized that the combination of freeze-dried aronia, red ginseng,
ultraviolet-irradiated shiitake mushroom and nattokinase would prevent or reverse insulin resistance,
improve insulin secretion, and help normalize serum glucose levels, due to changes in the gut
microbiome. We tested this hypothesis in Px rats, a non-obese type 2 diabetic animal model.
2. Materials and Methods
2.1. Preparation of the Product and Analysis of Ingredients
Each of aronia, red ginseng, and shiitake mushroom was washed, dried at room temperature,
freeze-dried, and powdered. Freeze-dried Aronia, red ginseng, shitake mushroom and nattokinase
were mixed with the ratio of (3.4:4.1:2.4:0.1) (Chakreis, AGM) and Chakreis was generously provided by
YD Nutraceuticals Ltd. (Yongin-si, Korea). The dosages were determined by considering preliminary
studies and previous studies [10,12,13,15,16,18]. The freeze-dried powder mixture was used for the
animal study. The mixture was extracted with in distilled water at 95 ◦C for 12 h and the extracts were
centrifuged at 10,000× g at 4 ◦C for 20 min. The supernatants were lyophilized in a freeze-dryer.
For measuring indicative components in the mixture, it was extracted with methanol and
lysophilized. The extracts were dissolved in methanol, and a syringe ﬁlter was used to remove
undissolved contents. The contents of ginsenoside Rg, cyanidin-galactoside, cyanidin-glucoside
and cyanidin-arabinoside in the extract were measured were analyzed by high performance liquid
chromatography using a Luna C18 column (4.6 mm × 250 mm; ID, 5 μm). The mobile phase solvents
were acetonitrile and 0.1% formic acid in water (6:4, vol:vol) with isocratic elution at a ﬂow rate of
1 mL/min, 40 ◦C in-column temperature, and UV detection at 270 nm. We used ginsenoside Rg,
cyanidin-galactose, cyanidin-glucose and cyanidin-arabinoside as standards to quantify the sample.
The β-glucan contents of shitake mushroom were sequentially digested with digestion enzymes
by incubating in lower temperature for 2 h. The enzymes used to digest the shitake mushroom were
amylase (20 units, pH 6.9) at 20 ◦C, cellulase (50 units, pH 5.0) at 37 ◦C, protease (10 units, pH 7.5) at
37 ◦C, and amyloglucosidase (70 units, pH 4.8) at 60 ◦C. The digested shiitake mushroom was mixed
with 95% ethanol and the mixture was left at 4 ◦C for 12 h. The mixture was centrifuged at 10,000 rpm
for 10 min and water was added into the precipitates. Sulfuric acid was added (1:5) into the diluted
precipitate. The mixture was left at room temperature for 20 min and the optical density was measured
at 470 nm. Glucose solution was used as a standard.
2.2. Animals and Ethics
Eight-week-old male Sprague–Dawley rats (weight, 218 ± 23 g) were housed individually
in stainless steel cages in a controlled environment (23 ◦C; 12-h light/dark cycle). All surgical
and experimental procedures were performed according to the guidelines of the Animal Care and
Use Review Committee of Hoseo University, Korea (HUACUC-17-57). The rats underwent a 90%
pancreatectomy using the Hosokawa technique [20] or received a sham pancreatectomy (sham) under
anesthesia induced by intramuscular injection of a mixture of ketamine and xylazine (100 and 10 mg/kg
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body weight, respectively). The pancreatectomized (Px) rats exhibited characteristics of type 2 diabetes
(random glucose levels >180 mg/dL), whereas the sham rats did not [20,21].
2.3. Experimental Design
A total of 40 Px rats were assigned randomly to the following four groups, which differed according
to diet: (1) 1 g dextrin/kg bw (negative-control) (2) 0.5 g AGM/kg bw, (3) 1 g AGM/kg bw, and (4)
120 mg/kg bw metformin (positive-control). Each group included 10 Px rats. The sham-operated
rats were given 1 g dextrin/kg bw for normal-control (n = 10). All experimental animals were given
free access to water and a high-fat diet containing either the assigned extracts or dextrin for 12 weeks.
The high-fat diet was a modiﬁed semi-puriﬁed AIN-93 formulation for experimental animals [22] that
consisted of 42% carbohydrate, 15% protein, and 43% fat. The major carbohydrate, protein, and fat
sources were starch and sugar, casein (milk protein), and lard (CJ Co., Seoul, Korea), respectively.
2.4. Body Composition Measurement
After calibrating a dual-energy X-ray Absorptiometer (DEXA; Norland pDEXA Sabre; Norland
Medical Systems Inc., Fort Atkinson, WI, USA) with a phantom supplied by the manufacturer, the body
compositions of the rats were measured at the 7th week of the experimental period. The animals were
anesthetized with ketamine and xylazine (100 and 10 mg/kg bw, respectively), and laid in a prone
position, with the posterior legs maintained in external rotation with tape. The hip, knee, and ankle
articulations were in 90◦ ﬂexion. Upon the completion of scanning, lean mass was determined in the
leg and hip using the DEXA instrument equipped with the appropriate software for the assessment of
bone density in small animals [22]. Similarly, the fat mass was measured in the leg and abdominal
areas using the DEXA instrument.
2.5. Glucose Homeostasis
Overnight fasted serum glucose levels, food intake, and body weights were measured every week.
An oral glucose tolerance test (OGTT) was performed at the 7th week in overnight-fasted animals by
orally administering 2 g glucose/kg body weight [23]. Blood samples were taken by tail bleeding at
0, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 120 min after glucose loading. The serum insulin levels were
determined at 0, 20, 40, 90, and 120 min. The averages of the total areas under the curves for the serum
glucose and insulin concentrations were calculated using the trapezoidal rule. At 3 days after OGTT,
an intraperitoneal insulin tolerance test (IPITT) was conducted after the food was removed for 6 h.
The serum glucose levels were measured every 15 min for 90 min after an intraperitoneal injection
of insulin (0.75 U/kg body weight). Serum glucose and insulin levels were analyzed with a Glucose
Analyzer II (Beckman Coulter, Palo Alto, CA, USA) and rat Ultrasensitive insulin kit (Crystal Chem,
Elk Grove Village, IL, USA), respectively.
2.6. Hyperglycemic Clamp and Cerebral Blood Flow
Catheters were surgically implanted into the right carotid artery and left jugular vein in all rats
after 7 weeks of treatment and anesthetization with ketamine and xylazine. A hyperglycemic clamp
was performed in 10 free-moving and overnight-fasted rats/group after 5–6 days of implantation to
determine insulin secretion capacity, as described previously [20,24,25]. During the clamp, glucose was
infused to maintain a serum glucose level of 5.5 mM above baseline, and serum insulin level was
measured at designated times. After the clamp, the rats were freely provided food and water for
2 days and then deprived of food for 16 h the next day. After anesthesia with a mixture of ketamine
and xylazine, the rats were placed in a stereotaxic device with a midline incision of the scalp exposing
the periosteum. A small pore was made with a drill in the right lateral ventricle with stereotaxic
coordinates: 1.0 mm posterior, 6 mm lateral, 3.7 mm ventral to bregma. A Doppler ﬂow probe was
placed on the cerebral vein and blood ﬂow was measured continuously with Laser Doppler Flowmetry
(LDF100C-1, BIOPAC Systems, Inc., Goleta, CA, USA) for 10min.
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After measuring cerebral blood ﬂow regular human insulin (5 U/kg body weight; Humulin;
Eli Lilly, Indianapolis, IN, USA) was injected through the inferior vena cava. The rats were euthanized
by decapitation 10 min later, and tissues were collected rapidly, frozen in liquid nitrogen, and stored
at −70 ◦C for further experiments. Insulin resistance was determined using the homeostasis model
assessment estimate of insulin resistance (HOMA-IR) and calculated using the following equation:
HOMA-IR = fasting insulin (μIU/mL) × fasting glucose (mM)/22.5. Lipid proﬁles in the circulation
were measured using colorimetry kits from Asan Pharmaceutical (Seoul, Korea).
2.7. Immunohistochemistry
Five rats from each group were injected with BrdU (100 μg/kg body weight) after 6 weeks of
treatment. The rats were anesthetized intraperitoneally 6 h post-injection with a mixture of ketamine
and xylazine, and the brain and pancreas were dissected immediately, perfused with saline and a 4%
paraformaldehyde solution (pH 7.2) sequentially, and post-ﬁxed with the same ﬁxative overnight at
room temperature [24].
Two serial 5-μm parafﬁn-embedded tissue sections were selected from the seventh or eighth
sections to avoid counting the same islets twice when measuring β-cell area, BrdU incorporation,
and apoptosis, were determined as described previously using an immunohistochemistry method [24].
Endocrine β-cells were identiﬁed by applying guinea pig anti-insulin and rabbit anti-glucagon
antibodies to the sections. Pancreatic β-cell area was measured by examining all non-overlapping
images in two insulin-stained sections from each rat at 10× magniﬁcation with a Zeiss Axiovert
microscope (Carl Zeiss Microimaging, Thornwood, NY, USA). Pancreatic β-cell mass, individual β-cell
size, β-cell proliferation by BrdU incorporation, and apoptotic β-cell were measured as described
previously [24].
2.8. Next Generation Sequencing of the Gut Microbiome
The gut microbiome composition was measured from feces of each rat by analyzing metagenome
sequencing using next-generation sequencing [26]. Bacterial DNA was extracted from the samples
of each rat using a Power Water DNA Isolation Kit (MoBio, Carlsbad, CA, USA) according to the
manufacturer’s instructions. Each library was prepared using polymerase chain reaction (PCR)
products according to the GS FLX plus library prep guide. The emPCR, corresponding to clonal
ampliﬁcation of the puriﬁed library, was carried out using the GS-FLX plus emPCR Kit (454 Life
Sciences, Branford, CT, USA). Libraries were immobilized onto DNA capture beads. The library-beads
were added to the ampliﬁcation mix and oil, and the mixture was vigorously shaken on a Tissue Lyser
II (Qiagen, Valencia, CA, USA) to create “micro-reactors” containing both ampliﬁcation mix and a
single bead. The emulsion was dispensed into a 96-well plate and the PCR ampliﬁcation program was
run with 16S universal primers in the FastStart High Fidelity PCR System (Roche, Basel, Switzerland)
according to the manufacturer’s recommendations. Sequencing of bacterial DNA in the feces was
performed by the Macrogen Ltd. (Seoul, Korea) by a Genome Sequencer FLX plus (454 Life Sciences)
as previously reported.
2.9. Statistical Analyses
All data are expressed as means± standard deviations, and all statistical analyses were performed
using SAS ver. 9.1 (SAS Institute, Cary, NC, USA). Signiﬁcant differences among the control, AGM-L,
AGM-H, positive-control and normal-control animal groups were identiﬁed with one-way analyses of
variance. Signiﬁcant differences in the main effects among the groups were detected using post-hoc
Tukey’s tests. A p-value <0.05 was considered signiﬁcant.
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3. Results
3.1. Contents of Anthocyanins and Ginsenoide Rg3
Aronia mainly contained cyanidin-galactoside, but also and cyanidin-glucoside, and cyanidin-
arabinoside, whereas red ginseng had mostly ginsenoside Rg3 (2.5 mg/g sample). Shiitake mushroom
contained 244 mg β-glucans/g sample (Table 1).
3.2. Body Composition
Body weight gains for 11 weeks were higher in the normal-control group than the control group
whereas the positive-control and AGM-H increased body weight more than the control group but less
than the normal-control (p < 0.05). Unlike body weight gain, food intake was not signiﬁcantly different
among the groups. Food efﬁciency decreased in the control group compared to the normal-control
group and its reduction was prevented by AGM-H the most (p < 0.05). Epididymal and retroperitoneal
fat contents and visceral fat mass, were much lower in the control group than the normal-control group
(Table 2). The visceral fat mass was higher in the AGM-L and AGM-H groups than the positive-control
group (p < 0.05), but it was not signiﬁcantly different between the control and positive-control groups
(Table 2). Thus, less increase of body weight and fat mass might be associated with urinary glucose loss.
Table 1. The contents of ingredients in the mixture.
Contents (mg/g Powder)
C3-Galactoside 6.22
C3-Glucoside 0.33
C3-Arabinoside 1.53
Total Anthocyanin 8.08
Ginsenoside Rg3 2.5
β-glucan 244
Table 2. Energy metabolism and visceral fat mass.
Normal-Control
(n = 10)
Control
(n = 10)
Positive-Control
(n = 10)
AGM-L
(n = 10)
AGM-H
(n = 10)
Body weight gain for 10 week (g) 283 ± 10.5 a 144 ± 10.7 b 169 ± 11.8 b 156 ± 19.1 b 155 ± 13.0 b
Food intake (g/day) 14.4 ± 1.0 a 15.1 ± 0.8 a 15.0 ± 1.0 a 13.4 ± 1.5 b 12.3 ± 1.5 b
Food efﬁciency 0.30 ± 0.01 a 0.15 ± 0.01 d 0.18 ± 0.12 c 0.19 ± 0.03 c 0.22 ± 0.02 b
Epididymal fat pads (g) 6.7 ± 0.7 a 3.0 ± 0.4 c 2.9 ± 0.3 c 3.8 ± 0.5 b 3.3 ± 0.4 c
Retroperitoneal fat mass (g) 8.1 ± 0.8 a 3.6 ± 0.5 c 3.8 ± 0.5 c 4.3 ± 0.6 b,c 5.0 ± 0.7 b
Visceral fat (g) 14.8 ± 1.6 a 6.7 ± 0.9 c 6.7 ± 0.8 c 8.1 ± 1.0 b 8.3 ± 1.0 b
Food efﬁciency: daily energy intake/daily weight gain × 100. Values are means ± standard deviation. The test
product was the mixture of free-dried aronia, red ginseng, mushroom and nattokinase. Px rats fed a high
fat diet supplemented with (1) 0.5 g mixture/kg bw/day (AGM-L), (2) 1 g mixture/kg bw/day (AGM-H),
(3) 1 g dextrin/kg bw/day (control), or (4) metformin (120 mg/kg body weight; positive-control) for 12 weeks.
Sham-operated rats (normal-control) fed the same diet of control. a,b,c,d Values on the same row with different
superscripts were signiﬁcantly different at p < 0.05.
BMD in the lumbar spine and femur was much lower in the control group than the normal-control
group whereas AGM-L and AGM-H prevented the decrease of BMD as much as the positive-control
group (p < 0.05; Figure 1A). LBM showed a similar pattern of BMD. LBM exhibited a lower value in
the control group than the normal-control and AGM-L and AGM-H protected against the decrease
of LBM as much as the positive-control group (p < 0.05; Figure 1B). Fat mass also showed the similar
tendency to LBM (Figure 1C).
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(A) 
(B) 
(C) 
Figure 1. Bone mineral density (BMD), lean body mass (LMB) and fat mass (FM) at the end of
experiment. Px rats were fed a high fat diet supplemented with aronia, red ginseng, shiitake mushroom,
and nattokinase powders (1) 0.5 g mixture/kg bw/day (AGM-L), (2) 1 g mixture/kg bw/day (AGM-H),
(3) 1 g dextrin/kg bw/day (control), or (4) metformin (120 mg/kg body weight; positive-control) for
12 weeks. Sham rats fed the same diet of control. BMD (A) in the lumbar spine and femurs, LBM (B) of
the hip and legs and FM of the abdomen and legs (C) were measured by DEXA. Each bar and error
bar represents the mean ± SD (n = 10 of each group). a,b,c Different superscripts on the bars represent
signiﬁcant differences at p < 0.05.
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3.3. Glucose Metabolism
Overnight-fasting serum glucose levels in the control group were higher than those in the
normal-control group indicating the diabetic conditions of the control group, and AGM-L and AGM-H
decreased the serum glucose levels at fating states (p < 0.05; Table 3). Overnight serum insulin
levels were lower in the control group than in the normal-control group. As calculated from serum
glucose and insulin levels at fasting state, HOMA-IR, an index of insulin resistance, was higher in
the control group than in the normal-control (Table 3). AGM-L and positive-control group showed
a similar HOMA-IR, and AGM-H was lowered the most (p < 0.05). Mean cerebral blood ﬂow was
lower in the control than normal-control and it was not signiﬁcantly different between the control and
positive-control. However, AGM-L and AGM-H protected against the decrease in cerebral blood ﬂow
in Px rats and the levels in AGM-L were similar to normal-control.
Table 3. Serum glucose and insulin levels at fasting states and insulin resistance.
Normal-Control
(n = 10)
Control
(n = 10)
Positive-Control
(n = 10)
AGM-L
(n = 10)
AGM-H
(n = 10)
Serum glucose at fasting state (mM) 5.4 ± 0.5 d 9.8 ± 0.6 a 8.4 ± 0.6 b 8.1 ± 0.7 b 7.2 ± 0.5 c
Serum insulin at fasting state (ng/mL) 3.78 ± 0.36 a 2.83 ± 0.32 c 3.55 ± 0.35 a,b 3.27 ± 0.34 b 3.23 ± 0.36 b
HOMA-IR 5.4 ± 0.6 d 9.8 ± 1.0 a 8.4 ± 0.9 b 8.1 ± 0.8 b 7.2 ± 0.8 c
Urinary glucose - ++++ +++ ++ +
Mean cerebral blood ﬂow (mm/s) 657 ± 45 a 405 ± 42 c 424 ± 45 c 643 ± 65 a 571 ± 67 b
+, ++, +++, ++++ higher amount of urinary glucose detection with more +. – No detection of urinary glucose.
Values are means ± standard deviation. The test product was the mixture of free-dried aronia, red ginseng,
mushroom and nattokinase. Px rats fed a high fat diet supplemented with (1) 0.5 g mixture/kg bw/day (AGM-L),
(2) 1 g mixture/kg bw/day (AGM-H), (3) 1 g dextrin/kg bw/day (control), or (4) metformin (120 mg/kg body
weight; positive-control) for 12 weeks. Sham-operated rats (normal-control) fed the same diet of control. a,b,c,d Values
on the same row with different superscripts were signiﬁcantly different at p < 0.05.
Cerebral blood ﬂow was much lower in the control group than the normal-control group and
positive-control did not improve blood ﬂow compared to the control. However, AGM-L and AGM-H
prevented the decrease and the level in the AGM-L group was similar to the normal-control group.
The OGTT revealed that glucose tolerance was highly impaired in the control group compared
to the normal-control group and it was improved by metformin in the positive-control group
(Figure 2A). AGM-L and AGM-H improved the glucose tolerance better than the positive-control
but the improvement did not return it to normal-control group values (p < 0.05; Figure 2A). AUC of
serum glucose levels during OGTT in the ﬁrst phase was much higher in the control group than
the normal-control group whereas AGM-L and AGM-H decreased the AUC of serum glucose levels
(p < 0.05; Figure 2B). In the second phase of OGTT, AUC of serum glucose concentrations were much
higher in the control group than in the normal-control group and AGM-L prevented the increase
(Figure 2B). AGM-H increased the 2nd part of the serum insulin levels in comparison to the control
but it was not signiﬁcantly different (Figure 2C).
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(A) 
(B) 
(C) 
Figure 2. Serum glucose and insulin levels and area under the curve (AUC) of serum glucose and
insulin during oral glucose tolerance test (OGTT). Px rats were fed a high fat diet supplemented
with aronia, red ginseng, shiitake mushroom, and nattokinase powders (1) 0.5 g mixture/kg bw/day
(AGM-L), (2) 1 g mixture/kg bw/day (AGM-H), (3) 1 g dextrin /kg bw/day (control), or (4) metformin
(120 mg/kg body weight; positive-control) for 12 weeks. Sham rats fed the same diet of control.
Changes of serum glucose levels (A) were measured after orally giving 2 g of glucose/kg body weight.
The average of the area under the curve (AUC) of glucose (B) and insulin (C) during the ﬁrst part
(0–40 min) and second part (40–120 min) of OGTT. Each dot and bar and error bar represent the
mean ± SD (n = 10 of each group). * Signiﬁcantly different among the groups at each time point at
p < 0.05. a,b,c Different superscripts on the bars represent signiﬁcant differences at S < 0.05.
3.4. Insulin Tolerance
At 6 h after food deprivation, serum glucose levels were much higher in the control group
than the normal-control group and the levels were lowered in the descending order of the control,
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positive-control, AGM-L and AGM-H (p < 0.05; Figure 3A). After insulin injection, serum glucose levels
decreased until 60 min in all groups and the levels were almost maintained in all groups except the
control group. The AUC of serum glucose concentrations were much higher in the control than in the
normal-control in the 1st and 2nd phase (Figure 3B). AGM-L and AGM-H markedly decreased serum
glucose levels during the 1st phase and the levels at the 2nd phase was similar to the normal-control
group (p < 0.05; Figure 3B). Thus, AGM-L and AGM-H improved insulin tolerance in comparison to
the control.
Figure 3. Changes of serum glucose concentrations during the intraperitoneal insulin tolerance test
(IPITT). Px rats were fed a high fat diet supplemented with aronia, red ginseng, shiitake mushroom,
and nattokinase powders (1) 0.5 g mixture/kg bw/day (AGM-L), (2) 1 g mixture/kg bw/day (AGM-H),
(3) 1 g dextrin /kg bw/day (control), or (4) metformin (120 mg/kg body weight; positive-control)
for 12 weeks. Sham rats fed the same diet of the control. IPITT was conducted with intraperitoneal
injection of 0.75 IU insulin/kg body weight and measured serum glucose concentrations in blood
collected from the tail every 15 min for 90 min. Changes of serum glucose levels were measured during
IPITT (A). The average of the area under the curve (AUC) of glucose (B) during the ﬁrst part (0–45 min)
and second part (45–120 min) of IPITT. Each dot and bar and error bar represents the mean ± SD (n = 10
of each group). * Signiﬁcantly different among the groups at each time point at p < 0.05. a,b,c,d Different
superscripts on the bars represent signiﬁcant differences at p < 0.05.
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3.5. Hyperglycemic Clamp
Serum insulin levels were much lower in the control group than normal-control group for 90 min
after glucose challenge (p < 0.05; Figure 4A). Serum insulin levels exhibited the 1st (0–10 min) and 2nd
(60–90 min) phases in all groups. The AUC of 1st and 2nd phases of serum insulin levels increased
in AGM-L the most whereas AGM-H elevated the AUC 1st and 2nd phases more than the control
but less than the AGM-L (p < 0.05; Figure 4B). Glucose infusion rates during hyperglycemic clamp
were much lower in the control group than the normal-control group whereas AGM-H prevented the
decrease in Px rats, but the levels were less than the normal-control (p < 0.05; Table 4). AGM-H showed
a higher glucose infusion rates and the levels were higher than the positive-control group (p < 0.05).
Insulin sensitivity in the hyperglycemic state markedly decreased in the control group compared to
the normal-control group and it was higher in the ascending order of control, AGM-H, positive-control
and AGM-L (p < 0.05; Table 4).
(A) 
(B) 
Figure 4. Insulin secretion during hyperglycemic clamp. Px rats were fed a high fat diet supplemented
with aronia, red ginseng, shiitake mushroom, and nattokinase powders (1) 0.5 g mixture/kg bw/day
(AGM-L), (2) 1 g mixture/kg bw/day (AGM-H), (3) 1 g dextrin /kg bw/day (control), or (4) metformin
(120 mg/kg body weight; positive-control) for 12 weeks. Sham rats fed the same diet of the control.
Hyperglycemic clamp was conducted in conscious, free moving, and overnight fasted rats to measure
glucose-stimulated insulin secretion. As exogenous glucose was infused into jugular vein to make
approximately 5.5 mM above overnight fasted serum glucose levels, serum insulin levels were
measured at 0, 2, 5, 10, 30, 60, 90 and 120 min (A). The average of the area under the curve (AUC)
of serum insulin levels (B) during the ﬁrst part (0–10 min) and second part (10–90 min) during
hyperglycemic clamp (B). Each dot and bar and error bar represents the mean ± SD (n = 10 of each
group). * Signiﬁcantly different among the groups at each time point at p < 0.05. a,b,c,d Different
superscripts on the bars represent signiﬁcant differences at p < 0.05.
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Table 4. Glucose metabolism during hyperglycemic clamp.
Normal-Control
(n = 10)
Control
(n = 10)
Positive-Control
(n = 10)
AGM-L
(n = 10)
AGM-H
(n = 10)
Serum glucose levels at 60 min (mM) 9.8 ± 0.9 c 17.7 ± 1.4 a 14.6 ± 1.7 b 15.1 ± 1.6 b 15.1 ± 1.1 b
Serum glucose levels at 90 min (mM) 9.9 ± 0.9 c 18.3 ± 1.7 a 15.6 ± 1.7 b 15.2 ± 1.3 b 14.6 ± 1.2 b
Serum insulin levels at 2 min (ng/mL) 6.2 ± 0.6 a 3.2 ± 0.5 d 4.0 ± 0.4 c 4.6 ± 0.5 b 3.7 ± 0.4 c
Serum insulin levels at 60 min (ng/mL) 5.1 ± 0.4 a 2.5 ± 0.4 d 3.7 ± 0.3 b,c 4.1 ± 0.5 b 3.3 ± 0.6 c
Glucose infusion rates (umol/kg bw/min) 59.4 ± 3.9 a 26.1 ± 2.8 d 35.6 ± 3.9 c 32.8 ± 4.4 c 43.9 ± 3.9 b
Insulin sensitivity at hyperglycemic state (μmol
glucose min−1 100 g−1 per μmol insulin/L) 33.3 ± 3.9
a 19.8 ± 2.4 d 25.8 ± 2.9 c 23.4 ± 2.6 c 28.9 ± 3.3 b
Values are means ± standard deviation (n = 10 of each group). The test product was the mixture of free-dried aronia,
red ginseng, mushroom and nattokinase. Px rats fed a high fat diet supplemented with (1) 0.5 g mixture/kg bw/day
(AGM-L), (2) 1 g mixture/kg bw/day (AGM-H), (3) 1 g dextrin /kg bw/day (control), or (4) metformin (120 mg/kg
body weight; positive-control) for 12 weeks. Sham-operated rats (normal-control) fed the same diet of the control.
a,b,c,d Values on the same row with different superscripts were signiﬁcantly different at p < 0.05.
3.6. Pancreatic β-cell Mass, Proliferation, and Apoptosis
Pancreatic β-cell area is calculated by the number and individual size of β-cells. The increased
number of β-cells improves diabetic status. However, individual β-cell size increases with β-cell
hypertrophy that is associated with increased insulin resistance. Pancreatic β-cell area was higher in
the control group than the normal-control group, but individual β-cell size was higher in the control
group than in the normal-control group (p < 0.05; Table 5). AGM-H increased pancreatic β-cell area
with smaller individual sized beta-cells, demonstrating that AGM-H increased β-cell number (Table 5).
Pancreatic β-cell mass, calculated by multiplying β-cell area by pancreatic weight, was much lower in
the control group than the normal-control group. Pancreatic β-cell mass increased in the ascending
order of the control, positive-control, AGM-L, and AGM-H (p < 0.05; Table 5).
Table 5. The modulation of islet morphometry in the pancreas section.
Normal-Control
(n = 5)
Control
(n = 5)
Positive-Control
(n = 5)
AGM-L
(n = 5)
AGM-H
(n = 5)
β-cell area (%) 5.5 ± 0.7 c 6.3 ± 0.8 b 6.8 ± 0.8 a,b 6.9 ± 0.8 a,b 7.6 ± 0.9 a
Individual β-cell size (μm2) 185 ± 23 c 239 ± 26 a 209 ± 23 b 206 ± 25 b 189 ± 22 b,c
Absolute β-cell mass (mg) 33.4 ± 2.9 a 17.9 ± 1.9 d 22.4 ± 2.6 c 23.7 ± 2.9 c 28.8 ± 3.5 b
BrdU+ cells (% BrdU+ cells of islets) 0.72 ± 0.09 c 0.84 ± 0.09 b 0.89 ± 0.11 b 0.90 ± 0.12 b 1.04 ± 0.12 a
Apoptosis (% apoptotic bodies of islets) 0.64 ± 0.07 a,b 0.70 ± 0.09 a 0.66 ± 0.07 a,b 0.65 ± 0.07 a,b 0.59 ± 0.07 b
Values are means ± standard deviation. The test product was the mixture of free-dried aronia, red ginseng,
mushroom and nattokinase. Px rats fed a high fat diet supplemented with (1) 0.5 g mixture/kg bw/day (AGM-L),
(2) 1 g mixture/kg bw/day (AGM-H), (3) 1 g dextrin /kg bw/day (control), or (4) metformin (120 mg/kg body
weight; positive-control) for 12 weeks. Sham-operated rats (normal-control) fed the same diet of the control.
a,b,c,d Values on the same row with different superscripts were signiﬁcantly different at p < 0.05.
The β-cell number is balanced by β-cell proliferation and β-cell apoptosis. The control rats
exhibited a higher β-cell apoptosis than the positive-control rats and AGM-H decreased β-cell
apoptosis (p < 0.05; Table 5). The β-cell proliferation was lower in the control group than the
normal-control group. AGM-H increased the β-cell proliferation (p < 0.05; Table 5). Therefore,
AGM-H increased β-cell mass by elevating β-cell proliferation and decreasing β-cell apoptosis.
3.7. Gut Microbiome
Community composition of the gut microbiota was compared with both total and shared
operational taxonomic units among the groups by analysis of molecular variance (AMOVA).
The AMOVA test revealed signiﬁcant differences between the fecal bacterial communities among
the groups (p < 0.01). Principal coordinate analysis (PCoA) illustrates the clustering of gut bacterial
community (Figure 5A). Normal-control and control showed a signiﬁcant separation of gut microbiota.
AGM-L and AGM-H also had separate gut microbiota clustering from control but they overlapped
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with the normal-control. However, positive-control exhibited a similar pattern to that of the control
group (Figure 5A). These results indicated that diabetes modulated the composition of gut microbiome
and AGM prevented the modulation of gut microbiome.
The bacterial distribution was different among the groups at the phylum and order levels
(Figure 5B,C). The major bacteria were Firmicutes, Bacteriodetes, Proteobacteria, Actinobacteria,
and Deferribacteres at the phylum level. The percentage of Firmicutes was higher in the control
group than the normal-control group and AGM-L and AGM-H reduced its percentage (Figure 5B).
In contrast to Firmicutes, the percentage of Bacteroidetes was lower in the control than the normal-control
and it increased with AGM-L and AGM-H (p < 0.05; Figure 5B). The percentages of Proteobacteria,
Actinobacteria, and Deferribacteres were not altered by diabetic status and AGM supplementation
(Figure 5B). The bacteria community was different among the groups in order level more than the
phylum level. The percentage of Bacteroidales was much lower in the control than the normal-control
and it was increased by AGM-L and AGM-H (Figure 5C). The percentages of Erysipelotrichales and
Clostridiales were higher in the control than the normal-control and they were decreased by AGM-L
and AGM-H. AGM-L increased the percentage of Desulfovibrionales (p < 0.05; Figure 5C). Thus, AGM-L
modulated gut microbiome to make it similar to the normal-control.
(A) 
 
(B) 
Figure 5. Cont.
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(C) 
Figure 5. The proﬁles of gut microbiomes Px rats were fed a high fat diet supplemented with aronia,
red ginseng, shiitake mushroom, and nattokinase powders (1) 0.5 g mixture/kg bw/day (AGM-L;
n = 8), (2) 1 g mixture/kg bw/day (AGM-H; n = 8), (3) 1 g dextrin/kg bw/day (control; n = 8), or (4)
metformin (120 mg/kg body weight; positive-control; n = 8) for 12 weeks. Sham rats were fed the same
diet as the control (n = 8). At the end of experimental periods feces were collected and the bacterial DNA
was analyzed. The fecal bacterial community was shown in principal coordinate analysis (PCoA) (A).
Proportion of taxonomic assignments [Phylum (B) and Order (C)] for gut microbiomes was analyzed.
4. Discussion
Aronia, red ginseng and ultraviolet-irradiated shiitake mushroom have been reported to inﬂuence
glucose metabolism. Based on a previous study, freeze-dried aronia, red ginseng, ultraviolet-irradiated
shiitake mushroom and nattokinase were mixed at the ratio of 3.4:4.1:2.5:0.1 and the anti-diabetic
activity was examined by assessing its efﬁcacy for improving insulin sensitivity and potentiating insulin
secretion in non-obese type 2 diabetic rats (Px rats). Px rats fed high fat diets, a well-established model
of Asians type 2 diabetes, were used as the animal model for investigating the efﬁcacy of the mixture
in the present study. The Px rats had hyperglycemia due to increased insulin resistance and decreased
insulin secretion. We used whole food not extracts since the gut microbiome is inﬂuenced by dietary
ﬁber in the ingredients and anthocyanins can be easily degraded due to high temperature during
extraction. Aronia, red ginseng, ultraviolet-irradiated shiitake mushroom and nattokinase contain
different effective components such as anthocyanins, ginsenoside and β-glucan with vitamin D [27–29].
The major ingredients are known to be beneﬁcial for alleviating type 2 diabetic symptoms and they are
not overlapped between the plants. Thus, the efﬁcacy of the mixture was examined for anti-diabetic
activity in the present study.
Hyperglycemia develops when there is insufﬁcient insulin secretion to compensate for insulin
resistance. Insulin resistance is due to the impairment of insulin signaling by inﬂammation,
oxidative stress and other factors. Elevated reactive oxygen species (ROS) and proinﬂammatory
cytokines are also associated with impaired insulin signaling and β-cell function, with increasing
β-cell apoptosis [30]. The decrease in ROS and proinﬂammatory cytokines alleviates the diabetic
symptoms [29,31]. Hyperglycemia also reduces blood ﬂow, which increases cardiovascular events [32].
The mixture of Aronia melanocarpa, red ginseng and mushroom is a good combination for anti-diabetic
activity. Aronia melanocarpa extracts are rich in anthocyanins that suppress the production of ROS
and proinﬂammatory cytokines [33,34]. Furthermore, aronia extracts prevent hyperglycemia by
inhibiting α-glucosidase activity in the small intestines, by their ROS scavenging in humans and animal
models [35,36]. Red ginseng can complement the anti-diabetic activity of aronia. Ginsenosides in red
ginseng are known to prevent insulin resistance by activating insulin signaling in cells, animals and
humans [11–13,28]. Red ginseng enhances insulin secretion and increases the pancreatic β-cell mass,
304
Nutrients 2018, 10, 948
which has hypoglycemic effects [14]. A systematic review and meta-analysis of randomized controlled
clinical trials demonstrates that ginseng modestly, but signiﬁcantly, improved fasting blood glucose in
non-diabetic and diabetic patients but it does not change hemoglobin A1c and plasma insulin levels [37].
However, Reeds et al. [28] reported that ginseng and ginsenoside Re do not improve insulin sensitivity
and β-cell function in obese type 2 diabetic patients. The ginsenosides are not detected in the blood
after ginseng and ginsenoside Re treatment due to poor systemic bioavailability of ginsenosides [28].
Shiitake mushroom, which is rich in β-glucans and vitamin D, also has anti-diabetic activities [5,38,39].
β-glucan changes the gut microbiome and may be associated with improving insulin sensitivity.
β-glucan mainly reduces insulin resistance to improve glucose metabolism [39]. Koreans have low
levels of 25-OH-cholecalciferol in the blood, indicating vitamin D insufﬁciency that may affect glucose
homeostasis with decreasing lean body mass [40,41]. Hyperglycemia increases platelet aggregation
and thrombose formation that elevate the susceptibility to cardiovascular events [32]. Nattokinase
is reported to suppress thrombosis [17,18]. The present study showed that AGM improved cerebral
blood ﬂow to as much as the normal-control. Since serum glucose levels in AGM were higher than
the normal-control, the improvement of cerebral blood ﬂow was associated with the factors beyond
serum glucose levels. Nattokinase might be involved in the increase of cerebral blood ﬂow in AGM.
Therefore, the combination of aronia, red ginseng, shiitake mushroom and nattokinase may have
a potent ant-diabetic activity and reduce the diabetic complications such as cardiovascular events.
We decided to investigate the anti-diabetic activity of the combination treatment in Px rats. The present
study showed that AGM-L and AGM-H improved glucose tolerance by improving insulin sensitivity
in a dose-dependent manner, but AGM-L potentiated glucose-stimulated insulin secretion more than
AGM-H. Thus, the combination supplementation alleviated the diabetic symptoms in Px rats.
The present study also showed that Px changed the body composition in comparison to the
normal-control rats: Body weight and body fat were lower in Px rats compared to the normal-control
rats due to increased urinary glucose loss. Fat mass was lower in the Px rats than the normal-control
rats and both AGM-L and AGM-H suppressed the decrease in fat mass, but the fat mass of the
AGM-L and AGM-H groups was still much lower than that of the normal-control. The suppression
of fat mass loss was associated with the reduction of urinary glucose loss. The decrease of fat
mass was not prevented as much as the urinary glucose loss. That may be associated with the
properties of aronia and ginseng to suppress body fat synthesis and to increase skeletal muscle
mass [42–44]. Furthermore, Px rats had lower BMD in the lumbar spine and femur and lower LBM
in the hip and leg in comparison to the normal-control. These results suggested that the decrease
of BMD is associated with lower insulin sensitivity and insulin secretion in diabetic rats. Sufﬁcient
insulin release promotes osteoblast activity by binding to insulin receptors in insulin insufﬁcient
states [45]. When osteoblasts are activated, osteocalcin is released from the bone and it binds to
osteocalcin receptors that are highly expressed in pancreatic β-cells [45]. V-D is weakly correlated with
osteocalcin [46] and it may not be involved in osteocalcin activity in insulin signaling. The activation
of osterocalcin receptor by binding with osteocalcin promotes β-cell proliferation to improve β-cell
function when glucose levels are elevated [47,48]. However, the osteocalcin effect on insulin resistance
is still controversial [49,50]. In addition, BMD is associated with peroxisome proliferator-activated
receptor (PPAR)-γ activation [41]. Skeletal muscle mass is reduced by decreasing anabolic signaling
in the myocytes [51]. Ginsenosides in ginseng are reported to activate the PPAR-γ pathway to
improve insulin sensitivity in various tissues [52,53]. The AGM-L inhibited the decrease of BMD
and LBM, indicating that the inhibition by AGM was associated with the improvement of insulin
sensitivity and potentiating insulin secretion. A potential limitation of the study is stress induced
by multiple invasive procedures. However, the stress effects were mitigated by separating invasive
procedures by at least one week to allow recovery from the stress. A unique aspect of this study
was the use whole herbs instead of their extracts since the gut microbiome plays an important role
in host metabolism of energy, glucose and lipids [54]. Dietary ﬁber works as food for gut microbes
which produce short-chain fatty acids [54]. Dietary ﬁbers in lyophilized aronia, red ginseng and
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shiitake mushroom may improve the composition and richness of the gut microbiome to establish
eubiosis. However, another limitation of this study was not to include an AGM extract group in this
study. The involvement of the gut microbiome in the development and progression of metabolic
diseases is well recognized. Qin et al. has reported that several Clostridium species are increased
in type 2 diabetes, and butyrate-producing bacteria are decreased [55]. Our preliminary study
demonstrated that metabolism of β-glucan produced propionate and butyrate more than dextrin
by 3.5 and 2 folds in vitro. However, the effects of dietary ﬁber in aronia and red ginseng on the
microbiome were not examined. The present study also showed that Clostridales and Erysipelorichales,
which are included in the Fircumicultes. was higher in the control than the normal-control but AGM
decreased them. These changes in the gut microbiome might be associated with modulating the
production of propionate and butyrate to inﬂuence gut-brain axis [56]. However, metformin treatment,
the positive-control, did not alter the Fircumicutes although it improved glucose tolerance in the present
study. Previous studies have shown that metformin modulates the gut microbiota composition by
increasing the growth of some bacteria, such as Akkermansia muciniphila, Escherichia spp. or Lactobacillus
and by decreasing the levels of some other bacteria such as Intestinibacter [57]. However, metformin
treatment has adverse effects such as diarrhea, nausea, heartburn and gas and it may negatively
inﬂuence the gut microbiome. Further study is needed to elucidate the metformin effect on gut
dysbiosis. The present study showed that AGM had a beneﬁcial effect on gut dysbiosis caused by type
2 diabetes: AGM inhibited the increase of Clostridales and increased Bacterioidales in the type 2 diabetic
rats. Therefore, AGM improved glucose metabolism and prevented gut dysbiosis.
5. Conclusions
Hyperglycemia caused gut dysbiosis by increasing Fircumicultes, and AGM protected against gut
dysbiosis. AGM improved glucose metabolism and lipid proﬁles in insulin insufﬁcient type 2 diabetic
rats, with Asian type 2 diabetes. The improved glucose metabolism protected against the decrease in
BMD. Thus, AGM may be useful for preventing type 2 diabetes in Asians.
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